<SEC-DOCUMENT>0001628280-23-028215.txt : 20230808
<SEC-HEADER>0001628280-23-028215.hdr.sgml : 20230808
<ACCEPTANCE-DATETIME>20230808162157
ACCESSION NUMBER:		0001628280-23-028215
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230808
DATE AS OF CHANGE:		20230808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyell Immunopharma, Inc.
		CENTRAL INDEX KEY:			0001806952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				833006753
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40502
		FILM NUMBER:		231151734

	BUSINESS ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650 695-0677

	MAIL ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lyel-20230630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:8f655eeb-886b-4b81-9c30-69669c77ca83,g:e402dc2a-90a6-40a3-91ac-ff661e6149b1,d:2d1fffa08fea4d9bb0dbd24f63ee408b--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:lyel="http://lyell.com/20230630" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lyel-20230630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001806952</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-26">December 31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lyel-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">lyel:AdjustmentToRevenueRelatedToChangeInEstimateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">lyel:AdjustmentToRevenueRelatedToChangeInEstimateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GoldmanSachsAndBofAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyel:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyel:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-04</xbrli:startDate><xbrli:endDate>2022-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">lyel:LyellImmunopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-99 f-100 f-98 f-101" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_1"></div><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2023</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Lyell Immunopharma, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">83-1300510</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">(State or other jurisdiction of</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">201 Haskins Way</ix:nonNumeric></span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94080</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:130%">(Zip Code)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">695-0677</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:37.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">LYEL</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:6pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of August&#160;3, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">251,026,997</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_10">Special Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_13">PART I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.72pt;padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_25">Condensed Consolidated Statements of Stockholders</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_25">&#8217;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_25"> Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_34">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_34">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_100">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_100">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_100">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_130">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_130">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_130">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_133">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_133">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_133">31</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_136">PART II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_139">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_139">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_139">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_142">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_142">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_142">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_172">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_172">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_172">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_175">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_175">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_175">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_178">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_178">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_178">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_181">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_181">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_181">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_187">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_187">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_187">69</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_190">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_190">71</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned nonclinical studies and clinical trials, results of nonclinical studies and clinical trials, research and development costs, planned regulatory submissions, regulatory approvals and the timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the accuracy and timing of our estimates regarding expenses, revenue opportunities, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope, progress, results and costs of developing LYL797, LYL845, LYL119 or any other product candidates we may develop, and conducting nonclinical studies and clinical trials, including for LYL797, LYL845 and LYL119;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing and costs involved in obtaining and maintaining regulatory approvals of LYL797, LYL845, LYL119 or any other product candidates we may develop, and the timing or likelihood of regulatory filings and approvals, including any expectations regarding seeking special designations for our product candidates for various diseases;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our plans relating to the commercialization of LYL797, LYL845, LYL119 or any other product candidates we may develop, if approved, including the geographic areas of focus and our ability to grow a sales force;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the size of the market opportunities for LYL797, LYL845, LYL119 or any other product candidates we may develop in each of the diseases we may target;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our reliance on third parties to conduct nonclinical research activities for LYL797, LYL845, LYL119 or any other product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the characteristics, safety, efficacy and therapeutic effects of LYL797, LYL845, LYL119 or any other product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our estimates of the number of patients in the United States who suffer from the diseases we target and the number of subjects that will enroll in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the progress and focus of our current and planned clinical trials of our product candidates, and the reporting of data from those trials, including the timing thereof;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability of our clinical trials to demonstrate the safety and efficacy of LYL797, LYL845, LYL119 or any other product candidates we may develop, and other clinical trial results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the success of competing therapies that are, or may become, available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developments relating to our competitors and our industry, including any existing or future competing product candidates or therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our plans relating to the further development and manufacturing of LYL797, LYL845, LYL119 or any other product candidates we may develop, including additional indications that we may pursue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">existing regulations and regulatory developments in the United States and other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our potential and ability to successfully manufacture and supply LYL797, LYL845, LYL119 or any other product candidates we may develop for clinical trials and for commercial use, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the rate and degree of market acceptance, as well as the pricing and reimbursement, of LYL797, LYL845, LYL119 or any other product candidates we may develop, if approved;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our continued reliance on third parties to assist us in conducting additional clinical trials of LYL797, LYL845, LYL119 or any other product candidates we may develop, and our potential reliance on third parties for the manufacture of our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope of protection we are able to establish and maintain for intellectual property rights, including covering our product candidates and technology platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to retain the continued service of our key personnel and to identify, hire and then retain additional qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our expectations regarding the impact of inflation, macroeconomic conditions and geopolitical conflicts on our business and operations, including on our manufacturing suppliers, collaborators, contract research organizations (CROs) and employees; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our anticipated use of our existing cash, cash equivalents and marketable securities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described under &#8220;Risk Factors&#8221; in Part II, Item 1A, and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in these forward-looking statements. Except as required by applicable law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those projected in these forward-looking statements, even if new information becomes available in the future. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_16"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Financial Statements.</span></div><div><span><br/></span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">224,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">123,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-32">371,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">516,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">10,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">11,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">606,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">651,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-38">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-39">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">36,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">70,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-42">32,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-43">44,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">113,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-45">123,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">41,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">43,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">4,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">4,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Total assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-50">835,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">937,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">LIABILITIES AND STOCKHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> EQUITY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">5,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">3,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accrued liabilities and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-54">24,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">28,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:SuccessPaymentLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">3,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:SuccessPaymentLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">34,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">37,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">60,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">63,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">3,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">4,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-64">98,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-65">104,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="f-66"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="f-67"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-68"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-69">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-71">10,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-73"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-75">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-78"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-79">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-81">500,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-83">251,027</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-85">249,567</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-86">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-87">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-88">1,637,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-89">1,608,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-90">2,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-91">7,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-92">898,329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-93">767,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">736,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">833,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Total liabilities and stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">835,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">937,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-98">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-99">35,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-100">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-101">36,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-102">47,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-103">43,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">92,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">79,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">19,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">30,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">38,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">64,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-110">569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-111">1,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-112">1,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-113">2,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-114">65,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-115">73,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-116">128,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-117">142,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">65,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">37,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">128,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">105,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-122">5,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-123">952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-124">9,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-125">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-126">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-127">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-128">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-129">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Impairment of other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">2,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="f-131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">12,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total other income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">2,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-135">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">2,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">63,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">36,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">130,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">104,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-142">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-143">1,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-144">5,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-145">6,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-146">62,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-147">38,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-148">125,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-149">111,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-150"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-151">0.26</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-152"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-153">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-154"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-155">0.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-156"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-157">0.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Weighted-average shares used to compute net loss per common share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-158"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-159">250,204</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-160"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-161">246,312</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-162"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-163">249,899</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-164"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-165">245,251</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">(1)&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-166"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-167">None</ix:nonFraction></ix:nonFraction> of the revenue for the three and six months ended June&#160;30, 2023 was from a related-party. Substantially all of the revenue for the three and six months ended June&#160;30, 2022 was from a related-party.</ix:footnote></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.238%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Three Months Ended June 30, 2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-168">249,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">1,622,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">3,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">834,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">783,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-174">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-175">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-176">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-177">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-178">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-179">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock in connection with restricted stock units, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-180">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-181">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-182">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-183">14,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-184">14,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-185">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-186">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">63,890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-188">63,890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of June&#160;30, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-189">251,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-190">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">1,637,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">2,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">898,329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">736,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.238%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Six Months Ended June 30, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-195">249,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-196">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">1,608,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-198">7,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-199">767,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-200">833,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-201">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-202">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-203">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-204">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-205">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-206">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-207">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-208">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-209">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-210">28,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-211">28,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-212">5,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-213">5,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-214">130,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">130,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of June&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-216">251,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-217">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-218">1,637,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-219">2,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">898,329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-221">736,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span><br/></span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.666%"><tr><td style="width:1.0%"></td><td style="width:40.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Three Months Ended June 30, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-222">245,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-223">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">1,540,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-225">6,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">652,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">881,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-228">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-229">1,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-230">1,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-231">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-232">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-233">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-234">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-235">22,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-236">22,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-237">1,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-238">1,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-239">36,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-240">36,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-241">247,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-242">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">1,565,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-244">8,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">688,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">868,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.555%"><tr><td style="width:1.0%"></td><td style="width:40.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Comprehensive Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-247">242,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-248">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">1,515,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">1,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">584,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-252">929,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-253">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-254">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-255">4,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-256">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-257">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-258">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-259">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-260">1,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-261">44,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-262">44,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-263">6,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-264">6,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">104,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-266">104,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Balance as of June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-267">247,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-268">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-269">1,565,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-270">8,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">688,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-272">868,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-273">130,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-274">104,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-275">28,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-276">44,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Impairment of other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-277">12,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-279">10,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-280">8,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net amortization and accretion on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-281">3,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-282">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Non-cash lease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lyel:NonCashLeaseIncomeExpense" scale="3" id="f-283">816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lyel:NonCashLeaseIncomeExpense" scale="3" id="f-284">655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Change in fair value of success payment liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lyel:FairValueAdjustmentOfSuccessPaymentLiabilities" scale="3" id="f-285">603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="lyel:FairValueAdjustmentOfSuccessPaymentLiabilities" scale="3" id="f-286">264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Loss on property and equipment disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-287">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-288">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Change in fair value of equity warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-290">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Prepaid expenses, other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-291">641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-292">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-293">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-294">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Accrued liabilities and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-295">3,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-296">7,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-298">36,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-300">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-301">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-302">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-303">85,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-304">92,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-305">2,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-306">16,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-307">141,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-308">185,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-309">329,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-310">201,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-311">185,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-312">1,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-313">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-314">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Proceeds from employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="f-315">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-316">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-317">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-319">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-320">5,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-321">100,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-322">88,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-323">123,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-324">294,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-325">224,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-326">206,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Represented by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-327">224,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-328">205,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-329">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-330">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-331">224,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-332">206,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">SUPPLEMENTAL CASH FLOW INFORMATION</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-333">5,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-334">5,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Cash received for amounts related to tenant improvement allowances</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances" format="ixt:num-dot-decimal" scale="3" id="f-336">2,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Purchases of property and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-337">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-338">3,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lyell Immunopharma, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-339" continuedAt="i0b1403aebc1b46bf971cfe0d309e9b70" escape="true">Organization</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i0b1403aebc1b46bf971cfe0d309e9b70" continuedAt="i85c197a54aa04597ad538a4b6b9ee973"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lyell Immunopharma, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware in June 2018. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ex&#160;vivo</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85c197a54aa04597ad538a4b6b9ee973"> genetic and epigenetic T&#8209;cell reprogramming technologies. The Company&#8217;s primary activities since incorporation have been to develop T&#8209;cell therapies, perform research and development, acquire technology, enter into strategic collaboration and license arrangements, enable and execute manufacturing activities in support of its product candidate development efforts, organize and staff the Company, conduct business planning, establish its intellectual property portfolio, submit regulatory submissions and other preparations to initiate and execute clinical trials, raise capital and provide general and administrative support for these activities.</ix:continuation> </span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-340" continuedAt="i3d1001f9c99d468db0ca8af588c3139e" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i3d1001f9c99d468db0ca8af588c3139e" continuedAt="i0aa0acd10ad24a9ba26f6596cc1a3ddc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-341" continuedAt="i460ff0d6c7074770acee4fcd010d1518" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i460ff0d6c7074770acee4fcd010d1518">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-342" escape="true">All significant intercompany transactions and balances have been eliminated in consolidation.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures typically included in the Company&#8217;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the periods presented, but are not necessarily indicative of results to be expected for any future annual or interim period. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company&#8217;s audited financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discovers and develops product candidates that involve experimental technologies. The product candidates may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources or from the issuance of equity or debt securities. The Company believes that its available cash, cash equivalents and marketable securities as of June&#160;30, 2023 will be adequate to fund its operations at least through the next 12&#160;months from the date these unaudited Condensed Consolidated Financial Statements are issued. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-343" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#8220;GSK&#160;Agreement&#8221;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#8220;GSK&#8221;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment increased revenue by $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-344"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-345">35.3</ix:nonFraction></ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-346"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-347">35.3</ix:nonFraction></ix:nonFraction>&#160;million and resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-348"><ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-349"><ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-350"><ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-351">0.14</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> reduction in the Company&#8217;s basic and diluted net loss per common share for the three and six months ended June&#160;30, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><ix:continuation id="i0aa0acd10ad24a9ba26f6596cc1a3ddc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-352" continuedAt="i17b6b293b6d84f40b15acd86a285eb89" escape="true">Concentrations of Credit Risk and Off-balance Sheet Risk</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i17b6b293b6d84f40b15acd86a285eb89">The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in bank accounts and is used as collateral associated with the Company&#8217;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#8209;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" id="f-353" escape="true">The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="lyel:SignificantAccountingPoliciesPolicyTextBlock" id="f-354" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-355" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric></ix:continuation><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. L<ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-356" continuedAt="ic0c9c53a3cf949d9b0b4fb46babd4b06" escape="true">icense, Collaboration and Success Payment Agreements</ix:nonNumeric></span></div><ix:continuation id="ic0c9c53a3cf949d9b0b4fb46babd4b06" continuedAt="i908c4856124d43dbb03440c574736d68"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fred Hutch</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a license agreement with Fred Hutchinson Cancer Center (&#8220;Fred Hutch&#8221;) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that grants the Company a worldwide, sublicensable license under certain patent rights (exclusive) and certain technology (non-exclusive) to research, develop and commercialize products and processes for all fields of use utilizing chimeric antigen receptors (&#8220;CARs&#8221;) and/or T-cell receptors (&#8220;TCRs&#8221;), subject to certain exceptions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay Fred Hutch annual license maintenance payments of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" format="ixt:num-dot-decimal" scale="0" id="f-357">50,000</ix:nonFraction> on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a research and collaboration agreement with Fred Hutch (&#8220;Fred Hutch Collaboration Agreement&#8221;) focused on research and development of cancer immunotherapy products. The Company funded aggregate research performed by Fred Hutch of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsResearchPayments" format="ixt:num-dot-decimal" scale="6" id="f-358">12.0</ix:nonFraction>&#160;million under the Fred Hutch Collaboration Agreement, with the research conducted in accordance with a research plan and budget approved by the parties. The Fred Hutch Collaboration Agreement has a <ix:nonNumeric contextRef="c-56" name="lyel:CollaborativeArrangementRightsAndObligationsResearchTerm" format="ixt-sec:durwordsen" id="f-359">six-year</ix:nonNumeric> term. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-360">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-361">0.5</ix:nonFraction>&#160;million in expense in connection with the Fred Hutch Collaboration Agreement for the three months ended June&#160;30, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-362">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-363">1.0</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company granted Fred Hutch rights to certain success payments, pursuant to the terms of the Fred Hutch Collaboration Agreement. The potential payments for the Fred Hutch success payments are based on multiples of increased value ranging from <ix:nonFraction unitRef="number" contextRef="c-61" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-364">10</ix:nonFraction>x to <ix:nonFraction unitRef="number" contextRef="c-62" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-365">50</ix:nonFraction>x based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $<ix:nonFraction unitRef="usdPerShare" contextRef="c-63" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-366">1.83</ix:nonFraction> per share issuance price of the Company&#8217;s Series A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The aggregate success payments to Fred Hutch are not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-367">200.0</ix:nonFraction>&#160;million, which would only occur upon a <ix:nonFraction unitRef="number" contextRef="c-62" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-368">50</ix:nonFraction>x increase in value. Each threshold is associated with a success payment, ascending from $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-369">10.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-370">18.29</ix:nonFraction> per share to $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-371">200.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-372">91.44</ix:nonFraction> per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, such that Fred Hutch does not receive multiple success payments in connection with the same threshold. The term of the success payment agreement ends on the earlier to occur of (i)&#160;the <ix:nonNumeric contextRef="c-56" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" format="ixt-sec:durwordsen" id="f-373">nine-year</ix:nonNumeric> anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="f-374" continuedAt="ie2d3925d24d14dba9778d101c3ca9ebb" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-64" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-375">10</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-376">20</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-377">30</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-67" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-378">40</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" scale="0" id="f-379">50</ix:nonFraction>x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-64" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-380">18.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-65" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-381">36.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-382">54.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-383">73.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-384">91.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-385">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-386">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-387">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-388">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-389">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><ix:continuation id="i908c4856124d43dbb03440c574736d68" continuedAt="ib4796aa8f4cd4174a4a849f601b13e9c"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the <ix:nonNumeric contextRef="c-56" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" format="ixt-sec:durwordsen" id="f-390">one-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO and each <ix:nonNumeric contextRef="c-56" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" format="ixt-sec:durwordsen" id="f-391">two-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of June&#160;30, 2023, <ix:nonFraction unitRef="usd" contextRef="c-69" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:fixed-zero" scale="0" id="f-392">no</ix:nonFraction> success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payment liability was estimated at fair value at inception and at each subsequent reporting period and the associated expense was accreted over the service period of the success payment obligations as research and development expense through 2022. As of December&#160;31, 2022, the Company&#8217;s associated success payment liability was fully accreted to fair value as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. For the three and six months ended June&#160;30, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other (expense) income, net, as the requisite service obligation had been met. The success payment liability was $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-393">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-394">2.5</ix:nonFraction>&#160;million as of June&#160;30, 2023 and December&#160;31, 2022, respectively. With respect to the Fred Hutch Collaboration Agreement success payment obligations, the Company recognized expense of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-395">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-396">2.2</ix:nonFraction>&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and gains of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-397"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-398">0.6</ix:nonFraction></ix:nonFraction>&#160;million for both the six months ended June&#160;30, 2023 and 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stanford</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In 2019, the Company entered into a license agreement with The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;) to license specified patent rights. The Company is required to pay Stanford annual license maintenance payments of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" format="ixt:num-dot-decimal" scale="0" id="f-399">50,000</ix:nonFraction> on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the date of the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments to Stanford of up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-400">3.7</ix:nonFraction>&#160;million per target are payable upon achievement of certain specified clinical and regulatory milestones. The Company is also obligated to pay Stanford $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-401">2.5</ix:nonFraction>&#160;million collectively for all licensed products upon the achievement of a certain commercial milestone. Additionally, low single&#8209;digit tiered royalties based on annual net sales of the licensed products are payable to Stanford.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company entered into a research and collaboration agreement with Stanford (&#8220;Stanford Collaboration Agreement&#8221;), focused on research and development of cellular immunotherapy products. The Stanford Collaboration Agreement has a <ix:nonNumeric contextRef="c-74" name="lyel:CollaborativeArrangementRightsAndObligationsResearchTerm" format="ixt-sec:durwordsen" id="f-402">four-year</ix:nonNumeric> term. The Company is committed to fund aggregate research performed by Stanford of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsResearchPayments" format="ixt:num-dot-decimal" scale="6" id="f-403">12.0</ix:nonFraction>&#160;million under the Stanford Collaboration Agreement, and the research will be conducted in accordance with a research plan and budget approved by the parties. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-404">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-405">0.8</ix:nonFraction>&#160;million in expense in connection with the Stanford Collaboration Agreement for the three months ended June&#160;30, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-406"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-407">1.5</ix:nonFraction></ix:nonFraction>&#160;million for both the six months ended June&#160;30, 2023 and 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company granted Stanford rights to certain success payments, pursuant to the terms of the Stanford Collaboration Agreement. The potential payments for the Stanford Collaboration Agreement success payments are based on multiples of increased value ranging from <ix:nonFraction unitRef="number" contextRef="c-79" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-408">10</ix:nonFraction>x to <ix:nonFraction unitRef="number" contextRef="c-80" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-409">50</ix:nonFraction>x based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $<ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-410">1.83</ix:nonFraction> issuance price of the Company&#8217;s Series A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the Company&#8217;s IPO. The aggregate success payments to Stanford are not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-411">200.0</ix:nonFraction>&#160;million, which would only occur upon a <ix:nonFraction unitRef="number" contextRef="c-80" decimals="0" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" scale="0" id="f-412">50</ix:nonFraction>x increase in value. Each threshold is associated with a success payment, ascending from $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-413">10.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-79" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-414">18.29</ix:nonFraction> per share to $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:num-dot-decimal" scale="6" id="f-415">200.0</ix:nonFraction>&#160;million at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-416">91.44</ix:nonFraction> per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, so that Stanford does not receive multiple success payments in connection with the same threshold. The term of each success payment agreement ends on the earlier to occur of (i)&#160;the <ix:nonNumeric contextRef="c-74" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" format="ixt-sec:durwordsen" id="f-417">nine-year</ix:nonNumeric> anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><ix:continuation id="ie2d3925d24d14dba9778d101c3ca9ebb"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-418">10</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-419">20</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-420">30</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-421">40</ix:nonFraction>x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" format="ixt:num-dot-decimal" id="f-422">50</ix:nonFraction>x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-423">18.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-424">36.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-425">54.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-426">73.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" scale="0" id="f-427">91.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-428">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-429">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-430">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-431">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" scale="6" id="f-432">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the <ix:nonNumeric contextRef="c-74" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" format="ixt-sec:durwordsen" id="f-433">one-year</ix:nonNumeric> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><ix:continuation id="ib4796aa8f4cd4174a4a849f601b13e9c" continuedAt="i3696dc9227f3445c84ab5ff6330e2957"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary of the Company&#8217;s IPO and each <ix:nonNumeric contextRef="c-74" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" format="ixt-sec:durwordsen" id="f-434">two-year</ix:nonNumeric> anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of June&#160;30, 2023, <ix:nonFraction unitRef="usd" contextRef="c-87" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" format="ixt:fixed-zero" scale="0" id="f-435">no</ix:nonFraction> success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of the success payments to Stanford as of June&#160;30, 2023 and December&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-436">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-437">3.3</ix:nonFraction>&#160;million, respectively. The success payment liability is estimated at the fair value at inception and at each subsequent reporting period and the expense is accreted over the service period of the Stanford Collaboration Agreement as research and development expense. The success payment liability was $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="f-438"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="f-439">1.9</ix:nonFraction></ix:nonFraction>&#160;million as of both June&#160;30, 2023 and December&#160;31, 2022. With respect to the Stanford Collaboration Agreement success payment obligations, the Company recognized expense of $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-440">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-441">1.4</ix:nonFraction>&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and expense of approximately <ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:fixed-zero" scale="6" id="f-442">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:num-dot-decimal" scale="6" id="f-443">0.4</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into the GSK Agreement with GSK for potential T&#8209;cell therapies that apply the Company&#8217;s platform technologies and cell therapy innovations with TCRs or CARs under distinct collaboration programs. The GSK Agreement defined two initial collaboration targets, LYL331 and LYL132, and allowed GSK to nominate seven additional targets through July 2024, though no additional targets were nominated over the life of the GSK Agreement. The Company was expected to perform research and development services for each selected target up until a defined point (the &#8220;GSK Option Point&#8221;), at which time GSK would decide whether or not to exercise an option to obtain a license from the Company (&#8220;License Option&#8221;) and take over the future development and commercialization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, GSK exercised the License Option on LYL331 (NY-ESO-1 TCR with c-Jun) and assumed sole responsibility for future development and commercialization of the program at its own cost and expense. The investigational new drug (&#8220;IND&#8221;) application for LYL132 was cleared in January 2022, though no patients were treated, and the IND for LYL331 was not submitted to the U.S. Food and Drug Administration. GSK terminated the GSK Agreement effective December&#160;24, 2022, and Lyell has also discontinued any further work on these programs. There are no future performance obligations associated with the GSK Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-444">45.0</ix:nonFraction>&#160;million under the GSK Agreement. In connection with the GSK Agreement, in May 2019, the Company also entered into a stock purchase agreement with GSK, pursuant to which the Company agreed to sell <ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="lyel:StockPurchaseAgreementSharesSold" format="ixt:num-dot-decimal" scale="0" id="f-445">30,253,189</ix:nonFraction> shares of Series&#160;AA convertible preferred stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="lyel:StockPurchaseAgreementSharesSoldPricePerShare" scale="0" id="f-446">6.78</ix:nonFraction> per share, which was above the issuance date estimated fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="lyel:StockPurchaseAgreementFairValueOfStockPerShare" scale="0" id="f-447">4.84</ix:nonFraction> per share. The difference between the per share values resulted in $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="lyel:RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" format="ixt:num-dot-decimal" scale="6" id="f-448">58.6</ix:nonFraction>&#160;million additional deemed consideration, bringing the total upfront consideration of the GSK Agreement to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-449">103.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GSK Agreement was deemed to be within the scope of Accounting Standards Codification (&#8220;ASC&#8221;)&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, because GSK engaged the Company to initially provide research and development services, which were outputs of its ongoing activities, in exchange for consideration. In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the GSK Agreement due to GSK and the Company mutually agreeing to conclude research activities on an undisclosed target for hematological cancers. The change in estimate decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-450"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-451">35.3</ix:nonFraction></ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-452"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-453">35.3</ix:nonFraction></ix:nonFraction>&#160;million and resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-454"><ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-455"><ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-456"><ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-457">0.14</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> reduction in the Company&#8217;s basic and diluted net loss per common share for the three and six months ended June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue related to the research and development services related to the two initial targets of <ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-458">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-459">35.7</ix:nonFraction>&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and <ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-460">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-461">36.3</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The Company had <ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="f-462"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="f-463">no</ix:nonFraction></ix:nonFraction> deferred revenue related to the GSK Agreement as of both June&#160;30, 2023 and December&#160;31, 2022. As of June&#160;30, 2023 and December&#160;31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="f-464"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="f-465"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="f-466"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="f-467">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to the license contract.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PACT</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a commitment agreement (&#8220;PACT Commitment Agreement&#8221;) with PACT Pharma, Inc. (&#8220;PACT&#8221;) to jointly develop and test a next generation personalized anti-cancer T-cell therapy against solid tumors. The Company paid PACT an upfront non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="lyel:PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement" format="ixt:num-dot-decimal" scale="6" id="f-468">50.0</ix:nonFraction>&#160;million upon execution of the PACT Commitment Agreement. In November 2020, the parties agreed to suspend research and development activity under the PACT Commitment Agreement, and neither party would be required to conduct any further work under the development plan (including manufacturing development) nor incur any financial obligations (including milestone payments) that might otherwise arise, for as long as the parties continued to negotiate in good faith to resolve the issues that had arisen between them relating to the PACT Commitment Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><ix:continuation id="i3696dc9227f3445c84ab5ff6330e2957"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 in connection with the entry into the PACT Commitment Agreement, the Company also entered into a stock purchase agreement with PACT (&#8220;PACT SPA&#8221;), pursuant to which the Company purchased <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="f-469">17,806,901</ix:nonFraction> shares of PACT Series&#160;C-1 convertible preferred stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare" scale="0" id="f-470">2.81</ix:nonFraction> per share. As of the purchase date, the estimated fair value of the Series&#160;C-1 convertible preferred stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare" scale="0" id="f-471">2.05</ix:nonFraction> per share, and the difference between the estimated fair value of the preferred stock as of the purchase date and the purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice" format="ixt:num-dot-decimal" scale="6" id="f-472">13.6</ix:nonFraction>&#160;million was deemed to be additional consideration for the PACT Commitment Agreement and recognized as research and development expense. As a result, the total upfront consideration paid in connection with the PACT Commitment Agreement was $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-473">63.6</ix:nonFraction>&#160;million and was included in research and development expenses. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="f-474">36.4</ix:nonFraction>&#160;million associated with the PACT Series&#160;C-1 convertible preferred stock was recorded in other investments. In the fourth quarter of 2021, the Company fully impaired the remaining balance of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-475">36.4</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company filed a demand for arbitration seeking, among other things, rescission of the PACT Commitment Agreement and the PACT SPA and recovery of the consideration paid thereunder. Arbitration hearings occurred in March and April 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;1, 2022, the Company entered into a settlement agreement with PACT, pursuant to which the parties agreed to resolve their outstanding legal dispute. In connection with the settlement agreement, the parties also entered into a stock purchase agreement, pursuant to which PACT issued shares of PACT&#8217;s Series&#160;D convertible preferred stock to the Company in exchange for the Company&#8217;s tender of its PACT Series&#160;C-1 convertible preferred stock and resolution of the arbitration. The issuance of PACT&#8217;s Series&#160;D convertible preferred stock, which are non-voting, have limited conversion rights and carry no right to appoint directors, resulted in the Company&#8217;s ownership increasing to approximately <ix:nonFraction unitRef="number" contextRef="c-104" decimals="2" name="lyel:LitigationSettlementPercentOfTotalEquityValue" scale="-2" id="f-476">80</ix:nonFraction>% of PACT&#8217;s fully diluted shares outstanding. The settlement agreement also included the termination of the PACT Commitment Agreement. The Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-477">2.9</ix:nonFraction>&#160;million in October 2022 for the estimated fair value of the PACT Series&#160;D convertible preferred stock received as part of the settlement agreement. The PACT Series&#160;D convertible preferred stock was recorded at its estimated fair value as of the settlement date and was included in other investments in the Company&#8217;s Condensed Consolidated Balance Sheets. In connection with the preparation of the financial statements for the three and six months ended June 30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment, resulting in the impairment of the $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-478"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-479">2.9</ix:nonFraction></ix:nonFraction>&#160;million PACT Series D convertible preferred stock investment. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details regarding the PACT investment impairment.</span></div></ix:continuation><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-480" continuedAt="i409d6cffe22f466c92344c0949576f37" escape="true">Cash Equivalents and Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i409d6cffe22f466c92344c0949576f37" continuedAt="i3d9612854110405687b159ca49d788c0"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-481" continuedAt="i774bf56c583d4c7aba4331f65972fef6" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-482" continuedAt="iee09a7a213d4401a9c61c112987bff7a" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-483">116,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-484">116,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-485">292,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-486">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-487">1,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-488">291,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-489">95,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-491">820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-492">94,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-493">106,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-495">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-496">106,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-497">611,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-498">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-499">2,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="f-500">609,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-501">200,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-502">371,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-503">36,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="f-504">609,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><ix:continuation id="i3d9612854110405687b159ca49d788c0"><ix:continuation id="i774bf56c583d4c7aba4331f65972fef6"><ix:continuation id="iee09a7a213d4401a9c61c112987bff7a"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-505">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-506">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-507">277,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-509">5,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-510">271,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-511">135,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-512">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-513">1,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-514">134,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-515">221,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-516">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-517">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-518">220,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-519">702,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-520">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-521">7,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="f-522">694,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-523">107,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-524">516,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-525">70,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="f-526">694,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of securities held by the Company in an unrealized loss position for less than 12&#160;months were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-527">261.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-528">287.8</ix:nonFraction>&#160;million as of June&#160;30, 2023 and December&#160;31, 2022, respectively. The fair values of securities held by the Company in an unrealized loss position for greater than 12&#160;months were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-529">101.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-530">278.7</ix:nonFraction>&#160;million as of June&#160;30, 2023 and December&#160;31, 2022, respectively. As of June&#160;30, 2023 and December&#160;31, 2022, all of the Company&#8217;s marketable securities had a maturity date of <ix:nonNumeric contextRef="c-116" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="f-531"><ix:nonNumeric contextRef="c-117" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="f-532">two years</ix:nonNumeric></ix:nonNumeric> or less, were available for use and were classified as available&#8209;for&#8209;sale. The Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before recovery of their amortized cost basis. The Company determined that there was no material change in the credit risk of the above investments as of both June&#160;30, 2023 and December&#160;31, 2022. As such, an allowance for credit losses has not been recognized. Gross realized gains and losses were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three and six months ended June&#160;30, 2023 and 2022 and as a result, amounts reclassified out of accumulated other comprehensive loss for the three and six months ended June&#160;30, 2023 and 2022 were also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note&#160;6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding cash equivalents and marketable securities.</span></div></ix:continuation><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="lyel:OtherInvestmentsTextBlock" id="f-533" continuedAt="i48e9c44ac2684dd59a376f25e00c1357" escape="true">Other Investments</ix:nonNumeric></span></div><ix:continuation id="i48e9c44ac2684dd59a376f25e00c1357" continuedAt="id7231d730da04f249dcc7611b28e551e"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company makes minority ownership strategic investments. As of June&#160;30, 2023 and December&#160;31, 2022, the aggregate carrying amounts of the Company&#8217;s strategic investments in non-publicly traded companies were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-534">32.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-535">44.9</ix:nonFraction>&#160;million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of June&#160;30, 2023 and December&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="f-536">17.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="f-537">5.0</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company received non-voting preferred stock pursuant to the settlement agreement with PACT (See Note 3, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company determined that PACT is a variable interest entity as PACT does not have sufficient equity at risk. The Company evaluated whether it was the primary beneficiary of PACT, including the Company&#8217;s ongoing rights and responsibilities, to assess whether the Company has the power to direct the activities of PACT. The Company&#8217;s only involvement in PACT is its PACT Series D convertible preferred stock investment, which are non-voting, have limited conversion rights and carry no right to appoint directors. Based on the above noted factors, the Company determined that it is not the primary beneficiary and does not consolidate PACT since it does not have the power to direct the activities that most significantly impact PACT&#8217;s economic performance. The Company does not </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have the ability to exercise significant influence over PACT and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounts for its investment in PACT preferred stock under the measurement alternative. The Company recognized its investment in PACT preferred stock at its estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-538">2.9</ix:nonFraction>&#160;million on October&#160;1, 2022, which was included in the Company&#8217;s Consolidated Balance Sheets within other investments. The Company&#8217;s maximum exposure to loss from PACT is limited to the carrying value of its investment in PACT preferred stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of the financial statements for the three months ended June 30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for the Company&#8217;s PACT Series D convertible preferred stock investment. While there was no single event or factor, the Company considered PACT&#8217;s operating cash flow requirements over the next year, liquid asset balances to fund </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id7231d730da04f249dcc7611b28e551e" continuedAt="i4c365f27c56241efac5d3987441bd0af">those requirements and PACT&#8217;s inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of the investment and determined the fair value to be negligible and the impairment to be other&#8209;than&#8209;temporary in nature. As a result, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-539"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-540">2.9</ix:nonFraction></ix:nonFraction>&#160;million impairment expense for the investment for the three and six months ended June&#160;30, 2023, which was recorded within impairment of other investments on the Condensed Consolidated Statement of Operations and Comprehensive Loss and as a reduction to the investment balance within other investments on the Condensed Consolidated Balance Sheet. </ix:continuation></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c365f27c56241efac5d3987441bd0af">In connection with the preparation of the financial statements for the three months ended March 31, 2023, the Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for one of the Company&#8217;s other investments with a carrying amount of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-541">10.0</ix:nonFraction>&#160;million. While there was no single event or factor, the Company considered the underlying company&#8217;s operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying company&#8217;s inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of the investment and determined the fair value to be negligible and the impairment to be other-than-temporary in nature. As a result, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-542">10.0</ix:nonFraction>&#160;million impairment expense for the investment for the six months ended June&#160;30, 2023, which was recorded within impairment of other investments on the Condensed Consolidated Statement of Operations and Comprehensive Loss and as a reduction to the investment balance within other investments on the Condensed Consolidated Balance Sheet.</ix:continuation> </span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-543" continuedAt="ib2387ff2af16450ab975112fe7c89eb8" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ib2387ff2af16450ab975112fe7c89eb8" continuedAt="i81eb44c6324149b9b630be15e04d8652"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-544" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-545">116,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-548">116,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-550">291,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-552">291,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-554">94,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-556">94,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-558">106,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-560">106,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-561">116,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-562">492,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-564">609,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-567">3,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-568">3,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-571">3,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-572">3,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-573">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-576">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-578">271,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-580">271,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-582">134,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-584">134,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-586">220,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-588">220,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-589">67,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-590">626,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-592">694,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-595">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lyel:SuccessPaymentLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-596">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-599">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-600">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Level&#160;2 marketable securities include U.S. Treasury securities, U.S. government agency securities and corporate debt securities. The Company&#8217;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services applied industry standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Level&#160;3 financial instruments fair values are estimated using valuation models, including Monte Carlo simulations for the Company&#8217;s success payment liabilities. Monte Carlo simulations model the future movement of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><ix:continuation id="i81eb44c6324149b9b630be15e04d8652"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock prices based on several key variables combined with empirical knowledge of the process governing the behavior of the stock price. The following variables were incorporated in the estimated fair value of the success payment liabilities: fair value of the Company&#8217;s common stock, expected volatility, the risk-free interest rate and the estimated number and timing of valuation measurement dates on the basis of which payments may be triggered. The computation of expected volatility was estimated based on available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-601" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="2" name="lyel:FairValueOfSeriesAConvertiblePreferredStock" scale="0" id="f-602">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="lyel:FairValueOfSeriesAConvertiblePreferredStock" scale="0" id="f-603">3.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-155" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-604">3.36</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-156" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-605">5.26</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-157" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-606">3.58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-158" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-607">4.65</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-159" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-608">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-160" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-609">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-161" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-610">0.96</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-162" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-611">4.47</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-163" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-612">0.46</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-613">4.97</ix:nonFraction></span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-165" decimals="2" name="lyel:FairValueOfSeriesAConvertiblePreferredStock" scale="0" id="f-614">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-166" decimals="2" name="lyel:FairValueOfSeriesAConvertiblePreferredStock" scale="0" id="f-615">3.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-167" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-616">3.36</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-617">5.26</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-618">3.58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-170" decimals="4" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-619">4.65</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-171" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-620">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-172" decimals="3" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="-2" id="f-621">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-173" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-622">0.96</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-174" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-623">6.25</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-175" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-624">0.46</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-176" decimals="2" name="lyel:SuccessPaymentLiabilityMeasurementInput" scale="0" id="f-625">6.75</ix:nonFraction></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes estimates and assumptions in determining the estimated success payment liabilities and associated changes in fair value. A small change in the valuation of the Company&#8217;s common stock may have a relatively large change in the estimated fair value of the success payment liability and associated changes in fair value.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-626" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-627" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-628">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-629">603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at June&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-630">3,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The changes in the fair value associated with the Fred Hutch success payment liabilities of approximately $(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" sign="-" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" scale="6" id="f-631">0.6</ix:nonFraction>) million are recorded in other&#160;(expense) income, net (See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). The changes in the fair value of approximately <ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" format="ixt:fixed-zero" scale="0" id="f-632">zero</ix:nonFraction> associated with the Stanford success payment liabilities are recorded as research and development expenses.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company received non-voting Series D convertible preferred stock pursuant to the settlement agreement with PACT (See Note 3, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company determined the fair value of PACT was a fraction of the aggregate liquidation preference of the Company&#8217;s PACT Series D convertible preferred stock. The Company determined that the fair value of its investment in PACT preferred stock is approximated by the fair value of the PACT business since the Company is the only party invested in PACT Series D convertible preferred stock, the most senior class of stock issued by PACT, as of October 1, 2022. The fair value of PACT was estimated at $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-633">2.9</ix:nonFraction>&#160;million as of October 1, 2022 using the cost approach. Under this approach, the fair value of an asset is measured by the cost to reconstruct or replace such asset with another one of like utility. The fair value of PACT was estimated by using significant unobservable inputs, including an estimate of insignificant fair value associated with PACT intangible assets. Accordingly, the Company classified the fair value measurement of PACT Series D convertible preferred stock on October 1, 2022 as Level 3 under the fair value hierarchy. In connection with the preparation of the financial statements for the three and six months ended June 30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment, resulting in the impairment of the $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-634"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-635">2.9</ix:nonFraction></ix:nonFraction>&#160;million PACT Series D convertible preferred stock investment. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details regarding the PACT investment impairment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="f-636" continuedAt="i91b2cf560b8f4064ba6c09e44875c4c6" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-637" continuedAt="ie584c37e01bd43abbefad4f854183997" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i91b2cf560b8f4064ba6c09e44875c4c6"><ix:continuation id="ie584c37e01bd43abbefad4f854183997"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-638" escape="true"><ix:nonNumeric contextRef="c-1" name="lyel:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-639" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of June&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining six months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-640">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-641">11,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-642">11,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-643">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-644">12,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lyel:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-645">35,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-646">89,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-647">23,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-648">66,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of June&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-649">5,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-650">60,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-651">66,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all operating leases were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-652">2.3</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-653">2.2</ix:nonFraction>&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-654">4.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-655">4.7</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June&#160;30, 2023 and 2022. Variable lease costs for operating leases were $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-656">1.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-657">1.2</ix:nonFraction>&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-658">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-659">2.5</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-660">7.3</ix:nonNumeric>&#160;and <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-661">7.8</ix:nonNumeric>&#160;years as of June&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted-average discount rates for operating leases were <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-662"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-663">8.5</ix:nonFraction></ix:nonFraction>% as of both June&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-181" decimals="-3" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-664">11,000</ix:nonFraction> square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-665"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-666">0.2</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended June&#160;30, 2023 and 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-667"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-668">0.4</ix:nonFraction></ix:nonFraction>&#160;million for both the six months ended June&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#8220;Sonoma&#8221;), a related party, whereby the Company agreed to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-186" decimals="-3" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-669">18,000</ix:nonFraction> square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a part of the sublease, in September 2021, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="f-670">4.6</ix:nonFraction>&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-671"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-672">0.5</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended June&#160;30, 2023 and 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-673"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-674">0.9</ix:nonFraction></ix:nonFraction>&#160;million for both the six months ended June&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-675" continuedAt="i3fe214dee4044a56b9e3e7ea55f01102" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i3fe214dee4044a56b9e3e7ea55f01102"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-676">10.0</ix:nonFraction>&#160;million shares of preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-677">0.0001</ix:nonFraction> per share. As of June&#160;30, 2023 and December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-678"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-679">no</ix:nonFraction></ix:nonFraction> shares of preferred stock were outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-680">500.0</ix:nonFraction>&#160;million shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-681">0.0001</ix:nonFraction> per share. As of June&#160;30, 2023 and December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-682">251,026,997</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-683">249,567,343</ix:nonFraction> shares of the Company&#8217;s common stock outstanding, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;4, 2022, the Company entered into an Equity Distribution Agreement with Goldman Sachs &amp; Co. LLC (&#8220;Goldman Sachs&#8221;) and BofA Securities, Inc. (&#8220;BofA&#8221;, and together with Goldman Sachs, the &#8220;Agents&#8221;) with respect to an at-the-market offering program (the &#8220;Equity Distribution Agreement&#8221;). In accordance with the terms of the Equity Distribution Agreement, the Company may offer and sell from time to time through the Agents shares of the Company&#8217;s common stock having an aggregate offering amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="INF" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-684">200.0</ix:nonFraction>&#160;million (the &#8220;Placement Shares&#8221;). Sales of the Placement Shares, if any, will be made at prevailing market prices on Nasdaq at the time of sale, or as otherwise agreed with the Agents, by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule&#160;415 of the Securities Act of 1933, as amended. The Company will pay commissions to the Agents of up to <ix:nonFraction unitRef="number" contextRef="c-192" decimals="INF" name="lyel:PercentageOfCommissionFromEachSaleOfShares" scale="-2" id="f-685">3.0</ix:nonFraction>% of the gross proceeds of the sale of the Placement Shares sold under the Equity Distribution Agreement and reimburse the Agents for certain expenses. Neither the Company nor the Agents are obligated to sell any shares and, to date, the Company has not made any sales under the Equity Distribution Agreement.</span></div></ix:continuation><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-686" continuedAt="i95474267d65d4837ad9d7a0462fe7d23" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="i95474267d65d4837ad9d7a0462fe7d23" continuedAt="iceda019723bd45838f2a1633858cb8ff"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;), which on the date of the underwriting agreement related to the Company&#8217;s IPO became effective with an initial reserve of <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-687">26,662,087</ix:nonFraction> shares, plus any shares subject to outstanding awards granted under the 2018 Equity Incentive Plan (&#8220;2018 Plan&#8221;) that, on or after the effectiveness of the 2021 Plan, terminate or expire before exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved for issuance under the 2021 Plan automatically increases on January&#160;1 of each year for a period of <ix:nonNumeric contextRef="c-194" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-688">ten years</ix:nonNumeric>, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1)&#160;<ix:nonFraction unitRef="number" contextRef="c-194" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="f-689">5</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by the Company&#8217;s board of directors no later than December&#160;31 of the immediately preceding year. On January&#160;1, 2023, the Company reserved an additional <ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-690">12,478,367</ix:nonFraction> shares of common stock for issuance under the 2021 Plan representing <ix:nonFraction unitRef="number" contextRef="c-195" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" scale="-2" id="f-691">5</ix:nonFraction>% of the total common shares outstanding as of December&#160;31, 2022. Under the 2021 Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), stock appreciation rights, performance awards and other stock-based awards. Terms of stock awards, including vesting requirements, are determined by the Company&#8217;s board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2021 Plan. The term of any stock option granted under the 2021 Plan cannot exceed <ix:nonNumeric contextRef="c-196" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-692">ten years</ix:nonNumeric>. Generally, awards granted by the Company vest over <ix:nonNumeric contextRef="c-194" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-693">four years</ix:nonNumeric> but may be granted with different vesting terms. In conjunction with adopting the 2021 Plan, the Company discontinued the 2018 Plan with respect to new equity awards.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-694">25,280,983</ix:nonFraction> shares were available for future issuance pursuant to the 2021 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Employee Stock Purchase Plan (&#8220;2021 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#8217;s IPO with an initial reserve of <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-695">2,470,000</ix:nonFraction> shares. The 2021 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="c-198" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-696">15</ix:nonFraction>% of their earnings, subject to plan limitations. Unless otherwise determined by the Company&#8217;s board of directors, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="c-199" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-697">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering or on the purchase date. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2021 ESPP automatically increases on January&#160;1 of each year for a period of <ix:nonNumeric contextRef="c-199" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-698">ten years</ix:nonNumeric>, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (1)&#160;<ix:nonFraction unitRef="number" contextRef="c-199" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="f-699">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, and (2)&#160;<ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="f-700">4,940,000</ix:nonFraction> shares; provided, however, that the Company&#8217;s board of directors may act to provide a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><ix:continuation id="iceda019723bd45838f2a1633858cb8ff" continuedAt="i08c86eeef083427f8ed5a077da6462ec"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lesser increase in number of shares. The Company&#8217;s board of directors elected to reserve no additional shares under the 2021 ESPP for the year beginning January&#160;1, 2023. The Company may specify offerings with durations not more than <ix:nonNumeric contextRef="c-199" name="lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" format="ixt-sec:durmonth" id="f-701">27</ix:nonNumeric>&#160;months and may specify shorter purchase periods within each offering. Under the 2021 ESPP, <ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-702"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-703">542,921</ix:nonFraction></ix:nonFraction> shares were issued for the three and six months ended June&#160;30, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-202" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-704"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-705">283,574</ix:nonFraction></ix:nonFraction>&#160;shares were issued for the three and six months ended June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-204" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-706">3,905,099</ix:nonFraction> shares were available for future issuance pursuant to the 2021 ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company established the 2018&#160;Plan that provided for the grant of incentive stock options, non&#8209;statutory stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. Terms of stock awards, including vesting requirements, were determined by the board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2018&#160;Plan. The term of any stock option granted under the 2018&#160;Plan cannot exceed <ix:nonNumeric contextRef="c-205" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-707">ten years</ix:nonNumeric>. Generally, awards granted by the Company vest over <ix:nonNumeric contextRef="c-205" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-708">four years</ix:nonNumeric>, but could have been granted with different vesting terms. Pursuant to the terms of the 2021&#160;Plan, any shares subject to outstanding options originally granted under the 2018&#160;Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof become available for issuance pursuant to awards granted under the 2021&#160;Plan. While <ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="f-709">no</ix:nonFraction> shares are available for future issuance under the 2018&#160;Plan, it continues to govern outstanding equity awards granted thereunder.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-710" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-711">5,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-712">4,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-713">9,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-714">7,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-715">8,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-716">18,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-717">18,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-718">36,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-719">14,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-720">22,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-721">28,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-722">44,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023, total stock-based compensation cost related to unvested awards not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-723">81.6</ix:nonFraction>&#160;million, which is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-724">2.86</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><ix:continuation id="i08c86eeef083427f8ed5a077da6462ec" continuedAt="if9fef5e6efcd434d809b8e3682b1eb68"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="f-725" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-726">872,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-727">5.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-728">1,997,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-216" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-729">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-730">127,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-216" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-731">5.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-732">117,669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-216" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-733">4.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of June&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-217" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-734">2,623,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-217" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-735">3.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-736" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-737">53,849,045</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-738">5.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-218" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-739">7.84</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-740">24,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-741">8,586,063</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-742">2.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-743">832,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-744">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-745">2,959,671</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-746">5.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-747">58,642,597</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-748">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-749">7.73</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-750">26,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options exercisable as of June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-751">30,365,614</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-752">4.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-753">6.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-754">18,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-755" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-756">4.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-757">2.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-758">92.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-759">85.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-760">5.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-761">5.98</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-762">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-763">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if9fef5e6efcd434d809b8e3682b1eb68">The weighted-average grant date fair value of options granted for the six months ended June&#160;30, 2023 and 2022 were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-764">1.72</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-765">4.27</ix:nonFraction> per share, respectively.</ix:continuation> </span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-766" continuedAt="i08ed2811827248118f978916ad8c4c5b" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i08ed2811827248118f978916ad8c4c5b">Basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#8217;s potentially dilutive shares, which include unvested RSAs, unvested RSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Shares subject to options to purchase common stock, unvested RSAs and unvested RSUs were all excluded from consideration in the calculation of diluted net loss per share in all periods presented due to their anti-dilutive effects.</ix:continuation> </span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-767" continuedAt="i784a3751e9614d19b660628c85289cc4" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i784a3751e9614d19b660628c85289cc4" continuedAt="i27abadf27cb9428885af623f980a921d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into certain license and collaboration agreements, including those identified in Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial milestones. The Company&#8217;s </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i27abadf27cb9428885af623f980a921d">obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs, including termination of such agreements. Due to the nature of these agreements, the future potential payments are inherently uncertain, and accordingly no amounts had been recorded for the potential future achievement of these targets as of both June&#160;30, 2023 and December&#160;31, 2022.</ix:continuation></span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-768" continuedAt="i91d15689af0e4b49af2ad872a9d3d667" escape="true">Related-party Transactions</ix:nonNumeric></span></div><ix:continuation id="i91d15689af0e4b49af2ad872a9d3d667" continuedAt="i465564df85c24db09f9eb15d9ba63143"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma (&#8220;Sonoma Sublease&#8221;), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="c-187" decimals="-3" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-769">18,000</ix:nonFraction> square feet of space in South San Francisco, California currently leased by the Company. Dr.&#160;Klausner, the Chair of the Company&#8217;s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="f-770">4.6</ix:nonFraction>&#160;million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both June&#160;30, 2023 and December&#160;31, 2022, there were accrued liabilities and other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-771"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-772">0.5</ix:nonFraction></ix:nonFraction>&#160;million, and as of June&#160;30, 2023 and December&#160;31, 2022, there were other non-current liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-773">3.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-774">3.5</ix:nonFraction>&#160;million, respectively, in connection with the Sonoma Sublease. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="f-775" continuedAt="i0b9d64fa30de41e3b34c73c8dfd88ab7" escape="true">Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#8220;other operating income, net&#8221; such as common area maintenance charges. See Note&#160;7, </ix:nonNumeric></span><ix:continuation id="i0b9d64fa30de41e3b34c73c8dfd88ab7" continuedAt="ibca3b2ec79154d909af3fca351e2bb5d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more detail on the Sonoma Sublease.</span></ix:continuation></div><div style="margin-top:6pt"><ix:continuation id="ibca3b2ec79154d909af3fca351e2bb5d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma other operating income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-776">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-777">658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-778">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-779">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma sublease income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-780">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-781">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-782">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-783">931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i465564df85c24db09f9eb15d9ba63143" continuedAt="id14eb8858f2f44818ba9d83bfae927f4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was party to the GSK Agreement with GSK, which is a holder of more than <ix:nonFraction unitRef="number" contextRef="c-221" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-784">10</ix:nonFraction>% of the Company&#8217;s outstanding common stock. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id14eb8858f2f44818ba9d83bfae927f4">. GSK terminated the GSK Agreement effective December&#160;24, 2022. The Company had <ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="f-785"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="f-786">no</ix:nonFraction></ix:nonFraction> current or non-current deferred revenue in connection with the GSK Agreement as of both June&#160;30, 2023 and December&#160;31, 2022. Revenue recognized in connection with the GSK agreement was <ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-787">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-788">35.7</ix:nonFraction>&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and <ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-789">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-790">36.3</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited Condensed Consolidated Financial Statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and analysis and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives and expectations for our business. Our actual results and the timing of selected events could differ materially from those described in or implied by these forward-looking statements as a result of several factors, including those set forth in the section titled &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form 10-Q. See also the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_103"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing our proprietary ex vivo genetic and epigenetic T&#8209;cell reprogramming technologies. Our investigational therapies use the patient&#8217;s own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to defeat solid tumors. Our innovative reprogramming technologies address what we believe are the primary barriers that limit consistent and long-lasting responses to T&#8209;cell therapy in solid tumors: T&#8209;cell exhaustion and lack of durable stemness. Our technologies are designed to generate T cells with the ability to persist and self&#8209;renew while driving durable tumor cytotoxicity, even in the setting of an immunosuppressive tumor microenvironment. Our goal is to provide patients with T cells that are potent and long-lasting to achieve durable antitumor responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technologies can be applied in a target agnostic manner to multiple T&#8209;cell modalities, including chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T&#8209;cell receptor (TCR) therapies. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply our technologies with the aim to develop T&#8209;cell therapies with improved and durable clinical outcomes. Our growing pipeline of promising cell product candidates targets solid tumor indications with large unmet needs that are collectively responsible for approximately 180,000 deaths in the US annually. Each of our programs provide opportunities to expand into additional indications beyond the patient populations we are initially targeting. Our lead product candidates are summarized in the table below:</span></div><div style="margin-top:6pt;text-align:center"><img src="lyel-20230630_g1.jpg" alt="10K_2022_Pipeline_v3.jpg" style="height:324px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in June 2018. Our primary activities to date have included developing T-cell therapies, performing research and development, acquiring technology, entering into strategic collaboration and license agreements, enabling and executing manufacturing activities in support of our product candidate development efforts, organizing and staffing our company, business planning, establishing our intellectual property portfolio, making regulatory submissions and other preparations to initiate and execute clinical trials, raising capital and providing general and administrative support for these activities. We are early in our research and development efforts and are in Phase 1 clinical development of LYL797, our ROR1 targeted CAR T-cell product candidate, and LYL845, our TIL product candidate. Two additional product candidates that each include novel genetic and epigenetic reprogramming technologies are in preclinical development: LYL119, a ROR1 targeted CAR T-cell product candidate and a second generation TIL product candidate. We do not have any products approved for sale. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenses and operating losses will increase substantially over the foreseeable future. The expected increase in expenses will be driven in large part by our ongoing activities, if and as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continue preclinical development of our current and future product candidates and initiate additional nonclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">commence and continue clinical trials of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">advance our genetic and epigenetic reprogramming technologies as well as other research and development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expand our manufacturing and process development capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek regulatory approval of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expand our operational, financial and management systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">attract, hire and retain qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acquire and license technology or technology platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continue to develop, protect and defend our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Programs and Operational Updates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Programs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing four wholly-owned product candidates, including two product candidates in Phase 1 clinical development, LYL797 and LYL845. Two additional product candidates, LYL119 and a second generation TIL product candidate, are in preclinical development. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL797 - A genetically and epigenetically reprogrammed ROR1 CAR T-cell product candidate designed for differentiated potency and durability targeting multiple solid tumor indications.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are applying our c-Jun and Epi&#8209;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technologies to our lead CAR T&#8209;cell product candidate, LYL797, which is expected to be an intravenously&#8209;administered CAR T&#8209;cell product targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) protein. ROR1 is a fetal protein expressed during embryogenesis and is believed to be important in cell migration, polarity and survival. It is expressed in several cancer types, including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), ovarian cancer and chronic lymphocytic leukemia, and is generally associated with a poor prognosis. LYL797 contains a CAR with a 4-1BB/CD3&#950; intracellular domain, a transmembrane domain, an optimized spacer domain and a single-chain variable fragment (scFv) derived from an R12 rabbit monoclonal antibody that recognizes and binds with high specificity to human ROR1. LYL797 also incorporates c-Jun overexpression and a proprietary optimized truncated version of human EGFR (EGFR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">opt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) used for tracking the CAR T cells in the peripheral blood post treatment and can also be used as a safety measure with the administration of cetuximab, if needed. LYL797 is manufactured utilizing our proprietary Epi&#8209;R technology.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are initially developing LYL797 for the treatment of ROR1-positive TNBC and NSCLC. Significant subsets of patients with common cancers express ROR1, including TNBC (~60%) and NSCLC (~40%), two of the highest ROR1&#8209;expressing solid tumor indications. If successful, we may expand into other ROR1-positive cancers with a lower incidence of ROR1 expression, including potentially hormone-receptor positive breast cancer, ovarian and other solid tumors. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Enrollment in the Phase&#160;1 clinical trial of LYL797 is ongoing. The study includes patients with relapsed or refractory triple-negative breast cancer or non-small cell lung cancer and is now open at 14 sites. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initial clinical data from the Phase&#160;1 trial of LYL797 are expected in the first half of 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The Phase&#160;1 clinical trial is designed as an open label, dose escalation and expansion trial in patients with relapsed/refractory TNBC who have failed at least two lines of therapy and patients with relapsed/refractory NSCLC who have failed at least one line of therapy. The study will enroll at least 15 patients each with relapsed or refractory TNBC or with NSCLC in the expansion phase of the study.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The Lyell START (Study of Tumor target Analysis for Referrals to Trials) ROR1 biomarker screening protocol was initiated in June 2023 to support the ongoing LYL797 Phase 1 trial, as well as potential future trials with LYL797 and our next-generation ROR1-targeted product candidate, LYL119. START provides a decentralized mechanism for patients anywhere in the United States to have their collected tumor tissue screened for ROR1 expression and, for ROR1 positive patients, be referred to clinical study sites.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL845 - A novel epigenetically reprogrammed TIL product candidate designed for differentiated potency and durability targeting multiple solid tumor indications. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are applying our Epi&#8209;R technology to our lead TIL product candidate, LYL845, which is expected to be an intravenously&#8209;administered autologous TIL therapy for multiple solid tumors. Our Epi&#8209;R manufacturing protocols comprise proprietary media, optimized cytokine compositions and well-defined cell activation and expansion protocols used during our manufacturing process.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TIL have previously shown clinical benefit in patients with advanced melanoma and other solid tumors with high mutational burden. Published data from third-party TIL trials show that treating metastatic melanoma patients with TIL can result in complete and durable responses. Response rates to TIL therapy in patients with other advanced solid tumors such as lung, colorectal and breast have been much lower than those observed in advanced melanoma. Broad TIL efficacy has been limited by poor enrichment of tumor-reactive T cells and the poor quality and limited growth potential of expanded T cells. Failure to maintain polyclonality of TIL during production may also limit their ability to eradicate cancer cells given the inherent heterogeneous nature of solid tumors. LYL845 incorporates our Epi&#8209;R technology that has been shown to generate TIL product with characteristics that have previously been associated with improved response rate, including a higher percentage of cytotoxic T cells and stemness phenotypes. We have also demonstrated that our Epi-R process led to enhanced T-cell potency and maintenance of tumor-reactive polyclonality in nonclinical experiments. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are initially developing LYL845 for advanced melanoma, NSCLC and colorectal cancer (CRC). Based on our success with those indications, we may include patients with other solid tumors, potentially including head and neck, cervical, breast and pancreatic cancer. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enrollment in the Phase 1 clinical trial for LYL845 is ongoing. The study includes patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC and CRC and is now open at nine sites. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initial clinical data from the Phase 1 trial of LYL845 are expected in 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase&#160;1 clinical trial is designed as an open label, dose escalation and expansion trial in patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC and CRC. The study will enroll at least 15 patients each with advanced melanoma, and relapsed or refractory NSCLC or CRC in the expansion phase of the study. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYL119 - An innovative ROR1 CAR T-cell product designed for enhanced cytotoxicity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key pillar of our strategy is to continually innovate to develop and advance novel, breakthrough technologies that address key barriers to successful cell therapy for solid tumors. We have advanced a new genetic reprogramming technology, NR4A3 knockout, and a new epigenetic reprogramming technology, Stim&#8209;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that are being applied in our next CAR T-cell product candidate, LYL119. These technologies are stackable and complementary to c-Jun and Epi&#8209;R and are designed to further improve the antitumor potency and durability of T cells. LYL119 is being advanced with the goal of potentially creating even greater benefit for patients with ROR1-positive solid tumors. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An investigational new drug (IND) application is expected to be submitted for LYL119 in the first half of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">T&#8209;cell rejuvenation technologies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and others have documented the impact of aging on T&#8209;cell function, which begins to decline after puberty, and at an increasingly accelerated rate after age 65. Morbidity and mortality from cancer also increase with age. Thus, we are working to advance another novel reprogramming technology that focuses on rejuvenation of antitumor T cells. We are developing a method to maintain T&#8209;cell identity while reducing the epigenetic age of the cells. This technology is currently in the research stage. We have generated data illustrating the ability to &#8220;turn back&#8221; the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epigenetic clock in a process called cellular rejuvenation, without changing the T&#8209;cell&#8217;s identity as would occur in the setting of induced pluripotent stem cell-derived T cells.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data demonstrating that T cells rejuvenated with Lyell&#8217;s technology have improved expansion capacity and increased expression of biomarkers associated with T-cell stemness, and also exhibit improved antitumor properties compared with non-rejuvenated T-cell controls in sequential cell-killing assays, were presented at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting on June 14th in Boston, MA. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Manufacturing Capabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe it is critically important to control and continuously monitor all aspects of the cell therapy manufacturing process to mitigate risks, including challenges in managing production, supply chain, patient specimen chain of custody and quality control. As we developed our technologies, we made a strategic decision to invest in building our own manufacturing facility to control our supply chain, maximize efficiencies in cell product production time, optimize cost and quality, and have the ability to rapidly incorporate disruptive advancements and new innovations. Controlling manufacturing also enables us to protect proprietary aspects of our reprogramming technologies. We view our manufacturing team and capabilities as a significant competitive advantage.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our LyFE&#8482; manufacturing center located in Bothell, Washington is approximately 73,000 square feet and is comprised of manufacturing suites, laboratories and offices. LyFE is commissioned and designed to be in compliance with U.S. and European Union current Good Manufacturing Practices (cGMP) standards and has a flexible and modular design enabling CAR T cell, TIL, TCR T cell and GMP viral vector production to control and de-risk the manufacturing sequence and timing of the major components of our supply chain. Owning our own facility has enabled seamless collaboration across research, process development and manufacturing for high-quality reproducibility at manufacturing scale.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently producing clinical supply for our Phase&#160;1 trials at LyFE. At full staffing and capacity, we expect to be able to manufacture approximately 500 infusions per year depending on product candidate mix. At this time, we believe this capacity is sufficient to support our pipeline programs into pivotal trials and, if approved, early commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Environment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and operations may be affected by worldwide economic conditions, which may continue to be impacted by global macroeconomic challenges such as the effects of the ongoing geopolitical conflicts in Ukraine, tensions in U.S.-China relations, the lingering effects of the COVID-19 pandemic, inflationary pressures, interest rate environment, instability in the banking industry and overall market volatility. Fiscal year 2022 and the first half of 2023 were marked by significant market uncertainty, increasing inflationary pressures, banking turmoil, supply constraints and lingering effects from the COVID-19 pandemic. These market dynamics may continue in the rest of 2023, and these and similar adverse market conditions may negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of trends, uncertainties and other factors that could impact our operating results, see the section entitled &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for sale and have never generated any revenue from product sales.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated revenue primarily from the recognition of the upfront payment under the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (GSK Agreement) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together, GSK). GSK terminated the GSK Agreement effective December 2022, and we do not expect further revenue from the collaboration. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10&#8209;Q, for additional details regarding termination of the GSK Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate additional revenue from other collaborations, strategic alliances, licensing agreements, product sales, or a combination of these.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, research and development expenses consist of costs incurred by us for the discovery and development of our technology platforms and product candidates and include costs incurred in connection with strategic collaborations, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs to license technology, personnel-related costs, including stock-based compensation expense, facility and technology related costs, research and laboratory expenses, as well as other expenses, which include consulting fees and other costs. Upfront payments and milestones paid to third parties in connection with technology platforms that have not reached technological feasibility and do not have an alternative future use are expensed as incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses also include non-cash expenses related to the change in the estimated fair value of the success payment obligations over their respective requisite service terms granted to Fred Hutchinson Cancer Center (Fred&#160;Hutch) and The Board of Trustees of the Leland Stanford Junior University (Stanford). As of December&#160;31, 2022, Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. For the three and six months ended June&#160;30, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other (expense) income, net, as the requisite service obligation had been met. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10&#8209;Q. Research and development expenses related to our success payment liabilities are unpredictable and may vary significantly from quarter&#8209;to&#8209;quarter and year&#8209;to&#8209;year due to changes in our assumptions used in the calculation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deploy our employee and infrastructure resources across multiple research and development programs for identifying and developing product candidates and establishing manufacturing capabilities. Due to the stage of development and number of ongoing programs and our ability to use resources across several programs, most of our research and development costs are not recorded on a program-specific basis. These include costs for personnel, laboratory and other indirect facility and operating costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities account for a significant portion of our operating expenses. We anticipate that our research and development expenses will increase over the foreseeable future as we expand our research and development efforts including completing nonclinical studies, commencing planned clinical trials, conducting and completing current and planned clinical trials, seeking regulatory approval of our product candidates, identifying new product candidates and incurring costs to acquire and license technology platforms. A change in the outcome of any of these variables could mean a significant change in the costs and timing associated with the development of our product candidates. Because we are early in our research and clinical development efforts of our product candidates, and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the nonclinical development, clinical development and commercialization of product candidates or whether, or when, we may achieve profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses may vary significantly based on factors such as:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number and scope of nonclinical and IND-enabling studies;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of trials required for approval;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of sites included in the trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the countries in which the trials are conducted;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of patients that participate in the trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">potential additional safety monitoring requested by regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the duration of patient participation in the trials and follow-up;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost and timing of manufacturing our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the phase of development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the efficacy and safety profile of our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the extent to which we establish additional collaboration or license agreements; and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether we choose to partner any of our product candidates and the terms of such partnership.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may never succeed in obtaining regulatory approval for any of our product candidates. We may obtain unexpected results from our nonclinical studies and clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative costs include personnel-related expenses, including stock-based compensation expense for personnel in executive, legal, finance and other administrative functions, legal costs, transaction costs related to collaboration and licensing agreements, as well as fees paid for accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expenses. Legal costs include those related to corporate, dispute and patent matters.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase over the foreseeable future to support our continued research and development activities, operations generally, future business development opportunities, consulting fees, as well as due to the increased costs of operating as a public company such as costs related to accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission (SEC) requirements, director and officer insurance costs and investor and public relations costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income, net consists primarily of service and occupancy fees received associated with subleases as well as losses on the retirement of property and equipment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net consists primarily of interest earned on our cash, cash equivalents and marketable securities balances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net consists primarily of the change in fair value associated with our success payment liabilities to Fred Hutch for three and six months ended June&#160;30, 2023 and primarily of changes in the fair value of an equity warrant investment held for the three and six months ended June&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Other Investments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other investments consists of a reduction in the value of certain other investments.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three and Six Months Ended June&#160;30, 2023 and 2022</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods presented (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"><tr><td style="width:1.0%"></td><td style="width:29.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(35,714)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(36,202)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">47,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">43,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">92,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">79,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">19,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">30,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(11,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">38,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">64,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(26,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">65,932&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73,002&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,070)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">128,553&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">142,131&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(13,578)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(65,905)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(37,261)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(28,644)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(128,461)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(105,837)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(22,624)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,264&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">952&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,312&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,761&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,349&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,412&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Impairment of other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(12,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(12,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total other income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,015&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">938&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,077&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,388)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,370&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3,758)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(63,890)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(36,323)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(27,567)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(130,849)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(104,467)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(26,382)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue was approximately zero and $35.7&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $0.1&#160;million and $36.3&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The GSK </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement was terminated in December 2022 and, therefore, no further research and development pursuant to the GSK Agreement was performed in the first half of 2023, which drove the decreases in revenue of $35.7 million and $36.2&#160;million, respectively, for the three and six months ended June&#160;30, 2023. The revenue for the three and six months ended June&#160;30, 2022 was primarily due to a $35.3&#160;million revenue adjustment recorded in 2022 due to a change in estimate in connection with the GSK Agreement due to a mutual agreement with GSK to conclude research activities on an undisclosed target for hematological cancers. The change in estimate decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements &#8211; GSK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q for additional information about the termination of the GSK Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our research and development expenses for the periods presented (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Personnel</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">17,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">41,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">34,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Facilities and technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">13,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">26,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">25,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research activities, collaborations and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">23,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">20,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">47,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">43,719&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,752&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">92,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">79,549&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $47.5&#160;million and $43.7&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively. The increase of $3.8&#160;million was primarily due to an increase of $4.7&#160;million in personnel&#8209;related expenses principally related to an increase in headcount to expand our research, development and manufacturing capabilities; a decrease of $3.0&#160;million associated with our success payment liabilities, noting $2.2&#160;million of the change was due to recognizing the Fred Hutch success payment liability fair value change in other (expense) income, net for the three months ended June&#160;30, 2023 and the remaining $0.8&#160;million was due to the decrease in the Stanford success payment liability driven by the decrease in our stock price; an increase of $1.2&#160;million in research activities, collaborations and outside services primarily driven by an increase in research and laboratory costs principally due to clinical trials, partially offset by a reduction in professional services and collaborations and license fees and expenses primarily related to the completion of certain sponsored research agreements; and an increase of $0.9&#160;million in facilities and technology costs primarily related to increased infrastructure to support our expansion in research and development, manufacturing capabilities and associated headcount growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $92.1&#160;million and $79.5&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The increase of $12.6&#160;million was primarily due to an increase of $7.8&#160;million in personnel-related expenses, that was principally related to an increase in headcount to expand our research, development and manufacturing capabilities to support increases in clinical trial enrollment; an increase of $3.4&#160;million in research activities, collaborations and outside services primarily driven by an increase in research and laboratory costs principally due to clinical trials, partially offset by a reduction professional services and in collaboration and license fees expenses primarily related to the completion of certain sponsored research agreements; an increase of $1.2&#160;million in facilities and technology costs primarily related to increased infrastructure to support our expansion in research and development, manufacturing capabilities and associated headcount growth; and an increase of $0.3&#160;million in expense associated with our success payment liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $19.0&#160;million and $30.5&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively. The decrease of $11.4&#160;million was primarily due to a decrease of $9.3&#160;million in stock-based compensation expense, primarily related to significant awards being fully expensed, a decrease of $1.2&#160;million in outside services primarily due to a decrease in legal and consulting expenses and a decrease of $0.6 million in other administrative expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $38.3&#160;million and $64.9&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The decrease of $26.6&#160;million was primarily due to a decrease of $18.3&#160;million in stock-based </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation expense, primarily related to significant awards being fully expensed, a decrease of $6.8&#160;million in outside services attributed to lower legal and consulting expenses and a decrease of $1.3&#160;million in other administrative expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income, net was $0.6&#160;million and $1.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $1.9&#160;million and $2.3&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net was $5.3&#160;million and $1.0&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $9.8&#160;million and $1.3&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The increase in interest income, net was primarily driven by higher interest rates in 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net was $(0.3)&#160;million and approximately zero for the three months ended June&#160;30, 2023 and 2022, respectively, and $0.8&#160;million and approximately zero for the six months ended June&#160;30, 2023 and 2022, respectively. The changes in other (expense) income, net were primarily due to the change in fair value associated with our success payment liabilities to Fred Hutch for the three and six months ended June&#160;30, 2023; the fair value changes of Fred Hutch success payment liabilities are recognized in other (expense) income, net for the three and six months ended June&#160;30, 2023 as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration as of December 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Other Investments </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2023, the $2.9 million impairment of other investments consisted of the full impairment of our investment in PACT Pharma, Inc. (PACT) Series D convertible preferred stock. For the six months ended June&#160;30, 2023, the $12.9 million impairment of other investments consisted of the full impairment of our investment in PACT Series D convertible preferred stock and one of our other investments. See Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10&#8209;Q, for additional details regarding the impairments of other investments.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_115"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have funded our operations primarily through the sale and issuance of convertible preferred stock, the sale of common stock in connection with our initial public offering (IPO) and business development activities. As of June&#160;30, 2023, we had $632.7&#160;million in cash, cash equivalents and marketable securities. Since our inception, we have incurred significant operating losses. We have not yet commercialized any product candidates, and we do not expect to generate revenue from sales of any product for a number of years, if ever. We had an accumulated deficit of $898.3&#160;million as of June&#160;30, 2023. From June 29, 2018 (inception) through June&#160;30, 2023, we raised an aggregate of $1,405.7&#160;million in gross proceeds from the sales of our convertible preferred stock prior to the IPO and sales of our common stock in the IPO.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;4, 2022, we entered into an Equity Distribution Agreement (the Equity Distribution Agreement) with Goldman Sachs &amp; Co. LLC (Goldman Sachs) and BofA Securities, Inc. (BofA, and together with Goldman Sachs, the Agents) with respect to an at-the-market offering program. In accordance with the terms of the Equity Distribution Agreement, we may offer and sell from time to time, through the Agents, shares of our common stock having an aggregate offering amount of up to $200.0&#160;million (the Placement Shares). Sales of the Placement Shares, if any, will be made at prevailing market prices on Nasdaq at the time of sale, or as otherwise agreed with the Agents, by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule&#160;415 of the Securities Act of 1933, as amended (the Securities Act). We will pay commissions to the Agents of up to 3.0% of the gross proceeds of the sale of the Placement Shares sold under the Equity Distribution Agreement and reimburse the Agents for certain expenses. Neither us nor the Agents are obligated to sell any shares and, to date, we have not made any sales under the Equity Distribution Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur additional losses in the foreseeable future as we conduct and expand our research and development efforts, including conducting nonclinical studies and clinical trials, developing new product candidates, establishing manufacturing capabilities and funding our operations generally. Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to meet our working capital and capital expenditure needs into 2026. However, we anticipate that we will need to raise additional capital in the future to fund our operations, including further development of our product candidates and the commercialization of any approved </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates. In addition, we regularly consider fund-raising opportunities and may decide, from time to time, to raise additional capital, including pursuant to the Equity Distribution Agreement, based on various factors, including market conditions and our plans of operation. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope, timing, progress, costs and results of discovery, nonclinical development and clinical trials for our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of clinical trials required for regulatory approval of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs, timing and outcome of regulatory review of any of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of manufacturing clinical and commercial supplies of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">further investment to build additional manufacturing facilities or expand the capacity of our existing ones;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to maintain existing, and establish new, collaborations, licenses, product acquisitions or other strategic transactions and the fulfillment of our financial obligations under any such agreements, including the timing and amount of any success payment, future contingent payments, milestone, royalty or other payments due under any such agreement;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expenses to attract, hire and retain skilled personnel;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs of operating as a public company;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">addressing any potential interruptions or delays resulting from factors related to any lingering effects of the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">addressing or responding to any potential disputes or litigation; and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the extent to which we acquire or invest in businesses, products and technology platforms.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we complete nonclinical and clinical development and receive regulatory approval of our product candidates and can generate significant revenue from product sales, if ever, we expect to finance our operations from the sale of additional equity or debt financings, or other capital that may come in the form of strategic collaborations, licensing, or other arrangements. In the event that additional capital is required, we may not be able to raise it on terms acceptable to us, or at all. If we raise additional funds through the issuance of equity or convertible debt securities, including pursuant to the Equity Distribution Agreement, it may result in dilution to our existing stockholders. Debt financing or preferred equity financing, if available, may result in increased fixed payment obligations, and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations. If we raise funds through strategic collaboration, licensing, or other arrangements, we may relinquish significant rights or grant licenses on terms that are not favorable to us. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from any lingering effects of the COVID-19 pandemic, actual or perceived changes in interest rates and economic inflation, the current or anticipated impact of geopolitical instability and otherwise. If we are unable to raise additional capital when desired, our business, results of operations and financial condition would be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually evaluate our liquidity and capital resources to ensure that we can adequately and efficiently finance our operations. As of June&#160;30, 2023, our material cash requirements consisted primarily of paying salaries and benefits, conducting clinical trials and research, improving our manufacturing capabilities, providing the technology and facilities necessary to support our operations, funding operating lease obligations and other payments related to our collaborative agreements, including anticipated success payments and license fees. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q, for additional information.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_118"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(85,373)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(92,185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">185,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">100,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(88,276)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2023, net cash used in operating activities was $85.4&#160;million, reflecting our net loss of $130.8&#160;million, partially offset by $46.2&#160;million of non-cash items primarily related to stock-based compensation of $28.1&#160;million, impairment of other investments of $12.9&#160;million and depreciation and amortization of $10.1&#160;million, partially offset by net amortization and accretion on marketable securities of $3.9&#160;million and non-cash lease income of $0.8&#160;million. Additionally, net operating assets and liabilities decreased $0.7&#160;million primarily driven by a $3.6&#160;million decrease in accrued liabilities and other current liabilities partially offset by a $2.4&#160;million increase in accounts payable and a $0.6 million increase in prepaid expenses, other current assets and other assets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, net cash used in operating activities was $92.2 million, reflecting our net loss of $104.5&#160;million, partially offset by non-cash items such as stock-based compensation expense of $44.4&#160;million and depreciation and amortization expense of $8.4&#160;million. Additionally, net operating assets and liabilities decreased $40.4&#160;million, primarily driven by a $36.3&#160;million decrease in deferred revenue and a $7.2&#160;million decrease in accrued liabilities and other current liabilities, offset by a $2.1&#160;million increase in operating lease liabilities and a $1.2&#160;million increase in accounts payable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2023, cash provided by investing activities was $185.1&#160;million, consisting of net maturities, sales and purchases of marketable securities of $187.5&#160;million offset by purchases of property and equipment of $2.5&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, cash used in investing activities was $1.1&#160;million, consisting of purchases of property and equipment of $16.9&#160;million offset by net maturities, sales and purchases of marketable securities of $15.8&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2023, cash provided by financing activities was $1.1&#160;million, consisting of proceeds from the employee stock purchase plan of $1.2&#160;million and proceeds from the exercise of stock options of $0.1&#160;million, partially offset by taxes paid related to the net share settlement of equity awards of $0.1&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, cash provided by financing activities was $5.0&#160;million, consisting of proceeds from the exercise of stock options of $4.1&#160;million and proceeds from the employee stock purchase plan of $0.9&#160;million.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we did not have, and we do not currently have, any off-balance sheet arrangements as defined under the applicable rules and regulations of the SEC.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_127"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited Condensed Consolidated Financial Statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these unaudited Condensed Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, as well as the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates as compared to those described in our Annual Report on Form 10&#8209;K for the year ended December&#160;31, 2022 (Annual Report).</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Our primary risks include interest rate sensitivities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash equivalents of $200.9&#160;million as of June&#160;30, 2023, which consisted of money market funds and highly liquid investments purchased with original maturities of three months or less from the purchase date. We also had marketable securities of $408.3&#160;million as of June&#160;30, 2023. The primary objective of our investment activities is to preserve capital to fund our operations, and we currently do not hedge our interest rate risk exposure. Because our marketable securities are primarily short-term in duration, we believe that our exposure to interest rate risk is not significant, and a hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material effect on our unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q. We had no debt outstanding as of June&#160;30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our employees and operations are currently located in the United States and our expenses are generally denominated in U.S. dollars. We therefore are not currently exposed to significant market risk related to changes in foreign currency exchange rates. However, we have contracted with and may continue to contract with non-U.S. vendors who we may pay in their local currency. Our operations may be subject to fluctuations in foreign currency exchange rates in the future. To date, foreign currency transaction gains and losses have not been material to our Condensed Consolidated Financial Statements, and we have not had a formal hedging program with respect to foreign currency. We believe a hypothetical 1% change in exchange rates during any of the periods presented would not have a material effect on our unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and our clinical trial costs. We believe that inflation has not had a material effect on our unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June&#160;30, 2023, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during the quarter ended June&#160;30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have been or may become involved in material legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not party to any legal proceedings material to our operations or of which any of our property is the subject, nor are we aware of any such proceedings that are contemplated by a government authority.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of outcome, any such proceedings or claims is subject to inherent uncertainties and can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_142"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business involves significant risks, some of which are described below. You should carefully consider the risks described below, as well as the other information contained in this Quarterly Report on Form 10-Q, including our unaudited Condensed Consolidated Financial Statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. The risk factors set forth below that are marked with an asterisk (*) contain substantive changes to the similarly titled risk factors included in, or did not appear as separate risk factors in, Item 1A of our Annual Report, which was filed with the SEC on February 28, 2023.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_145"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, follows this summary. This summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are an early clinical stage biopharmaceutical company and have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We operate in a rapidly evolving field and have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We currently have no products approved for sale and have never generated revenue from product sales. We may never generate revenue from product sales or achieve profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our success payment obligations in our success payment agreements may result in dilution to our stockholders or may be a drain on our cash resources to satisfy the payment obligations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are early in our research and clinical development efforts of our product candidates. If we are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business may be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our product candidates and technology platforms are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business could continue to be adversely affected by the effects of health epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We currently manufacture drug products for our clinical trials ourselves. Delays in further qualifying or in receiving regulatory approvals for any manufacturing facility or product candidates could delay our development plans and thereby limit our ability to generate product revenues.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The manufacturing of cellular therapies is very complex. We are subject to a multitude of manufacturing risks, including risks associated with supply chain complexity related to patient materials, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If a sole clinical or commercial manufacturing facility or any of our contract manufacturing organizations are damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may rely on third parties to manufacture our product candidates, which subjects us to risks and could delay or prevent our development and/or commercialization, if approved, of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We intend to rely on third parties to conduct, supervise and monitor a significant portion of our research and nonclinical studies and clinical trials for our product candidates, and, if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have in the past, and we may in the future, form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We depend on the enrollment and retention of patients in our current and planned clinical trials for our product candidates. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our cellular therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The results of research, nonclinical studies or earlier clinical trials are not necessarily predictive of future results. Any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Clinical development involves a lengthy and expensive process with an uncertain outcome.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have in-licensed a significant portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could potentially lose the ability to continue the development and potential commercialization of one or more of our product candidates.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_148"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early clinical stage biopharmaceutical company and have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to prove safe and effective, gain regulatory approval or become commercially viable. We are an early clinical stage biopharmaceutical company, and we do not have any products approved by regulatory authorities and have incurred significant research, development and other expenses related to our ongoing operations and expect to continue to incur such expenses. Since our inception, we have not generated any revenue from product sales and have incurred significant net losses. Substantially all of our net losses since inception have resulted from our research and development programs and general and administrative costs associated with our operations. As of June&#160;30, 2023, we had an accumulated deficit of $898.3&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate revenue from product sales for the foreseeable future, if at all. We also expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals for our product candidates, expand our manufacturing capabilities, in-license or acquire additional technologies and potentially begin to commercialize product candidates that may achieve regulatory approval. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period&#8209;to&#8209;period comparison of our results of operations may not be a good indication of our future performance. If any of our product candidates fails in research and development or clinical trials or does not gain regulatory approval, or, if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenses and operating losses will increase substantially over the foreseeable future. The expected increase in expenses will be driven in large part by our ongoing activities, if and as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continue nonclinical development of our current and future product candidates and initiate additional nonclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">commence and continue clinical trials of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">advance our genetic and epigenetic reprogramming technologies as well as other research and development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">attract, hire and retain qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek regulatory approval of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expand our manufacturing and process development capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expand our operational, financial and management systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acquire and license technology or technology platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continue to develop, protect and defend our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a rapidly evolving field and have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a rapidly evolving field and, having commenced operations in June 2018, have a limited operating history, which makes it difficult to evaluate our business and prospects. Our primary activities to date have included developing T&#8209;cell therapies, performing research and development, acquiring technology, entering into strategic collaboration and license agreements, enabling and executing manufacturing activities in support of our product candidate development efforts, organizing and staffing the company, business planning, establishing our intellectual property portfolio, regulatory submissions and other preparations to initiate and execute clinical trials, raising capital and providing general and administrative support for these activities. Any predictions about our future success, performance or viability, may not be as accurate as they could be if we had a longer operating history or approved products on the market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, any of our quarterly or annual periods&#8217; results are not indicative of future operating performance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no products approved for sale and have never generated revenue from product sales. We may never generate revenue from product sales or achieve profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenues from product sales. Our ability to generate revenues from product sales and achieve profitability will depend on our ability to successfully develop and subsequently obtain regulatory approval for and commercialize our product candidates. Our ability to generate revenues and achieve profitability also depends on a number of additional factors, including our ability to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully complete our research activities to identify the technologies and product candidates to further investigate in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully complete development activities, including the necessary clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">complete and submit regulatory submissions to the FDA, the European Medicines Agency (EMA) or other agencies and obtain regulatory approval for indications for which there is a commercial market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain coverage and adequate reimbursement from third parties, including government and private payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">set commercially viable prices for our products, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">develop manufacturing and distribution processes for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">produce commercial quantities of our products at acceptable cost levels;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintain adequate supply of our product candidates, including the starting materials and reagents needed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintain the supply of our product candidates in a manner that is compliant with global legal requirements or to the extent necessary;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establish and maintain manufacturing relationships with reliable third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">achieve market acceptance of our products, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">attract, hire and retain qualified personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">protect our rights in our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">develop a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves in the markets in which we choose to commercialize on our own; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">find suitable distribution partners to help us market, sell and distribute our approved products in other markets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues for any product for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. In addition, we anticipate incurring significant costs associated with commercializing any approved product. As a result, even if we generate revenue from product sales, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to expend substantial resources for the foreseeable future to advance and expand our research pipeline, conduct nonclinical studies and pursue clinical development and manufacturing of our product candidates. We also expect to continue to expend resources for the development of our technology platforms. These expenditures will include costs associated with research and development, potentially acquiring or licensing new technologies, conducting nonclinical studies and clinical trials and potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for sale, if any. We will also need to make significant expenditures to develop a commercial organization capable of sales, marketing and distribution for any products, if any, that we intend to sell ourselves in the markets in which we choose to commercialize. In addition, we may be required to make substantial payments related to our success payment agreements and other contingent consideration payments under our license and collaboration agreements. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the discovery, development and commercialization of our potential product candidates, and other unanticipated costs may arise.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, we had approximately $632.7&#160;million in cash, cash equivalents and marketable securities. As a result of expense timing, as well as diligent expense management, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to meet our working capital and capital expenditure needs into 2026. However, our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will in any event require additional capital to complete clinical development of any of our current programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external source of funds. Additional funds may not be available when we need them on terms that are acceptable to us, or at all, and our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions or conditions in the biotechnology sector of the market, including disruptions to, or volatility in the credit and financial markets in the United States and worldwide resulting from any lingering effects of the COVID-19 pandemic, actual or perceived changes in interest rates and economic inflation, the current or anticipated impact of geopolitical instability and otherwise. If adequate funds are not available to us on a timely basis, including pursuant to the Equity Distribution Agreement, we may be required to delay, limit, reduce or terminate nonclinical studies, clinical trials or other development activities for our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing and distribution capabilities or other activities that may be necessary to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success payment obligations in our success payment agreements may result in dilution to our stockholders or may be a drain on our cash resources to satisfy the payment obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed to make success payments payable in cash or publicly-tradeable shares of our common stock at our discretion pursuant to our success payment agreements with Fred Hutch and Stanford. On each contractually prescribed measurement date, we may be required to make success payments based on increases in the per share fair value of our common stock. The total amount of success payments that we may become obligated to make is currently $400.0&#160;million and may increase in the future due to amendments of our existing success payment agreements. For information related to our success payment obligations, see Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form&#160;10&#8209;Q.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to satisfy our obligations to make these success payments, if and when they are triggered, we may issue equity or convertible debt securities that may cause dilution to our stockholders, or we may use our existing cash to satisfy the success payment obligation in cash, which may adversely affect our financial position. In addition, these success payments may impede our ability to raise money in future public offerings of debt or equity securities or to obtain a third-party line of credit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The success payment agreements may cause operating results to fluctuate significantly from quarter to quarter and year to year, which may reduce the usefulness of our consolidated financial statements.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success payment obligations are recorded as liabilities on our Condensed Consolidated Balance Sheets. Under U.S. generally accepted accounting principles (GAAP), we are required to estimate the fair value of these liabilities as of each quarter end and changes in the estimated fair value are accreted to research and development expense over the service period of the collaboration agreement. Once the requisite service obligation to earn the potential success payment consideration is met under our continued collaboration agreements, the change in the success payment liabilities fair value is recognized in other income or expense, net. For example, in December 2022, Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration; accordingly in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 and future periods, the change in the success payments liability fair value is recognized in other income or expense, net.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may lead to increases or decreases in the estimated fair value of our success payment liabilities include, among others, changes in the value of the common stock, changes in volatility and changes in the risk-free rate. As a result, our operating results and financial condition as reported by GAAP may fluctuate significantly from quarter to quarter and from year to year and may reduce the usefulness of our GAAP consolidated financial statements. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_151"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are early in our research and clinical development efforts. If we are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are early in our research and clinical development efforts of our product candidates. Besides LYL797 and LYL845, which are in Phase 1 clinical development, our other proprietary product candidates are currently in preclinical development. We have not yet demonstrated our ability to successfully complete any clinical trials (including any Phase&#160;3 or other pivotal clinical trials), obtain regulatory approvals, manufacture a commercial&#8209;scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. We have invested substantial resources in developing our technology platforms and our product candidates, conducting nonclinical studies, commencing clinical trials and building our manufacturing facilities and capabilities, each of which will be required prior to any regulatory approval and commercialization. Our ability to generate revenue from product sales, which we do not expect will occur for several years, if ever, will depend heavily on the successful research and development and eventual commercialization of one or more product candidates. The success of our efforts to identify and develop product candidates will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">timely and successful completion of our nonclinical studies and research activities to identify and develop product candidates to investigate in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">submission of INDs to the FDA to proceed with clinical trials, or comparable applications to foreign regulatory authorities that allow the commencement of our planned clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successful enrollment and completion of clinical trials in compliance with Good Clinical Practice (GCP) requirements with positive results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the level of efficacy observed with our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the prevalence and severity of adverse events experienced with any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully developing, or making arrangements with third parties for, manufacturing and distribution processes for our product candidates and for commercial manufacturing and distribution for any of our product candidates that receive regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">receipt of timely regulatory approvals from applicable authorities for our product candidates for their intended uses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">protecting our rights in our intellectual property portfolio, including by obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establishing capabilities and infrastructure to obtain the tumor tissues needed to develop and, if successful, commercialize approved products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">manufacturing our product candidates at an acceptable cost;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">launching commercial sales of our products, if approved by applicable regulatory authorities, whether alone or in collaboration with others;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acceptance of our products, if approved by applicable regulatory authorities, by patients and the medical community;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved by applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">effectively competing with other marketed therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining compliance with regulatory requirements, including the cGMP requirements;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining a continued acceptable benefit/risk profile of the products following approval; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining and growing an organization of scientists and functional experts who can develop and commercialize our products and technology.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which could harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates and technology platforms are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking to identify and develop a broad pipeline of product candidates using our proprietary technology platforms. The scientific research that forms the basis of our efforts to develop product candidates with our technology platforms is still ongoing. We are not aware of any FDA approved therapeutics utilizing similar technology. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our technology platforms are both preliminary and limited. Additionally, although LYL797 and LYL845 are in Phase 1 clinical development, our current clinical data are limited, and nonclinical data from murine tumor models and in vitro experiments with tumor cell lines may not translate into humans or may not accurately predict the safety and efficacy of our product candidates in humans. As a result, we are exposed to a number of unforeseen risks, and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the novelty of our technology platforms, we intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, due to a lack of relevant experiences, the regulatory pathway with the FDA and comparable regulatory authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory agencies may lack experience in evaluating the safety and efficacy of our product candidates developed using our technology platforms, which could result in a longer than expected regulatory review process, increase our expected development costs and delay or prevent commercialization of our product candidates. The validation process takes time and resources, may require independent third-party analyses and may not be accepted or approved by the FDA and comparable foreign regulatory authorities. There can be no assurance as to the length of clinical development, the number of patients that the FDA may require to be enrolled in clinical trials to establish the safety, purity and potency of our product candidates or the acceptability to the FDA of data generated in these clinical trials to support marketing approvals. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel and, if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, manufacturing, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors and our inability to find suitable replacements could result in delays in product development and harm our business. We conduct substantially all of our operations at our facilities in the San Francisco, Seattle and Bothell metropolitan areas. These regions are headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in these markets is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We have in the past and could again in the future experience resignations of executives and employees given the intensity of the competition for talent in the biotechnology industry, particularly in the San Francisco and Seattle metropolitan areas. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity that vests over time. The value to employees of equity incentives that vest over time may be significantly affected by factors beyond our control, including market conditions and volatility, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any litigation or adversarial proceedings could be costly and time-consuming to defend.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been and may in the future become subject to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by us or third parties in connection with commercial disputes or employment claims made by our current or former employees. Litigation or adversarial proceedings might result in substantial costs and may divert management&#8217;s attention and resources, which might seriously harm our business, reputation, overall financial condition and operating results. For example, in February 2021, we filed a demand for arbitration seeking, among other things, rescission of each of the joint-development agreement and stock purchase agreement with PACT Pharma, Inc. (PACT) and recovery of the consideration paid thereunder and in October 2022, we entered into a settlement agreement with PACT to resolve the outstanding legal dispute. Insurance might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims and might not continue to be available on terms acceptable to us. Any claim brought by us or against us that is uninsured or underinsured could result in unanticipated costs, thereby harming our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot maintain our company culture as we grow, our success and our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our culture has been a key contributor to our success to date. Any failure to preserve our culture could negatively affect our ability to retain and recruit personnel, which is critical to our growth, and to effectively focus on and pursue our objectives. As we grow and are required to implement more complex organizational management structures, we may find it increasingly difficult to maintain the beneficial aspects of our culture. If we fail to maintain our company culture, our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no marketing, sales and distribution capabilities. To support commercial marketing and distribution of any of our product candidates that complete clinical development and are approved, we would either establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in a legally compliant manner or outsource this function to a third party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks, including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could continue to be adversely affected by the effects of health epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could continue to be adversely affected by health epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations. For example, health epidemics, including the COVID-19 pandemic, have in the past and could again in the future result in quarantines, stay-at-home orders, remote work policies or other similar events that may disrupt businesses, delay our research and development programs and timelines, negatively impact productivity and increase risks associated with cybersecurity, the future magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations. These types of events presented substantial public health and economic challenges around the world and affected employees, patients, communities and business operations, as well as the United States and international economy and financial markets. In this regard, the COVID-19 pandemic and government measures taken in response have had a significant impact in the last three years, both direct and indirect, on businesses and commerce, as significant reductions in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business-related activities have occurred, supply chains have been disrupted, availability and cost of materials have been affected and manufacturing and clinical development activities have been impacted.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lingering effects of the COVID-19 pandemic may also continue to negatively impact healthcare and hospital resources, including both front-line and administrative staff, which may delay enrollment in our current and planned clinical trials. Some patients may not be able to comply with clinical trial protocols due to lack of healthcare support or potential interruptions of healthcare services. Our ability to recruit and retain patients, principal investigators and site staff (who as healthcare providers may have heightened exposure) may be hindered, which would adversely affect our trial operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global credit and financial markets have experienced extreme volatility and disruptions (including as a result of the COVID-19 pandemic and actual or perceived changes in interest rates and economic inflation), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability and swings in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of supply chain disruptions, labor shortages, fluctuations in currency exchange rates, changes in interest rates, military conflict, acts of terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to geopolitical conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions, including disruption to enrollment within our ongoing trials and our ability to purchase necessary supplies on acceptable terms, if at all. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to bank failures and market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. Similarly, later in March 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. While the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program, there is no guarantee that such programs will be sufficient. Additionally, it is uncertain whether the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any adverse impact to our liquidity or to our current and projected business operations, financial condition or results of operations as a result of the matters relating to SVB, Signature Bank and Silvergate Capital Corp, uncertainty remains over liquidity concerns in the broader financial services industry, and our business, our business partners or industry as a whole may be adversely impacted in ways that we cannot predict at this time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we assess our banking relationships as we believe necessary or appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we have banking relationships and, in turn, us. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could also include factors involving financial markets or the financial services industry generally. The results of events or concerns that involve one or more of these factors could include a variety of material and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; or termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></div><div><span><br/></span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_154"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently manufacture drug products for our clinical trials ourselves. Delays in further qualifying or in receiving regulatory approvals for any manufacturing facility or product candidates could delay our development plans and thereby limit our ability to generate product revenues.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built our own manufacturing facility in Bothell, Washington. The facility is designed to support the production of nonclinical and clinical development product candidates and early commercialization of products, and ongoing facility and equipment qualification to support clinical production as required. If we are not able to further qualify the facility or the appropriate regulatory approvals for the facility are delayed, we may be unable to manufacture sufficient quantities of our product candidates, if at all, which would limit our development activities and our opportunities for growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing facility will be subject to ongoing, periodic inspection by the FDA, EMA or other applicable regulatory agencies to ensure compliance with cGMPs and current Good Tissue Practices (cGTPs). Our failure to follow and document our adherence to these regulations or other regulatory requirements may lead to significant delays in the availability of products for clinical or, in the future, commercial use. This may result in the termination of or a hold on a clinical trial or may delay or prevent filing or approval of commercial marketing applications for our product candidates. We also may encounter problems with the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">achieving adequate or clinical-grade materials that meet regulatory agency standards or specifications with consistent and acceptable production yield and costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">maintaining continuity among our key manufacturing-related electronic systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">shortages of qualified personnel, raw materials or key contractors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">ongoing compliance with cGMP regulations and other requirements of the FDA, EMA or other comparable regulatory agencies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulations could also result in sanctions being imposed on us, including fines, injunctions, civil penalties, a requirement to suspend or put on hold one or more of our clinical trials, failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing advanced manufacturing techniques and process controls is required to fully utilize our facility. Without further investment, advances in manufacturing techniques may render our facility and equipment inadequate or obsolete. We may also require further investment to build additional manufacturing facilities or expand the capacity of our existing ones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacturing of cellular therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing commercially viable manufacturing processes for cellular therapies is a difficult and uncertain task and requires significant expertise and capital investment. We are developing and implementing manufacturing processes for our product candidates. In particular, for autologous cell therapies, the starting material is the patient&#8217;s own cells, which inherently adds complexity and variability to the manufacturing process. In addition, our ability to consistently and reliably manufacture our cellular therapy product candidates is essential to our success, and there are risks associated with scaling </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the level required for advanced clinical trials or commercialization, including cost overruns, potential problems with process scale-up, process reproducibility, stability issues, consistency and timely availability of reagents or raw materials. Furthermore, our manufacturing processes may have significant dependencies on third parties, which will pose additional risks to our manufacturing capabilities. Additionally, we do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the factors mentioned above, the overall process of manufacturing cellular therapies is extremely susceptible to product loss due to low cell viability, contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing and distribution processes for any of our product candidates could result in reduced production yields, impact to key product quality attributes and other supply disruptions. Product defects can also occur unexpectedly. These deviations and disruptions could delay our programs. If we are not able to capably manage this complexity and variability, our ability to timely and successfully provide our product candidates to patients could be delayed. In addition, the complexities of utilizing a patient&#8217;s own cells as the starting material requires that we have suitable cells capable of yielding a viable cellular therapy product, which may not be possible for severely immune-compromised or heavily pre-treated patients.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of successfully manufacturing products for clinical testing and commercialization may be particularly challenging, even if such products otherwise prove to be safe and effective. The manufacture of these product candidates involves complex processes. Some of these processes require specialized equipment and highly skilled and trained personnel. The process of manufacturing these product candidates will be susceptible to additional risks, given the need to maintain aseptic conditions throughout the manufacturing process. Contamination with microbes, viruses or other pathogens in either the donor material or materials utilized in the manufacturing process or ingress of microbiological material at any point in the process may result in contaminated, unusable product or necessitate the closing of a manufacturing facility for an extended period of time to allow us to investigate and remedy the contamination. These types of contaminations could result in delays in the manufacture of products, which could result in delays in the development of our product candidates. These contaminations could also increase the risk of adverse side effects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting manufacturing operations for our product candidates may result in lot failures, inventory shortages, shipment delays, product withdrawals or recalls or other interruptions in supply that could delay the development of our product candidates. If we are unable to obtain sufficient supply of our product candidates, whether due to production shortages or other supply interruptions resulting from any lingering effects of the COVID-19 pandemic, the Russia-Ukraine conflict or otherwise, our clinical trials or regulatory approvals may be delayed. We may also have to write off inventory, incur other charges and expenses for supply of product that fails to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. In addition, parts of the supply chain may have long lead times or may come from a small number of suppliers. If we are not able to appropriately manage our supply chain, our ability to successfully produce our product candidates could be delayed or harmed. Inability to meet the demand for our product candidates could damage our reputation and the reputation of our products among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the manufacturing facilities in which our product candidates will be made could be adversely affected by earthquakes and other natural disasters, equipment failures, labor shortages, power failures, health epidemics and numerous other factors. If any of these events were to occur and impact our manufacturing facilities, our business would be materially and adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our sole clinical or commercial manufacturing facility or any of our contract manufacturing organizations is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a single manufacturing facility in Bothell, Washington and may rely on third-party contract manufacturing organizations to meet our current and future manufacturing needs. If our manufacturing facility or any facility in our manufacturing network, or the equipment in these facilities, is either damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity, if at all. In the event of a temporary or protracted loss of a facility or its equipment, we may not be able to transfer manufacturing to a third party in the time required to maintain supply. Even if we could transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary regulatory requirements or may require regulatory approval before selling any products manufactured at that facility. Such an event could substantially delay our clinical trials or commercialization of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet our requirements for our product candidates if there were a catastrophic event or failure of our current manufacturing facility or processes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on third parties to manufacture our product candidates, which subjects us to risks and could delay or prevent our development and/or commercialization, if approved, of our product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely on third parties to manufacture our current or future product candidates. We may be unable to identify manufacturers for our product candidates or the materials required to develop the cellular therapy on acceptable terms or at all because the number of potential manufacturers is limited. Engaging a third-party manufacturer will require testing and regulatory interactions, and a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any. Such potential third-party manufacturers may be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the facilities used by manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state agencies to ensure strict compliance with government regulations and corresponding foreign standards, and we do not have control over third-party manufacturers&#8217; compliance with cGMPs for the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to obtain and/or maintain regulatory approval for our product candidates manufactured in these facilities. In addition, we have no control over the ability of our third-party manufacturers to maintain adequate control, quality assurance and qualified personnel required to meet our clinical and commercial needs, if any. If the FDA or a comparable foreign regulatory authority does not approve the manufacture of our product candidates at these facilities or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates or that any approvals we have obtained could be revoked, which would adversely affect our business and reputation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products. Also, our third-party manufacturers could breach or terminate their agreement with us because of their own financial difficulties or business priorities at a time that is costly or otherwise inconvenient for us. If we were unable to find adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our third-party manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Each of these risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require many specialty raw materials. As a result, we may be required to outsource aspects of our manufacturing supply chain. Many of the specialty raw materials may be manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. Switching suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we may not be able to develop, manufacture and market our product candidates in a timely and competitive manner, or at all. An inability to continue to source product from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, those suppliers may not have the capacity to support commercial products manufactured by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection, or medical crises such as widespread contamination. We may not be able to contract with these companies on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing. In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. These factors could cause the delay of studies or trials, regulatory submissions, required approvals or commercialization of product candidates that we develop, cause us to incur higher costs and prevent us from commercializing our product candidates successfully.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_157"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to rely on third parties to conduct, supervise and monitor a significant portion of our research and nonclinical studies and clinical trials for our product candidates, and, if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GCP-compliant clinical trials on our product candidates properly and on time. For example, we are relying on CROs to conduct significant parts of our LYL797 and LYL845 Phase&#160;1 clinical trials. Negotiating budgets and contracts with CROs and study sites may result in delays to our development timelines and increased costs. Switching or adding CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any third parties conducting our clinical trials or nonclinical studies will not be our employees, and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials or nonclinical studies may be extended, delayed or terminated, and we may not be able to obtain regulatory approval or successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on these parties for execution of our nonclinical studies and clinical trials, and generally do not control their activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP conditions. Our failure to comply with these regulations may require us to add patients to or repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with the third parties that we currently use or that we may use in the future terminates, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. As a result, delays occur, which can materially impact our ability to meet desired research and clinical development timelines.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do and will continue to or intend to rely on outside scientists and clinical trial investigators and their third-party research institutions for research and development and early clinical testing of our product candidates. These scientists, investigators and institutions may have other commitments or conflicts of interest, which could limit our access to their expertise and harm our ability to leverage our technology platforms.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our third-party research institution collaborators for some research capabilities. However, the research we are funding constitutes only a small portion of the overall research of each research institution. Other research being conducted by these institutions may at times receive higher priority than research on the programs we are funding. We typically have less control of the research, clinical trial protocols and patient enrollment than we might with activity led by our employees.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outside scientists and clinical trial investigators who conduct the research and development upon which portions of our product candidate pipeline depends are not our employees; rather, they serve as either independent contractors or the primary investigators under research collaboration agreements that we have with their sponsoring academic or research institution. Such scientists and collaborators may have other commitments that would limit their availability to us. Although our scientific advisors generally agree not to do competing work, if an actual or potential conflict of interest between their work for us and their work for another entity arises, we may lose their services. These factors could adversely affect the timing of the clinical trials, the timing of receipt and reporting of clinical data, the timing of our IND submissions and our ability to conduct our current and planned clinical trials. It is also possible that some of our valuable proprietary knowledge may become publicly known through these scientific advisors if they breach their confidentiality agreements with us, which would cause competitive harm to, and have an adverse effect on, our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have in the past, and we may in the future, form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into research and development collaborations in the past, and may in the future, enter into additional license and collaboration arrangements. Any collaboration arrangement that we enter into is subject to numerous risks, which may include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator has significant discretion in determining the efforts and resources that they will apply to a program or product candidate under the collaboration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may delay or halt clinical trials, provide insufficient funding for a clinical trial, preferentially enroll patients on a portion of a clinical trial not testing our product candidates, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may not commit sufficient resources to marketing and distribution of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disputes may arise between us and the collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaboration may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the collaborator may own or co-own intellectual property covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, failure by any collaborator to meet its obligations under our collaboration agreements or to apply sufficient efforts at developing and commercializing collaboration products may adversely affect our business, financial condition and our results of operations. For example, we were previously party to a research and development collaboration </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with GSK for our NY-ESO-1 program and other potential product opportunities and, effective December 2022, GSK terminated the agreement and discontinued its development of product candidates targeting NY-ESO-1, including the second&#8209;generation product candidates that incorporated our genetic and epigenetic reprogramming technologies. No patients had been treated with these product candidates and, given the early stage of these second&#8209;generation programs, the termination was not based on any clinical efficacy or safety data from these programs. We have also discontinued any further work on these programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates, our research and any future product candidates that we may pursue. Such alliances will be subject to many of the risks set forth above. Moreover, any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these risks, we may not be able to realize the benefit of our existing collaboration or any future collaborations or licensing agreements we may enter into. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of potential future collaborations, licenses, product acquisitions or other strategic transactions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may desire to enter into in the future, collaborations, licenses or other strategic transactions for the acquisition of products or business opportunities, in each case where we believe such arrangement will complement or augment our existing business. These relationships or transactions, or those like them, may require us to incur nonrecurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, reduce the potential profitability of the products that are the subject of the relationship or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic alliances and transactions and the negotiation process is time-consuming and complex, and there can be no assurance that we can enter into any of these transactions even if we desire to do so. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates or programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate a positive benefit/risk profile. Any delays in entering into new strategic alliance agreements related to our product candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we license products or acquire businesses, we may not be able to realize the benefit of these transactions if we are unable to successfully integrate them with our existing operations and company culture. There are other risks and uncertainties involved in these transactions, including unanticipated liabilities related to acquired intellectual property rights, products or companies and disruption in our relationship with collaborators or suppliers as a result of such a transaction. We cannot be certain that, following an acquisition or license, we will achieve the financial or strategic results that would justify the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on the enrollment and retention of patients in our current and planned clinical trials for our product candidates. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful and timely completion of clinical trials require that we enroll and retain a sufficient number of patient candidates. Any clinical trials we conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, manufacturing failures resulting in patients being unable to be treated, patient withdrawal or adverse events.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These types of developments could cause us to delay the trial or halt further development. For example, we announced in 2022 that enrollment for the Phase 1 trial of LYL797 had been slower than anticipated due to delays in clinical site activations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Moreover, enrolling patients in clinical trials for diseases in which there is an approved standard of care is challenging, as patients will first receive the applicable standard of care. Many patients who respond positively to the standard of care do not enroll in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials. This may limit the number of eligible patients able to enroll in our clinical trials who have the potential to benefit from our product candidates and could extend development timelines or increase costs for these programs. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved drug candidates. However, these prior treatment regimens may render our therapies less effective in clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment depends on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the size and nature of the patient population;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">eligibility criteria for the trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the proximity of patients to clinical sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the design of the clinical protocol;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability to obtain and maintain patient consents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">perceived risks and benefits of the product candidate under evaluation, including any perceived risks associated with genetically modified product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the availability of competing clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any lingering effects of the COVID-19 pandemic on the availability of such patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the availability of new drugs approved for the indication the clinical trial is investigating; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available approved or investigational therapies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and private and public research institutions. Our ability to enroll clinical trials or our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop. Additionally, our commercial opportunities will be reduced or eliminated if novel upstream products or changes in treatment protocols reduce the overall incidence or prevalence of our current or future target diseases. Competition could result in reduced sales and pricing pressure on our product candidates, if approved by applicable regulatory authorities. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before us and impair any ability to commercialize our product candidates.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_160"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulation and Legal Compliance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are in the first phase of clinical development of our product candidates, and our future success is dependent on the successful development and regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products approved for commercial sale, and we are in the first phase of clinical development of our product candidates. Besides LYL797 and LYL845, which are in Phase 1 clinical development, our other proprietary product candidates are currently in preclinical development. The future success of our business is substantially dependent on our ability to obtain regulatory approval for our product candidates for the indications we seek, and, if approved, to successfully commercialize one or more product candidates in a timely manner. Each of our programs and product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates will require clinical development, regulatory approval, obtaining manufacturing supply, capacity and expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment and significant marketing efforts before we generate any revenue from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize marketable products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot commercialize product candidates in the United States without first obtaining regulatory approval for the product from the FDA; similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence from and to the satisfaction of the FDA and foreign regulatory authorities, that the product candidate is safe, pure and potent for use for that target indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate to assure safety, purity and potency.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of nonclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any future product candidates will ever obtain regulatory approval. Furthermore, the regulatory approval process for novel product candidates, such as T-cell product candidates and next-generation T-cell programs, can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our cellular therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on the successful development of our cellular therapies in general and our development product candidates, in particular. Because these programs represent a new approach to the treatment of cancer, developing and, if approved, commercializing our product candidates subject us to a number of challenges. Moreover, we cannot be sure that the manufacturing processes used in connection with our cellular therapy product candidates will yield a sufficient supply of satisfactory products that are safe, pure and potent, scalable or profitable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to oversight by the FDA and by institutional review boards (IRBs) under guidelines promulgated by the National Institutes of Health (NIH), gene therapy clinical trials, such as those for LYL797 which evaluates T cells expressing a synthetic CAR and overexpressing c-Jun, are also subject to review and oversight by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Although the FDA decides whether trials of cell therapies that involve genetic engineering may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved by applicable regulatory authorities, of physicians to subscribe to the novel treatment mechanics. The FDA or other applicable regulatory authorities may ask for specific post-marketing requirements, and additional information informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Physicians may not be willing to undergo training to adopt this novel therapy, may decide the therapy is too complex to adopt without appropriate training or not cost-efficient and may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of research, nonclinical studies or earlier clinical trials are not necessarily predictive of future results. Any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in research, nonclinical studies and early clinical trials does not ensure that later clinical trials will generate similar results and otherwise provide adequate data to demonstrate the efficacy and safety of an investigational product. Likewise, a number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant setbacks in late-stage clinical trials, even after seeing promising results in earlier nonclinical studies or clinical trials. Thus, even if the results from our initial research and nonclinical activities appear positive, we do not know whether subsequent late-stage clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, final study results may not be consistent with interim study results. If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates may be adversely impacted. Even if we believe that we have adequate data to support an application for regulatory approval to market any of our product candidates, the FDA or other regulatory authorities may not agree and may require that we conduct additional clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process with an uncertain outcome.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the first phase of clinical development of our product candidates. Besides LYL797 and LYL845, which are in Phase 1 clinical development, our other proprietary product candidates are currently in preclinical development. The risk of failure of our product candidates is high. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive nonclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates are subject to regulation as biological products, we will need to demonstrate that they are safe, pure and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical testing that will be required for any product candidates we choose to advance is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Failure can occur at any time during the clinical trial process. Even if our current and planned clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of our product candidates for their targeted indications or support continued clinical development of such product candidates. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through nonclinical and clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not fully enrolled or completed any clinical trials required for the approval of our product candidates. We may experience delays in initiating, enrolling or conducting our current and planned clinical trials, and we do not know whether clinical trials will begin or enroll subjects on time, will need to be redesigned, will achieve expected enrollment rates or will be completed on schedule, if at all. Obtaining sufficient and specific tumor tissues is needed for our Phase&#160;1 clinical trials of LYL797 and LYL845 in multiple solid tumor indications. Our inability to obtain the specific tumor tissues or sufficient amount of tumor tissues in a timely manner or at all could delay or preclude our ability to initiate and execute the clinical trials. There can be no assurance that the FDA or comparable foreign regulatory authorities will not put clinical trials of any of our product candidates on clinical hold in the future. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including in connection with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inability to generate sufficient nonclinical, toxicology, or other in vivo or in vitro data to support the initiation of clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in reaching agreement with the FDA or other regulatory authorities as to the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining regulatory authorization to commence a clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reaching an agreement on acceptable terms with clinical trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining IRB or ethics committee approval at each trial site;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">recruiting suitable patients to participate in a clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">having patients complete a clinical trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inspections of clinical trial sites or operations by applicable regulatory authorities, or the imposition of a clinical hold;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinical sites, CROs or other third parties deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to perform in accordance with applicable regulatory requirements, including the FDA&#8217;s GCP requirements, or applicable regulatory requirements in other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">addressing patient safety concerns that arise during the course of a trial, including occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">adding a sufficient number of clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">manufacturing sufficient quantities of product candidate for use in clinical trials; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspensions or terminations by IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including those described above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, the Data Monitoring Committee for such trial or the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict with any certainty whether or when we might complete a given clinical trial, if at all. If we experience delays or quality issues in the conduct, completion or termination of any clinical trial of our product candidates, the approval and commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. As a result of safety or toxicity issues that we may experience in our clinical trials, we may not continue the development of nor receive approval to market any product candidates, which could prevent us from ever generating product revenues or achieving profitability. For example, previous clinical trials utilizing CAR T&#160;cells to treat hematologic tumors have shown an increased risk of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Adverse events may also be associated with the lymphodepletion or IL-2 regimen utilized with cellular therapies. Additionally, ROR1 is expressed on a number of normal tissues. As a result, ROR1 could cause on-target, off-tumor toxicity. c-Jun is also potentially an oncogene and could cause healthy cells to transform into </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">malignant cells. Results of our trials could reveal an unacceptably high severity and incidence of side effects, or side effects outweighing the benefits of our product candidates. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development or deny approval of our product candidates for any or all targeted indications. The side effects experienced could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of our product candidates receives regulatory approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may withdraw or limit approvals of such products and require us to take our approved product off the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy (REMS) plan to ensure that the benefits of the product outweigh its risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to change the dose or the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be subject to limitations on how we may promote or manufacture the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">sales of the product may decrease significantly;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of any products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, topline or preliminary data from our nonclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Further, modifications or improvements to our manufacturing processes for a therapy may result in changes to the characteristics or behavior of the product candidate that could cause our product candidates to perform differently and affect the results of our ongoing clinical trials. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose preliminary or interim data from our nonclinical studies and clinical trials. Preliminary or interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Additionally, disclosure of preliminary or interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. If the interim, topline or preliminary data we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, any of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our potential product candidates may be harmed, which could harm our business, operating results, prospects, or financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA regulatory approval process is lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approval of our product candidates, our business will be substantially harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the novel nature of our product candidates to create challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of T-cell therapies for cancer. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize any drug product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe, pure and potent for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional nonclinical studies or clinical trials for our product candidates either prior to or after approval, or it may object to elements of our clinical development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the approval policies or regulations of the FDA or comparable foreign authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval and marketing authorization process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if physicians experience unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, the Data Monitoring Committee for such trial, the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and approval process and jeopardize our ability to commence product sales and generate revenue. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, testing, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to monitor the safety and efficacy of the product if approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations, as well as, for the manufacture of certain of our product candidates, the FDA&#8217;s cGTPs for the use of human cellular and tissue products to prevent the introduction, transmission or spread of communicable diseases. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs, cGTPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, quality control and distribution.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include issuing warning letters or untitled letters, imposing fines on us, imposing restrictions on the product or its manufacture and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we have any product candidate approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. In the United States, the FDA and the Federal Trade Commission (FTC) strictly regulate the promotional claims that may be made about pharmaceutical products to ensure that any claims about such products are consistent with regulatory approvals, not misleading or false in any particular way and adequately substantiated by clinical data. The promotion of a drug product in a manner that is false, misleading, unsubstantiated or for unapproved (or off-label) uses may result in enforcement letters, inquiries and investigations and civil and criminal sanctions by the FDA, FTC and other regulatory authorities. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions and may result in false claims litigation under federal and state statutes, which can lead to consent decrees, civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The government has also required that companies enter into consent decrees and/or imposed permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">issue warning letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">issue, or require us to issue, safety-related communications, such as safety alerts, field alerts, &#8220;Dear Doctor&#8221; letters to healthcare professionals, or import alerts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">impose civil or criminal penalties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend, limit or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend any of our nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refuse to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">impose restrictions on our operations, including closing our and our contract manufacturers&#8217; facilities; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seize or detain products, refuse to permit the import or export of products, or require us to conduct a product recall.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, during the Trump administration several executive actions were taken, including the issuance of a number of Executive Orders, that imposed significant burdens on, or otherwise delayed, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how similar orders in the future would be implemented, and the extent to which they would impact the FDA&#8217;s ability to exercise its regulatory authority. If executive actions are taken that impose restrictions on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to applicable fraud and abuse, including anti-kickback and false claims, transparency, health information privacy and security and other healthcare laws. Failure to comply with such laws, may result in substantial penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to broadly applicable healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research, market, sell and distribute any product candidates for which we obtain marketing approval. The healthcare laws that may affect us include: the federal fraud and abuse laws, including the federal anti-kickback, and false claims and civil monetary penalties laws; federal data privacy and security laws, including the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act; and federal transparency laws related to ownership and investment interests and payments and/or other transfers of value made to or held by physicians (including doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. In addition, many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating compliance efforts. Moreover, several states require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Additionally, some state and local laws require the registration of biopharmaceutical sales representatives in the jurisdiction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and/or oversight if a corporate integrity agreement or similar agreement is executed to resolve allegations of non-compliance with these laws and the curtailment or restructuring of operations. In addition, violations may also result in reputational harm, diminished profits and lower future earnings. For additional detail on healthcare laws that may affect our business, see &#8220;Other Healthcare Laws&#8221; in the business section of our Annual Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in healthcare policies, laws and regulations may impact our ability to obtain approval for, or commercialize our product candidates, if approved.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality and expand access to care. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives, as well as executive, judicial and Congressional challenges to existing healthcare laws that have significantly affected, and could continue to significantly affect, the healthcare industry. For example, there have been efforts to repeal, substantially modify or invalidate some or all of the provisions of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), some of which have been successful. While the U.S. Supreme Court dismissed in June 2021 a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress, such efforts may continue. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there continues to be heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs and review the relationship between pricing and manufacturer patient programs. For example, President Biden issued an executive order in July 2021 supporting legislation to enact drug pricing reforms and, in response, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices in September 2021 with specific legislative and administrative policies that Congress could enact to help improve affordability of, and access to, prescription drugs. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things: (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. Additionally, the IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. These provisions will take effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center, which will be evaluated on their ability to lower the cost of drugs, promote accessibility and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">organizations will have an effect on our ability to successfully commercialize our product candidates. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a payor-by-payor basis. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that a procedure is safe, effective and medically necessary; appropriate for the specific patient; cost effective; supported by peer-reviewed medical journals; included in clinical practice guidelines; and neither cosmetic, experimental, nor investigational. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, a significant trend in the healthcare industry is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. As such, cost containment reform efforts may result in an adverse effect on our operations. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Similarly, because our product candidates will be physician-administered, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may or may not be reimbursed for providing the treatment or procedure in which our product is used.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to be cleared or approved biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough FDA employees and stop critical activities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. In February 2022, the FDA resumed on-site inspections of domestic manufacturing facilities, subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, in April 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an in-person inspection would not be prioritized or deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic or other health epidemics. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secrets and confidentiality agreements to protect the intellectual property related to our technology and product candidates. We own or possess certain intellectual property, and other intellectual property are owned or possessed by our partners and are in-licensed to us. When we refer to &#8220;our&#8221; technologies, inventions, patents, patent applications or other intellectual property rights, we are referring to both the rights that we own or possess as well as those that we in-license, many of which are critical to our intellectual property protection and our business. If the intellectual property that we rely on is not adequately protected, competitors may be able to use our technologies and erode or negate any competitive advantage we may have.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patentability of inventions and the validity, enforceability and scope of patents in the biotechnology field is uncertain because it involves complex legal, scientific and factual considerations, and it has in recent years been the subject of significant litigation. Moreover, the standards applied by the U.S. Patent and Trademark Office (USPTO) and non-U.S. patent offices in granting patents are not always applied uniformly or predictably. There is also no assurance that all potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the instances where searching was done. We may be unaware of prior art that could be used to invalidate an issued patent or prevent a pending patent application from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe affects the validity, enforceability or patentability of a claim of one of our patents or patent applications, which may, nonetheless, ultimately be found to affect the validity, enforceability or patentability of such claim. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the United States or in other countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if patents have issued or do successfully issue from patent applications, and even if these patents cover our product candidates, third parties may challenge the validity, enforceability or scope thereof, which may result in these patents being narrowed, invalidated or held to be unenforceable. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable. Even if unchallenged, our patents and patent applications or other intellectual property rights may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. The possibility exists that others will develop products on an independent basis which have the same effect as our product candidates and which do not infringe our patents or other intellectual property rights, or that others will design around the claims of patents that we have had issued that cover our product candidates. If the breadth or strength of protection provided by our patents and patent applications with respect to our product candidates is threatened, it could jeopardize our ability to commercialize our product candidates and dissuade companies from collaborating with us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also desire to seek licenses from third parties who own or have rights to intellectual property that may be useful for providing exclusivity for our product candidates, or for providing the ability to develop and commercialize a product candidate in an unrestricted manner. There is no guarantee that we will be able to obtain such licenses from third parties on commercially reasonable terms, or at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the USPTO and various foreign governmental or inter-governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during and after the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete, irreversible loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States patent applications containing or that at any time contained a claim not entitled to a priority date before March&#160;16, 2013 are subject to the &#8220;first to file&#8221; system implemented by the America Invents Act (2011). The first to file system requires us to be cognizant going forward of the time from invention to filing of a patent application. Because patent applications in the U.S. and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our partners were the first to file any patent application related to a product candidate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our registered or unregistered trademarks or trade names may be challenged, infringed or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we view as valuable to building name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties have adopted or may adopt trade names or trademarks </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion and/or litigation. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce, protect or defend our proprietary rights related to trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first nonprovisional effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. While the patent term of certain patents can also be extended with respect to a specific product to recapture time lost in clinical trials and regulatory review by the FDA, a patent&#8217;s life also can be shortened by a terminal disclaimer over an earlier filed patent or patent application. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, enforcing and defending patents on all of our product candidates in all countries throughout the world would be prohibitively expensive. Our intellectual property rights in certain countries outside the United States may be less extensive than those in the United States. In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we and our partners may not be able to prevent third parties from practicing our inventions in countries outside the United States, or from selling or importing infringing products made using our inventions in other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection or where we do not have exclusive rights under the relevant patents to develop their own products and, further, may export otherwise-infringing products to territories where we and our partners have patent protection but where enforcement is not as strong as that in the U.S. These infringing products may compete with our product candidates in jurisdictions where we or our partners have no issued patents or where we do not have exclusive rights under the relevant patents, or our patent claims and other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us and our partners to stop the infringement of our patents or marketing of competing products in violation of our intellectual property rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us or our partners. We or our partners may not prevail in any lawsuits that we or our licensors initiate, and even if we or our licensors are successful, the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, we or our partners may have limited remedies, which could materially diminish the value of such patent. If we or our partners are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing or misappropriating the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on us and our partners not infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation and other adversarial proceedings, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interference or derivation proceedings, oppositions, and inter partes and post-grant review proceedings before the USPTO and non-U.S. patent offices. Numerous U.S. and non-U.S. issued patents and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pending patent applications owned by third parties exist in the fields in which we are developing, and may develop, product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of third parties&#8217; patent rights, as it may not always be clear to industry participants, including us, which patents cover various types of products, methods of making or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert infringement or misappropriation claims against us based on existing or future intellectual property rights, alleging that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacturing of our product candidates that we failed to identify. For example, patent applications covering our product candidates could have been filed by others without our knowledge, since these applications generally remain confidential for some period of time after their filing date. Even pending patent applications that have been published, including some of which we are aware, could be later amended in a manner that could cover our product candidates or their use or manufacture. In addition, we may have analyzed patents or patent applications of third parties that we believe are relevant to our activities and believe that we are free to operate in relation to any of our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, which may block our efforts or potentially result in any of our product candidates or our activities infringing their claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners are sued for patent infringement, we would need to demonstrate that our product candidates, products and methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving that a patent is invalid is difficult and even if we are successful in the relevant proceedings, we may incur substantial costs, and the time and attention of our management and scientific personnel could be diverted from other activities. If one or more claims of any issued third-party patents were held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture or methods for treatment, we could be forced, including by court order, to cease developing, manufacturing or commercializing the relevant product candidate until the relevant patent expired. Alternatively, we may desire or be required to obtain a license from such third party in order to use the infringing technology and to continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonably terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property licensed to us. If we are unable to obtain a necessary license on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third-party&#8217;s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defending against intellectual property claims, regardless of their merit, could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle before a final judgment, any litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions and other interim proceedings in the litigation and these announcements may have negative impact on the perceived value of our product candidates, programs or intellectual property. In the event of a successful intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent, or to redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. In addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, and the parties making claims against us may obtain injunctive or other equitable relief, which could impose limitations on the conduct of our business. We may also elect to enter into license agreements in order to settle patent infringement claims prior to litigation, and any of these license agreements may require us to pay royalties and other fees that could be significant. As a result of all of the foregoing, any actual or threatened intellectual property claim could prevent us from developing or commercializing a product candidate or force us to cease some aspect of our business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have in-licensed a significant portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could potentially lose the ability to continue the development and potential commercialization of one or more of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold rights under license agreements with our partners. Our discovery and development technology platforms are built, in part, around intellectual property rights in-licensed from our partners. Under our existing license agreements, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we are subject to various obligations, which may include diligence obligations with respect to development and commercialization activities, payment obligations upon achievement of certain milestones and royalties on product sales. If there is any conflict, dispute, disagreement or issue of nonperformance between us and our counterparties regarding our rights or obligations under these license agreements, including any conflict, dispute or disagreement arising from our failure to satisfy diligence or payment obligations, we may be liable to pay damages and our counterparties may have a right to terminate the affected license. The termination of any license agreement with one of our partners could adversely affect our ability to utilize the intellectual property that is subject to that license agreement in our discovery and development efforts, our ability to enter into future collaboration, licensing and/or marketing agreements for one or more affected product candidates and our ability to commercialize the affected product candidates. Furthermore, disagreements under any of these license agreements may arise, including those related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether and the extent to which our technology and processes may infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These disagreements may harm our relationship with the partner, which could have negative impacts on other aspects of our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own, to develop our product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations, manufacturing methods or technologies to work effectively and efficiently, and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms; such failure would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired or licensed, or may require in the future, intellectual property rights that have been generated through the use of U.S. government funding or grant. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may infringe our patents or misappropriate or otherwise violate our intellectual property rights. Our patent applications cannot be enforced against third parties practicing the technology claimed in these applications unless and until a patent issues from the applications, and then only to the extent the issued claims cover the technology. In the future, we or our partners may elect to initiate legal proceedings to enforce or defend our or our partners&#8217; intellectual property rights, to protect our or our partners&#8217; trade secrets or to determine the validity or scope of our intellectual property rights. Any claims that we or our partners assert against perceived infringers could also provoke these parties to assert counterclaims against us or our partners alleging that we or our partners infringe their intellectual property rights or that our intellectual property rights are invalid. In patent litigation in the United States, defendant counterclaims alleging noninfringement, invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert noninfringement, invalidity or unenforceability of a patent. The outcome following legal assertions of noninfringement, unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity of patent rights, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference, derivation or opposition proceedings provoked by third parties, brought by us or our partners, or brought by the USPTO or any non-U.S. patent authority, may be necessary to determine the priority of inventions or matters of inventorship with respect to our patents or patent applications. We or our partners may also become involved in other proceedings, such as reexamination or opposition proceedings, inter partes review, post-grant review or other pre-issuance or post-grant proceedings in the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property of others. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. An unfavorable outcome in any of these proceedings could require us or our partners to cease using the related technology and commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our partners a license on commercially reasonable terms if any license is offered at all. Even if we or our licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any intellectual property proceedings can be expensive and time-consuming. Our or our partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our partners can. Accordingly, despite our or our partners&#8217; efforts, we or our partners may not be able to prevent third parties from infringing upon or misappropriating our intellectual property rights, particularly in countries where the laws may not protect our rights as fully as in the U.S. Even if we are successful in the relevant proceedings, we may incur substantial costs, and the time and attention of our management and scientific personnel could be diverted from other activities. In addition, in an infringement proceeding, a court may decide that one or more of our patents is invalid or unenforceable, in whole or in part, may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question and/or may require us to pay the other party attorneys&#8217; fees. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be adversely affected and our business could be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and other elements of our technology, discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with our product candidates, thus eroding our competitive position in the market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets can be difficult to protect. We seek to protect our proprietary, confidential technology and processes, in part, by entering into confidentiality agreements and invention assignment agreements with our employees, consultants and outside scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, or outside scientific advisors might intentionally or inadvertently disclose our trade secrets or confidential, proprietary information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, the laws of certain foreign countries do not protect proprietary rights such as trade secrets to the same extent or in the same manner as the laws of the U.S. Misappropriation or unauthorized disclosure of our trade secrets to third parties could impair our competitive advantage in the market and could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have breached non-compete or non-solicit obligations and/or wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise breached non-compete or non-solicit obligations with respect to such individuals&#8217; prior employers, or used or disclosed confidential information of these third parties or such individuals&#8217; former employers. Dealing with such claims and negotiating with potential claimants could result in substantial cost and be a distraction to our management and employees. In addition, litigation may be necessary to defend against these claims, and even if we are successful in defending against these claims, such litigation could result in further costs to us and distraction to our management and employees.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_166"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our organizational documents:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establish that our board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with each class serving staggered three-year terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide that our directors may be removed only for cause;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">eliminate cumulative voting in the election of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">permit stockholders to take actions only at a duly called annual or special meeting and not by unanimous written consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">prohibit stockholders from calling a special meeting of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">authorize our board of directors, by a majority vote, to amend certain provisions of the bylaws; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware (DGCL) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, which is generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees, or stockholders to us or our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation and bylaws; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any action asserting a claim governed by the internal affairs doctrine.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, to prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation also provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. However, these provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Any person purchasing or otherwise acquiring or holding any interest in shares of our capital stock is deemed to have received notice of and consented to the foregoing provisions. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds more favorable for disputes with us or with our directors, officers, other employees or agents or our other stockholders, which may discourage such lawsuits against us and such other persons, or may result in additional expense to a stockholder seeking to bring a claim against us. Alternatively, if a court were to find this choice of forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls over financial reporting or identify additional material weaknesses in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may significantly harm our business and the value of our common stock.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section&#160;404 of the Sarbanes-Oxley Act (Section&#160;404) requires that we evaluate and determine the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. Our independent registered public accounting firm is also required to attest to the effectiveness of our internal control over financial reporting. These assessments need to include the disclosure of any material weaknesses in such internal control. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. We and our independent auditors have previously identified a material weakness in our internal control over financial reporting, and we cannot assure you that we will not identify other material weaknesses in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we may not have identified all material weaknesses, and our current controls and any new controls that we develop may become inadequate because of changes in personnel or conditions in our business or otherwise. Accordingly, we cannot assure you that any future material weaknesses will not result in a material misstatement of our consolidated financial statements and/or our failure to meet our public reporting obligations. In addition, if we and/or our independent registered public accounting firm are unable to conclude that our internal control over financial reporting is effective in the future, investor confidence in the accuracy and completeness of our consolidated financial statements would be adversely affected, which could significantly harm our business and the value of our common stock. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_169"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act, and we must maintain disclosure controls and procedures designed to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement, causing us to fail to make a required related party transaction disclosure or identify a potential conflict of interest. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile, which could result in substantial losses for investors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be volatile and may fluctuate substantially as a result of a variety of factors, many of which are beyond our control. Some of the factors that may cause the market price of our common stock to fluctuate are listed below and other factors described in this &#8220;Risk Factors&#8221; section:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing and results of nonclinical studies and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure or discontinuation of any of our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the success of existing or new competitive product candidates or technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">results of clinical trials or regulatory approvals of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">commencement or termination of collaborations for our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developments or disputes including those concerning patent applications, issued patents, or other proprietary rights;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">any lingering effects of the COVID-19 pandemic on our business and on global economic conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">labor discord or disruption, geopolitical events, social unrest, war, including repercussions of the recent military conflict between Russia and Ukraine, tensions in U.S.-China relations, terrorism, political instability, acts of public violence, boycotts, hostilities and social unrest and other health pandemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the level of expenses related to any of our research programs or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">actual or anticipated changes in our estimates as to our financial results or development timelines;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether our financial results, forecasts and development timelines meet the expectations of securities analysts or investors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">sales of our common stock by us, our insiders, or other stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">market conditions in the healthcare sector;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">general economic, industry and market conditions beyond our control, such as inflationary pressures, labor shortages and supply chain disruptions, bank failures and other macroeconomic factors and associated economic downturn; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, stock markets in general, and the market for biotechnology companies in particular, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors have affected and may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they publish negative or neutral evaluations of our stock, the price of our stock could decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies in part on the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts covering our business initiate coverage with a neutral or sell rating or downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders could cause the price of our common stock to decline.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time, sales of a substantial number of shares of our common stock in the public market could occur, or there could be a perception in the market that the holders of a large number of shares of common stock intend to sell shares, and any such event could reduce the market price of our common stock. As of June&#160;30, 2023, we have 251,026,997 shares of common stock outstanding. Substantially all of the shares of our common stock outstanding and shares issued upon the exercise of stock options outstanding under our equity incentive plans, subject to applicable securities law restrictions and excluding shares of restricted stock, may be able to be sold in the public market. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, certain holders of shares of our common stock have rights, subject to conditions, to require us to file registration statements with the SEC covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing securities issued in any such transactions. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the amount, timing or nature of any future offerings. In August 2022, we entered into an Equity Distribution Agreement pursuant to which we may offer and sell, from time to time, up to $200.0&#160;million in shares of our common stock. To the extent that we raise additional capital through the sale of equity or debt securities, including pursuant to the Equity Distribution Agreement, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships, alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or our products, or grant licenses on terms unfavorable to us. Certain of the foregoing transactions may require us to obtain stockholder approval, which we may not be able to obtain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are no longer an &#8220;emerging growth company&#8221;, and the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; no longer apply, which increases our costs as a result of being a public company and demands on management.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2022, we are no longer classified as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). As such, we will incur significant additional expenses that we did not previously incur in complying with the Sarbanes-Oxley Act and rules implemented by the SEC. For instance, the cost of compliance with Section 404 has required, and will continue to require, us to incur substantial accounting expense and expend significant management time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements, which could divert management attention and adversely affect our business, operating results and financial condition. Moreover, if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, investor perceptions of our company may suffer if, in the future, material weaknesses are found, and this could cause a decline in the market price of our stock. Irrespective of compliance with Section 404, any failure of our internal control over financial reporting could have a material effect on our stated operating results. If we are unable to implement these changes effectively or efficiently, it could harm our operations, financial reporting or financial results and could result in an adverse opinion on internal control from our independent registered public accounting firm.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a &#8220;large accelerated filer,&#8221; we are required to hold a say-on-pay vote and a say-on-frequency vote at our 2023 annual meeting of stockholders. As a result, we required additional attention from management with respect to our disclosures and have incurred and will incur increased costs, including higher legal fees, accounting fees, consultant fees and fees associated with investor relations activities, among others, and, as a result, our business, operating results and financial condition could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future acquisitions, strategic investments, partnerships or alliances could be difficult to identify and integrate, divert the attention of management, disrupt our business, dilute stockholder value and adversely affect our operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek to acquire or invest in businesses, products or technologies that we believe could complement or expand our technology platforms, enhance our technical capabilities, or otherwise offer growth opportunities. The pursuit of potential acquisitions or strategic investments may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions or investments, whether or not such transactions are completed. In addition, we have only limited experience in acquiring or investing in other businesses, and we may not successfully identify desirable targets, or if we acquire additional businesses, we may not be able to integrate them effectively following the acquisition. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, as well as unfavorable accounting treatment and exposure to claims and disputes by third parties, including intellectual property claims. We also may not generate sufficient financial returns to offset the costs and expenses related to any acquisitions. In addition, if an acquired business fails to meet our expectations, our business, operating results and financial condition may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company require our management to devote substantial time to compliance initiatives and corporate governance practices and could divert management&#8217;s attention and strain our resources.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. Section&#160;404, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements and rules of The Nasdaq Stock Market LLC (Nasdaq Listing Rules) and other applicable U.S. rules </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We continue to need to hire additional accounting, finance and other personnel in connection with our efforts to comply with the requirements of being a public company, and our management and other personnel will continue to need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements have and will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, the rules and regulations applicable to us as a public company have made it more expensive for us to obtain director and officer liability insurance. We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017 (the Tax Act), the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) and the recently enacted IRA made many significant changes to the U.S. tax laws. For example, the Tax Act made broad and complex changes to the U.S. tax code, including, among other things, reducing the federal corporate tax rate. Additionally, beginning in 2022, the Tax Act required the capitalization of research and experimentation expenses with amortization periods over five and fifteen years pursuant to Section 174 of the U.S. Internal Revenue Code of 1986, as amended (the Code). If the requirement to capitalize Section 174 expenditures is not modified, it may impact our effective tax rate and our cash tax liability in future years. We expect further guidance regarding Section 174 may be forthcoming from the Financial Accounting Standards Board and the SEC, as well as regulations, interpretations and rulings from federal and state agencies, which could impact our consolidated financial statements. Future guidance from the U.S. Internal Revenue Service and other tax authorities with respect to any such tax legislation may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations and the deductibility of expenses under the Tax Act or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition or results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Act, as modified by the CARES Act, our net operating losses (NOLs) generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. There is variation in how states have responded and may continue to respond to the Tax Act and CARES Act. In addition, under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. We may have experienced ownership changes in the past, including as a result of our IPO, and may experience future ownership changes as a result of subsequent shifts in our stock ownership (some of which may be outside our control). As a result, our ability to use our pre-change NOLs and tax credits to offset post-change taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of computer system failures or security breaches.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems, and those of our partners, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. We exercise little or no control over these third parties, which increases our vulnerability to problems with their systems. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development of our product candidates could be delayed and our business could be otherwise adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any material system failure, accident or security breach to date, we cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs, and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnity provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection and other losses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreements with third parties may include indemnification provisions under which we agree to indemnify them for losses suffered or incurred as a result of claims of intellectual property infringement or other liabilities relating to or arising from our contractual obligations. Large indemnity payments could harm our business and financial condition. Although we normally contractually limit our liability with respect to such obligations, we may still incur substantial liability. Any dispute with a third party with respect to such obligations could have adverse effects on our relationship with that third party and relationships with other existing or new partners, harming our business.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_172"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from our Initial Public Offering of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we completed our IPO, pursuant to which we issued and sold 25,000,000 shares of our common stock at a price to the public of $17.00 per share. The shares were registered pursuant to a registration statement on Form S-1 (File No. 333-256470) that was declared effective on June 16, 2021. As a result of our IPO, we raised a total of approximately $391.8 million in net proceeds after deducting underwriting discounts and commissions of $29.8 million and offering expenses of $3.4 million. Goldman Sachs &amp; Co. LLC, BofA Securities, J.P. Morgan and Morgan Stanley acted as joint book-running managers for the IPO. Upon receipt, the net proceeds from our IPO were held in cash, cash equivalents and investments. No payments were made from our net proceeds directly or indirectly to our officers or directors, to persons owning 10% or more of any class of our equity securities or to any of our affiliates, other than payments in the ordinary course of business to officers for salaries and to non-employee directors as compensation for services on our board. We are holding a significant portion of the balance of the net proceeds from the offering in money market funds and short-term investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from the IPO have been used to fund ongoing operations, including the development of our product candidates and our clinical trials and research programs, and for working capital and general corporate purposes. There has been no material change in the planned use of proceeds from the IPO from that described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on June&#160;21, 2021 (the Prospectus). We cannot predict with certainty all of the particular uses for the net proceeds from our IPO, or the amounts that we will actually spend on the uses set forth in the Prospectus and above. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including our ability to access additional financing, the relative success and cost of our research, nonclinical and clinical development programs and whether we are able to enter into future collaboration and licensing arrangements. As a result, our management will continue to have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from our IPO.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_178"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_181"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, none of our directors or executive officers <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-791"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-792">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-793"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-794">terminated</ix:nonNumeric></ix:nonNumeric> a Rule&#160;10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement as defined in Item 408(a) and (c) of Regulation&#160;S-K, respectively.</span></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_187"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">File Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Exhibit/<br/>Appendix<br/>Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Filing<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Filed<br/>Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521195237/d136326dex41.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-257249</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">06/21/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521195237/d136326dex42.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-257249</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">06/21/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521185918/d168165dex41.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-256470</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">06/09/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165dex42.htm">Amended and Restated Investors' Rights Agreement, by and among the Registrant and certain of its stockholders, dated March&#160;5,&#160;2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">333-256470</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">05/25/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230630x10qxexx101.htm">Release and Separation Agreement, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230630x10qxexx101.htm">effective June 24, 2023, by and among the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230630x10qxexx101.htm">Registrant and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230630x10qxexx101.htm"> Rahsaan Thompson</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230630x10qxexx311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230630x10qxexx312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">32.1*&#171;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;text-decoration:underline" href="lyel-20230630x10qxexx321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">X</span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed herewith.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#171;&#160;&#160;&#160;&#160;The certification attached as Exhibit&#160;32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><div id="i2d1fffa08fea4d9bb0dbd24f63ee408b_190"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2d1fffa08fea4d9bb0dbd24f63ee408b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Lyell Immunopharma, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date: August&#160;8, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">/s/ CHARLES NEWTON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Charles Newton</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Chief Financial Officer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>lyel-20230630x10qxexx101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib1c13a185df24c3d95bc06e2d6837afd_1"></div><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="padding-left:0.05pt;padding-right:116.15pt;text-align:right"><font><br></font></div><div style="padding-left:58.1pt;padding-right:58.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RELEASE AND SEPARATION AGREEMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Release and Separation Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made and entered into by and between Lyell Immunopharma, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the undersigned employee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). All capitalized terms used in this Agreement that are not defined herein shall have the same respective meanings as set forth in the Lyell Immunopharma, Inc. Officer Severance Plan, effective July 29, 2019, and amended and restated as of February 11, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:81.62pt;padding-right:81.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Employee&#8217;s employment with the Company terminates effective as of June 16, 2023&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company presented Employee with this Agreement on June 16, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Presentation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties wish to resolve fully and finally any and all matters between them including any potential disputes regarding Employee&#8217;s employment with the Company or the termination thereof&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, in order to accomplish this end, the Parties wish to enter into this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual promises and undertakings contained herein and for other good and valuable consideration, including the consideration described in Section 4 of this Agreement, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Separation and Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee&#8217;s last day of employment with the Company was June 16, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This Agreement shall not become effective until the eighth (8th) day after Employee signs this Agreement without having exercised any legal right to revoke this Agreement prior to such date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). No payments due to Employee under this Agreement shall be made or begin before the Effective Date.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Wage Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee acknowledges that, as of the Separation Date, Employee has been properly paid all wages, including bonus or incentive compensation, for all work performed for the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Transition Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon request by the Company, Employee shall provide up to ten (10) hours per month of advisory and transition services as an independent contractor to the Company during the period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transition Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) starting on the Separation Date until the earlier of (i) September 29, 2023 and (ii) the date that the Company terminates Employee&#8217;s engagement for Cause as defined in the Severance Plan. As an independent contractor during the Transition Period, Employee will have the right of sole control of the manner and means and methods of performing the services under this Agreement, provided, however, that Employee shall accept any reasonable directions issued by the Company pertaining to the Company&#8217;s operations. While providing any such advisory and transition services to the Company during the Transition Period, Employee agrees to (i) act</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:41pt;padding-right:6.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the best interests of the Company and (ii) use Employee&#8217;s reasonable best efforts to promote the success of the Company. As compensation for services Employee provide during the Transition Period, the Company shall pay Employee an hourly fee of $220. Employee&#8217;s Continuous Service (as defined in the Company&#8217;s 2021 Equity Incentive Plan) shall not terminate by reason of his change of status from employee to independent contractor but shall terminate at the end of the Transition Period.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.05pt;text-decoration:underline">Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">In exchange for Employee timely signing and returning the Agreement to the Company (and allowing the releases contained herein to become effective), in each case following the Presentation Date, the release of claims in Section 5 below, the Company will provide Employee with the following amounts and benefits (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.67pt">The equivalent of twelve (12) months of Employee&#8217;s base salary in effect as of the Separation Date plus a pro-rated annual bonus for 2023 paid at target in proportion to the percentage of the year in which Employee was employed by the Company, less applicable taxes, withholdings and deductions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to which Employee is not otherwise entitled, pursuant to the applicable timing set forth in Section 2.3 of the Severance Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.34pt">If Employee is eligible for and timely elects group health plan continuation coverage under COBRA, upon Employee&#8217;s submission to the Company of evidence of Employee&#8217;s and Employee&#8217;s dependents, if applicable, enrollment in COBRA, the Company will pay a portion of the Employee&#8217;s premiums for the Employee and the Employee&#8217;s dependents to continue group medical, vision and dental coverage under COBRA directly to the insurer or COBRA administrator, as applicable, until the earliest of&#58; (A) the date that is twelve (12) months following the Separation Date, (B) the date on which Employee and Employee&#8217;s eligible dependents, if applicable, become covered by the group health plan of a subsequent employer and (C) the expiration of Employee&#8217;s eligibility for continuation coverage under COBRA (the earliest of clauses (A), (B), and (C) the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The amount of this portion will be the same portion of the premium cost as was borne by the Company under the level of coverage selected by Employee and in effect on the Separation Date. The period of continued benefits under this paragraph shall run concurrently with (and shall count against) the Company&#8217;s obligation to provide continuation coverage pursuant to COBRA.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:113pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits above without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu thereof, the Company will pay Employee</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:113pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the last day of each remaining month of the COBRA Payment Period a fully taxable cash payment equal to the monthly portion of the premium cost for group medical, vision and dental coverage as was borne by the Company under the level of coverage selected by Employee and in effect on the Separation Date, subject to applicable tax withholding (such amount, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Special Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), provided that any Special Severance Payments that otherwise would be payable prior to or on the Effective Date shall be paid in a single lump sum on the first regularly scheduled payroll date of the Company following the Effective Date, and any remaining Special Severance Payments will be paid in accordance with the schedule described above. Any Special Severance Payments will be made regardless of whether Employee elects COBRA continuation coverage.</font></div><div><font><br></font></div><div style="padding-left:113pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.01pt">If Employee signs this Agreement by July 7, 2023 and does not exercise any legal right to revoke it prior to July 15, 2023, each Company stock option granted to Employee that is outstanding as of the Separation Date (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall continue to vest until the end of the Transition Period and shall continue to be exercisable until the earlier of June 30, 2024 and the original expiration date of the Stock Option, subject to the Company&#8217;s ability to terminate such Stock Option earlier in the event of a corporate transaction or a dissolution or liquidation of the Company to the extent permitted by the terms of the governing equity plan. Except as provided in the foregoing sentence, the terms of all Stock Options shall remain the same and the Stock Options shall continue to be governed in all respects by the governing equity plan documents and agreements. Employee should consult with Employee&#8217;s personal tax advisor regarding the implications of the above-described extension of the post-termination exercise period of any Stock Option that is an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt">Notwithstanding any contrary provision in Employee&#8217;s offer letter dated September 12, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Offer Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Employee shall not be required to repay the Sign-On Bonus Advance provided for in the Offer Letter.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee understands, acknowledges, and agrees that these benefits exceed what Employee is otherwise entitled to receive upon Employee&#8217;s separation from employment with the Company, and are being given as consideration in exchange for executing this Agreement, including the general release contained herein.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employee Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee specifically represents, warrants, and confirms that Employee&#58; has read this Agreement and agrees to the conditions and obligations set forth in it&#59; has been advised to consult with an attorney of Employee's choosing before signing this Agreement&#59; has been advised, as required by California Government Code Section 12964.5(b)(4) that Employee has a right to consult an attorney regarding this Agreement and that Employee was given a reasonable time period not less than five (5) business days to do so&#59; knowingly,</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:77pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">freely, and voluntarily assents to all of this Agreement's terms and conditions including, without limitation, the waiver, release, and covenants&#59; is signing this Agreement, including the waiver and release, in exchange for good and valuable consideration in addition to anything of value to which Employee is otherwise entitled&#59; is not waiving or releasing rights or claims that may arise after Employee signs this Agreement&#59; has not filed any claims, complaints, or actions of any kind against the Company with any court of law, or local, state, or federal government or agency&#59; and has not engaged in and is not aware of any unlawful conduct relating to the business of the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.05pt;text-decoration:underline">General Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:5.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">In exchange for the Release Consideration provided in this Agreement, Employee, for Employee and for Employee&#8217;s affiliates, successors, heirs, subrogees, assigns, principals, agents, partners, employees, associates, attorneys, and representatives, voluntarily, knowingly, and intentionally releases and discharges the Company, Parent, and each of its and their Affiliates, predecessors, successors, parents, subsidiaries, and assigns, and each of its and their respective officers, directors, principals, shareholders, board members, committee members, insurers, employees, agents, and attorneys, in their corporate and individual capacities, (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from any and all claims, actions, liabilities, demands, rights, damages, costs, expenses, and attorneys&#8217; fees (including, but not limited to, any claim of entitlement for attorneys&#8217; fees under any contract, statute, or rule of law allowing a prevailing party or plaintiff to recover attorneys&#8217; fees) of every kind and description, whether known or unknown, from the beginning of time through the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.05pt">The Released Claims include, but are not limited to,</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.67pt">Any and all claims under Title VII of the Civil Rights Act of 1964 (Title VII), the Americans with Disabilities Act (ADA), the Family and Medical Leave Act (FMLA) (regarding existing but not prospective claims), the Fair Labor Standards Act (FLSA), the Equal Pay Act, the Employee Retirement Income Security Act (ERISA) (regarding unvested benefits), the Civil Rights Act of 1991, Section 1981 of U.S.C. Title 42, the Fair Credit Reporting Act (FCRA), the Worker Adjustment and Retraining Notification (WARN) Act, the National Labor Relations Act (NLRA), the Age Discrimination in Employment Act (ADEA), the Uniform Services Employment and Reemployment Rights Act (USERRA), the Genetic Information Nondiscrimination Act (GINA), the Immigration Reform and Control Act (IRCA), the California Fair Employment and Housing Act, the California Constitution, the California Labor Code, any claim under Title 20 of the State Government Article of the Maryland Annotated Code, the Washington Industrial Welfare Act (IWA), the Washington Law Against Discrimination (WLAD), the Washington Family Leave Act (FLA), the Washington Leave Law, the Washington Minimum Wage Requirements and Labor Standards Act, Title 49 of the Revised Code of Washington, the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:113pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Washington Equal Pay Opportunity Act (EPOA), the Washington Fair Chance Act (FCA), and including all of their respective implementing regulations and any other federal, state, local or foreign law (statutory, regulatory, or otherwise) that may be legally waived and released&#59; however, the identification of specific statutes is for purposes of example only, and the omission of any specific statute or law shall not limit the scope of this general release in any manner&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.34pt">Any and all claims arising under tort, contract, and quasi-contract law, including but not limited to claims of breach of an express or implied contract, wrongful or retaliatory discharge, fraud, defamation, negligent or intentional infliction of emotional distress, tortious interference with a contract or prospective business advantage, breach of the covenant of good faith and fair dealing, promissory estoppel, detrimental reliance, invasion of privacy, false imprisonment, nonphysical injury, personal injury or sickness, or any other harm&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;padding-right:5.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.01pt">Any and all claims for compensation of any type whatsoever, including but not limited to claims for wages, salary, bonuses, commissions, incentive compensation, vacation, sick pay, and severance that may be legally waived and released&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt">Any and all claims for monetary or equitable relief, including but not limited to attorneys' fees, back pay, front pay, reinstatement, experts' fees, medical fees or expenses, costs and disbursements, punitive damages, liquidated damages, and penalties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the Released Claims and the ADEA Release in Section 7 (below) specifically exclude&#58; (i) any rights to workers&#8217; compensation, unemployment, or disability benefits under applicable law&#59; (ii) any rights to file an unfair labor practice charge under the National Labor Relations Act&#59; (iii) any rights to vested benefits under ERISA, such as pension or retirement benefits, the rights to which are governed by the terms of the applicable plan documents and award agreements&#59; (iv) any right to file an administrative charge or complaint with, or testify, assist, or participate in an investigation, hearing, or proceeding conducted by, the Equal Employment Opportunity Commission, or other similar federal or state administrative agencies&#59; (v) any rights based on any violation of any federal, state, or local statutory or public policy entitlement that may not be waived under applicable law, such as claims for unemployment benefits and workers&#8217; compensation&#59; (vi) any rights to indemnification, advancement, or contribution&#59; and (vi) any claim that is based on any act or omission that occurs after the date Employee delivers Employee&#8217;s signature on this Agreement to the Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Waiver of Section 1542</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement is intended to be effective as a general release of and bar to all claims as stated in Section 5. Accordingly, Employee expressly waives all rights under Section 1542 of the California Civil Code (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1542</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;) or any similar statute or common law doctrine under applicable law in any other jurisdiction. Section 1542 states as follows&#58; &#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:41pt;padding-right:6.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED</font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTY.&#8221; Employee acknowledges that Employee may later discover claims or facts in addition to or different from those that Employee now knows or believes to exist with regard to the subject matter of this Agreement, and that, if known or suspected at the time of executing this Agreement, may have materially affected its terms. Nevertheless, Employee waives any and all claims that might arise as a result of such different or additional claims or facts.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Specific Release and Waiver of ADEA Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In further consideration of the payments and benefits provided to Employee in this Agreement, Employee irrevocably and unconditionally fully and forever waives, releases, and discharges the Company from any and all claims, whether known or unknown, from the beginning of time through the date of Employee's execution of this Agreement arising under the Age Discrimination in Employment Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADEA Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as amended, and its implementing regulations. By signing this Agreement, Employee acknowledges and confirms that&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt">Employee has read this Agreement in its entirety and understands all of its terms&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;padding-right:6.25pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Employee has been advised in writing to consult with an attorney of Employee's choosing before signing this Agreement&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;padding-right:6.05pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">Employee knowingly, freely, and voluntarily agrees to all of the terms and conditions in this Agreement including, without limitation, the waiver, release, and covenants&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Employee is signing this Agreement, including the waiver and release, in exchange for good and valuable consideration in addition to anything of value to which Employee is otherwise entitled&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">Employee was given at least twenty-one (21) days to consider the terms of this Agreement and consult with an attorney of Employee's choice, although Employee may sign it sooner if desired&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt">Employee understands that Employee has seven (7) days after signing this Agreement to revoke the release in this Section by delivering written notice of revocation to Lynn Seely at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">lseely&#64;lyell.com</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by e-mail before the end of the seven (7) day period&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:6.05pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Employee understands that the release in this Section does not apply to rights and claims that may arise after Employee signs this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">No Admission of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Nothing in this Agreement constitutes an admission of liability by the Company, any of the Released Parties or Employee concerning any aspect of Employee&#8217;s employment with or separation from the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Return of Property and Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee represents and warrants that, prior to Employee&#8217;s execution of this Agreement, Employee will return to the Company any and all property, documents, and files, work product, including any documents (in any recorded media, such as papers, computer disks and other data storage devices, copies, photographs, and maps) that relate in any way to the Company or the Company&#8217;s business. Employee agrees that, to the extent that Employee possesses any files, data, work product, or information relating in any way to the Company or the Company&#8217;s business on any personal computer, device, or account, Employee will return to the Company and then delete those files, data, or information (and will retain no copies in any form). Employee also will return any tools, equipment, calling cards, credit cards, access cards or keys, any keys to any filing cabinets, vehicles, vehicle keys, and all other property in any form prior to the date Employee executes this Agreement.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee agrees that after the Separation Date, Employee will reasonably cooperate with and assist the Company (a) to transition Employee's job duties on an as- needed basis by responding to reasonable requests for information and answering questions, and (b) with any investigation, lawsuit, arbitration, or other proceeding to which the Company is subjected. Employee will make himself or herself available for preparation for, and attendance of, hearings, proceedings or trial, including pretrial discovery and trial preparation. Employee further agrees to perform all acts and execute any documents that may be necessary to carry out the provisions of this Section 10.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Nondisparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee agrees not to disparage the Company, its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents, in any manner likely to be harmful to its or their business, business reputation, or personal reputation&#59; provided however that&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;padding-right:6.05pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">Employee may respond accurately and fully to any request for information if required by legal process or in connection with a government investigation.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;padding-right:5.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">This provision and this Agreement do not prohibit or restrain Employee in any manner from making disclosures protected under the whistleblower provisions of federal or state law or regulation or other applicable law or regulation.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">This provision and this Agreement do not limit Employee&#8217;s ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the California Department of Fair Employment and Housing, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Government Agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">This provision and this Agreement do not limit Employee&#8217;s ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:77pt;padding-right:5.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">This provision and this Agreement do not limit Employee&#8217;s right to receive an award for information provided to the Securities and Exchange Commission&#59; however, Employee understands and agrees that, to maximum extent permitted by law, Employee is otherwise waiving any and all rights Employee may have to individual relief based on any claims that Employee has released and any rights Employee has waived by signing this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt">This provision and this Agreement do not prohibit Employee from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Employee has reason to believe is unlawful.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For its part, the Company agrees that it will not direct any of its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents to disparage the business or personal reputation of Employee.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Neutral References</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any third party seeking a reference for Employee (or otherwise inquiring about Employee&#8217;s employment) will be informed of the title of the position last held and the time frames of employment. Inquiries for salary information from a third party will be answered with the individual&#8217;s latest salary information only if the inquiry is submitted in writing and expressly authorized by Employee.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Employee Invention Assignment and Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee acknowledges and reaffirms Employee&#8217;s continuing obligations under the Employee Invention Assignment and Confidentiality Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) between Employee and the Company, which is incorporated herein by reference.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. It is intended that payments and benefits under this Agreement not subject Employee to taxation under Section 409A of the Code and, accordingly, this Agreement shall be interpreted and administered to be in compliance therewith. Any payments described in this Agreement that are due within the &#8220;short term deferral period&#8221; as defined in Section 409A of the Code, or that qualify as &#8220;involuntary separation pay&#8221; within the meaning of Treas. Reg. &#167;1.409A-1(b)(9) shall not be treated as deferred compensation unless applicable law requires otherwise. To the extent required to avoid an accelerated or additional tax under Section 409A, amounts reimbursable to Employee under this Agreement shall be paid to Employee on or before the last day of the calendar year following the calendar year in which the expense was incurred and the amount of expenses eligible for reimbursement during any one calendar year may not effect amounts reimbursable or provided in any subsequent calendar year. Notwithstanding anything herein to the contrary, in no event shall the timing of Employee&#8217;s execution of the release described in Section 5, directly or indirectly, result in the Employee designating the calendar year of payment, and if a payment that is subject to execution of the general release could be made in more than one taxable year, payment shall be made in the later taxable year. No interpretation or amendment of this Agreement shall require the Company to incur any additional costs or to reimburse Employee for any taxes or penalties that might be imposed upon the Employee as a result of Section 409A of the Code.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any provision of this Agreement is held illegal, invalid, or unenforceable, such holding shall not affect the validity of any other provisions hereof, which shall remain in full force and effect to continue to be binding on the Parties. In the event any provision is held illegal, invalid, or unenforceable, such provision shall be limited so as to affect the intent of the Parties to the fullest extent permitted by applicable law. Any claim by Employee against the Company shall not constitute a defense to enforcement by the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:6.05pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as otherwise provided in this Agreement, this Agreement, and the rights and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators and legal representatives. The Company may assign any of its rights and obligations under this Agreement. The Employee shall not assign, whether voluntarily or by operation of law, any of its rights and obligations under this Agreement, except with the prior written consent of the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties acknowledge and agree that each of the Released Parties, including, but not limited to, Parent and each of its Affiliates, is an intended third- party beneficiary of this Agreement and has the right to enforce and benefit from any legal or equitable right, benefit, or remedy of any nature whatsoever under or by reason of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement constitutes the entire agreement among the Parties with respect to the subject matter hereof and thereof and supersedes any prior understandings, agreements or representations by or between the Parties, written or oral, to the extent that they are related in any way to the subject matter hereof or thereof, provided, however, that this Agreement shall not supersede the Employee&#8217;s obligations in the Employee&#8217;s Employment, Confidential Information and Invention Assignment Agreement with the Company, except to the extent that there is a conflict between such agreement and this Agreement, in which case the terms and conditions of this Agreement shall govern.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law&#59; Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement will be governed by and construed in accordance with the laws of the state of the Employee&#8217;s residence on the Effective Date, without giving effect to its laws pertaining to conflict of laws. If any court or arbitrator of competent jurisdiction determines that any provision of this Agreement is invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be amended only by a written agreement executed by each of the parties hereto. No amendment, waiver, or modification of any obligation under this Agreement will be enforceable unless set forth in a writing signed by the party against which enforcement is sought. Any amendment effected in accordance with this section will be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of any provision of this</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib1c13a185df24c3d95bc06e2d6837afd_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:41pt;padding-right:5.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement shall constitute a waiver of that provision as to that or any other instance. Waiver granted as to any one provision herein shall not constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute the waiver of any performance other than the actual performance specifically waived.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:6pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed electronically. The Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. Photographic, computerized, electronic, PDF or facsimile copies of such signed counterparts may be used in lieu of the originals for any purpose.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Acknowledgment of Full Understanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. EMPLOYEE ACKNOWLEDGES AND AGREES THAT EMPLOYEE HAS FULLY READ, UNDERSTANDS, AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT EMPLOYEE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF EMPLOYEE'S CHOICE BEFORE SIGNING THIS AGREEMENT. EMPLOYEE FURTHER ACKNOWLEDGES THAT EMPLOYEE'S SIGNATURE BELOW IS AN AGREEMENT TO RELEASE THE COMPANY FROM ANY AND ALL CLAIMS THAT CAN BE RELEASED AS A MATTER OF LAW.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:81.62pt;padding-right:81.62pt;text-align:center"><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib1c13a185df24c3d95bc06e2d6837afd_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="margin-top:3.95pt;padding-right:116.15pt;text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have entered into this Separation and Release of Claims Agreement on the date first above written.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lyell Immunopharma, Inc.</font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:273.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><img alt="lseelysignaturea.jpg" src="lseelysignaturea.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:102px"></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:273.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Lynn Seely</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; President &#38; Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYEE&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:317.95pt"><img alt="image_0b.jpg" src="image_0b.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:264px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Name&#58; Rahsaan Thompson Date&#58; June 16, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:81.77pt;padding-right:81.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Separation and Release of Claims Agreement&#93;</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>lyel-20230630x10qxexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2da9198ebe80441ea906589f37e97527_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lynn Seely, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Lyell Immunopharma, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; August&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; LYNN SEELY</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Lynn Seely, M.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>lyel-20230630x10qxexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i46353ae513e84d0f93d49a45ad426570_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles Newton, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Lyell Immunopharma, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; August&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; CHARLES NEWTON</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Charles Newton</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>lyel-20230630x10qxexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4af16d0b3dda4790bd03ea9c3a9c10cb_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in her or his capacity as an officer of Lyell Immunopharma, Inc, Inc. (the&#160;&#8220;Company&#8221;), that, to the best of her or his knowledge&#58;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:6.34pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended June&#160;30, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; August&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; LYNN SEELY</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Lynn Seely, M.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Date&#58; August&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#47;s&#47; CHARLES NEWTON</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Charles Newton</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>lyel-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8f655eeb-886b-4b81-9c30-69669c77ca83,g:e402dc2a-90a6-40a3-91ac-ff661e6149b1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lyel="http://lyell.com/20230630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://lyell.com/20230630">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://lyell.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://lyell.com/role/Organization">
        <link:definition>0000008 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://lyell.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreements" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements">
        <link:definition>0000010 - Disclosure - License, Collaboration, and Success Payment Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecurities" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecurities">
        <link:definition>0000011 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherInvestments" roleURI="http://lyell.com/role/OtherInvestments">
        <link:definition>0000012 - Disclosure - Other Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://lyell.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://lyell.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://lyell.com/role/StockholdersEquity">
        <link:definition>0000015 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://lyell.com/role/StockbasedCompensation">
        <link:definition>0000016 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://lyell.com/role/NetLossPerShare">
        <link:definition>0000017 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://lyell.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactions" roleURI="http://lyell.com/role/RelatedpartyTransactions">
        <link:definition>0000019 - Disclosure - Related-party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://lyell.com/role/SubsequentEvents">
        <link:definition>0000020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreementsTables" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables">
        <link:definition>9954702 - Disclosure - License, Collaboration, and Success Payment Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesTables" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables">
        <link:definition>9954703 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://lyell.com/role/FairValueMeasurementsTables">
        <link:definition>9954704 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://lyell.com/role/LeasesTables">
        <link:definition>9954705 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://lyell.com/role/StockbasedCompensationTables">
        <link:definition>9954706 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsTables" roleURI="http://lyell.com/role/RelatedpartyTransactionsTables">
        <link:definition>9954707 - Disclosure - Related-party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954708 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails">
        <link:definition>9954709 - Disclosure - License, Collaboration, and Success Payment Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails">
        <link:definition>9954710 - Disclosure - License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>9954711 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1">
        <link:definition>9954711 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesNarrativeDetails" roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails">
        <link:definition>9954712 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherInvestmentsDetails" roleURI="http://lyell.com/role/OtherInvestmentsDetails">
        <link:definition>9954713 - Disclosure - Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954714 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" roleURI="http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails">
        <link:definition>9954715 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liability Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" roleURI="http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails">
        <link:definition>9954716 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://lyell.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954717 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" roleURI="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails">
        <link:definition>9954718 - Disclosure - Leases - Summary of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" roleURI="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1">
        <link:definition>9954718 - Disclosure - Leases - Summary of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://lyell.com/role/LeasesNarrativeDetails">
        <link:definition>9954719 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://lyell.com/role/StockholdersEquityDetails">
        <link:definition>9954720 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://lyell.com/role/StockbasedCompensationNarrativeDetails">
        <link:definition>9954721 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails">
        <link:definition>9954722 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitsDetails" roleURI="http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails">
        <link:definition>9954723 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>9954724 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails" roleURI="http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails">
        <link:definition>9954725 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsNarrativeDetails" roleURI="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails">
        <link:definition>9954726 - Disclosure - Related-party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" roleURI="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails">
        <link:definition>9954727 - Disclosure - Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" abstract="false" name="CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_EquityMultipleAxis" abstract="true" name="EquityMultipleAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_FredHutchSuccessPaymentLiabilityMember" abstract="true" name="FredHutchSuccessPaymentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_StockPurchaseAgreementSharesSold" abstract="false" name="StockPurchaseAgreementSharesSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lyel_StockPurchaseAgreementSharesSoldPricePerShare" abstract="false" name="StockPurchaseAgreementSharesSoldPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_LyellImmunopharmaMember" abstract="true" name="LyellImmunopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsResearchTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" abstract="false" name="RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_TwoThousandTwentyOneEquityIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_TwentyTimesMember" abstract="true" name="TwentyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilitiesCurrent" abstract="false" name="SuccessPaymentLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" abstract="false" name="CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_EquityDistributionAgreementMember" abstract="true" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" abstract="true" name="AdjustmentToRevenueRelatedToChangeInEstimateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare" abstract="false" name="CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_EquityMultipleDomain" abstract="true" name="EquityMultipleDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_FortyTimesMember" abstract="true" name="FortyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased" abstract="false" name="CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lyel_LitigationSettlementPercentOfTotalEquityValue" abstract="false" name="LitigationSettlementPercentOfTotalEquityValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_TwoThousandEighteenEquityIncentivePlanMember" abstract="true" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_StanfordMember" abstract="true" name="StanfordMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_ThirtyTimesMember" abstract="true" name="ThirtyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" abstract="true" name="CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lyel_NonCashLeaseIncomeExpense" abstract="false" name="NonCashLeaseIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_GSKMember" abstract="true" name="GSKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lyel_SonomaMember" abstract="true" name="SonomaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lyel_FairValueOfSeriesAConvertiblePreferredStock" abstract="false" name="FairValueOfSeriesAConvertiblePreferredStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_StockPurchaseAgreementFairValueOfStockPerShare" abstract="false" name="StockPurchaseAgreementFairValueOfStockPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" abstract="true" name="GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilitiesFairValueDisclosure" abstract="false" name="SuccessPaymentLiabilitiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_CashEquivalentsFairValueDisclosure" abstract="false" name="CashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_SouthSanFranciscoCaliforniaMember" abstract="true" name="SouthSanFranciscoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" abstract="false" name="CashReceivedForAmountsRelatedToTenantImprovementAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_PACTPharmaIncMember" abstract="true" name="PACTPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_PercentageOfCommissionFromEachSaleOfShares" abstract="false" name="PercentageOfCommissionFromEachSaleOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_GoldmanSachsAndBofAMember" abstract="true" name="GoldmanSachsAndBofAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_SignificantAccountingPoliciesPolicyTextBlock" abstract="false" name="SignificantAccountingPoliciesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilityMeasurementInput" abstract="false" name="SuccessPaymentLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="lyel_OtherInvestmentsTextBlock" abstract="false" name="OtherInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lyel_SuccessPaymentLiabilityMember" abstract="true" name="SuccessPaymentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_TenTimesMember" abstract="true" name="TenTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement" abstract="false" name="PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_FiftyTimesMember" abstract="true" name="FiftyTimesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_OtherInvestmentMember" abstract="true" name="OtherInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_StanfordSuccessPaymentLiabilityMember" abstract="true" name="StanfordSuccessPaymentLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" abstract="false" name="FairValueAdjustmentOfSuccessPaymentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" abstract="false" name="CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lyel_SeriesAAConvertiblePreferredStockMember" abstract="true" name="SeriesAAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" abstract="false" name="CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" abstract="false" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsResearchPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lyel_FredHutchMember" abstract="true" name="FredHutchMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice" abstract="false" name="CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare" abstract="false" name="CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>lyel-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8f655eeb-886b-4b81-9c30-69669c77ca83,g:e402dc2a-90a6-40a3-91ac-ff661e6149b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a8216c62-887b-493e-b766-6d13d6441450" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_72fed0b6-451c-42e0-ba83-0334fa5d5572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8216c62-887b-493e-b766-6d13d6441450" xlink:to="loc_us-gaap_LiabilitiesCurrent_72fed0b6-451c-42e0-ba83-0334fa5d5572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4cda2795-95d8-41ce-8e3f-1fb8f4124fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8216c62-887b-493e-b766-6d13d6441450" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4cda2795-95d8-41ce-8e3f-1fb8f4124fc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4d5cf2d6-a61e-4c84-ae97-55e2e4ab4100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8216c62-887b-493e-b766-6d13d6441450" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4d5cf2d6-a61e-4c84-ae97-55e2e4ab4100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d01bd13-c135-4691-bbb4-5ca792de106a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_99a7091d-499a-417a-a65c-852427d5e3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d01bd13-c135-4691-bbb4-5ca792de106a" xlink:to="loc_us-gaap_PreferredStockValue_99a7091d-499a-417a-a65c-852427d5e3e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1823949f-4621-4d3f-8f1f-30faccbcaff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d01bd13-c135-4691-bbb4-5ca792de106a" xlink:to="loc_us-gaap_CommonStockValue_1823949f-4621-4d3f-8f1f-30faccbcaff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9cb451df-08e3-4022-bf10-8f15450a6586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d01bd13-c135-4691-bbb4-5ca792de106a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9cb451df-08e3-4022-bf10-8f15450a6586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_af8e8765-dce3-45b8-aae6-f2ef5a3b494b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d01bd13-c135-4691-bbb4-5ca792de106a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_af8e8765-dce3-45b8-aae6-f2ef5a3b494b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7dc05117-3c3b-4d30-b549-f2d9d7816e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d01bd13-c135-4691-bbb4-5ca792de106a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7dc05117-3c3b-4d30-b549-f2d9d7816e5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_471499b0-080b-4048-93ec-7a3960437c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_475089b3-724e-4375-a0ad-006272fe7cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_471499b0-080b-4048-93ec-7a3960437c60" xlink:to="loc_us-gaap_AccountsPayableCurrent_475089b3-724e-4375-a0ad-006272fe7cb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_49850f25-1259-47a0-af30-f9f3596f4a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_471499b0-080b-4048-93ec-7a3960437c60" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_49850f25-1259-47a0-af30-f9f3596f4a0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesCurrent_212f1315-6d48-4723-a8b3-dfa13f9d45e8" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_471499b0-080b-4048-93ec-7a3960437c60" xlink:to="loc_lyel_SuccessPaymentLiabilitiesCurrent_212f1315-6d48-4723-a8b3-dfa13f9d45e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f28e6356-1ffa-4b7a-a870-2e14b7bb948a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_43fa18c4-17c8-4fef-97cf-5f170c67ffed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f28e6356-1ffa-4b7a-a870-2e14b7bb948a" xlink:to="loc_us-gaap_Liabilities_43fa18c4-17c8-4fef-97cf-5f170c67ffed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b084ebe9-1764-4646-b6b5-6bb5bf45f535" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f28e6356-1ffa-4b7a-a870-2e14b7bb948a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b084ebe9-1764-4646-b6b5-6bb5bf45f535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4d1d2df0-88d4-48c9-afd8-07bb55e2069e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f28e6356-1ffa-4b7a-a870-2e14b7bb948a" xlink:to="loc_us-gaap_StockholdersEquity_4d1d2df0-88d4-48c9-afd8-07bb55e2069e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_935d1736-7fe8-4811-8525-8d9fd5a599a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_571250b1-9eae-4c8b-a372-d88c7f652022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_935d1736-7fe8-4811-8525-8d9fd5a599a3" xlink:to="loc_us-gaap_AssetsCurrent_571250b1-9eae-4c8b-a372-d88c7f652022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_655ed525-dc80-4c3f-9cee-5b35c5329a94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_935d1736-7fe8-4811-8525-8d9fd5a599a3" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_655ed525-dc80-4c3f-9cee-5b35c5329a94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_29ded920-f69d-457c-833f-8a926245bce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_935d1736-7fe8-4811-8525-8d9fd5a599a3" xlink:to="loc_us-gaap_OtherInvestments_29ded920-f69d-457c-833f-8a926245bce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_258a9f1d-fa6b-48d6-8560-f3acd6d30f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_935d1736-7fe8-4811-8525-8d9fd5a599a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_258a9f1d-fa6b-48d6-8560-f3acd6d30f5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_75ddb159-b9c0-4c0a-aee5-fd9c39b02630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_935d1736-7fe8-4811-8525-8d9fd5a599a3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_75ddb159-b9c0-4c0a-aee5-fd9c39b02630" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3a8ae83c-6a1e-4b59-8347-598bae1bdc83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_935d1736-7fe8-4811-8525-8d9fd5a599a3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3a8ae83c-6a1e-4b59-8347-598bae1bdc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9c905423-76cb-4607-9c1f-687c1c111e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_935d1736-7fe8-4811-8525-8d9fd5a599a3" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9c905423-76cb-4607-9c1f-687c1c111e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ebd8deba-42a5-4c13-9af6-c59295bd9dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d0597fc6-65b3-40f2-be9a-3508484ac1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ebd8deba-42a5-4c13-9af6-c59295bd9dd9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d0597fc6-65b3-40f2-be9a-3508484ac1ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_8894aab4-b243-4a65-a555-f51ba845db17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ebd8deba-42a5-4c13-9af6-c59295bd9dd9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_8894aab4-b243-4a65-a555-f51ba845db17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4ba90d81-9a4e-408e-98fc-8a411ad6e67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ebd8deba-42a5-4c13-9af6-c59295bd9dd9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4ba90d81-9a4e-408e-98fc-8a411ad6e67e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_21538a3f-52f9-4d7e-a7de-3b453f64fa40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b7a46e63-467d-45c3-9cef-a383f30ee573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_21538a3f-52f9-4d7e-a7de-3b453f64fa40" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b7a46e63-467d-45c3-9cef-a383f30ee573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_71dba357-f5d1-4d2c-950c-25f1464d82c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_21538a3f-52f9-4d7e-a7de-3b453f64fa40" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_71dba357-f5d1-4d2c-950c-25f1464d82c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_f24388ea-682c-4236-b21c-27257115cd46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_21538a3f-52f9-4d7e-a7de-3b453f64fa40" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_f24388ea-682c-4236-b21c-27257115cd46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_04e55f21-6f98-4998-ada4-0f2e9b089c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ccb4f01f-6569-4cbd-a4f0-73296416acda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_04e55f21-6f98-4998-ada4-0f2e9b089c9f" xlink:to="loc_us-gaap_NetIncomeLoss_ccb4f01f-6569-4cbd-a4f0-73296416acda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_421ce8d6-190f-4392-8bee-d7033183f38b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_04e55f21-6f98-4998-ada4-0f2e9b089c9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_421ce8d6-190f-4392-8bee-d7033183f38b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20a18199-3372-433b-be34-252549351650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0aaa86fd-44f4-47d3-9e31-457d922731f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_20a18199-3372-433b-be34-252549351650" xlink:to="loc_us-gaap_OperatingExpenses_0aaa86fd-44f4-47d3-9e31-457d922731f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cd764772-fbe0-446b-ba1e-f7530160c846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_20a18199-3372-433b-be34-252549351650" xlink:to="loc_us-gaap_Revenues_cd764772-fbe0-446b-ba1e-f7530160c846" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d270a968-9be7-4f2c-a439-c5761e2dd93c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e013cc83-af15-4f8c-a600-2d1162d7b8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d270a968-9be7-4f2c-a439-c5761e2dd93c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e013cc83-af15-4f8c-a600-2d1162d7b8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aff06316-81f4-4e14-a1ef-65adbb3a4563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d270a968-9be7-4f2c-a439-c5761e2dd93c" xlink:to="loc_us-gaap_OperatingIncomeLoss_aff06316-81f4-4e14-a1ef-65adbb3a4563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7fc581db-fc69-4b78-af2d-26dc7531455b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_eb533d1a-cb7f-4efb-8258-4007e7285c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7fc581db-fc69-4b78-af2d-26dc7531455b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_eb533d1a-cb7f-4efb-8258-4007e7285c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8f981c26-6f36-4888-9fa5-2163d45b73dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7fc581db-fc69-4b78-af2d-26dc7531455b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8f981c26-6f36-4888-9fa5-2163d45b73dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_b31e7aef-a965-49b1-a4fc-84f5784fddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7fc581db-fc69-4b78-af2d-26dc7531455b" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_b31e7aef-a965-49b1-a4fc-84f5784fddf3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9edb44f6-94e6-4a31-8c5e-1fedc226e026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a91255e6-e2dc-412b-a9c9-e469f5f8b300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9edb44f6-94e6-4a31-8c5e-1fedc226e026" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a91255e6-e2dc-412b-a9c9-e469f5f8b300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e8c1b0db-e00f-4c73-bec4-2cb259aca4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9edb44f6-94e6-4a31-8c5e-1fedc226e026" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e8c1b0db-e00f-4c73-bec4-2cb259aca4ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_68dfe462-2224-425d-b1ab-22738ca8f7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9edb44f6-94e6-4a31-8c5e-1fedc226e026" xlink:to="loc_us-gaap_ProceedsFromStockPlans_68dfe462-2224-425d-b1ab-22738ca8f7b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72924720-0b13-4e03-99bd-da80c4373e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1685aa72-7a09-49b6-b7d6-b52030829fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72924720-0b13-4e03-99bd-da80c4373e7a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1685aa72-7a09-49b6-b7d6-b52030829fec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_aa986e5f-6f43-4e05-8904-d0a1b2f43ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72924720-0b13-4e03-99bd-da80c4373e7a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_aa986e5f-6f43-4e05-8904-d0a1b2f43ccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ed1aeb5-5173-4d10-99f0-e5a6586958ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac961373-5a33-4f70-8e5a-98a038691198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ed1aeb5-5173-4d10-99f0-e5a6586958ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac961373-5a33-4f70-8e5a-98a038691198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae55ce89-d2e9-4ee0-9c7c-420d6a3bf471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ed1aeb5-5173-4d10-99f0-e5a6586958ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae55ce89-d2e9-4ee0-9c7c-420d6a3bf471" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2eafcdac-0187-4625-89f4-70a37bfac625" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ed1aeb5-5173-4d10-99f0-e5a6586958ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2eafcdac-0187-4625-89f4-70a37bfac625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d90e4fa0-c10d-4da7-994c-970e2b7715c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d90e4fa0-c10d-4da7-994c-970e2b7715c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fddaa42b-7db1-4246-8b41-9f641b9a62be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fddaa42b-7db1-4246-8b41-9f641b9a62be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d7f0d840-6a76-4997-9887-920bdc9b633a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_ShareBasedCompensation_d7f0d840-6a76-4997-9887-920bdc9b633a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0a971afa-f55c-4157-b88b-6ea0ea695955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0a971afa-f55c-4157-b88b-6ea0ea695955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_4fea2c93-c744-4fb8-88e3-b0b6f182a82e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_4fea2c93-c744-4fb8-88e3-b0b6f182a82e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5cc3e2b9-3d0e-40a0-aa08-e2174fb3d154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5cc3e2b9-3d0e-40a0-aa08-e2174fb3d154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9a588cf5-23d0-4ec3-b957-f9df08a4d861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9a588cf5-23d0-4ec3-b957-f9df08a4d861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_706e34a4-1457-4d23-bc98-d703712e3d20" xlink:href="lyel-20230630.xsd#lyel_FairValueAdjustmentOfSuccessPaymentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_706e34a4-1457-4d23-bc98-d703712e3d20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6264eebf-b351-4407-9882-cefa1788a648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_NetIncomeLoss_6264eebf-b351-4407-9882-cefa1788a648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_60ddf670-a60a-4540-99ad-0e3f278828d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_60ddf670-a60a-4540-99ad-0e3f278828d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_57833375-bf7d-40f5-a8ea-7a100f95f6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_57833375-bf7d-40f5-a8ea-7a100f95f6dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d8695adc-2f3c-43a1-b02e-4f29dfb2d949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d8695adc-2f3c-43a1-b02e-4f29dfb2d949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_NonCashLeaseIncomeExpense_9a523b85-6bbd-41b0-86e2-77c90e2e71cb" xlink:href="lyel-20230630.xsd#lyel_NonCashLeaseIncomeExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_lyel_NonCashLeaseIncomeExpense_9a523b85-6bbd-41b0-86e2-77c90e2e71cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_97262815-cae2-4e55-9fed-e855d3e9be2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_97262815-cae2-4e55-9fed-e855d3e9be2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_80273310-c862-4d18-baba-3655ebc94b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3af800a9-e3c0-4fa9-879c-d96b4e31acad" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_80273310-c862-4d18-baba-3655ebc94b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9a78cbd1-deec-43cc-821b-c43866b5d393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0ec1d0d5-1008-48f3-a014-90a8d405a8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9a78cbd1-deec-43cc-821b-c43866b5d393" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0ec1d0d5-1008-48f3-a014-90a8d405a8ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2929b74b-6a34-4642-a2ea-a9e464583fad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9a78cbd1-deec-43cc-821b-c43866b5d393" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2929b74b-6a34-4642-a2ea-a9e464583fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bf8ddf02-84d8-47e2-8347-6d6eb8431880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9a78cbd1-deec-43cc-821b-c43866b5d393" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bf8ddf02-84d8-47e2-8347-6d6eb8431880" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_e26c4d25-0f1b-4e94-8852-bf535316ec23" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92cab311-81be-4fa1-8980-6800fe5f7b82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_e26c4d25-0f1b-4e94-8852-bf535316ec23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92cab311-81be-4fa1-8980-6800fe5f7b82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ce9f33d2-1408-4da0-bbfb-7db3f6e65d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_e26c4d25-0f1b-4e94-8852-bf535316ec23" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ce9f33d2-1408-4da0-bbfb-7db3f6e65d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_057b0129-2359-43a0-86b5-9a795fa10dbb" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_88fd6d89-0192-492a-993e-94a458c70db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_057b0129-2359-43a0-86b5-9a795fa10dbb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_88fd6d89-0192-492a-993e-94a458c70db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5adda72f-b949-4a59-926d-764f6494727f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_057b0129-2359-43a0-86b5-9a795fa10dbb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5adda72f-b949-4a59-926d-764f6494727f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e77556b-de01-426e-a41e-122d90bca98d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31235ddb-8010-48d0-b220-0a4185bc99ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e77556b-de01-426e-a41e-122d90bca98d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31235ddb-8010-48d0-b220-0a4185bc99ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a2537d8-e0ce-496b-9756-9619e1698d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73d5574c-f5ec-43b8-84cc-e17a074e9464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a2537d8-e0ce-496b-9756-9619e1698d84" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73d5574c-f5ec-43b8-84cc-e17a074e9464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b024e1b9-fccb-448b-8dc1-a5d99a9092ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a2537d8-e0ce-496b-9756-9619e1698d84" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b024e1b9-fccb-448b-8dc1-a5d99a9092ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_93e9f795-fe1d-4877-bdbd-4b700d9790aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a2537d8-e0ce-496b-9756-9619e1698d84" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_93e9f795-fe1d-4877-bdbd-4b700d9790aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" xlink:type="simple" xlink:href="lyel-20230630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_272156f2-df87-4cb2-8de0-02016006cb69" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b677ce09-9d4f-4620-9fa6-d3e1b5ac43c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_272156f2-df87-4cb2-8de0-02016006cb69" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b677ce09-9d4f-4620-9fa6-d3e1b5ac43c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosure_b270fbf3-45da-491f-9ef4-881e1386478e" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_272156f2-df87-4cb2-8de0-02016006cb69" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosure_b270fbf3-45da-491f-9ef4-881e1386478e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_a25104a0-00db-4d9c-9496-e2a45c1425d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_272156f2-df87-4cb2-8de0-02016006cb69" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_a25104a0-00db-4d9c-9496-e2a45c1425d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_ec06314a-6b72-4715-944d-8dc24b7b81f0" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_42748b8c-7a9b-4475-9f5b-7686ed542803" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_ec06314a-6b72-4715-944d-8dc24b7b81f0" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_42748b8c-7a9b-4475-9f5b-7686ed542803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5e7b944a-7452-40c6-969f-5f19283778ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_ec06314a-6b72-4715-944d-8dc24b7b81f0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5e7b944a-7452-40c6-969f-5f19283778ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0f822c3d-9564-4c69-81bf-21107387e579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_ec06314a-6b72-4715-944d-8dc24b7b81f0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0f822c3d-9564-4c69-81bf-21107387e579" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ff66fe55-a17d-4c0f-bd44-b243c83cebb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92285f60-5b9b-457c-a9cf-781d21bd6f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ff66fe55-a17d-4c0f-bd44-b243c83cebb5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92285f60-5b9b-457c-a9cf-781d21bd6f77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a6a8b943-0807-44f4-b75f-295da3ce4e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ff66fe55-a17d-4c0f-bd44-b243c83cebb5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a6a8b943-0807-44f4-b75f-295da3ce4e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2273fd17-1f3b-4e0c-b3bc-39589fa4f414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_ffa2f7a5-96be-41be-82bd-eb06b0d6b6de" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2273fd17-1f3b-4e0c-b3bc-39589fa4f414" xlink:to="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_ffa2f7a5-96be-41be-82bd-eb06b0d6b6de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"/>
  <link:calculationLink xlink:role="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc705102-aa53-481f-9a23-1466d3023ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_14d600e1-0330-4ec5-8bba-24582bf318eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc705102-aa53-481f-9a23-1466d3023ca6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_14d600e1-0330-4ec5-8bba-24582bf318eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8a5a7e20-2558-4a50-843b-fa08a0c1b401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc705102-aa53-481f-9a23-1466d3023ca6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8a5a7e20-2558-4a50-843b-fa08a0c1b401" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a01b6e1d-35e2-49ef-9a22-cc03d4d08ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc705102-aa53-481f-9a23-1466d3023ca6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a01b6e1d-35e2-49ef-9a22-cc03d4d08ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7ba60f52-a451-408e-b358-286f1d721e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc705102-aa53-481f-9a23-1466d3023ca6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7ba60f52-a451-408e-b358-286f1d721e0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8548c031-684c-4b27-baed-3a8dca5aee12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc705102-aa53-481f-9a23-1466d3023ca6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8548c031-684c-4b27-baed-3a8dca5aee12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7e202e87-297e-4bf3-9124-1d8d3eecee8d" xlink:href="lyel-20230630.xsd#lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc705102-aa53-481f-9a23-1466d3023ca6" xlink:to="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7e202e87-297e-4bf3-9124-1d8d3eecee8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_05b43588-cb16-4ca6-9c45-0c43c3ab25e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d39011f3-8482-44dc-8e22-d44d84a52567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_05b43588-cb16-4ca6-9c45-0c43c3ab25e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d39011f3-8482-44dc-8e22-d44d84a52567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4bc10975-b9d2-45ed-a145-593749d28e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_05b43588-cb16-4ca6-9c45-0c43c3ab25e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4bc10975-b9d2-45ed-a145-593749d28e0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="simple" xlink:href="lyel-20230630.xsd#LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1"/>
  <link:calculationLink xlink:role="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d1a644c2-64c8-46f6-b695-85c0c27d1420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fab38f9b-8e5a-46d5-a298-469d1d55501f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d1a644c2-64c8-46f6-b695-85c0c27d1420" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fab38f9b-8e5a-46d5-a298-469d1d55501f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fe515ed8-0809-4ef5-a369-fa0e53704d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d1a644c2-64c8-46f6-b695-85c0c27d1420" xlink:to="loc_us-gaap_OperatingLeaseLiability_fe515ed8-0809-4ef5-a369-fa0e53704d9a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>lyel-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8f655eeb-886b-4b81-9c30-69669c77ca83,g:e402dc2a-90a6-40a3-91ac-ff661e6149b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended" id="i9801c51dfa7b41b0ae81ccc8e823d302_CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3dbad76c-8615-4f90-9c13-ac16ebcfc9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aa15753c-2a8c-4782-8f2b-928e6ceaa4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3dbad76c-8615-4f90-9c13-ac16ebcfc9ef" xlink:to="loc_us-gaap_Revenues_aa15753c-2a8c-4782-8f2b-928e6ceaa4f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_453d2cdc-4a38-4748-838e-e18ef76e1c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3dbad76c-8615-4f90-9c13-ac16ebcfc9ef" xlink:to="loc_us-gaap_StatementTable_453d2cdc-4a38-4748-838e-e18ef76e1c38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48ff5553-5c40-4db8-801e-2328a09031d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_453d2cdc-4a38-4748-838e-e18ef76e1c38" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48ff5553-5c40-4db8-801e-2328a09031d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_48ff5553-5c40-4db8-801e-2328a09031d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48ff5553-5c40-4db8-801e-2328a09031d6" xlink:to="loc_us-gaap_RelatedPartyDomain_48ff5553-5c40-4db8-801e-2328a09031d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8841a148-16d1-4b29-93d3-0eb728b3db43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48ff5553-5c40-4db8-801e-2328a09031d6" xlink:to="loc_us-gaap_RelatedPartyDomain_8841a148-16d1-4b29-93d3-0eb728b3db43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_95aeeb8d-5d4b-43d9-b3af-e8b1a2897ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8841a148-16d1-4b29-93d3-0eb728b3db43" xlink:to="loc_us-gaap_RelatedPartyMember_95aeeb8d-5d4b-43d9-b3af-e8b1a2897ecd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="idae0174c3c48442aac2933c5b8815557_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d963c9b3-79a9-490b-9ec2-dbb1bbb44c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d963c9b3-79a9-490b-9ec2-dbb1bbb44c8b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5373fc83-74ae-4ef6-8ded-7b96caae6996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5373fc83-74ae-4ef6-8ded-7b96caae6996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e86fe1fc-2169-4abb-b923-330289d041b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockholdersEquity_e86fe1fc-2169-4abb-b923-330289d041b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c501ebfe-a616-4f3c-8005-849368f11a22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c501ebfe-a616-4f3c-8005-849368f11a22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4cc2b5ae-4515-4154-8eea-9a9575f6614e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4cc2b5ae-4515-4154-8eea-9a9575f6614e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2a6d136f-bb47-4fcb-b90a-d362d40d33f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2a6d136f-bb47-4fcb-b90a-d362d40d33f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b55b2044-b58d-42d0-816a-d72a84debe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b55b2044-b58d-42d0-816a-d72a84debe6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_882498eb-771c-4e4b-bf31-2043f6134124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_882498eb-771c-4e4b-bf31-2043f6134124" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_85ad20f2-b385-49b9-ba8a-81699e1fd3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_85ad20f2-b385-49b9-ba8a-81699e1fd3a1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ce92afd9-6f97-4cb4-b13f-2edbfdea2c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ce92afd9-6f97-4cb4-b13f-2edbfdea2c16" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_65b4acc4-a382-4515-9124-5d9ddeb2091c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_65b4acc4-a382-4515-9124-5d9ddeb2091c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84d6bcb0-b7c3-4f19-99f7-754c9ff0c183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84d6bcb0-b7c3-4f19-99f7-754c9ff0c183" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_550f42ee-b7c1-43f2-906a-ffac82869e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_NetIncomeLoss_550f42ee-b7c1-43f2-906a-ffac82869e76" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_59375902-82ef-4475-a7ae-c84d263fc245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9a140b77-a9f4-4709-a698-8252ca2d26bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0b2f01eb-6d3a-413e-8d31-7a9813481a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d963c9b3-79a9-490b-9ec2-dbb1bbb44c8b" xlink:to="loc_us-gaap_StatementTable_0b2f01eb-6d3a-413e-8d31-7a9813481a2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20f3c082-cf98-4430-8a91-79b85c99f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0b2f01eb-6d3a-413e-8d31-7a9813481a2d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20f3c082-cf98-4430-8a91-79b85c99f6a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_20f3c082-cf98-4430-8a91-79b85c99f6a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20f3c082-cf98-4430-8a91-79b85c99f6a1" xlink:to="loc_us-gaap_EquityComponentDomain_20f3c082-cf98-4430-8a91-79b85c99f6a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20f3c082-cf98-4430-8a91-79b85c99f6a1" xlink:to="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf612860-35dd-47ab-a93d-a07a25b1d6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:to="loc_us-gaap_CommonStockMember_cf612860-35dd-47ab-a93d-a07a25b1d6cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2d3e2945-13aa-453b-a858-858736817a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2d3e2945-13aa-453b-a858-858736817a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_066af1b0-356b-45c5-9b98-c8eb1ecb7993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_066af1b0-356b-45c5-9b98-c8eb1ecb7993" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9110608e-b6be-4c0a-ad13-e2d1fc5d4829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:to="loc_us-gaap_RetainedEarningsMember_9110608e-b6be-4c0a-ad13-e2d1fc5d4829" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i662515a6405b40209114f16b676da5ea_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a121fc4a-7695-466c-9408-51227a92573e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:to="loc_us-gaap_Revenues_a121fc4a-7695-466c-9408-51227a92573e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_533e8423-b315-443e-b72e-f8db0874f840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:to="loc_us-gaap_NetIncomeLoss_533e8423-b315-443e-b72e-f8db0874f840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cf4c935c-1441-4b16-8d5d-570741572388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:to="loc_us-gaap_EarningsPerShareBasic_cf4c935c-1441-4b16-8d5d-570741572388" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ea376b84-3a11-4598-ac45-811f62db4186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ea376b84-3a11-4598-ac45-811f62db4186" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_86ff08c4-c4d8-4e41-9c65-fa5f278c0db1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:to="loc_srt_CounterpartyNameAxis_86ff08c4-c4d8-4e41-9c65-fa5f278c0db1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86ff08c4-c4d8-4e41-9c65-fa5f278c0db1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_86ff08c4-c4d8-4e41-9c65-fa5f278c0db1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86ff08c4-c4d8-4e41-9c65-fa5f278c0db1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e6e57ce-bc82-499c-a348-0a3e9d1d305f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_86ff08c4-c4d8-4e41-9c65-fa5f278c0db1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e6e57ce-bc82-499c-a348-0a3e9d1d305f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_6513d9d2-643d-47b2-9110-c6630a39de8b" xlink:href="lyel-20230630.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e6e57ce-bc82-499c-a348-0a3e9d1d305f" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_6513d9d2-643d-47b2-9110-c6630a39de8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ff2fc83b-93b2-4fe9-8e8a-6e2b9395a0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ff2fc83b-93b2-4fe9-8e8a-6e2b9395a0ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ff2fc83b-93b2-4fe9-8e8a-6e2b9395a0ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ff2fc83b-93b2-4fe9-8e8a-6e2b9395a0ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ff2fc83b-93b2-4fe9-8e8a-6e2b9395a0ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f69ee9c-02fb-4d69-877c-a6f250790edb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ff2fc83b-93b2-4fe9-8e8a-6e2b9395a0ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f69ee9c-02fb-4d69-877c-a6f250790edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_98cfebb1-ae66-4a1c-93d9-527945a9f8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f69ee9c-02fb-4d69-877c-a6f250790edb" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_98cfebb1-ae66-4a1c-93d9-527945a9f8eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_960bbb31-b196-42b1-886f-e7c6cc833595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_960bbb31-b196-42b1-886f-e7c6cc833595" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_960bbb31-b196-42b1-886f-e7c6cc833595_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_960bbb31-b196-42b1-886f-e7c6cc833595" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_960bbb31-b196-42b1-886f-e7c6cc833595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_24850a3d-3d21-45cb-8543-27c32f8255bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_960bbb31-b196-42b1-886f-e7c6cc833595" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_24850a3d-3d21-45cb-8543-27c32f8255bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_ded7e761-4f69-4862-959b-9468de44dc92" xlink:href="lyel-20230630.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_24850a3d-3d21-45cb-8543-27c32f8255bc" xlink:to="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_ded7e761-4f69-4862-959b-9468de44dc92" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="extended" id="idbfd4a7fbc9148e3bdd76c0d35f4ecf0_LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_a3bb5dcb-1893-4314-994b-d8ad8000aa1f" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_a3bb5dcb-1893-4314-994b-d8ad8000aa1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_0e7052a4-d299-422f-90b4-ac8e0cc187cc" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_0e7052a4-d299-422f-90b4-ac8e0cc187cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_d9630763-b1a1-4ca4-800f-0f9e993e2d42" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_d9630763-b1a1-4ca4-800f-0f9e993e2d42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_64891a1a-d4b6-49a2-a1d6-e07d7e533af8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_64891a1a-d4b6-49a2-a1d6-e07d7e533af8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_b39cd44c-7f60-429c-9103-e8395f965063" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_b39cd44c-7f60-429c-9103-e8395f965063" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_994dc1d6-a491-47ce-aad1-9c248aa05bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_994dc1d6-a491-47ce-aad1-9c248aa05bc5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_01063908-71e4-440b-b722-96f1b5b60a60" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_01063908-71e4-440b-b722-96f1b5b60a60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_936b6835-9630-4431-ae70-67431b0665c2" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_936b6835-9630-4431-ae70-67431b0665c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_3ac2d7a6-c61b-4529-a636-993192c425f5" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_3ac2d7a6-c61b-4529-a636-993192c425f5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_6ec19227-05a3-4258-a6f2-e612d5347587" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_6ec19227-05a3-4258-a6f2-e612d5347587" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_52dde57b-f088-4d3b-a4d5-273fea7d270c" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_52dde57b-f088-4d3b-a4d5-273fea7d270c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_34fca0c1-e48a-441c-ac73-70165720e81b" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_34fca0c1-e48a-441c-ac73-70165720e81b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_6a756238-c2db-4e68-9c22-e69dedd23894" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_6a756238-c2db-4e68-9c22-e69dedd23894" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_db92a7e7-4adc-4e1c-8956-d63cfbeeab84" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_db92a7e7-4adc-4e1c-8956-d63cfbeeab84" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_0e750385-6226-464d-9b10-25b0a304b71d" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_0e750385-6226-464d-9b10-25b0a304b71d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_020ad9e3-6a5c-4554-aed9-e76bff81c09e" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_020ad9e3-6a5c-4554-aed9-e76bff81c09e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2b059a84-e0a0-4a38-bc70-a97fe12170dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2b059a84-e0a0-4a38-bc70-a97fe12170dd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSold_6d8970fb-98bf-4c66-9f5b-d8cc1960ce02" xlink:href="lyel-20230630.xsd#lyel_StockPurchaseAgreementSharesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_StockPurchaseAgreementSharesSold_6d8970fb-98bf-4c66-9f5b-d8cc1960ce02" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare_9e54add0-d2cd-4b13-a4ff-01634174a8bc" xlink:href="lyel-20230630.xsd#lyel_StockPurchaseAgreementSharesSoldPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare_9e54add0-d2cd-4b13-a4ff-01634174a8bc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare_93445b84-8758-4d3c-ae07-259e6cf4b828" xlink:href="lyel-20230630.xsd#lyel_StockPurchaseAgreementFairValueOfStockPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare_93445b84-8758-4d3c-ae07-259e6cf4b828" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_526d7166-909c-41e6-b880-187c8eb29c5e" xlink:href="lyel-20230630.xsd#lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_526d7166-909c-41e6-b880-187c8eb29c5e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c998ee61-2f60-4f57-b1e8-f2b82fbf06d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c998ee61-2f60-4f57-b1e8-f2b82fbf06d1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68fffa51-df91-4c6a-9dd0-ea4a866d3594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68fffa51-df91-4c6a-9dd0-ea4a866d3594" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_da9b7c00-f7a6-4fa9-924a-ba5dc00bc8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_da9b7c00-f7a6-4fa9-924a-ba5dc00bc8a3" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement_ece24c9c-3b50-4e15-8256-18579929810e" xlink:href="lyel-20230630.xsd#lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement_ece24c9c-3b50-4e15-8256-18579929810e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased_39b9f7d2-c03f-4261-90e4-a6e463044dde" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased_39b9f7d2-c03f-4261-90e4-a6e463044dde" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare_1e0fd328-0a18-4987-88d9-1402b54bda4d" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare_1e0fd328-0a18-4987-88d9-1402b54bda4d" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare_1c780593-72bf-4ac4-8380-bbf9da5b254f" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare_1c780593-72bf-4ac4-8380-bbf9da5b254f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice_769acc6e-4214-4d44-95ff-8cf39b5e5c17" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice_769acc6e-4214-4d44-95ff-8cf39b5e5c17" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_f4b4efc6-1d77-42a4-8e3f-b8acbb565b8b" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_f4b4efc6-1d77-42a4-8e3f-b8acbb565b8b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f66b75e-bff7-44d8-909d-8043fb486277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f66b75e-bff7-44d8-909d-8043fb486277" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_3793b501-9df8-49c9-8ca5-62c75e667038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_3793b501-9df8-49c9-8ca5-62c75e667038" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LitigationSettlementPercentOfTotalEquityValue_b213349c-9efe-4692-9081-516f8e590725" xlink:href="lyel-20230630.xsd#lyel_LitigationSettlementPercentOfTotalEquityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_LitigationSettlementPercentOfTotalEquityValue_b213349c-9efe-4692-9081-516f8e590725" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3cc0c86e-0725-4e3d-a5d9-eaae254f2e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3cc0c86e-0725-4e3d-a5d9-eaae254f2e97" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c93a8f7-7837-4adf-97f3-3e970e4cb8ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_srt_CounterpartyNameAxis_5c93a8f7-7837-4adf-97f3-3e970e4cb8ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c93a8f7-7837-4adf-97f3-3e970e4cb8ba_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5c93a8f7-7837-4adf-97f3-3e970e4cb8ba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c93a8f7-7837-4adf-97f3-3e970e4cb8ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5c93a8f7-7837-4adf-97f3-3e970e4cb8ba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_81bfce72-593c-476d-9e8e-ac420ebc3763" xlink:href="lyel-20230630.xsd#lyel_FredHutchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:to="loc_lyel_FredHutchMember_81bfce72-593c-476d-9e8e-ac420ebc3763" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_f90fbaeb-6f40-4c49-ad51-f0a330c73fbf" xlink:href="lyel-20230630.xsd#lyel_StanfordMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:to="loc_lyel_StanfordMember_f90fbaeb-6f40-4c49-ad51-f0a330c73fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_f950d15a-b5d4-42ed-bcc7-460f97d15d0a" xlink:href="lyel-20230630.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_f950d15a-b5d4-42ed-bcc7-460f97d15d0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_e3cf0bde-0114-4d6a-8628-5ab5dc543a63" xlink:href="lyel-20230630.xsd#lyel_PACTPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:to="loc_lyel_PACTPharmaIncMember_e3cf0bde-0114-4d6a-8628-5ab5dc543a63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0bfbd065-8fe5-4a45-827e-b1e59a94f60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0bfbd065-8fe5-4a45-827e-b1e59a94f60c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bfbd065-8fe5-4a45-827e-b1e59a94f60c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0bfbd065-8fe5-4a45-827e-b1e59a94f60c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bfbd065-8fe5-4a45-827e-b1e59a94f60c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b21add1-bec4-4ee5-83ff-9aa3e011afd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0bfbd065-8fe5-4a45-827e-b1e59a94f60c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b21add1-bec4-4ee5-83ff-9aa3e011afd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_2b734981-1472-439d-9644-dd53e208368b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b21add1-bec4-4ee5-83ff-9aa3e011afd8" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_2b734981-1472-439d-9644-dd53e208368b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6afaefa8-60bb-4063-8a96-6188e83c1284" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_srt_RangeAxis_6afaefa8-60bb-4063-8a96-6188e83c1284" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6afaefa8-60bb-4063-8a96-6188e83c1284_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6afaefa8-60bb-4063-8a96-6188e83c1284" xlink:to="loc_srt_RangeMember_6afaefa8-60bb-4063-8a96-6188e83c1284_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e99be475-322f-498b-a19d-e43c3c46cac9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6afaefa8-60bb-4063-8a96-6188e83c1284" xlink:to="loc_srt_RangeMember_e99be475-322f-498b-a19d-e43c3c46cac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cfba40d8-f364-4dbc-ab81-b6b42cf8ab80" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e99be475-322f-498b-a19d-e43c3c46cac9" xlink:to="loc_srt_MinimumMember_cfba40d8-f364-4dbc-ab81-b6b42cf8ab80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2030319c-10f3-4f52-9252-9aa689a5ea6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e99be475-322f-498b-a19d-e43c3c46cac9" xlink:to="loc_srt_MaximumMember_2030319c-10f3-4f52-9252-9aa689a5ea6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3e504c02-2dff-41eb-b2e2-5a0dab269a3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_srt_ProductOrServiceAxis_3e504c02-2dff-41eb-b2e2-5a0dab269a3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3e504c02-2dff-41eb-b2e2-5a0dab269a3b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3e504c02-2dff-41eb-b2e2-5a0dab269a3b" xlink:to="loc_srt_ProductsAndServicesDomain_3e504c02-2dff-41eb-b2e2-5a0dab269a3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bcedb060-b24b-42d0-bbff-e1276dc59a7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3e504c02-2dff-41eb-b2e2-5a0dab269a3b" xlink:to="loc_srt_ProductsAndServicesDomain_bcedb060-b24b-42d0-bbff-e1276dc59a7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_2e76759d-b2d7-490a-b17b-17b791856e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bcedb060-b24b-42d0-bbff-e1276dc59a7f" xlink:to="loc_us-gaap_LicenseMember_2e76759d-b2d7-490a-b17b-17b791856e59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_07ad10b0-d422-42a4-b65d-f55fc4f8b24f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_StatementClassOfStockAxis_07ad10b0-d422-42a4-b65d-f55fc4f8b24f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_07ad10b0-d422-42a4-b65d-f55fc4f8b24f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07ad10b0-d422-42a4-b65d-f55fc4f8b24f" xlink:to="loc_us-gaap_ClassOfStockDomain_07ad10b0-d422-42a4-b65d-f55fc4f8b24f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ff340f5f-5076-48f0-ba58-3155ceefb5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07ad10b0-d422-42a4-b65d-f55fc4f8b24f" xlink:to="loc_us-gaap_ClassOfStockDomain_ff340f5f-5076-48f0-ba58-3155ceefb5a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAConvertiblePreferredStockMember_0b26f348-e95a-484e-aeef-efbe4ea55298" xlink:href="lyel-20230630.xsd#lyel_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ff340f5f-5076-48f0-ba58-3155ceefb5a3" xlink:to="loc_lyel_SeriesAConvertiblePreferredStockMember_0b26f348-e95a-484e-aeef-efbe4ea55298" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAAConvertiblePreferredStockMember_72c9bed7-f7ae-4cf6-b80e-0d23e684de28" xlink:href="lyel-20230630.xsd#lyel_SeriesAAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ff340f5f-5076-48f0-ba58-3155ceefb5a3" xlink:to="loc_lyel_SeriesAAConvertiblePreferredStockMember_72c9bed7-f7ae-4cf6-b80e-0d23e684de28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_24e7a2cf-c3f7-45b8-a892-338feb7aacb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_InvestmentTypeAxis_24e7a2cf-c3f7-45b8-a892-338feb7aacb7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_24e7a2cf-c3f7-45b8-a892-338feb7aacb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_24e7a2cf-c3f7-45b8-a892-338feb7aacb7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_24e7a2cf-c3f7-45b8-a892-338feb7aacb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d08200ce-b106-45ff-9a6b-cf4245e82d47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_24e7a2cf-c3f7-45b8-a892-338feb7aacb7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d08200ce-b106-45ff-9a6b-cf4245e82d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_c60b4f36-18b9-4842-8fa4-8e6913e7559c" xlink:href="lyel-20230630.xsd#lyel_OtherInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d08200ce-b106-45ff-9a6b-cf4245e82d47" xlink:to="loc_lyel_OtherInvestmentMember_c60b4f36-18b9-4842-8fa4-8e6913e7559c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ad9d8848-c041-43b7-96e4-2436111073f4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ad9d8848-c041-43b7-96e4-2436111073f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ad9d8848-c041-43b7-96e4-2436111073f4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ad9d8848-c041-43b7-96e4-2436111073f4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ad9d8848-c041-43b7-96e4-2436111073f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_67b0428f-1ee0-4b1c-85a2-dcddd7b9edd7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ad9d8848-c041-43b7-96e4-2436111073f4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_67b0428f-1ee0-4b1c-85a2-dcddd7b9edd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_84ad7fd8-b124-401b-909f-da729745e4db" xlink:href="lyel-20230630.xsd#lyel_PACTPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_67b0428f-1ee0-4b1c-85a2-dcddd7b9edd7" xlink:to="loc_lyel_PACTPharmaIncMember_84ad7fd8-b124-401b-909f-da729745e4db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_0a4a57b1-b73f-4701-865c-562e614c4a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_LitigationStatusAxis_0a4a57b1-b73f-4701-865c-562e614c4a45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_0a4a57b1-b73f-4701-865c-562e614c4a45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_0a4a57b1-b73f-4701-865c-562e614c4a45" xlink:to="loc_us-gaap_LitigationStatusDomain_0a4a57b1-b73f-4701-865c-562e614c4a45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_25b574eb-eca5-4d4d-8a88-04fb03415d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_0a4a57b1-b73f-4701-865c-562e614c4a45" xlink:to="loc_us-gaap_LitigationStatusDomain_25b574eb-eca5-4d4d-8a88-04fb03415d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_1dbbd2a9-5322-4992-9d56-5457f641bfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_25b574eb-eca5-4d4d-8a88-04fb03415d85" xlink:to="loc_us-gaap_SettledLitigationMember_1dbbd2a9-5322-4992-9d56-5457f641bfe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ef94902f-806c-4405-9cd6-76d65682e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ef94902f-806c-4405-9cd6-76d65682e5c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ef94902f-806c-4405-9cd6-76d65682e5c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ef94902f-806c-4405-9cd6-76d65682e5c7" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ef94902f-806c-4405-9cd6-76d65682e5c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9bb9632a-e217-40a1-a92d-e0c95fe5aa50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ef94902f-806c-4405-9cd6-76d65682e5c7" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9bb9632a-e217-40a1-a92d-e0c95fe5aa50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_25de5753-ae5b-4609-9599-879a3b102518" xlink:href="lyel-20230630.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9bb9632a-e217-40a1-a92d-e0c95fe5aa50" xlink:to="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_25de5753-ae5b-4609-9599-879a3b102518" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="extended" id="idcee29f136d84817bd1f4aab2bbe1289_LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_55df5d57-ccd5-4d66-8516-f90edae7971e" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_55df5d57-ccd5-4d66-8516-f90edae7971e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_ddf3eb49-5bda-414e-a341-7d1f446b5bc1" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_ddf3eb49-5bda-414e-a341-7d1f446b5bc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_850c2ddc-9253-4b25-ab72-864bb1c0c5d1" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_850c2ddc-9253-4b25-ab72-864bb1c0c5d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_246888f4-b416-4e3f-9664-7bd60a7e939b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_246888f4-b416-4e3f-9664-7bd60a7e939b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_246888f4-b416-4e3f-9664-7bd60a7e939b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_246888f4-b416-4e3f-9664-7bd60a7e939b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_246888f4-b416-4e3f-9664-7bd60a7e939b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1dcf131b-8690-4638-8a46-4c9f523df323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_246888f4-b416-4e3f-9664-7bd60a7e939b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1dcf131b-8690-4638-8a46-4c9f523df323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_53c5b61a-bbd5-419e-85be-d7a430f5fd19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1dcf131b-8690-4638-8a46-4c9f523df323" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_53c5b61a-bbd5-419e-85be-d7a430f5fd19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleAxis_8130a01e-3644-4de0-a0ca-638bf18cc8f1" xlink:href="lyel-20230630.xsd#lyel_EquityMultipleAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:to="loc_lyel_EquityMultipleAxis_8130a01e-3644-4de0-a0ca-638bf18cc8f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain_8130a01e-3644-4de0-a0ca-638bf18cc8f1_default" xlink:href="lyel-20230630.xsd#lyel_EquityMultipleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lyel_EquityMultipleAxis_8130a01e-3644-4de0-a0ca-638bf18cc8f1" xlink:to="loc_lyel_EquityMultipleDomain_8130a01e-3644-4de0-a0ca-638bf18cc8f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:href="lyel-20230630.xsd#lyel_EquityMultipleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lyel_EquityMultipleAxis_8130a01e-3644-4de0-a0ca-638bf18cc8f1" xlink:to="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TenTimesMember_fba506fc-4167-45d5-87bc-99cb541dd936" xlink:href="lyel-20230630.xsd#lyel_TenTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_TenTimesMember_fba506fc-4167-45d5-87bc-99cb541dd936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwentyTimesMember_91bb329f-a727-4ce1-ab30-d46e8ea44013" xlink:href="lyel-20230630.xsd#lyel_TwentyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_TwentyTimesMember_91bb329f-a727-4ce1-ab30-d46e8ea44013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ThirtyTimesMember_6f95166e-716a-419a-9741-d1778d0aec81" xlink:href="lyel-20230630.xsd#lyel_ThirtyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_ThirtyTimesMember_6f95166e-716a-419a-9741-d1778d0aec81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FortyTimesMember_eae0ef18-82e9-4691-a7a8-230d1575a588" xlink:href="lyel-20230630.xsd#lyel_FortyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_FortyTimesMember_eae0ef18-82e9-4691-a7a8-230d1575a588" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FiftyTimesMember_b24f6be2-0a73-414e-b583-59388959c60b" xlink:href="lyel-20230630.xsd#lyel_FiftyTimesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_FiftyTimesMember_b24f6be2-0a73-414e-b583-59388959c60b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fd999fd7-8a71-4118-a26a-4449527ba824" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:to="loc_srt_CounterpartyNameAxis_fd999fd7-8a71-4118-a26a-4449527ba824" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd999fd7-8a71-4118-a26a-4449527ba824_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fd999fd7-8a71-4118-a26a-4449527ba824" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd999fd7-8a71-4118-a26a-4449527ba824_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87634e91-7ea0-4dab-a5b0-36f2d9360682" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fd999fd7-8a71-4118-a26a-4449527ba824" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87634e91-7ea0-4dab-a5b0-36f2d9360682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_e795e6fa-8bb1-4438-9391-0dd9a2a9f5fe" xlink:href="lyel-20230630.xsd#lyel_FredHutchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87634e91-7ea0-4dab-a5b0-36f2d9360682" xlink:to="loc_lyel_FredHutchMember_e795e6fa-8bb1-4438-9391-0dd9a2a9f5fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_ac6f14a7-909c-4c5f-9ed0-b2c3fc2c9245" xlink:href="lyel-20230630.xsd#lyel_StanfordMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87634e91-7ea0-4dab-a5b0-36f2d9360682" xlink:to="loc_lyel_StanfordMember_ac6f14a7-909c-4c5f-9ed0-b2c3fc2c9245" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="idfa65e886f9449bbb0ba3fd2253d9146_CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da118e7b-0cb1-451c-8c7b-03d6421bce13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da118e7b-0cb1-451c-8c7b-03d6421bce13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1d3e04d-41dd-48d2-b564-ba75f87b8308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1d3e04d-41dd-48d2-b564-ba75f87b8308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_898939ea-5530-4a79-8c22-ee7828ac8cc2" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_898939ea-5530-4a79-8c22-ee7828ac8cc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_33c32797-29cd-4ea8-97a2-bf85847dc32b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_33c32797-29cd-4ea8-97a2-bf85847dc32b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1076bca0-2566-4c3c-8af2-b34895eb2155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1076bca0-2566-4c3c-8af2-b34895eb2155" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c754fea-09a6-496b-ad69-c781d07d7184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c754fea-09a6-496b-ad69-c781d07d7184" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4a77f21-7740-4692-8bf9-551de2fdfc40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4a77f21-7740-4692-8bf9-551de2fdfc40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_170514b4-e3b9-40fa-bd03-db5ee4b6c350" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_170514b4-e3b9-40fa-bd03-db5ee4b6c350" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosure_44d5c963-67c0-4418-beaf-13521c7d0e2c" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosure_44d5c963-67c0-4418-beaf-13521c7d0e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_02ab1770-3765-47e1-9fee-65a6b83ea7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_02ab1770-3765-47e1-9fee-65a6b83ea7a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_887611e3-ad3b-44c2-b047-1d89a4aa6c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_887611e3-ad3b-44c2-b047-1d89a4aa6c7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_969cb944-7d18-4f71-bb22-c34a97d93108" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_45478bb1-6034-4b9a-8e2e-f5cf007559eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_MarketableSecuritiesTable_45478bb1-6034-4b9a-8e2e-f5cf007559eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5d266f78-1ef3-424f-afc3-a8354e028c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_45478bb1-6034-4b9a-8e2e-f5cf007559eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5d266f78-1ef3-424f-afc3-a8354e028c2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d266f78-1ef3-424f-afc3-a8354e028c2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5d266f78-1ef3-424f-afc3-a8354e028c2d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d266f78-1ef3-424f-afc3-a8354e028c2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_262ee032-91cf-4b74-8494-8fea5b745025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5d266f78-1ef3-424f-afc3-a8354e028c2d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_262ee032-91cf-4b74-8494-8fea5b745025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_234c8848-d5c6-41d9-84b2-ed5fb000bd25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_262ee032-91cf-4b74-8494-8fea5b745025" xlink:to="loc_us-gaap_MoneyMarketFundsMember_234c8848-d5c6-41d9-84b2-ed5fb000bd25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6049c959-bf4d-4cbc-85f4-ec0c088d4035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_45478bb1-6034-4b9a-8e2e-f5cf007559eb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6049c959-bf4d-4cbc-85f4-ec0c088d4035" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6049c959-bf4d-4cbc-85f4-ec0c088d4035_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6049c959-bf4d-4cbc-85f4-ec0c088d4035" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6049c959-bf4d-4cbc-85f4-ec0c088d4035_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6049c959-bf4d-4cbc-85f4-ec0c088d4035" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6acccf42-806c-464d-a2e4-fe14f8b5c0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6acccf42-806c-464d-a2e4-fe14f8b5c0ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e8b1b24b-3d49-49b8-b917-70ee5da683a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e8b1b24b-3d49-49b8-b917-70ee5da683a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_38a8a73d-ef22-4a00-8fab-5f31ca62fac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_38a8a73d-ef22-4a00-8fab-5f31ca62fac2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#CashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended" id="i9b2dbfd5df864b57b6abd6ab549dca31_CashEquivalentsandMarketableSecuritiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e470f54d-d7ac-4c51-b7f1-5f0702e06797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e470f54d-d7ac-4c51-b7f1-5f0702e06797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d387edb6-851a-430b-a659-e40f5cd7e1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d387edb6-851a-430b-a659-e40f5cd7e1a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_3cd50f06-9ef9-4504-bf98-5cc6681f270e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_3cd50f06-9ef9-4504-bf98-5cc6681f270e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_caf1e2b5-6258-4b73-912d-2ac85843fadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:to="loc_us-gaap_MarketableSecuritiesTable_caf1e2b5-6258-4b73-912d-2ac85843fadd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d28371fe-dc1f-46be-9c42-55951338ad6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_caf1e2b5-6258-4b73-912d-2ac85843fadd" xlink:to="loc_srt_RangeAxis_d28371fe-dc1f-46be-9c42-55951338ad6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d28371fe-dc1f-46be-9c42-55951338ad6c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d28371fe-dc1f-46be-9c42-55951338ad6c" xlink:to="loc_srt_RangeMember_d28371fe-dc1f-46be-9c42-55951338ad6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c752f2f-a43e-425c-a294-d55e62bb5cbe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d28371fe-dc1f-46be-9c42-55951338ad6c" xlink:to="loc_srt_RangeMember_0c752f2f-a43e-425c-a294-d55e62bb5cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cb76a96e-3fd9-40de-86c9-b44606df7c89" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c752f2f-a43e-425c-a294-d55e62bb5cbe" xlink:to="loc_srt_MaximumMember_cb76a96e-3fd9-40de-86c9-b44606df7c89" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#OtherInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="extended" id="ic550e019a27f46ad88ebd73b3566fc7e_OtherInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_0d95faae-4a66-47a0-ac61-7b3eb1d0abb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:to="loc_us-gaap_OtherInvestments_0d95faae-4a66-47a0-ac61-7b3eb1d0abb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_a92ea7bb-8807-4fb6-bb18-e30818ec2d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_a92ea7bb-8807-4fb6-bb18-e30818ec2d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6de63da1-66b8-420d-92c7-134f4d7dc672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6de63da1-66b8-420d-92c7-134f4d7dc672" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_39ea1815-2d0c-4749-a6cf-fb5d54db3b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_39ea1815-2d0c-4749-a6cf-fb5d54db3b4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_536c9113-3929-494b-9756-4fb700c3b49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_536c9113-3929-494b-9756-4fb700c3b49e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_086424d7-3495-4c8a-8259-7278201cc1c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_536c9113-3929-494b-9756-4fb700c3b49e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_086424d7-3495-4c8a-8259-7278201cc1c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_086424d7-3495-4c8a-8259-7278201cc1c7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_086424d7-3495-4c8a-8259-7278201cc1c7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_086424d7-3495-4c8a-8259-7278201cc1c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a1fc622a-24d6-42eb-99c4-941a10cc452e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_086424d7-3495-4c8a-8259-7278201cc1c7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a1fc622a-24d6-42eb-99c4-941a10cc452e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_fdfeaf4f-05fb-49a8-9e58-7c161738753b" xlink:href="lyel-20230630.xsd#lyel_OtherInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a1fc622a-24d6-42eb-99c4-941a10cc452e" xlink:to="loc_lyel_OtherInvestmentMember_fdfeaf4f-05fb-49a8-9e58-7c161738753b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_063fac03-d8d8-48cc-bfc6-87ceb9a50224" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_536c9113-3929-494b-9756-4fb700c3b49e" xlink:to="loc_srt_CounterpartyNameAxis_063fac03-d8d8-48cc-bfc6-87ceb9a50224" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_063fac03-d8d8-48cc-bfc6-87ceb9a50224_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_063fac03-d8d8-48cc-bfc6-87ceb9a50224" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_063fac03-d8d8-48cc-bfc6-87ceb9a50224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe84c1f6-40c0-4062-9df5-cc314022eba2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_063fac03-d8d8-48cc-bfc6-87ceb9a50224" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe84c1f6-40c0-4062-9df5-cc314022eba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_e474d28a-a71d-4a3a-ab6e-ed55f3200ee8" xlink:href="lyel-20230630.xsd#lyel_PACTPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe84c1f6-40c0-4062-9df5-cc314022eba2" xlink:to="loc_lyel_PACTPharmaIncMember_e474d28a-a71d-4a3a-ab6e-ed55f3200ee8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i9e57c87286ee4234af91d3e1cbb7abd4_FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7caa9e70-1ffe-47d3-93c2-d1e813ca671c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7caa9e70-1ffe-47d3-93c2-d1e813ca671c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f26d49d9-7bb2-4e02-a5e8-6f3cef107bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f26d49d9-7bb2-4e02-a5e8-6f3cef107bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dc34ac7-7018-402b-b434-24a0f575a737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dc34ac7-7018-402b-b434-24a0f575a737" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3a1b6cc3-ad9a-412c-92ac-e12283d6ab1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3a1b6cc3-ad9a-412c-92ac-e12283d6ab1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_67731ec3-090e-4577-903c-d89734026890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7caa9e70-1ffe-47d3-93c2-d1e813ca671c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_67731ec3-090e-4577-903c-d89734026890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_0dc98e28-479b-4b59-bcac-f8bec4ddd85b" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_67731ec3-090e-4577-903c-d89734026890" xlink:to="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_0dc98e28-479b-4b59-bcac-f8bec4ddd85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_36e60c49-6ad5-4664-bfb3-b62e32cb3668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_67731ec3-090e-4577-903c-d89734026890" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_36e60c49-6ad5-4664-bfb3-b62e32cb3668" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7caa9e70-1ffe-47d3-93c2-d1e813ca671c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a2e3581-fb04-435f-b81d-de52324291a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a2e3581-fb04-435f-b81d-de52324291a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a2e3581-fb04-435f-b81d-de52324291a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a2e3581-fb04-435f-b81d-de52324291a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a2e3581-fb04-435f-b81d-de52324291a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a2e3581-fb04-435f-b81d-de52324291a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ef994f5d-64b3-4394-b050-fc5447e41e73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ef994f5d-64b3-4394-b050-fc5447e41e73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_763ce1bb-1b99-4ca3-9f74-e6edb4a6d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_763ce1bb-1b99-4ca3-9f74-e6edb4a6d7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2fcd046-7596-4529-a1f8-02d896e37808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2fcd046-7596-4529-a1f8-02d896e37808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_0d18a99b-2b2b-4ee7-9aa7-e885cb6e94d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_0d18a99b-2b2b-4ee7-9aa7-e885cb6e94d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d18a99b-2b2b-4ee7-9aa7-e885cb6e94d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_0d18a99b-2b2b-4ee7-9aa7-e885cb6e94d7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d18a99b-2b2b-4ee7-9aa7-e885cb6e94d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ec4962-58fe-4132-b042-118215ef1897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_0d18a99b-2b2b-4ee7-9aa7-e885cb6e94d7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ec4962-58fe-4132-b042-118215ef1897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b0f2c6f0-a032-4782-8455-adb985546713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ec4962-58fe-4132-b042-118215ef1897" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b0f2c6f0-a032-4782-8455-adb985546713" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ca4d2716-090f-42ba-b5ac-4cd6af6975f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ca4d2716-090f-42ba-b5ac-4cd6af6975f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca4d2716-090f-42ba-b5ac-4cd6af6975f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca4d2716-090f-42ba-b5ac-4cd6af6975f4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca4d2716-090f-42ba-b5ac-4cd6af6975f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca4d2716-090f-42ba-b5ac-4cd6af6975f4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7f0c82b6-a6d0-499a-bd1b-c1cc03ed3644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7f0c82b6-a6d0-499a-bd1b-c1cc03ed3644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2be3d8ae-59b6-4c3c-97b3-ac81c7e9e8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2be3d8ae-59b6-4c3c-97b3-ac81c7e9e8c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1d961405-9429-47dd-818d-78f9e5641bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1d961405-9429-47dd-818d-78f9e5641bfc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="extended" id="if979ef087c5d44d28f2d14441ae45755_FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df305579-ef3d-4c34-8e40-31aead82fada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock_b9447ce7-0914-41ad-869b-42c4a0e053a5" xlink:href="lyel-20230630.xsd#lyel_FairValueOfSeriesAConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df305579-ef3d-4c34-8e40-31aead82fada" xlink:to="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock_b9447ce7-0914-41ad-869b-42c4a0e053a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMeasurementInput_390a13f1-35bf-4519-9674-68b074e58caf" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df305579-ef3d-4c34-8e40-31aead82fada" xlink:to="loc_lyel_SuccessPaymentLiabilityMeasurementInput_390a13f1-35bf-4519-9674-68b074e58caf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df305579-ef3d-4c34-8e40-31aead82fada" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_41cc3396-c5d2-48a1-9c9e-ab07ef2e106f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_41cc3396-c5d2-48a1-9c9e-ab07ef2e106f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_41cc3396-c5d2-48a1-9c9e-ab07ef2e106f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_41cc3396-c5d2-48a1-9c9e-ab07ef2e106f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_41cc3396-c5d2-48a1-9c9e-ab07ef2e106f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_97a1b331-0276-4724-ab80-1bb3d364d11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_41cc3396-c5d2-48a1-9c9e-ab07ef2e106f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_97a1b331-0276-4724-ab80-1bb3d364d11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchSuccessPaymentLiabilityMember_57db08c8-0cfb-4346-93b0-050b60e1a049" xlink:href="lyel-20230630.xsd#lyel_FredHutchSuccessPaymentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_97a1b331-0276-4724-ab80-1bb3d364d11f" xlink:to="loc_lyel_FredHutchSuccessPaymentLiabilityMember_57db08c8-0cfb-4346-93b0-050b60e1a049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordSuccessPaymentLiabilityMember_a3471994-91f9-48a1-b281-835b8a6bfa87" xlink:href="lyel-20230630.xsd#lyel_StanfordSuccessPaymentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_97a1b331-0276-4724-ab80-1bb3d364d11f" xlink:to="loc_lyel_StanfordSuccessPaymentLiabilityMember_a3471994-91f9-48a1-b281-835b8a6bfa87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f86cf14c-8480-4ab2-88c6-f196ad827d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f86cf14c-8480-4ab2-88c6-f196ad827d85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f86cf14c-8480-4ab2-88c6-f196ad827d85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f86cf14c-8480-4ab2-88c6-f196ad827d85" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f86cf14c-8480-4ab2-88c6-f196ad827d85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f86cf14c-8480-4ab2-88c6-f196ad827d85" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6c01be57-2c01-43d6-a5ea-94763fb2c092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6c01be57-2c01-43d6-a5ea-94763fb2c092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2df41f32-7a8c-421f-a7ee-b2f42a9031d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2df41f32-7a8c-421f-a7ee-b2f42a9031d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_56e1eca0-2a9c-41dc-b3bb-442c43a1f7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_56e1eca0-2a9c-41dc-b3bb-442c43a1f7ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81c9e33b-303d-4b98-aa67-842553ea91fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:to="loc_srt_RangeAxis_81c9e33b-303d-4b98-aa67-842553ea91fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81c9e33b-303d-4b98-aa67-842553ea91fa_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_81c9e33b-303d-4b98-aa67-842553ea91fa" xlink:to="loc_srt_RangeMember_81c9e33b-303d-4b98-aa67-842553ea91fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_66440270-66ba-4e93-8590-17fca6c03801" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_81c9e33b-303d-4b98-aa67-842553ea91fa" xlink:to="loc_srt_RangeMember_66440270-66ba-4e93-8590-17fca6c03801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_39ca7f89-df87-47b2-ad8b-9b08f7697210" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_66440270-66ba-4e93-8590-17fca6c03801" xlink:to="loc_srt_MinimumMember_39ca7f89-df87-47b2-ad8b-9b08f7697210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b71eee4-c586-4a50-ae9a-496cdb3cac82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_66440270-66ba-4e93-8590-17fca6c03801" xlink:to="loc_srt_MaximumMember_2b71eee4-c586-4a50-ae9a-496cdb3cac82" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="extended" id="i86a4748fd85c471ba3600267b01aa2ca_FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb36d070-eeb5-46ec-abfc-dc3dc4ed01c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73164575-5dc0-4cd5-aff4-3b24d85d8aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb36d070-eeb5-46ec-abfc-dc3dc4ed01c4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73164575-5dc0-4cd5-aff4-3b24d85d8aee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_54ecce91-40e7-45c9-8b93-74e9d1363065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73164575-5dc0-4cd5-aff4-3b24d85d8aee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_54ecce91-40e7-45c9-8b93-74e9d1363065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_269e6b45-616e-48f5-9386-0229da99f752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73164575-5dc0-4cd5-aff4-3b24d85d8aee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_269e6b45-616e-48f5-9386-0229da99f752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0009faf9-e442-41f5-9dfb-56c8962fa409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_b84b39af-c128-401d-9b69-935a0e459235" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb36d070-eeb5-46ec-abfc-dc3dc4ed01c4" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_b84b39af-c128-401d-9b69-935a0e459235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb36d070-eeb5-46ec-abfc-dc3dc4ed01c4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4b99aa77-9c34-4f5d-a436-b4bf0018f009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:to="loc_us-gaap_InvestmentTypeAxis_4b99aa77-9c34-4f5d-a436-b4bf0018f009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4b99aa77-9c34-4f5d-a436-b4bf0018f009_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4b99aa77-9c34-4f5d-a436-b4bf0018f009" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4b99aa77-9c34-4f5d-a436-b4bf0018f009_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_62f506b7-1b0f-4e6f-94cd-be5a9a10e56d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4b99aa77-9c34-4f5d-a436-b4bf0018f009" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_62f506b7-1b0f-4e6f-94cd-be5a9a10e56d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMember_c17a4156-7f46-4013-9e4e-32d4e7017fe6" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62f506b7-1b0f-4e6f-94cd-be5a9a10e56d" xlink:to="loc_lyel_SuccessPaymentLiabilityMember_c17a4156-7f46-4013-9e4e-32d4e7017fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7f49eccc-e9ad-4c97-b848-3b9a36b8dbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7f49eccc-e9ad-4c97-b848-3b9a36b8dbfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f49eccc-e9ad-4c97-b848-3b9a36b8dbfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7f49eccc-e9ad-4c97-b848-3b9a36b8dbfb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f49eccc-e9ad-4c97-b848-3b9a36b8dbfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d3ceb0f-6641-4639-8512-06782d5b6f01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7f49eccc-e9ad-4c97-b848-3b9a36b8dbfb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d3ceb0f-6641-4639-8512-06782d5b6f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1bb6cc65-79d8-4e0b-9d32-ff44969d00b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d3ceb0f-6641-4639-8512-06782d5b6f01" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1bb6cc65-79d8-4e0b-9d32-ff44969d00b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5ce7cf84-1e6c-41f2-9ed8-ffb9586b8ce5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:to="loc_srt_CounterpartyNameAxis_5ce7cf84-1e6c-41f2-9ed8-ffb9586b8ce5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ce7cf84-1e6c-41f2-9ed8-ffb9586b8ce5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5ce7cf84-1e6c-41f2-9ed8-ffb9586b8ce5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ce7cf84-1e6c-41f2-9ed8-ffb9586b8ce5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43e6dcfe-0e98-48d5-bdc1-bdf2a784ddc0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5ce7cf84-1e6c-41f2-9ed8-ffb9586b8ce5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43e6dcfe-0e98-48d5-bdc1-bdf2a784ddc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_48c75bd1-d81e-4acc-bce2-ea348bf41a37" xlink:href="lyel-20230630.xsd#lyel_FredHutchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43e6dcfe-0e98-48d5-bdc1-bdf2a784ddc0" xlink:to="loc_lyel_FredHutchMember_48c75bd1-d81e-4acc-bce2-ea348bf41a37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_41a7517c-e549-4316-816c-bd5a97a6e491" xlink:href="lyel-20230630.xsd#lyel_StanfordMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43e6dcfe-0e98-48d5-bdc1-bdf2a784ddc0" xlink:to="loc_lyel_StanfordMember_41a7517c-e549-4316-816c-bd5a97a6e491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e60e90ff-d76d-42d5-baba-befd319d25e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e60e90ff-d76d-42d5-baba-befd319d25e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e60e90ff-d76d-42d5-baba-befd319d25e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e60e90ff-d76d-42d5-baba-befd319d25e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e60e90ff-d76d-42d5-baba-befd319d25e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6867f0c1-fae9-428b-a6fa-95fc791f708e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e60e90ff-d76d-42d5-baba-befd319d25e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6867f0c1-fae9-428b-a6fa-95fc791f708e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_53de2841-58c4-49f3-a629-58655767fcca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6867f0c1-fae9-428b-a6fa-95fc791f708e" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_53de2841-58c4-49f3-a629-58655767fcca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i4d33a01c303e48a1b715b15781f0c72f_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_809735b5-cbd0-4b9e-901b-813562a512b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_0a469ff3-0edb-4ca1-9d4a-afad15776976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_809735b5-cbd0-4b9e-901b-813562a512b9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_0a469ff3-0edb-4ca1-9d4a-afad15776976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_4ade328b-5d63-454d-bd97-e845a05fb164" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_809735b5-cbd0-4b9e-901b-813562a512b9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_4ade328b-5d63-454d-bd97-e845a05fb164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe95b602-eea7-420b-be7b-26bd3e5cdbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_809735b5-cbd0-4b9e-901b-813562a512b9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe95b602-eea7-420b-be7b-26bd3e5cdbc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_56beb382-4a8f-427b-8c2a-65f391face83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe95b602-eea7-420b-be7b-26bd3e5cdbc6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_56beb382-4a8f-427b-8c2a-65f391face83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_56beb382-4a8f-427b-8c2a-65f391face83_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_56beb382-4a8f-427b-8c2a-65f391face83" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_56beb382-4a8f-427b-8c2a-65f391face83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e31237c2-36bc-439e-ad2b-2ae13227e041" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_56beb382-4a8f-427b-8c2a-65f391face83" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e31237c2-36bc-439e-ad2b-2ae13227e041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_ed97a9a8-a127-4bd1-9c24-1a688b1dbdde" xlink:href="lyel-20230630.xsd#lyel_OtherInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e31237c2-36bc-439e-ad2b-2ae13227e041" xlink:to="loc_lyel_OtherInvestmentMember_ed97a9a8-a127-4bd1-9c24-1a688b1dbdde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_db973d10-2335-4dfe-9921-a048e63f02cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe95b602-eea7-420b-be7b-26bd3e5cdbc6" xlink:to="loc_srt_CounterpartyNameAxis_db973d10-2335-4dfe-9921-a048e63f02cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db973d10-2335-4dfe-9921-a048e63f02cf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_db973d10-2335-4dfe-9921-a048e63f02cf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db973d10-2335-4dfe-9921-a048e63f02cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_df41698f-fed2-4f43-9ee3-28d298ef1168" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_db973d10-2335-4dfe-9921-a048e63f02cf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_df41698f-fed2-4f43-9ee3-28d298ef1168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_1b1088b7-d2d2-4a9c-9256-f4a6cc3a0afa" xlink:href="lyel-20230630.xsd#lyel_PACTPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_df41698f-fed2-4f43-9ee3-28d298ef1168" xlink:to="loc_lyel_PACTPharmaIncMember_1b1088b7-d2d2-4a9c-9256-f4a6cc3a0afa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i8c0fc2806b4d4263b83869689347f540_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_415cb622-c251-495d-b7a3-6d838d47d8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_OperatingLeaseCost_415cb622-c251-495d-b7a3-6d838d47d8b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_c1a57e5c-e2f9-4de3-8dee-9b727b889e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_VariableLeaseCost_c1a57e5c-e2f9-4de3-8dee-9b727b889e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_18c9ca52-a94c-4ced-b057-d806be52b930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_18c9ca52-a94c-4ced-b057-d806be52b930" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7ed2bbf9-919b-42b5-b163-4a1cb87574aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7ed2bbf9-919b-42b5-b163-4a1cb87574aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_fb57b9ea-3659-4a32-bb41-61a3381004b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_NetRentableArea_fb57b9ea-3659-4a32-bb41-61a3381004b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_2a866ab6-7056-4946-884b-ae3d12050d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_SubleaseIncome_2a866ab6-7056-4946-884b-ae3d12050d1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_73147aa0-f726-44c5-9b26-025e55784e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_TenantImprovements_73147aa0-f726-44c5-9b26-025e55784e4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d9dc51-8c83-4685-adc2-eb8db1210c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d9dc51-8c83-4685-adc2-eb8db1210c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e2d9dc51-8c83-4685-adc2-eb8db1210c95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d9dc51-8c83-4685-adc2-eb8db1210c95" xlink:to="loc_us-gaap_RelatedPartyDomain_e2d9dc51-8c83-4685-adc2-eb8db1210c95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e1bf9dbf-b21e-4605-8d45-9829e82ed760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d9dc51-8c83-4685-adc2-eb8db1210c95" xlink:to="loc_us-gaap_RelatedPartyDomain_e1bf9dbf-b21e-4605-8d45-9829e82ed760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_2e437952-3336-4091-919a-282252f7d9be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e1bf9dbf-b21e-4605-8d45-9829e82ed760" xlink:to="loc_us-gaap_RelatedPartyMember_2e437952-3336-4091-919a-282252f7d9be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c7602155-44e1-4ea0-8921-7c45268b6efe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:to="loc_srt_StatementGeographicalAxis_c7602155-44e1-4ea0-8921-7c45268b6efe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c7602155-44e1-4ea0-8921-7c45268b6efe_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c7602155-44e1-4ea0-8921-7c45268b6efe" xlink:to="loc_srt_SegmentGeographicalDomain_c7602155-44e1-4ea0-8921-7c45268b6efe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3b2ddf4b-1958-43eb-9f92-f3fc031e8609" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c7602155-44e1-4ea0-8921-7c45268b6efe" xlink:to="loc_srt_SegmentGeographicalDomain_3b2ddf4b-1958-43eb-9f92-f3fc031e8609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SouthSanFranciscoCaliforniaMember_37de9c9f-d83c-4986-96a0-338827e1eed1" xlink:href="lyel-20230630.xsd#lyel_SouthSanFranciscoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3b2ddf4b-1958-43eb-9f92-f3fc031e8609" xlink:to="loc_lyel_SouthSanFranciscoCaliforniaMember_37de9c9f-d83c-4986-96a0-338827e1eed1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c0711711-06c0-4ec1-b3e8-e0a62f5b921e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:to="loc_srt_CounterpartyNameAxis_c0711711-06c0-4ec1-b3e8-e0a62f5b921e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0711711-06c0-4ec1-b3e8-e0a62f5b921e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c0711711-06c0-4ec1-b3e8-e0a62f5b921e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0711711-06c0-4ec1-b3e8-e0a62f5b921e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a6dcb43-5152-4837-8a16-bca3053cd504" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c0711711-06c0-4ec1-b3e8-e0a62f5b921e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a6dcb43-5152-4837-8a16-bca3053cd504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_3647d9eb-dd2e-4e6d-9d94-5d660f6e491b" xlink:href="lyel-20230630.xsd#lyel_SonomaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a6dcb43-5152-4837-8a16-bca3053cd504" xlink:to="loc_lyel_SonomaMember_3647d9eb-dd2e-4e6d-9d94-5d660f6e491b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockholdersEquityDetails" xlink:type="extended" id="ic74827a65fbd4d0dae78603315e9342f_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_67429e1a-54c6-4270-8e1b-73b1f2f73fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_67429e1a-54c6-4270-8e1b-73b1f2f73fd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e9d329d7-96b3-448a-a9fb-dda67f7705c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e9d329d7-96b3-448a-a9fb-dda67f7705c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4228b668-e69d-4ba3-893c-3023aeb6e093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4228b668-e69d-4ba3-893c-3023aeb6e093" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_62e28911-9256-47ac-8ca0-c841f7cb4af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_62e28911-9256-47ac-8ca0-c841f7cb4af9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_94a49bf5-27a2-461f-9227-3a172f1a962f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_94a49bf5-27a2-461f-9227-3a172f1a962f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a3fb5b19-92ec-48a8-a10e-f9fd8a960011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a3fb5b19-92ec-48a8-a10e-f9fd8a960011" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_abbdb907-ee24-4de7-ada6-b425847370c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_abbdb907-ee24-4de7-ada6-b425847370c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PercentageOfCommissionFromEachSaleOfShares_cf9f0cc1-ab46-468a-9a28-f23d063d6463" xlink:href="lyel-20230630.xsd#lyel_PercentageOfCommissionFromEachSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_lyel_PercentageOfCommissionFromEachSaleOfShares_cf9f0cc1-ab46-468a-9a28-f23d063d6463" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cc11e206-12bd-4444-a03b-a38a91a4d0a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:to="loc_srt_CounterpartyNameAxis_cc11e206-12bd-4444-a03b-a38a91a4d0a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc11e206-12bd-4444-a03b-a38a91a4d0a0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cc11e206-12bd-4444-a03b-a38a91a4d0a0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc11e206-12bd-4444-a03b-a38a91a4d0a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e637d27-6efe-479c-9714-92f0674db011" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cc11e206-12bd-4444-a03b-a38a91a4d0a0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e637d27-6efe-479c-9714-92f0674db011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GoldmanSachsAndBofAMember_e4c0a3f0-7ca5-4ab5-b55d-55c486f7838d" xlink:href="lyel-20230630.xsd#lyel_GoldmanSachsAndBofAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e637d27-6efe-479c-9714-92f0674db011" xlink:to="loc_lyel_GoldmanSachsAndBofAMember_e4c0a3f0-7ca5-4ab5-b55d-55c486f7838d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_69766001-8ad7-459b-a1cf-3a32caf340f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_69766001-8ad7-459b-a1cf-3a32caf340f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_69766001-8ad7-459b-a1cf-3a32caf340f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_69766001-8ad7-459b-a1cf-3a32caf340f5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_69766001-8ad7-459b-a1cf-3a32caf340f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fb5e0656-7612-4d91-aec5-435606b3e301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_69766001-8ad7-459b-a1cf-3a32caf340f5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fb5e0656-7612-4d91-aec5-435606b3e301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AtTheMarketOfferingMember_f5e674b3-e90a-42f1-abef-c4cac27a46c5" xlink:href="lyel-20230630.xsd#lyel_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fb5e0656-7612-4d91-aec5-435606b3e301" xlink:to="loc_lyel_AtTheMarketOfferingMember_f5e674b3-e90a-42f1-abef-c4cac27a46c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_42c81a70-acf4-43e0-a50c-fad15b82e834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_42c81a70-acf4-43e0-a50c-fad15b82e834" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_42c81a70-acf4-43e0-a50c-fad15b82e834_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_42c81a70-acf4-43e0-a50c-fad15b82e834" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_42c81a70-acf4-43e0-a50c-fad15b82e834_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b152a65a-1dfc-41f7-8d04-ba11634e7f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_42c81a70-acf4-43e0-a50c-fad15b82e834" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b152a65a-1dfc-41f7-8d04-ba11634e7f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityDistributionAgreementMember_ac54b864-8954-499a-9569-3c6ff4f5adcc" xlink:href="lyel-20230630.xsd#lyel_EquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b152a65a-1dfc-41f7-8d04-ba11634e7f97" xlink:to="loc_lyel_EquityDistributionAgreementMember_ac54b864-8954-499a-9569-3c6ff4f5adcc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended" id="id1f167f7c72042bbbad27c5c3465646f_StockbasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7f8ddf17-9dbe-4c59-bce3-13b232c9577a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7f8ddf17-9dbe-4c59-bce3-13b232c9577a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a49d3f0b-e79a-498e-9843-ff7810285b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a49d3f0b-e79a-498e-9843-ff7810285b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_66fd6e17-4493-4c7f-bf9e-886855ea12d7" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_66fd6e17-4493-4c7f-bf9e-886855ea12d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e1ad16ea-79d5-40cc-b349-9c3da9edcbef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e1ad16ea-79d5-40cc-b349-9c3da9edcbef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_4ed99291-69a3-4993-b4c9-2275dabddb4d" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_4ed99291-69a3-4993-b4c9-2275dabddb4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f78b6928-b34c-4f38-877d-cf9cdf456453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f78b6928-b34c-4f38-877d-cf9cdf456453" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5c2ea814-5a7a-4ebf-8ade-4c37a88b15a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5c2ea814-5a7a-4ebf-8ade-4c37a88b15a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1b3483f3-bd66-41a9-8df5-74f926c2166a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1b3483f3-bd66-41a9-8df5-74f926c2166a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d94f2997-4e6a-4ed3-876c-9086daca9ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d94f2997-4e6a-4ed3-876c-9086daca9ffe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_daebaff9-90e2-4cde-adaa-f6337f302355" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_daebaff9-90e2-4cde-adaa-f6337f302355" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_4359d020-dbb5-406f-ad45-3cc6635d8273" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_4359d020-dbb5-406f-ad45-3cc6635d8273" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b90d9aed-6932-4601-b815-ff72a2fc6dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b90d9aed-6932-4601-b815-ff72a2fc6dea" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_838cedcf-a8a2-47c8-a073-63d12b3da750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_838cedcf-a8a2-47c8-a073-63d12b3da750" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f48f7835-288c-42ea-9ae3-fbb8d0877178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f48f7835-288c-42ea-9ae3-fbb8d0877178" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70be2b0f-1240-4e37-81c5-8782e40ebcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70be2b0f-1240-4e37-81c5-8782e40ebcd2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dceb0bf0-f335-424a-8aab-33e77d924a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dceb0bf0-f335-424a-8aab-33e77d924a59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f1ea1e82-a53c-4cc3-93e0-534bfad23527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dceb0bf0-f335-424a-8aab-33e77d924a59" xlink:to="loc_us-gaap_PlanNameAxis_f1ea1e82-a53c-4cc3-93e0-534bfad23527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f1ea1e82-a53c-4cc3-93e0-534bfad23527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f1ea1e82-a53c-4cc3-93e0-534bfad23527" xlink:to="loc_us-gaap_PlanNameDomain_f1ea1e82-a53c-4cc3-93e0-534bfad23527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f1ea1e82-a53c-4cc3-93e0-534bfad23527" xlink:to="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_e78c7889-1a6f-463f-b001-47be3b7ce161" xlink:href="lyel-20230630.xsd#lyel_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:to="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_e78c7889-1a6f-463f-b001-47be3b7ce161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_8f13cde9-85e8-4318-8066-32012081ad80" xlink:href="lyel-20230630.xsd#lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:to="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_8f13cde9-85e8-4318-8066-32012081ad80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_c2e3da95-1c3b-4d64-a41f-f394b34d266e" xlink:href="lyel-20230630.xsd#lyel_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:to="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_c2e3da95-1c3b-4d64-a41f-f394b34d266e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0811df76-dbc9-444c-9c16-c775746786bf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dceb0bf0-f335-424a-8aab-33e77d924a59" xlink:to="loc_srt_RangeAxis_0811df76-dbc9-444c-9c16-c775746786bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0811df76-dbc9-444c-9c16-c775746786bf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0811df76-dbc9-444c-9c16-c775746786bf" xlink:to="loc_srt_RangeMember_0811df76-dbc9-444c-9c16-c775746786bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3be84ecc-69d6-426b-81fb-233ab40604a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0811df76-dbc9-444c-9c16-c775746786bf" xlink:to="loc_srt_RangeMember_3be84ecc-69d6-426b-81fb-233ab40604a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8e669895-4a6b-4135-bb30-59014f73b170" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3be84ecc-69d6-426b-81fb-233ab40604a8" xlink:to="loc_srt_MaximumMember_8e669895-4a6b-4135-bb30-59014f73b170" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="extended" id="ia6f5b95472b3468785dbd77b94daf62f_StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d44cf635-a169-4ce5-bf1d-2fddade981cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a1e018b6-500f-448c-a4d6-3aba2f1aa9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d44cf635-a169-4ce5-bf1d-2fddade981cd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a1e018b6-500f-448c-a4d6-3aba2f1aa9e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2245e922-f259-4629-86ec-bbe0227b72df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d44cf635-a169-4ce5-bf1d-2fddade981cd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2245e922-f259-4629-86ec-bbe0227b72df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2b04756-66b3-49b1-b470-57f54c83d708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2245e922-f259-4629-86ec-bbe0227b72df" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2b04756-66b3-49b1-b470-57f54c83d708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2b04756-66b3-49b1-b470-57f54c83d708_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2b04756-66b3-49b1-b470-57f54c83d708" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2b04756-66b3-49b1-b470-57f54c83d708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_29971a0b-6ff8-4520-92fd-4b56f2ff01d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2b04756-66b3-49b1-b470-57f54c83d708" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_29971a0b-6ff8-4520-92fd-4b56f2ff01d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e031a51-8ca5-4573-8ba2-f51fc5c7b2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29971a0b-6ff8-4520-92fd-4b56f2ff01d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e031a51-8ca5-4573-8ba2-f51fc5c7b2b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d531a23d-7310-42ee-b880-fafdffbb631d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29971a0b-6ff8-4520-92fd-4b56f2ff01d7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d531a23d-7310-42ee-b880-fafdffbb631d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensationRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" id="i30f5e8871e0746de819122975072532e_StockbasedCompensationRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f3678db-5146-4ea7-b271-c1ac632fb857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f3678db-5146-4ea7-b271-c1ac632fb857" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90a31d3c-78de-4cfd-a773-6266e93450bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90a31d3c-78de-4cfd-a773-6266e93450bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfcccaef-87e0-4574-9135-3d8d701d96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfcccaef-87e0-4574-9135-3d8d701d96cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_365181dc-fbe5-4886-a829-2872b55a931b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_365181dc-fbe5-4886-a829-2872b55a931b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0203ff0b-298e-457a-945c-8ed9ca0a05a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0203ff0b-298e-457a-945c-8ed9ca0a05a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_31964821-99d7-44cf-b27b-52c0874b2715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f3678db-5146-4ea7-b271-c1ac632fb857" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5c325cf-e508-45e7-a86b-5b960d5cc9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5c325cf-e508-45e7-a86b-5b960d5cc9b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a85d4636-eb40-44cc-8922-6e36ec928dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a85d4636-eb40-44cc-8922-6e36ec928dea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b4e96ed-be3f-42c5-9c38-6382bc235c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b4e96ed-be3f-42c5-9c38-6382bc235c46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0a6b3118-53d4-4df3-a309-a0093530b569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0a6b3118-53d4-4df3-a309-a0093530b569" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_46aca48b-f310-484e-972b-c75bc24a816c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391c709a-e53f-4662-81b8-c3132cf21bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f3678db-5146-4ea7-b271-c1ac632fb857" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391c709a-e53f-4662-81b8-c3132cf21bba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_176cba02-0bdb-463b-bbed-56e506e6bc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391c709a-e53f-4662-81b8-c3132cf21bba" xlink:to="loc_us-gaap_AwardTypeAxis_176cba02-0bdb-463b-bbed-56e506e6bc3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_176cba02-0bdb-463b-bbed-56e506e6bc3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_176cba02-0bdb-463b-bbed-56e506e6bc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_176cba02-0bdb-463b-bbed-56e506e6bc3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31d2f3ae-df16-43d7-91b9-f869a7dbd2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_176cba02-0bdb-463b-bbed-56e506e6bc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31d2f3ae-df16-43d7-91b9-f869a7dbd2e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0156b4cf-79d5-463f-861f-de069a9da4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31d2f3ae-df16-43d7-91b9-f869a7dbd2e3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0156b4cf-79d5-463f-861f-de069a9da4a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#RelatedpartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="extended" id="i10ff2def6f384879aec5748c799b0ca0_RelatedpartyTransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_8777c4e4-5070-4604-aacd-073bac23d9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_NetRentableArea_8777c4e4-5070-4604-aacd-073bac23d9ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_e8ac743e-94bb-4d86-9d71-1d8a7619bd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_TenantImprovements_e8ac743e-94bb-4d86-9d71-1d8a7619bd3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_aa18a0f3-9f17-4aba-be92-a9fe1f69fec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_aa18a0f3-9f17-4aba-be92-a9fe1f69fec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f47a3c3b-09ac-481a-80e3-e1de5d9d3a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f47a3c3b-09ac-481a-80e3-e1de5d9d3a10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_86a8a7f3-b01b-4d2d-8fed-d04e1517be35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_86a8a7f3-b01b-4d2d-8fed-d04e1517be35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eff13771-243f-4431-af5b-b29ada23de4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eff13771-243f-4431-af5b-b29ada23de4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa313399-79de-4d1b-9ca5-7273e76e213d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa313399-79de-4d1b-9ca5-7273e76e213d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2be2a44b-064e-4d8e-b1c7-a61406365f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2be2a44b-064e-4d8e-b1c7-a61406365f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2be2a44b-064e-4d8e-b1c7-a61406365f6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2be2a44b-064e-4d8e-b1c7-a61406365f6c" xlink:to="loc_us-gaap_RelatedPartyDomain_2be2a44b-064e-4d8e-b1c7-a61406365f6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2829fb17-5e6a-45c6-99a9-c22cba7fe502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2be2a44b-064e-4d8e-b1c7-a61406365f6c" xlink:to="loc_us-gaap_RelatedPartyDomain_2829fb17-5e6a-45c6-99a9-c22cba7fe502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_738b8d52-4a43-4201-96b4-05b78c72e6df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2829fb17-5e6a-45c6-99a9-c22cba7fe502" xlink:to="loc_us-gaap_RelatedPartyMember_738b8d52-4a43-4201-96b4-05b78c72e6df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e8291762-d51c-4234-8ad3-27ed5810d03e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_srt_RangeAxis_e8291762-d51c-4234-8ad3-27ed5810d03e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8291762-d51c-4234-8ad3-27ed5810d03e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e8291762-d51c-4234-8ad3-27ed5810d03e" xlink:to="loc_srt_RangeMember_e8291762-d51c-4234-8ad3-27ed5810d03e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3019e31e-c8d9-49d3-8836-ab48f1e2fd00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e8291762-d51c-4234-8ad3-27ed5810d03e" xlink:to="loc_srt_RangeMember_3019e31e-c8d9-49d3-8836-ab48f1e2fd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f809761d-7156-44f4-8149-64bde0645a96" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3019e31e-c8d9-49d3-8836-ab48f1e2fd00" xlink:to="loc_srt_MinimumMember_f809761d-7156-44f4-8149-64bde0645a96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a30a5b14-842c-420a-a826-53c113f072e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_srt_OwnershipAxis_a30a5b14-842c-420a-a826-53c113f072e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a30a5b14-842c-420a-a826-53c113f072e9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_a30a5b14-842c-420a-a826-53c113f072e9" xlink:to="loc_srt_OwnershipDomain_a30a5b14-842c-420a-a826-53c113f072e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_513e19f1-56c2-4daf-a959-79e1d49b5e2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_a30a5b14-842c-420a-a826-53c113f072e9" xlink:to="loc_srt_OwnershipDomain_513e19f1-56c2-4daf-a959-79e1d49b5e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LyellImmunopharmaMember_3650dd5c-9f29-4c39-a26c-36261c5edfbc" xlink:href="lyel-20230630.xsd#lyel_LyellImmunopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_513e19f1-56c2-4daf-a959-79e1d49b5e2c" xlink:to="loc_lyel_LyellImmunopharmaMember_3650dd5c-9f29-4c39-a26c-36261c5edfbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_532d0117-97da-4e92-951b-aa45efecc306" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_dei_LegalEntityAxis_532d0117-97da-4e92-951b-aa45efecc306" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_532d0117-97da-4e92-951b-aa45efecc306_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_532d0117-97da-4e92-951b-aa45efecc306" xlink:to="loc_dei_EntityDomain_532d0117-97da-4e92-951b-aa45efecc306_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_188490ba-3e5c-4584-bfb7-a921685dc9cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_532d0117-97da-4e92-951b-aa45efecc306" xlink:to="loc_dei_EntityDomain_188490ba-3e5c-4584-bfb7-a921685dc9cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_62a28a41-8235-4561-a800-0c00ea49474f" xlink:href="lyel-20230630.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_188490ba-3e5c-4584-bfb7-a921685dc9cd" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_62a28a41-8235-4561-a800-0c00ea49474f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fa28cb58-02d7-47f3-86fd-c07981fb3423" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_srt_CounterpartyNameAxis_fa28cb58-02d7-47f3-86fd-c07981fb3423" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa28cb58-02d7-47f3-86fd-c07981fb3423_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fa28cb58-02d7-47f3-86fd-c07981fb3423" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa28cb58-02d7-47f3-86fd-c07981fb3423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29cbd25b-0e5b-46a9-b070-bf394a621208" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fa28cb58-02d7-47f3-86fd-c07981fb3423" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29cbd25b-0e5b-46a9-b070-bf394a621208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_8bb54dbd-22fc-4d64-b03c-cc898d79703a" xlink:href="lyel-20230630.xsd#lyel_SonomaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29cbd25b-0e5b-46a9-b070-bf394a621208" xlink:to="loc_lyel_SonomaMember_8bb54dbd-22fc-4d64-b03c-cc898d79703a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GSKMember_ba231c91-cc68-4d91-bc3c-7de186759ae1" xlink:href="lyel-20230630.xsd#lyel_GSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29cbd25b-0e5b-46a9-b070-bf394a621208" xlink:to="loc_lyel_GSKMember_ba231c91-cc68-4d91-bc3c-7de186759ae1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"/>
  <link:definitionLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="extended" id="i8794d5d8c7304a6d83129f061fc5bd24_RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d2d13593-7491-4441-8d41-08351e3f18ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_ebe5f9a4-88de-4d43-b4aa-21b8f5031baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d2d13593-7491-4441-8d41-08351e3f18ab" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_ebe5f9a4-88de-4d43-b4aa-21b8f5031baf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_7eeb082a-3115-4bce-a69c-01e068d13352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d2d13593-7491-4441-8d41-08351e3f18ab" xlink:to="loc_us-gaap_SubleaseIncome_7eeb082a-3115-4bce-a69c-01e068d13352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad942493-6fc2-42a6-974d-da97775f8159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d2d13593-7491-4441-8d41-08351e3f18ab" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad942493-6fc2-42a6-974d-da97775f8159" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca1d38e-5721-4b51-99f6-c37d2f43dfef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad942493-6fc2-42a6-974d-da97775f8159" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca1d38e-5721-4b51-99f6-c37d2f43dfef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5ca1d38e-5721-4b51-99f6-c37d2f43dfef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca1d38e-5721-4b51-99f6-c37d2f43dfef" xlink:to="loc_us-gaap_RelatedPartyDomain_5ca1d38e-5721-4b51-99f6-c37d2f43dfef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_aa94cfba-ece9-40a7-b20b-f5ac896fbdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca1d38e-5721-4b51-99f6-c37d2f43dfef" xlink:to="loc_us-gaap_RelatedPartyDomain_aa94cfba-ece9-40a7-b20b-f5ac896fbdd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_411ab773-b73d-4a83-aa50-aa56300824bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_aa94cfba-ece9-40a7-b20b-f5ac896fbdd8" xlink:to="loc_us-gaap_RelatedPartyMember_411ab773-b73d-4a83-aa50-aa56300824bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d62ec459-1ae3-4f8d-aea4-d3d54f0ad4b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad942493-6fc2-42a6-974d-da97775f8159" xlink:to="loc_srt_CounterpartyNameAxis_d62ec459-1ae3-4f8d-aea4-d3d54f0ad4b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d62ec459-1ae3-4f8d-aea4-d3d54f0ad4b8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d62ec459-1ae3-4f8d-aea4-d3d54f0ad4b8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d62ec459-1ae3-4f8d-aea4-d3d54f0ad4b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be56be7e-2429-4c0d-9d14-09899bc5b2a9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d62ec459-1ae3-4f8d-aea4-d3d54f0ad4b8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be56be7e-2429-4c0d-9d14-09899bc5b2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_7e0e8572-c4a4-4664-bed1-6e674e48457a" xlink:href="lyel-20230630.xsd#lyel_SonomaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be56be7e-2429-4c0d-9d14-09899bc5b2a9" xlink:to="loc_lyel_SonomaMember_7e0e8572-c4a4-4664-bed1-6e674e48457a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>lyel-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8f655eeb-886b-4b81-9c30-69669c77ca83,g:e402dc2a-90a6-40a3-91ac-ff661e6149b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_6caa1c54-de46-4844-ae13-f47b6739ed3e_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum offering period</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_366918d2-18ed-4c90-9c96-e695a2ca1721_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_43fdf1b1-9a61-4cc7-adb2-f5388fcb4544_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f5cece0d-b7ff-42a4-ab93-78f3afb2d774_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9b534619-4ed4-42e6-b76a-7e73afb78b82_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9ee271c-3430-477b-94eb-cefdc4c6aa17_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_6e91980b-1e03-4fc2-be75-3f4719a7463c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_11d7122a-6c09-4b44-9522-d80603611c7e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c85d06bc-3bad-4d4f-b9f7-32a4878f855a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_faefdbf4-8886-461a-85f2-f5436d453d6e_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1d5d61cd-acde-4583-9c80-a85e4071a54f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1b3f5e9b-814b-4cf6-a2da-22c6b499e23f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_10a8993b-c57e-4eb3-8e6b-8fc1720e39f9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3db2829c-9e4f-4842-956f-ab0653f12718_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_a6910a20-4c5a-43af-940c-16fb9e338d28_terseLabel_en-US" xlink:label="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets and Liabilities</link:label>
    <link:label id="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="lyel-20230630.xsd#lyel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_lyel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_88d57b1d-be34-4845-a259-b22c36ad4128_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Amortized Cost of Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_391e5291-1501-4f58-a3e9-5d6a2b6179d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2ca543fe-1abc-4b8d-800b-074474ee27ca_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e1123ea4-b610-4f72-b416-a2a36c308a1d_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_f87557bb-7420-46a3-983e-81ff6c2132c7_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ec28915b-a261-4027-b16e-788973cf972a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a735d784-ab8a-4a2f-875d-65cf65c0ba57_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (loss), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b56a2758-fc76-4def-a011-21961bf9af2b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_f610bd2a-5e25-4cda-8677-cfdf35f81e7b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_231feadd-cc51-4e91-8c34-222655491674_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_e663c9a8-89d4-4064-9787-bc3ea8963a04_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b9919763-5993-4d51-b07b-0a67d3358c5a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_73ffe4c1-8a70-4c34-8adc-74c08159818d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b0f2acd3-8924-4fd5-955e-7745b5dff9fc_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_00a00e55-2feb-4256-b6ae-34519f572951_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_4091bc65-3d07-4aea-ac18-208b7cbec8a2_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment liabilities</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:to="lab_lyel_SuccessPaymentLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_349ce296-80cf-4076-b815-e24803211ce7_terseLabel_en-US" xlink:label="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement portion of transaction price</link:label>
    <link:label id="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_label_en-US" xlink:label="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program</link:label>
    <link:label id="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_documentation_en-US" xlink:label="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:href="lyel-20230630.xsd#lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:to="lab_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_edf29a3b-2330-4851-a429-fbc23a30ef51_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_7c0c4018-1f9f-4515-9f47-e067facab44b_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0f55c81b-20b4-4235-ab2d-476bd8d37865_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f5235138-e0e2-4e75-ba93-17065e08c350_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_b83e1e04-c581-4575-aa53-f022243e53e0_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4a5946e9-a2ae-415e-bac2-151ea3a505e8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_17a1c2d9-2b7b-48f8-928b-3e726a673d1d_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of success payment agreement</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_745e75e0-2982-4d38-9273-35866efcd803_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_3a927e82-1909-4d93-a04d-7d843bafde5a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized at June&#160;30, 2023 and December&#160;31, 2022; no shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4ea5b17-cfdf-43ff-9d86-09619a386f5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Value at Grant Date Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_337077d7-44ec-4643-a00f-b7f2a049c44a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_cf492980-4283-4c52-b5bb-130a5c358897_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_63be0846-8aac-447e-81f1-d8d0f9f1b422_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_490a3a71-4c3c-4e74-8b86-b2f30762b537_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_EquityMultipleDomain_96827208-d993-4979-ac69-7a132ff0ea05_terseLabel_en-US" xlink:label="lab_lyel_EquityMultipleDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple [Domain]</link:label>
    <link:label id="lab_lyel_EquityMultipleDomain_label_en-US" xlink:label="lab_lyel_EquityMultipleDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple [Domain]</link:label>
    <link:label id="lab_lyel_EquityMultipleDomain_documentation_en-US" xlink:label="lab_lyel_EquityMultipleDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple Domain.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain" xlink:href="lyel-20230630.xsd#lyel_EquityMultipleDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_EquityMultipleDomain" xlink:to="lab_lyel_EquityMultipleDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_EquityMultipleAxis_e80c5f31-6e94-430c-a333-bef54fa629d5_terseLabel_en-US" xlink:label="lab_lyel_EquityMultipleAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple [Axis]</link:label>
    <link:label id="lab_lyel_EquityMultipleAxis_label_en-US" xlink:label="lab_lyel_EquityMultipleAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple [Axis]</link:label>
    <link:label id="lab_lyel_EquityMultipleAxis_documentation_en-US" xlink:label="lab_lyel_EquityMultipleAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Multiple Axis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleAxis" xlink:href="lyel-20230630.xsd#lyel_EquityMultipleAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_EquityMultipleAxis" xlink:to="lab_lyel_EquityMultipleAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9482c7ca-18ee-4fa1-9501-49d27d51c531_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_e162fdb6-f4eb-4d8a-865a-56c1e3a63ef0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ThirtyTimesMember_0069b7e4-bc0d-404b-ba7e-d34d1bf1d7c0_terseLabel_en-US" xlink:label="lab_lyel_ThirtyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty Times</link:label>
    <link:label id="lab_lyel_ThirtyTimesMember_label_en-US" xlink:label="lab_lyel_ThirtyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty Times [Member]</link:label>
    <link:label id="lab_lyel_ThirtyTimesMember_documentation_en-US" xlink:label="lab_lyel_ThirtyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty Times (30x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ThirtyTimesMember" xlink:href="lyel-20230630.xsd#lyel_ThirtyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ThirtyTimesMember" xlink:to="lab_lyel_ThirtyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a69087c3-57b6-49bf-a003-0cab4c513d33_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a5de89d1-9993-440a-95e9-7d48539ff842_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSold_69d3447c-28b7-4df5-8c56-1ba2830d86c7_terseLabel_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sold under stock purchase program (in shares)</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSold_label_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Shares Sold</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSold_documentation_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Shares Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSold" xlink:href="lyel-20230630.xsd#lyel_StockPurchaseAgreementSharesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StockPurchaseAgreementSharesSold" xlink:to="lab_lyel_StockPurchaseAgreementSharesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_154bf54c-462e-4c99-b12b-cbbbd7dd835e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bb98804c-d07a-4558-bf68-83b970835472_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_78fa01e2-3601-4519-b593-6de706679d92_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b9237c3c-56c4-46c4-85f3-26d52260a1e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e2e1c04e-04ef-4fed-b447-dec349167e6c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_670d706b-30ad-4bfc-915c-2a2d721522d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a95510d7-1e38-4d48-9ce8-63520ab6f4c6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8bd83b31-6981-4a01-a596-5ea9d6a2ca35_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_a1774c46-3509-4634-8dc5-b9476a358036_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront payment paid</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8107b2e6-43a2-4c87-ab97-f12912194d11_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a32821c9-931a-428e-ba2d-a28ba5d1b553_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_75319f7a-f664-4e49-bcc1-eecc81261c2c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20e957fb-165a-4a5f-b6c0-14f1eadc9f4b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c29c4005-e31e-4f2f-bcb6-48aa4b81a162_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a0c385f4-9f73-4507-a3f4-0804614fe7ab_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_064fb8d3-8119-4d14-aae9-6253961a7dac_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9a631bc4-0888-40ce-9095-91ad441eccf0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91412e44-2af6-41dc-be83-0e8d3bf2cd8e_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2443a635-a740-4e65-84ee-9f962d7fd1ab_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_ac684d7d-6b3e-4826-8215-92bb46dbc28b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_GoldmanSachsAndBofAMember_bf37f9e3-e32b-473c-b712-913d822abb7e_terseLabel_en-US" xlink:label="lab_lyel_GoldmanSachsAndBofAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goldman Sachs and BofA</link:label>
    <link:label id="lab_lyel_GoldmanSachsAndBofAMember_label_en-US" xlink:label="lab_lyel_GoldmanSachsAndBofAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goldman Sachs and BofA [Member]</link:label>
    <link:label id="lab_lyel_GoldmanSachsAndBofAMember_documentation_en-US" xlink:label="lab_lyel_GoldmanSachsAndBofAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goldman Sachs and BofA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GoldmanSachsAndBofAMember" xlink:href="lyel-20230630.xsd#lyel_GoldmanSachsAndBofAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_GoldmanSachsAndBofAMember" xlink:to="lab_lyel_GoldmanSachsAndBofAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_fedf4e74-1e00-4683-922a-0dbe7f70efad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Estimated Fair Value of Level 3 Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_LitigationSettlementPercentOfTotalEquityValue_0edc65dd-096d-4c65-bcea-d46d285f206b_terseLabel_en-US" xlink:label="lab_lyel_LitigationSettlementPercentOfTotalEquityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership of fully diluted shares (as a percent)</link:label>
    <link:label id="lab_lyel_LitigationSettlementPercentOfTotalEquityValue_label_en-US" xlink:label="lab_lyel_LitigationSettlementPercentOfTotalEquityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Percent Of Total Equity Value</link:label>
    <link:label id="lab_lyel_LitigationSettlementPercentOfTotalEquityValue_documentation_en-US" xlink:label="lab_lyel_LitigationSettlementPercentOfTotalEquityValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Percent Of Total Equity Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LitigationSettlementPercentOfTotalEquityValue" xlink:href="lyel-20230630.xsd#lyel_LitigationSettlementPercentOfTotalEquityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_LitigationSettlementPercentOfTotalEquityValue" xlink:to="lab_lyel_LitigationSettlementPercentOfTotalEquityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8340d438-efad-45d9-90ac-2fb56ad8e4c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_41a3093e-2ba0-4ca0-b382-385ddce0281c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_459e29fe-13ca-4a34-9a85-5887edeb503e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_53f59e75-130c-4539-ae50-9d0aca4a89f2_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_19d8a2c5-9c64-4416-99d4-0d02a353f7f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2873564c-24fa-4140-afde-445f12bc4db9_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_e7fe646d-59b5-4583-8e20-31a3e0a1c2ab_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_bd5381f0-a99f-45ba-aa4a-7c9825109a2d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0b74c146-910a-4ece-ae3e-a21663ca5518_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8bb99438-cef0-4e09-b226-61f0932d636a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a9773c82-e3f9-44d3-9143-ef8e54a227bf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_29ea5255-6fe6-4687-aaf4-66afdf7a043f_terseLabel_en-US" xlink:label="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:href="lyel-20230630.xsd#lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fb916343-f87e-4232-a439-db47c71678d8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_829c4779-b0aa-4985-a617-5259e792c104_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_40cb90de-8b5c-43c8-931c-3c5d02cfe48e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_ad62bbc4-a40e-4850-a6fd-3abf810207e0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_bcb136ac-ac1e-47fc-9ec7-c1ad03d7fc8c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_477d0e5a-5f55-427b-b3d6-ce9e899fce3e_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in proportion of common shares reserved for future issuance (as a percent)</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d2a47378-b57f-421a-8485-0af9e7780b71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_029f4319-42c7-4a19-ac3b-4f86492fd461_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f4fd209-ea1e-4663-be87-dc4283225adc_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_dc588113-2447-49f0-9e6d-233cea4a324d_terseLabel_en-US" xlink:label="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Revenue Related To Change In Estimate</link:label>
    <link:label id="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_label_en-US" xlink:label="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Revenue Related To Change In Estimate [Member]</link:label>
    <link:label id="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_documentation_en-US" xlink:label="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Revenue Related To Change In Estimate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:href="lyel-20230630.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:to="lab_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_ddbfd854-7492-46a8-9bd8-ed4e982800f6_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of stock outstanding (as a percent)</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMeasurementInput_fdaed855-b875-4744-8968-811f5278393f_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment liability, measurement input (as a percent)</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMeasurementInput_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability, Measurement Input</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:to="lab_lyel_SuccessPaymentLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7a8a968d-c93c-4978-a026-fc83fa2e15ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Commitments, Including Expected Lease Incentives to be Received</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_48dc1835-b7f0-4d87-ab40-44daa45c478c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative impairments of strategic investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_952efed0-ea0b-47e7-aa9b-9318c140f189_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_e9f0a060-b18d-4302-b49b-966e0d79483b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_053867ba-d68a-4038-83c2-119d8d2f2d2d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_7ef8544d-23aa-4577-ae5c-ebc0a20e0bed_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_27027573-e0c8-4407-bb0a-16ce86e70b6c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fef5347f-f14d-40d3-80ab-4518b8a653c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_d744d8e6-fa88-4b7f-9c2d-ab9dad503d6d_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_926bfef6-ccb9-4659-99de-14ff5b5bb06a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba7d6d29-40bc-41c8-8a69-a8329acf3dbd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_afdb5474-07ed-450c-9cc2-fc9efa933125_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_16d78921-c910-41b2-91e2-8ba1491d8efa_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7d90e117-4b2a-44e2-bceb-c825e7146699_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3a0cbf34-8863-43b9-a8af-2918350f39be_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a092634c-d5cc-4331-91ec-1ef5f00f661a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_10803cfd-f5bd-4969-8ae6-4b952879a632_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f10cba1e-94a6-4c5a-9ff0-f0a11c7c7821_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_31960fa1-b186-4806-8cd3-0896e538b1a3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f61f766c-0ec5-489a-983c-b36bae2d3d92_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b264be9e-ae68-40e5-9dc2-1420401d6c92_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_cc2d066e-035b-41fc-b113-c95f5e99e161_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b69a13ac-d058-413e-b603-4e2863934179_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2d81af6c-1f04-47b8-8cea-980ed8cf585e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_4e6267a3-65ab-41e8-a5bf-e1b6223c6995_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate success payment(s) (in millions)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_62eb929c-697b-436f-a745-dfe5b5d676b0_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiple of initial equity value at issuance</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_ccdb385d-6655-4299-924c-ea248f5dd146_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare_2284bcd6-d6b2-497b-9bcb-72556afa9d8c_terseLabel_en-US" xlink:label="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per share of stock sold under stock purchase program (in dollars per share)</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare_label_en-US" xlink:label="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Fair Value Of Stock Per Share</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare_documentation_en-US" xlink:label="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Fair Value Of Stock Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:href="lyel-20230630.xsd#lyel_StockPurchaseAgreementFairValueOfStockPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:to="lab_lyel_StockPurchaseAgreementFairValueOfStockPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_487fc3db-c681-42b4-a670-c87cb7ecd80b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1346dfd9-81f1-4383-883b-87872931a062_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_195da8a2-1a88-4e19-9491-b233ad7a3a0b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c656ff5f-4de9-4ee8-b61b-6c4aaba805e7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1674930f-172f-4056-a3e8-4b82b3a8c6d4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FortyTimesMember_76ed2e62-ecee-46dd-a6f7-eefbc97a7938_terseLabel_en-US" xlink:label="lab_lyel_FortyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Times</link:label>
    <link:label id="lab_lyel_FortyTimesMember_label_en-US" xlink:label="lab_lyel_FortyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Times [Member]</link:label>
    <link:label id="lab_lyel_FortyTimesMember_documentation_en-US" xlink:label="lab_lyel_FortyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Times (40x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FortyTimesMember" xlink:href="lyel-20230630.xsd#lyel_FortyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FortyTimesMember" xlink:to="lab_lyel_FortyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e2630512-d417-4f41-805a-f9a3418c8a6a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07750b70-524a-490a-88fc-4064e0eb6dee_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9323375e-8215-43a2-a19a-40e4bd4ac704_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_680a2c3d-de79-4622-b74b-55c148537cc2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0c2d5e86-f85c-46bc-87c4-7e9bb58fb867_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_38811fc0-2776-4866-a269-c5295cf2565e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_ca24db75-9450-4d93-a36b-91015c1237a6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_26897857-d90f-4c65-80e2-3cffe845bf42_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d0f58111-b41a-4ed1-914e-1d0d8a056ecb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities held in a continuous unrealized loss position for greater than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0bad2852-c22e-4b83-8205-9ba02a999627_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_074732b6-692d-457a-8698-5a5f4d4373dd_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2d6dbd7b-3169-410e-ab32-72cb0692112d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6dc902a9-20ec-4985-93c0-ebdc23595ddd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_dafaa2cb-967a-45c4-a91c-e4241abd171e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_53b9dab3-1cc0-4a8a-a224-40b74cc73c28_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering amount</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bf68092c-0dbf-4843-b122-4b1f820c1246_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_53ac7f54-31db-4263-814e-42638fa1d20b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration, and Success Payment Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock_38454d51-7a70-44f4-bdee-2b1a2ae3a3b6_terseLabel_en-US" xlink:label="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock Series A convertible preferred stock</link:label>
    <link:label id="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock_label_en-US" xlink:label="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock_documentation_en-US" xlink:label="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Series A convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:href="lyel-20230630.xsd#lyel_FairValueOfSeriesAConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:to="lab_lyel_FairValueOfSeriesAConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_41dc6e9c-82d1-4584-8916-c65c9f4dac1a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted-average period compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1497ccd4-b919-47df-9977-a630643e7f10_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5b29a6a0-16c1-4eb7-80ef-a8892e8787b5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bf921259-467d-460c-9dd1-579cd91705ba_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation cost related to unvested awards not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c66ff0fc-0200-4ce7-a2e7-edcba1f2761f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_cb17fd3f-9ba8-4462-937a-e51b1de057f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Income Attributable to Sonoma Sublease</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_02006f86-607c-4375-80bd-7f948c192615_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address Line</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_1435ac7b-7c51-4f43-af35-85794fe38a90_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3af542aa-0ea5-4d94-9661-298c923677fe_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement_44d960b0-a7a3-411d-8cf4-e6f12aa9156d_terseLabel_en-US" xlink:label="lab_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement_label_en-US" xlink:label="lab_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Upfront Payments For Research And Development Agreement</link:label>
    <link:label id="lab_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement_documentation_en-US" xlink:label="lab_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Upfront Payments For Research And Development Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement" xlink:href="lyel-20230630.xsd#lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement" xlink:to="lab_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35632892-b292-4522-adc5-2d77a743ec3e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_982c37c7-6428-443e-94b3-511d70f609f2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_73228097-e2ab-49c9-acd1-527ff8e68e28_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4bb6affb-6dca-4c12-8792-16a91d268448_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_17e1ae42-3073-4bbe-8269-8942ce3d6e50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_7c0a1059-83b7-44f2-912d-cc3a80dc18d3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a95086e8-012a-485f-9436-b56ae7e30e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock at discount (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_976cd915-6f83-4a6a-9911-773156bf3ac1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_6ed5462f-f437-45c1-a74b-90fcd7631f78_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share common stock price required for payment (in dollars per share)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_fe0e55c2-8ea5-4ca4-869e-73e091237676_terseLabel_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares to be purchased under ESPP (in shares)</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_label_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:label id="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_documentation_en-US" xlink:label="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:to="lab_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_30fce807-72a9-4be5-8132-e802bb4b4393_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1728cb40-db95-438b-b2d5-5ef74b416639_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security12b Title</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_30d21b4a-d6e8-4375-a706-16860b6cd561_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d8d1de1-9a15-4852-9a3d-320472dc0133_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_70c03957-71b8-496e-b369-555c2a23c3a9_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trigger period thereafter</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period After Initial Public Offering</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_a354fa53-5d83-4922-88db-31cedb5a610c_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_d122fd7c-d93a-44d6-8edb-56b5aec65c0d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_aab7bcf8-8890-49bf-a235-92ddf918a807_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SeriesAConvertiblePreferredStockMember_2a30f6b9-ef00-4aed-a6c8-dd40fc6ef8a9_terseLabel_en-US" xlink:label="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_lyel_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_lyel_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAConvertiblePreferredStockMember" xlink:href="lyel-20230630.xsd#lyel_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SeriesAConvertiblePreferredStockMember" xlink:to="lab_lyel_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8256aa11-a0d6-41da-b479-84a99938ec52_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4cd24242-bd97-4718-ac22-f180a46409aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_371a9ce8-a112-4728-b244-c6ddedace5bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice_b36bc3b7-4528-49e3-9560-de2693c69b8b_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional purchase price consideration</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Additional Purchase Price</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Additional Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6b349502-b4f9-4bcd-a6f8-172221d7945a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_be00dfab-69c9-4794-a90c-f4a7d8015118_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d680525-c982-4176-a188-cae1e984a9c6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8b224a93-467d-417f-9ef9-e07a5eaea26b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_eac0bc24-6ab3-440b-9f28-0f1f3d214354_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ca6b77af-c1f0-4d04-89e2-968accc6dde2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_32aa1e0d-a266-4d0d-acae-6cd189ca649f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_2d80584c-bc37-40d9-a712-c8d95b72fad9_terseLabel_en-US" xlink:label="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_label_en-US" xlink:label="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline Intellectual Property (No. 5) Limited And Glaxo Group Limited [Member]</link:label>
    <link:label id="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_documentation_en-US" xlink:label="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline Intellectual Property (No. 5) Limited And Glaxo Group Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:href="lyel-20230630.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:to="lab_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_25d8dfa9-8ac9-4c28-8fe2-11cc98152411_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_AtTheMarketOfferingMember_2b6f29bf-a87c-496a-b209-15256c0292bd_terseLabel_en-US" xlink:label="lab_lyel_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_lyel_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_lyel_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_lyel_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_lyel_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AtTheMarketOfferingMember" xlink:href="lyel-20230630.xsd#lyel_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_AtTheMarketOfferingMember" xlink:to="lab_lyel_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e81327b0-ee27-41c6-b3c2-47ed9469b921_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d4711c20-17f1-4cfd-a63e-5c6265166dd8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6cf56740-bf14-4d2d-8f6a-16134d9e8574_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8194f4b0-caee-4976-b6d0-db2d309c8302_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_03ca8e4b-f3eb-4f94-997d-e8b43207c527_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8b9a4ad4-3d3d-4927-b414-f98dfc961f9d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_79e7d8c0-5910-46c6-a008-2d44962acd53_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_93c5a6bf-cd14-45be-9de8-add7849e777c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock at fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_366a219e-8703-4ce1-931b-e6fb2c9f8778_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1fd635c5-5dc8-4faf-a735-2ecc07add376_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3a763aa2-815a-44f1-b888-e4fb978c498c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80c1d61d-c4a8-43cd-a94e-75065d6d4a6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_PACTPharmaIncMember_7f4b5348-ebe5-4631-b353-4f02f0e64105_terseLabel_en-US" xlink:label="lab_lyel_PACTPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PACT</link:label>
    <link:label id="lab_lyel_PACTPharmaIncMember_label_en-US" xlink:label="lab_lyel_PACTPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PACT Pharma, Inc. [Member]</link:label>
    <link:label id="lab_lyel_PACTPharmaIncMember_documentation_en-US" xlink:label="lab_lyel_PACTPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PACT Pharma, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember" xlink:href="lyel-20230630.xsd#lyel_PACTPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_PACTPharmaIncMember" xlink:to="lab_lyel_PACTPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5979e215-44e8-476c-b662-fe367a60c631_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3efd95ee-bb8d-4f71-ac6a-1688de6c490d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_df0ada05-0996-4bf6-a1ff-1fbc8a8ea69f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestments_35f14c66-6a31-4337-91e2-54a8b1445802_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestments_label_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="lab_us-gaap_OtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_fa14151c-4bd8-4d03-8805-c63ee034c490_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_adc3d0c1-b4e1-4443-ba56-e422f9fa56aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_31ff9aa1-e24b-43fe-9a79-85c559c23669_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_0821d8d5-26f9-4998-b60f-13aa677a287f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_31c7b667-00fd-455b-b3d0-9fa467980ce4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70054a08-4fae-4d7e-8c4b-3eb4a8ba6644_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_866cfbf3-e564-478f-af6a-9ff7694c14fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_657accae-8ae7-44b2-8b51-d35603753f16_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_84ee0002-11d2-4241-aaff-c78c7d86877a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_aef28cf6-f93d-4c1b-8412-2a0da8ead01d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_NonCashLeaseIncomeExpense_df9f00db-6a9b-4dc3-9a8c-239063b1e0fb_negatedTerseLabel_en-US" xlink:label="lab_lyel_NonCashLeaseIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease income</link:label>
    <link:label id="lab_lyel_NonCashLeaseIncomeExpense_label_en-US" xlink:label="lab_lyel_NonCashLeaseIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Income (Expense)</link:label>
    <link:label id="lab_lyel_NonCashLeaseIncomeExpense_documentation_en-US" xlink:label="lab_lyel_NonCashLeaseIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_NonCashLeaseIncomeExpense" xlink:href="lyel-20230630.xsd#lyel_NonCashLeaseIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_NonCashLeaseIncomeExpense" xlink:to="lab_lyel_NonCashLeaseIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fc3236d3-bb25-4fc6-abb7-e89cb2870596_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b98aa293-f637-43eb-b4f1-8ea9f3266496_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0dfd3e41-33c6-4b64-b090-bcf1cf5e0b74_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f645cf6e-3d0a-4779-860d-4f6f8405fb92_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses, other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_90f1fe4a-2d60-4d07-b7cc-c452a2088889_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4b72f42f-aebf-4365-9108-c1eba65e4665_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future issuance of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember_2c51e869-40d8-4f8f-bacd-5e69adb7d0b3_terseLabel_en-US" xlink:label="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:label id="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:href="lyel-20230630.xsd#lyel_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="lab_lyel_TwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_929c589c-bfed-40fb-acb9-21b9e668e5fa_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7455363e-ef77-4601-aec1-de29e0c675f7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f2c957f3-e669-48d0-b5eb-c823c1789556_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5322427c-9ca6-4e4e-a624-717bf07e216d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 500,000 shares authorized at June&#160;30, 2023 and December&#160;31, 2022; 251,027 and 249,567 shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ee655f59-9d38-46ff-894c-9d2aae5e28fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities held in a continuous unrealized loss position for less than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_4e5fee22-a92e-437c-aaff-fb5596cb3768_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e6032a47-f658-499f-993e-e72e64c5e5c9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27eff29d-1712-4b9c-9cea-56d2ec9989ba_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_bc7cbe73-a934-483c-9eb9-8e020c83e7be_terseLabel_en-US" xlink:label="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of success payment liabilities</link:label>
    <link:label id="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_label_en-US" xlink:label="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment Of Success Payment Liabilities</link:label>
    <link:label id="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_documentation_en-US" xlink:label="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment of success payment liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:href="lyel-20230630.xsd#lyel_FairValueAdjustmentOfSuccessPaymentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:to="lab_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_71a621c5-c35f-45e8-9800-954e2edeac2c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_27ed1bf5-3ebf-43f2-9971-de98970b9923_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_a5fa2d3e-daa6-4c2c-a045-7a48cd0fd228_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaborative arrangement for research</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Term</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_86a0a349-71c5-46b7-94af-6a4b60d66e6b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_bb86c7e4-e10e-4e84-bea7-36288e2ee260_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b247b480-b2ca-4fa0-aa86-0b936bcd6faa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_182f62b0-ab5f-4cf2-aa34-abc4a7dc0a90_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8d9b8aa7-995e-49e8-8ab3-e1a6b24d0904_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_39af1a2b-e3bc-4809-8cf6-6d1bea4288ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4877165b-b35b-4918-a596-41143e35fc50_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_88aac6b5-763d-4821-9b20-fbc585082c3a_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_d3b1a3da-10da-4642-8f77-686c11956659_terseLabel_en-US" xlink:label="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for amounts related to tenant improvement allowances</link:label>
    <link:label id="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_label_en-US" xlink:label="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received For Amounts Related To Tenant Improvement Allowances</link:label>
    <link:label id="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_documentation_en-US" xlink:label="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for amounts related to tenant improvement allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:href="lyel-20230630.xsd#lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:to="lab_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_eb9e6955-d02c-4c7f-a359-acfff50556e7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_7a5c81e3-0766-4c42-9f40-ce18cbe308ac_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_520c97d1-304b-4202-a3ce-b70ef97547c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_f02c983e-794a-46b5-b5ff-50237d039cb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2e30be0f-7788-4e65-b68e-47fcac41b378_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_aaf5237d-1100-43bc-9992-ce32aec07568_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_33fc9c16-dee0-4225-9d59-dd076c8b0d1d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_97c3215e-7bca-49bc-9078-365f5dade2fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_f691be1d-1af9-4d5a-a66b-f24798b9d860_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_4c2420b4-f770-467d-b24c-25a26d846400_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity warrant</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4144b7fd-3b6b-4cc0-8184-89f4ab6c5bac_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_GSKMember_96ec8a3d-5c0f-426c-8295-b7aec6a57f2f_terseLabel_en-US" xlink:label="lab_lyel_GSKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_lyel_GSKMember_label_en-US" xlink:label="lab_lyel_GSKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_lyel_GSKMember_documentation_en-US" xlink:label="lab_lyel_GSKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GSKMember" xlink:href="lyel-20230630.xsd#lyel_GSKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_GSKMember" xlink:to="lab_lyel_GSKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_ca350892-ffea-40ff-8614-6c51969cadb8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_953a52c2-faa8-4284-83eb-0c2c8a7b3dbe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_5c76359a-ce42-4689-8fa3-ce93471b73e6_terseLabel_en-US" xlink:label="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="lyel-20230630.xsd#lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosure_acf142f8-4b4e-4e9d-a526-2878dea550a9_terseLabel_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosure" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosure" xlink:to="lab_lyel_CashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c32eaf40-2ae7-426d-9c68-1d7d5d3fe651_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b847f0e4-f525-4344-a5e9-0446e2d191bc_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d184cc94-81eb-418e-915d-2ee1b543ae9a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e3356959-8e64-49d1-b668-b9313b0140ab_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_dc3fb271-6ee4-485f-8434-11512609739e_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_967db95a-177c-4129-a7eb-de2f16d64eb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c702834e-0032-4f64-ac06-753de5e470f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Success Payment Liability Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_9092839b-771a-4cdc-987e-184149da9e1d_terseLabel_en-US" xlink:label="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classified as:</link:label>
    <link:label id="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_label_en-US" xlink:label="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Debt Securities, Available-For-Sale [Abstract]</link:label>
    <link:label id="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_documentation_en-US" xlink:label="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Debt Securities, Available-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:to="lab_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock_80a6ac53-0f32-4585-96d3-c38c1459dd58_terseLabel_en-US" xlink:label="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock_label_en-US" xlink:label="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Policy Text Block]</link:label>
    <link:label id="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock_documentation_en-US" xlink:label="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:href="lyel-20230630.xsd#lyel_SignificantAccountingPoliciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:to="lab_lyel_SignificantAccountingPoliciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7af61071-1a35-40ef-8344-b9471dc297e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3939184a-f057-4568-9091-4c6ee4a9e1c7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_6566cef3-0084-4477-8b6d-af76c2ccf907_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SouthSanFranciscoCaliforniaMember_d3df3748-4087-42d1-a515-640d0d05cabc_terseLabel_en-US" xlink:label="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California</link:label>
    <link:label id="lab_lyel_SouthSanFranciscoCaliforniaMember_label_en-US" xlink:label="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California [Member]</link:label>
    <link:label id="lab_lyel_SouthSanFranciscoCaliforniaMember_documentation_en-US" xlink:label="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SouthSanFranciscoCaliforniaMember" xlink:href="lyel-20230630.xsd#lyel_SouthSanFranciscoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SouthSanFranciscoCaliforniaMember" xlink:to="lab_lyel_SouthSanFranciscoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8d36c7b7-e821-41a9-9554-a18372c66adc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_a877dcfe-c20e-47f0-89eb-e2e2371f72c8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_53580c2f-6d58-4e06-bae5-12a085ae9269_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FiftyTimesMember_c998562f-1c76-4e97-9818-b5d488fad6c7_terseLabel_en-US" xlink:label="lab_lyel_FiftyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifty Times</link:label>
    <link:label id="lab_lyel_FiftyTimesMember_label_en-US" xlink:label="lab_lyel_FiftyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifty Times [Member]</link:label>
    <link:label id="lab_lyel_FiftyTimesMember_documentation_en-US" xlink:label="lab_lyel_FiftyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifty Times (50x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FiftyTimesMember" xlink:href="lyel-20230630.xsd#lyel_FiftyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FiftyTimesMember" xlink:to="lab_lyel_FiftyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2124758d-0def-416b-ba62-bdff32ba4403_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31fbaa89-e18d-4800-aada-0e441f29f55e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b79a6834-6b1f-49ef-be0c-259e4cfe48ad_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_80bda204-13e2-4cbc-b4c6-ba98187d4f67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_04c03945-429e-4213-abb8-e16016f1bce8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_LyellImmunopharmaMember_5a7c1aa8-4c11-4984-989b-b152193c5ee7_terseLabel_en-US" xlink:label="lab_lyel_LyellImmunopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lyell Immunopharma</link:label>
    <link:label id="lab_lyel_LyellImmunopharmaMember_label_en-US" xlink:label="lab_lyel_LyellImmunopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lyell Immunopharma [Member]</link:label>
    <link:label id="lab_lyel_LyellImmunopharmaMember_documentation_en-US" xlink:label="lab_lyel_LyellImmunopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lyell Immunopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LyellImmunopharmaMember" xlink:href="lyel-20230630.xsd#lyel_LyellImmunopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_LyellImmunopharmaMember" xlink:to="lab_lyel_LyellImmunopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_d797d0f2-dcb8-4765-83f7-d39041677bbb_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment liability</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_015acea1-1818-4239-b2a3-5c035e1c262e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c153bd12-c9ea-4980-bbb1-8058565bd441_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f99168e9-dd2d-4e96-8b2e-6db18c30bd96_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5942cdf7-1df6-4176-b2b2-87422637c30f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0248ef06-bd50-4568-a228-9e91d96884f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9a14de3a-93ed-4996-a057-d1471e53a9eb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1b8ce574-cedf-4628-8418-da81f17996ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_bcc58c04-9632-4739-a9d8-5f17c74d263e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_aa4c6f46-cbf6-4a1e-91ff-179813ccc549_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_fcbe29fe-5606-4553-956c-8186145798ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a13d95d1-9cd5-4edd-bc27-c359a2eb162f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Estimated Fair Value of Level 3 Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f622f6a6-1b48-479d-a9b5-3fa77549fbea_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7a8a9c9d-e3a1-415f-9396-e961bd45aeb9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_319f84ab-e453-4e59-9e46-9446a515d652_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_332ddc7e-d28d-4da1-8487-d52fa5f3c29f_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of potential success payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7f497085-07f6-4a10-b4ed-165672e4ac38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Aggregate Potential Success Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_90e3fa81-c195-4db8-be82-62c49a0cddfd_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bb5f29e8-8678-4a7d-a9e5-94cf8fc30022_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bbb45000-c639-47cf-9d5c-7c5b0d42c20c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StanfordMember_5f6b0583-016c-4a0d-96cf-4948969cad1e_terseLabel_en-US" xlink:label="lab_lyel_StanfordMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford</link:label>
    <link:label id="lab_lyel_StanfordMember_label_en-US" xlink:label="lab_lyel_StanfordMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford [Member]</link:label>
    <link:label id="lab_lyel_StanfordMember_documentation_en-US" xlink:label="lab_lyel_StanfordMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember" xlink:href="lyel-20230630.xsd#lyel_StanfordMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StanfordMember" xlink:to="lab_lyel_StanfordMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_152df3f2-5d65-40fd-a663-8e2543013589_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_00dee680-d728-4ec3-8865-1dae622a396b_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trigger period from IPO date</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c8196ff5-a0ec-43e7-8994-87318201d5d9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_2ffd7078-2407-436a-a238-40b8a9c41afa_terseLabel_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_label_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand twenty one equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:href="lyel-20230630.xsd#lyel_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="lab_lyel_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_01f26450-c987-46dc-b97a-e171157f9dd9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6e36908f-61f7-414b-8145-30e721ef6a39_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_25bec0a5-c534-422e-af2c-94315e08476f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_a5026fb3-1071-4175-a6d7-562a59a232c0_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb229459-0cfd-4a44-a047-57d45a7feefa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9b661d0f-ab3e-436e-b2b3-3c4393755700_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4caa951f-add5-4bc3-8b10-52b475edcd81_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6c1e5c19-e91b-4db9-95c4-139b11228a9c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased_62964eb5-e064-4626-bdef-df165ed719c6_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, stock purchased (in shares)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Shares Purchased</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7cc7d4bd-5f92-4f97-9a7c-6a34bb69a3e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense by Classification</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_24f25074-6d7c-4ba8-9ccd-43884b21d221_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization and accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_36f5b3d7-40f8-46ef-8b37-709df895c254_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0d8fb4c8-1873-4ae3-89eb-775c1bb1e081_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2cbc6ce0-e238-4201-a0c5-4bae0754156d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_d325286c-5ab6-4f82-88a2-57386bf654a7_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9cbe67b1-63f8-45d3-aeb8-43f407681d31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1f0e14ff-d6e1-4550-b7be-063dab442d3e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b1150b4c-3be9-4819-acbb-81f8506d6b60_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_42371089-d90a-4b54-93a8-a2f1b2374bbd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4e9bc19f-5c02-4066-a054-9569d0bcbbcf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c372207a-9a3a-4766-b4d6-7276d76f3cfe_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3ab29cc4-ee01-4116-b910-8b909584abb9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SonomaMember_ecd512c9-4d2c-46ea-87b6-cf9327ef01bd_terseLabel_en-US" xlink:label="lab_lyel_SonomaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma</link:label>
    <link:label id="lab_lyel_SonomaMember_label_en-US" xlink:label="lab_lyel_SonomaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma [Member]</link:label>
    <link:label id="lab_lyel_SonomaMember_documentation_en-US" xlink:label="lab_lyel_SonomaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember" xlink:href="lyel-20230630.xsd#lyel_SonomaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SonomaMember" xlink:to="lab_lyel_SonomaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3f9ae4ac-f3f2-4895-acdf-383b027d92e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_e06e3235-66fd-4916-a4bb-2798b0570260_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2f635b13-949e-484b-a2d1-d233b17e33c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidations</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_3efc622e-f2f1-44e4-80d8-8cfc4c2f1979_terseLabel_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_464483da-cf56-4cc6-aac5-a080955dc30f_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a6300c14-be9d-4e62-8816-3b547b3b4b32_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesCurrent_93049e11-2914-41ae-be90-83acbc3384ea_terseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment liabilities</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesCurrent_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities, Current</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilitiesCurrent_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesCurrent" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilitiesCurrent" xlink:to="lab_lyel_SuccessPaymentLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2d47ba08-b489-44fc-ad3f-2aa34eb7aae4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a2c7a44c-14c6-48ef-945d-6d78b4c92aa6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5686769e-22c2-49fd-a8d0-8a014327b0e2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c169875c-d37b-4353-b83f-1e35a0216ae1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_EquityDistributionAgreementMember_8c6b9ec2-12ce-4af6-aaf0-f4c013789c3e_terseLabel_en-US" xlink:label="lab_lyel_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:label id="lab_lyel_EquityDistributionAgreementMember_label_en-US" xlink:label="lab_lyel_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_lyel_EquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_lyel_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityDistributionAgreementMember" xlink:href="lyel-20230630.xsd#lyel_EquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_EquityDistributionAgreementMember" xlink:to="lab_lyel_EquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_942726e4-9adf-4e8e-835f-d8c63c706e97_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment expense (gain)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b64663e1-d9bf-41f9-bce7-a2bc02d3f1f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d1b7eb0d-9b00-4fbb-9c6b-51c58e722411_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad987d19-c640-49a8-8a51-6220c403b566_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_4c709dd1-f78a-4eea-aa84-0666d4ed3862_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FredHutchMember_f3002d6d-ec71-4f88-82d2-7c364b932f2f_terseLabel_en-US" xlink:label="lab_lyel_FredHutchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch</link:label>
    <link:label id="lab_lyel_FredHutchMember_label_en-US" xlink:label="lab_lyel_FredHutchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch [Member]</link:label>
    <link:label id="lab_lyel_FredHutchMember_documentation_en-US" xlink:label="lab_lyel_FredHutchMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember" xlink:href="lyel-20230630.xsd#lyel_FredHutchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FredHutchMember" xlink:to="lab_lyel_FredHutchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_4c726f5c-f4f6-47eb-a207-b5a2c650f9dd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_fa344f2d-5f84-4343-93cb-09242b92378c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare_614ba6a2-6590-454b-97c4-4addb6937e92_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, purchase price per share (in dollars per share)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Purchase Agreement, Purchase Price Per Share</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Purchase Agreement, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_543cfce3-62ca-4c20-8e51-518a9d91ce4b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SeriesAAConvertiblePreferredStockMember_4086c26e-ff61-494e-8b89-aba237894613_terseLabel_en-US" xlink:label="lab_lyel_SeriesAAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series AA Convertible Preferred Stock</link:label>
    <link:label id="lab_lyel_SeriesAAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_lyel_SeriesAAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_lyel_SeriesAAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_lyel_SeriesAAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series AA Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAAConvertiblePreferredStockMember" xlink:href="lyel-20230630.xsd#lyel_SeriesAAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SeriesAAConvertiblePreferredStockMember" xlink:to="lab_lyel_SeriesAAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f33f0e1-2d8c-4524-b490-b97c81390b13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited or canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_ed80e61f-ce99-42b6-97c6-bfa897f9303b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07183335-fe3d-4648-adef-4f53df95168f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_67f76a0f-9b56-45e2-939c-80adda1a46ca_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on property and equipment disposals</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_158bb3f1-3024-4a0f-bd61-8b21c23e5839_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4a3a0f84-7fad-4e34-8769-07e34fec2377_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_263ec499-e0b0-412b-853e-218c86f97d5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited or canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_f5c2d10d-e9d0-467b-a00e-2e29132feed4_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4ae89f4-bbd4-4288-b6e1-aa72dfb0149e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_be25af64-64d5-40ba-8c24-b3c8dd8006a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_PercentageOfCommissionFromEachSaleOfShares_fd168962-b989-47e1-82d4-7422ecb721d3_terseLabel_en-US" xlink:label="lab_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission from each sale of shares</link:label>
    <link:label id="lab_lyel_PercentageOfCommissionFromEachSaleOfShares_label_en-US" xlink:label="lab_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Commission From Each Sale Of Shares</link:label>
    <link:label id="lab_lyel_PercentageOfCommissionFromEachSaleOfShares_documentation_en-US" xlink:label="lab_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Commission From Each Sale Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:href="lyel-20230630.xsd#lyel_PercentageOfCommissionFromEachSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:to="lab_lyel_PercentageOfCommissionFromEachSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ce3d72a4-45a1-4443-b2ed-5606431ace73_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5fd5f27e-0805-471f-ad15-1caf703d87f4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f33a3550-f4d9-46d2-8852-eeffc12c3d43_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_91319890-f027-4c1a-91cc-a0568c7a80fc_terseLabel_en-US" xlink:label="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represented by:</link:label>
    <link:label id="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represented By Cash And Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represented by Cash and Cash Equivalents and Restricted Cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:href="lyel-20230630.xsd#lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_586c01a4-1ef3-4af4-bc2c-d2efa2d89e8b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_30b4c25a-afc7-4ace-ac2c-372bfedef81b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5757798f-6227-4208-ab9c-74b0dbf71111_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9f462ce4-c3cf-4780-ac3c-ded03287afab_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_ebb3af45-3064-40ce-8190-04af44de6202_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2a2b2fbf-eeff-442b-8055-83b53ace6093_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_c6ba8004-0ec5-45bf-a6ab-375c6281302a_totalLabel_en-US" xlink:label="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost</link:label>
    <link:label id="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_OtherInvestmentMember_0bc630f6-838e-40a2-a963-1e44571e7884_terseLabel_en-US" xlink:label="lab_lyel_OtherInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment</link:label>
    <link:label id="lab_lyel_OtherInvestmentMember_label_en-US" xlink:label="lab_lyel_OtherInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment [Member]</link:label>
    <link:label id="lab_lyel_OtherInvestmentMember_documentation_en-US" xlink:label="lab_lyel_OtherInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember" xlink:href="lyel-20230630.xsd#lyel_OtherInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_OtherInvestmentMember" xlink:to="lab_lyel_OtherInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMember_c0bfc626-9dda-44f5-b574-2d014db4a699_verboseLabel_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liabilities</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMember_label_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability [Member]</link:label>
    <link:label id="lab_lyel_SuccessPaymentLiabilityMember_documentation_en-US" xlink:label="lab_lyel_SuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMember" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_SuccessPaymentLiabilityMember" xlink:to="lab_lyel_SuccessPaymentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fa2fa73a-4edc-40fa-95d6-e79d38425903_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_0cd45e70-c9bc-4f62-b97d-205d8544df0b_terseLabel_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_9dca93bf-69e0-40f3-a147-b44213ead96a_totalLabel_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale</link:label>
    <link:label id="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:to="lab_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_85ef6b0c-8222-418a-ace7-9702257d8c8b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on other investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_fe5b78fe-39dc-49ed-8ed7-1767595c5c10_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_862fed15-2770-4c07-b5ec-7956b1c29cfe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97bf5fc4-4809-42d1-af41-f45995744fe8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_d7ae91cc-55d8-4285-988f-9bdbfd573f59_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_abbf2d63-d003-412a-a548-c7c7955f0cf3_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rentable area</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2f88fb79-1746-4186-9910-c9dbc40241be_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_70d62b1d-2d83-4f0f-96d5-7a5d2e586684_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d60bfa0b-d4b0-4f3c-ac81-3ec709c70805_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_8f2c0326-2238-4c34-994c-9d417107c30e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_OtherInvestmentsTextBlock_1b639084-2c86-4c51-820e-c2b8f97ece95_terseLabel_en-US" xlink:label="lab_lyel_OtherInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:label id="lab_lyel_OtherInvestmentsTextBlock_label_en-US" xlink:label="lab_lyel_OtherInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Text Block]</link:label>
    <link:label id="lab_lyel_OtherInvestmentsTextBlock_documentation_en-US" xlink:label="lab_lyel_OtherInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentsTextBlock" xlink:href="lyel-20230630.xsd#lyel_OtherInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_OtherInvestmentsTextBlock" xlink:to="lab_lyel_OtherInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fd6a2ed-208c-43d7-beb0-fa77ed864cf5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c82881b-249b-49a0-8d84-36ad314180cb_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0928a756-2af9-4418-9a8a-9735d3dc6df2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_4a7388f2-0b67-4fa4-a906-46d7913b5f2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_fc54f11a-f285-4bd8-bafd-02089e3a1ded_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare_4e6d6dd2-dff7-42e8-adf8-24af1261b339_terseLabel_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share of stock sold under stock purchase program (in dollars per share)</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare_label_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Shares Sold, Price Per Share</link:label>
    <link:label id="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare_documentation_en-US" xlink:label="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Shares Sold, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:href="lyel-20230630.xsd#lyel_StockPurchaseAgreementSharesSoldPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:to="lab_lyel_StockPurchaseAgreementSharesSoldPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_917b5a47-a6d5-4253-b265-3edac82d4d6e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_4f9c68a0-b882-4c17-bc3e-44a1c9ae32ab_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0647eab7-eefe-4609-b7d8-aa7faa8657aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_041e90b5-cf5d-4897-a010-d03c864b6671_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_edd3f3e3-d0fe-449d-a6e1-23aa4cd337c2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_StanfordSuccessPaymentLiabilityMember_493764df-024d-4118-9e09-5af30cc307f3_terseLabel_en-US" xlink:label="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford</link:label>
    <link:label id="lab_lyel_StanfordSuccessPaymentLiabilityMember_label_en-US" xlink:label="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford Success Payment Liability [Member]</link:label>
    <link:label id="lab_lyel_StanfordSuccessPaymentLiabilityMember_documentation_en-US" xlink:label="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford Success Payment Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordSuccessPaymentLiabilityMember" xlink:href="lyel-20230630.xsd#lyel_StanfordSuccessPaymentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_StanfordSuccessPaymentLiabilityMember" xlink:to="lab_lyel_StanfordSuccessPaymentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_cd5d8678-3462-4d18-9124-0e57f96ceb50_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_be89ecd1-f288-4c68-abbb-f956212a1456_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_FredHutchSuccessPaymentLiabilityMember_26d57849-9de8-4b04-8de6-9bb7f161d555_terseLabel_en-US" xlink:label="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch</link:label>
    <link:label id="lab_lyel_FredHutchSuccessPaymentLiabilityMember_label_en-US" xlink:label="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch Success Payment Liability [Member]</link:label>
    <link:label id="lab_lyel_FredHutchSuccessPaymentLiabilityMember_documentation_en-US" xlink:label="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fred Hutch Success Payment Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:href="lyel-20230630.xsd#lyel_FredHutchSuccessPaymentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:to="lab_lyel_FredHutchSuccessPaymentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_71de27b5-35f7-407c-86d5-1a278db46f9b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TenTimesMember_849c317a-a67d-40e5-9f74-291911d3e256_terseLabel_en-US" xlink:label="lab_lyel_TenTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ten Times</link:label>
    <link:label id="lab_lyel_TenTimesMember_label_en-US" xlink:label="lab_lyel_TenTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ten Times [Member]</link:label>
    <link:label id="lab_lyel_TenTimesMember_documentation_en-US" xlink:label="lab_lyel_TenTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ten Times (10x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TenTimesMember" xlink:href="lyel-20230630.xsd#lyel_TenTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TenTimesMember" xlink:to="lab_lyel_TenTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_f1ab501a-eb46-4f11-b5d9-12bece3c3d81_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_31f6abf2-6dcc-4b5e-881e-77c96266f3b8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e51de09b-f0a9-442b-942e-fc60daac5e15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9045c82b-1193-4160-a2b7-20f11f58ecf4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9183cc74-2d9e-47b0-ae82-a2b0db4e960e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_423a7635-60aa-4e67-a910-9687cc3b53b7_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_2d7f1866-5a1b-4205-8fe6-e5ffa1a91d9d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_65f373fe-c586-4db3-82e5-c9aeaedacbba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_06e9d730-7b6e-4151-b70d-5ab06331b0b2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b5c182b5-bfe1-40b1-88b5-f2b6be7484ec_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5eae9f86-95ce-491c-8482-60a0ab63481a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_3735cda2-04b3-4e36-a3c8-be240d73d684_terseLabel_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand twenty one employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:href="lyel-20230630.xsd#lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="lab_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_af376420-5349-45eb-9ddc-c56f4a0fe72b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_143b9eee-5406-404a-adda-31988b073e11_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee purchase of shares, proportion of fair value (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_TwentyTimesMember_876682ad-7e0f-49d9-bca7-4d08362912bb_terseLabel_en-US" xlink:label="lab_lyel_TwentyTimesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Times</link:label>
    <link:label id="lab_lyel_TwentyTimesMember_label_en-US" xlink:label="lab_lyel_TwentyTimesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Times [Member]</link:label>
    <link:label id="lab_lyel_TwentyTimesMember_documentation_en-US" xlink:label="lab_lyel_TwentyTimesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Times (20x).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwentyTimesMember" xlink:href="lyel-20230630.xsd#lyel_TwentyTimesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_TwentyTimesMember" xlink:to="lab_lyel_TwentyTimesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_aed8e10f-2226-4f5f-a407-9c20ed6d1b88_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f1f0ff3c-4724-443f-9791-5fa48b2414b4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_293c8a4e-7166-4863-9e9a-9fd8f01564d6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare_85d1e581-7a68-4ea2-8268-c7e889181ec0_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, fair value per share (in dollars per share)</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Fair Value Per Share</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Fair Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_bfa9c1d1-a073-4434-8be2-3c5bedab1438_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cd917d95-68c2-4631-a02c-907af3d0896b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ea9a0459-f5bb-4bb2-8992-a26c8dd78f21_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_62bc7bec-8a16-4e3a-8ad7-e3b2a655e4b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7683ea47-45d0-413f-a71e-93d9c0989314_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fb4009cb-068e-406d-ba87-53fe6de5fdfb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Amortized Cost of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_6567ab43-9efa-4028-a5e7-e8e4b6f873eb_terseLabel_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate research payments due</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_label_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Payments</link:label>
    <link:label id="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_documentation_en-US" xlink:label="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:to="lab_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_28bec25d-3e20-4379-bf16-b0322bf0257b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>lyel-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8f655eeb-886b-4b81-9c30-69669c77ca83,g:e402dc2a-90a6-40a3-91ac-ff661e6149b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lyell.com/role/Cover" xlink:type="simple" xlink:href="lyel-20230630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://lyell.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_74410d2d-60ca-4001-a4ce-436dd9676d9e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_DocumentType_74410d2d-60ca-4001-a4ce-436dd9676d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_6e9ab8ef-c12c-4f28-8921-cdfae914faaa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_DocumentQuarterlyReport_6e9ab8ef-c12c-4f28-8921-cdfae914faaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9c9bfb30-ea18-4813-9749-84296d21702d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_DocumentPeriodEndDate_9c9bfb30-ea18-4813-9749-84296d21702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_25f77809-1a55-459c-9ad6-cf9c7a7aeac0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_DocumentTransitionReport_25f77809-1a55-459c-9ad6-cf9c7a7aeac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f8d60893-3937-4d57-a01b-1b3c1e960654" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityFileNumber_f8d60893-3937-4d57-a01b-1b3c1e960654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e51674e7-0955-43ff-bdd1-5477c26d4947" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityRegistrantName_e51674e7-0955-43ff-bdd1-5477c26d4947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2b9ed37b-4d9b-48e4-9107-6d0b5c1ca686" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2b9ed37b-4d9b-48e4-9107-6d0b5c1ca686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_74ade64f-a967-4cd2-9048-9f1d62ecbad0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityTaxIdentificationNumber_74ade64f-a967-4cd2-9048-9f1d62ecbad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_39a97d12-305a-48a6-8c58-d821c20f5410" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityAddressAddressLine1_39a97d12-305a-48a6-8c58-d821c20f5410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7393b3bf-12d4-448b-ba13-a3ab34dec215" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityAddressCityOrTown_7393b3bf-12d4-448b-ba13-a3ab34dec215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_60e97b38-beda-4bb7-a2d8-81730a70cfc3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityAddressStateOrProvince_60e97b38-beda-4bb7-a2d8-81730a70cfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f32ab052-646b-4ac9-b937-2c59c8430e5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityAddressPostalZipCode_f32ab052-646b-4ac9-b937-2c59c8430e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_017ff424-5d87-436e-9781-5c5a659c5d2a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_CityAreaCode_017ff424-5d87-436e-9781-5c5a659c5d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9ad42e70-14c3-40d3-8aee-73a176c070fd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_LocalPhoneNumber_9ad42e70-14c3-40d3-8aee-73a176c070fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e04ebe01-95ce-423e-9c1b-3f40b9d84c18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_Security12bTitle_e04ebe01-95ce-423e-9c1b-3f40b9d84c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_90558fde-738f-4a7a-bb1c-b7444ad8fcbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_TradingSymbol_90558fde-738f-4a7a-bb1c-b7444ad8fcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f3e2dbc6-8d59-424a-9ad7-aa8c93d1bdbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_SecurityExchangeName_f3e2dbc6-8d59-424a-9ad7-aa8c93d1bdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9b8c51aa-4d0e-4310-bc81-e8cc04abdfcf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityCurrentReportingStatus_9b8c51aa-4d0e-4310-bc81-e8cc04abdfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3c08c3cb-663f-4091-a246-9ea9e42a9472" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityInteractiveDataCurrent_3c08c3cb-663f-4091-a246-9ea9e42a9472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d2ef8d51-d3cc-43b7-ae02-70a0ae28c00d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityFilerCategory_d2ef8d51-d3cc-43b7-ae02-70a0ae28c00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8e50fe98-9438-4afc-847d-9726415bf41d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntitySmallBusiness_8e50fe98-9438-4afc-847d-9726415bf41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2dafe739-19d9-49cc-b620-e1182389c267" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityEmergingGrowthCompany_2dafe739-19d9-49cc-b620-e1182389c267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b4266400-ed25-49ad-99e6-5faff3b63e18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityShellCompany_b4266400-ed25-49ad-99e6-5faff3b63e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_aeb01cb5-970f-42f2-af0a-38826f39f9f6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_aeb01cb5-970f-42f2-af0a-38826f39f9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_82650df4-9a55-47b9-bc74-528e56036541" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_EntityCentralIndexKey_82650df4-9a55-47b9-bc74-528e56036541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a71d38a8-5430-410c-84a1-d5149c7dfec7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_CurrentFiscalYearEndDate_a71d38a8-5430-410c-84a1-d5149c7dfec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8331be16-3a37-444e-9e04-e8a14d7d84fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_DocumentFiscalYearFocus_8331be16-3a37-444e-9e04-e8a14d7d84fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ce54ecc5-4663-4996-ad26-728facb030d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ce54ecc5-4663-4996-ad26-728facb030d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c55b67ab-9d93-44fd-8811-04e7ff2b0822" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42ecc732-a6fc-4a26-8690-cfb683859288" xlink:to="loc_dei_AmendmentFlag_c55b67ab-9d93-44fd-8811-04e7ff2b0822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8733a534-63be-4c5b-b2e9-b016af4aa926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8733a534-63be-4c5b-b2e9-b016af4aa926" xlink:to="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c9579317-fc69-43ec-9678-67eb91ad5a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c9579317-fc69-43ec-9678-67eb91ad5a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2742d1fb-cda1-43e1-bdb1-ba7b9c76f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9579317-fc69-43ec-9678-67eb91ad5a53" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2742d1fb-cda1-43e1-bdb1-ba7b9c76f81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ea4ae576-2956-4815-b2f4-e056fa775d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9579317-fc69-43ec-9678-67eb91ad5a53" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ea4ae576-2956-4815-b2f4-e056fa775d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_96b651ae-b8cc-4b73-ac6a-bf680c9e9873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9579317-fc69-43ec-9678-67eb91ad5a53" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_96b651ae-b8cc-4b73-ac6a-bf680c9e9873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_13b6e14d-18e3-48a7-adcb-536c3cee5153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c9579317-fc69-43ec-9678-67eb91ad5a53" xlink:to="loc_us-gaap_AssetsCurrent_13b6e14d-18e3-48a7-adcb-536c3cee5153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_17cc90fb-3b5b-4a81-898b-3d852ac8d787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_17cc90fb-3b5b-4a81-898b-3d852ac8d787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_0c907d64-3aff-4c9b-8102-a9dd97f02776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_0c907d64-3aff-4c9b-8102-a9dd97f02776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_13555ce4-e4f5-4d1e-bfe3-e05291ea6846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:to="loc_us-gaap_OtherInvestments_13555ce4-e4f5-4d1e-bfe3-e05291ea6846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9f58203c-9512-4e1b-b883-6112c699d108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9f58203c-9512-4e1b-b883-6112c699d108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_425ae1eb-723b-4923-ab26-29e1f9c15a13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_425ae1eb-723b-4923-ab26-29e1f9c15a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e1b98339-2ce1-43a1-a608-780d61d0b666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e1b98339-2ce1-43a1-a608-780d61d0b666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_81de55f4-f238-4646-aaad-210652d1f28a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b047c06-b5d7-4695-850f-18bbdd742196" xlink:to="loc_us-gaap_Assets_81de55f4-f238-4646-aaad-210652d1f28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_837b244d-3f6b-4f91-8076-0c93b2f69595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8733a534-63be-4c5b-b2e9-b016af4aa926" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_837b244d-3f6b-4f91-8076-0c93b2f69595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_feace0f4-ee47-4cbc-8a2c-3c768d8fafa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_837b244d-3f6b-4f91-8076-0c93b2f69595" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_feace0f4-ee47-4cbc-8a2c-3c768d8fafa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b768b3d7-4891-445f-9214-c4c5aca44814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_feace0f4-ee47-4cbc-8a2c-3c768d8fafa7" xlink:to="loc_us-gaap_AccountsPayableCurrent_b768b3d7-4891-445f-9214-c4c5aca44814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_55bcb292-92ee-4e42-9191-21afbbbe2d58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_feace0f4-ee47-4cbc-8a2c-3c768d8fafa7" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_55bcb292-92ee-4e42-9191-21afbbbe2d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesCurrent_8307d3a1-f4d7-46eb-a09d-0ee4dab95bed" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_feace0f4-ee47-4cbc-8a2c-3c768d8fafa7" xlink:to="loc_lyel_SuccessPaymentLiabilitiesCurrent_8307d3a1-f4d7-46eb-a09d-0ee4dab95bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_34fbde62-731e-4073-8e34-f5725b307f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_feace0f4-ee47-4cbc-8a2c-3c768d8fafa7" xlink:to="loc_us-gaap_LiabilitiesCurrent_34fbde62-731e-4073-8e34-f5725b307f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6c9588eb-9205-4374-92c2-288b62a56ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_837b244d-3f6b-4f91-8076-0c93b2f69595" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6c9588eb-9205-4374-92c2-288b62a56ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_96199aef-b9c6-4a64-81e3-3c542ffd9ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_837b244d-3f6b-4f91-8076-0c93b2f69595" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_96199aef-b9c6-4a64-81e3-3c542ffd9ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_efa2cd15-1d34-421c-99db-f71d3e814c15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_837b244d-3f6b-4f91-8076-0c93b2f69595" xlink:to="loc_us-gaap_Liabilities_efa2cd15-1d34-421c-99db-f71d3e814c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_76a16b44-bb32-402e-9603-35a4e86713fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_837b244d-3f6b-4f91-8076-0c93b2f69595" xlink:to="loc_us-gaap_CommitmentsAndContingencies_76a16b44-bb32-402e-9603-35a4e86713fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773fa18c-8cfa-444e-8eab-ed1216c6f588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_837b244d-3f6b-4f91-8076-0c93b2f69595" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773fa18c-8cfa-444e-8eab-ed1216c6f588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d3b38220-478a-42d7-b728-002aae5d6879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773fa18c-8cfa-444e-8eab-ed1216c6f588" xlink:to="loc_us-gaap_PreferredStockValue_d3b38220-478a-42d7-b728-002aae5d6879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a75ac966-b951-430a-bca6-53e3799810e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773fa18c-8cfa-444e-8eab-ed1216c6f588" xlink:to="loc_us-gaap_CommonStockValue_a75ac966-b951-430a-bca6-53e3799810e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fd692d5b-5188-4056-83db-672eee7baf39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773fa18c-8cfa-444e-8eab-ed1216c6f588" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fd692d5b-5188-4056-83db-672eee7baf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2eb7b342-de06-4da2-8c5d-481833d337a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773fa18c-8cfa-444e-8eab-ed1216c6f588" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2eb7b342-de06-4da2-8c5d-481833d337a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1fc93ca2-8032-4c5f-9503-6b4b6c4c40d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773fa18c-8cfa-444e-8eab-ed1216c6f588" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1fc93ca2-8032-4c5f-9503-6b4b6c4c40d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c7312eb4-41c4-497e-8b69-dae28899fdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_773fa18c-8cfa-444e-8eab-ed1216c6f588" xlink:to="loc_us-gaap_StockholdersEquity_c7312eb4-41c4-497e-8b69-dae28899fdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_506b3174-bcb0-46f6-91bb-1709eadc3334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_837b244d-3f6b-4f91-8076-0c93b2f69595" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_506b3174-bcb0-46f6-91bb-1709eadc3334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d9be3c32-b967-481e-9c1e-f5d2906e9855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a807b838-8b24-4b22-86b8-6a1a27799262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9be3c32-b967-481e-9c1e-f5d2906e9855" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a807b838-8b24-4b22-86b8-6a1a27799262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ec52aa2e-42b0-4c9e-be85-e145050f781d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9be3c32-b967-481e-9c1e-f5d2906e9855" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ec52aa2e-42b0-4c9e-be85-e145050f781d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_24c3d8f6-fd10-40c5-ab0d-c1f25ba9c243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9be3c32-b967-481e-9c1e-f5d2906e9855" xlink:to="loc_us-gaap_PreferredStockSharesIssued_24c3d8f6-fd10-40c5-ab0d-c1f25ba9c243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f08858c1-a8ae-4a06-9a78-b9b93bd5b0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9be3c32-b967-481e-9c1e-f5d2906e9855" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f08858c1-a8ae-4a06-9a78-b9b93bd5b0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_16cad707-72d1-49f8-9047-d9fe340dda1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9be3c32-b967-481e-9c1e-f5d2906e9855" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_16cad707-72d1-49f8-9047-d9fe340dda1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b8710a52-44b0-4f54-80e5-e510e715829c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9be3c32-b967-481e-9c1e-f5d2906e9855" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b8710a52-44b0-4f54-80e5-e510e715829c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_24fca5bd-5831-4ca2-a08e-32dc009ccb99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9be3c32-b967-481e-9c1e-f5d2906e9855" xlink:to="loc_us-gaap_CommonStockSharesIssued_24fca5bd-5831-4ca2-a08e-32dc009ccb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_72923849-d6d7-4d3c-92e0-d2193b175a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9be3c32-b967-481e-9c1e-f5d2906e9855" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_72923849-d6d7-4d3c-92e0-d2193b175a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a675cea5-534e-4ffb-a2cd-0e6362a384f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_Revenues_a675cea5-534e-4ffb-a2cd-0e6362a384f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_30c3749a-3890-41ee-9f47-b7c0febf0888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_30c3749a-3890-41ee-9f47-b7c0febf0888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_203d0e23-ee8e-407b-bf50-2e7af025d5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_30c3749a-3890-41ee-9f47-b7c0febf0888" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_203d0e23-ee8e-407b-bf50-2e7af025d5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_793d22bf-fad0-46f8-b9c9-6c172fd7b66b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_30c3749a-3890-41ee-9f47-b7c0febf0888" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_793d22bf-fad0-46f8-b9c9-6c172fd7b66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_554859f1-0383-4786-a383-1fce71d2d07c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_30c3749a-3890-41ee-9f47-b7c0febf0888" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_554859f1-0383-4786-a383-1fce71d2d07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a7cb0393-7dab-4efb-9739-7bfd87f0fa53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_30c3749a-3890-41ee-9f47-b7c0febf0888" xlink:to="loc_us-gaap_OperatingExpenses_a7cb0393-7dab-4efb-9739-7bfd87f0fa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6991dde5-114c-4fa3-a228-ccc10015be45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_OperatingIncomeLoss_6991dde5-114c-4fa3-a228-ccc10015be45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_69fbfa0b-1dce-4f05-aa59-77f9b72f15fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_69fbfa0b-1dce-4f05-aa59-77f9b72f15fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7f71f5b0-db34-4fe1-a431-e07cb6be8383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7f71f5b0-db34-4fe1-a431-e07cb6be8383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_2bbd6b1d-7b43-49d1-9ff5-c94ab7ad4039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_2bbd6b1d-7b43-49d1-9ff5-c94ab7ad4039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5ce64878-096e-406e-b708-19f37a86d9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5ce64878-096e-406e-b708-19f37a86d9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c77bfcd-768f-4bca-869b-99609706f9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_NetIncomeLoss_8c77bfcd-768f-4bca-869b-99609706f9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_dde423f2-6e17-474a-a90e-e854e7653175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_dde423f2-6e17-474a-a90e-e854e7653175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_dfa0b8d4-7d42-414f-8f9d-1212b5263c21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_dde423f2-6e17-474a-a90e-e854e7653175" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_dfa0b8d4-7d42-414f-8f9d-1212b5263c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_baefaa2c-0cda-4d49-a10a-89ce269515bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_dde423f2-6e17-474a-a90e-e854e7653175" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_baefaa2c-0cda-4d49-a10a-89ce269515bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b09c9095-e1c7-4c09-a404-20d57c002aff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_EarningsPerShareBasic_b09c9095-e1c7-4c09-a404-20d57c002aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_33c7caa7-2689-464c-8b3d-fbae7d00be0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_33c7caa7-2689-464c-8b3d-fbae7d00be0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26e2b965-1151-4070-8ef6-15bca7b05adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26e2b965-1151-4070-8ef6-15bca7b05adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ba80283b-8c67-4855-93a0-20c4361a29f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_323acc7d-bae0-48e1-bb4f-cd74b7f447f8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ba80283b-8c67-4855-93a0-20c4361a29f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9469220c-03cb-4480-afa8-3a700c68849d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_453d2cdc-4a38-4748-838e-e18ef76e1c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9469220c-03cb-4480-afa8-3a700c68849d" xlink:to="loc_us-gaap_StatementTable_453d2cdc-4a38-4748-838e-e18ef76e1c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48ff5553-5c40-4db8-801e-2328a09031d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_453d2cdc-4a38-4748-838e-e18ef76e1c38" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48ff5553-5c40-4db8-801e-2328a09031d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8841a148-16d1-4b29-93d3-0eb728b3db43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48ff5553-5c40-4db8-801e-2328a09031d6" xlink:to="loc_us-gaap_RelatedPartyDomain_8841a148-16d1-4b29-93d3-0eb728b3db43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_95aeeb8d-5d4b-43d9-b3af-e8b1a2897ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8841a148-16d1-4b29-93d3-0eb728b3db43" xlink:to="loc_us-gaap_RelatedPartyMember_95aeeb8d-5d4b-43d9-b3af-e8b1a2897ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3dbad76c-8615-4f90-9c13-ac16ebcfc9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_453d2cdc-4a38-4748-838e-e18ef76e1c38" xlink:to="loc_us-gaap_StatementLineItems_3dbad76c-8615-4f90-9c13-ac16ebcfc9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aa15753c-2a8c-4782-8f2b-928e6ceaa4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3dbad76c-8615-4f90-9c13-ac16ebcfc9ef" xlink:to="loc_us-gaap_Revenues_aa15753c-2a8c-4782-8f2b-928e6ceaa4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5d7f4483-5c45-4c70-8e35-e961ef61c768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0b2f01eb-6d3a-413e-8d31-7a9813481a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5d7f4483-5c45-4c70-8e35-e961ef61c768" xlink:to="loc_us-gaap_StatementTable_0b2f01eb-6d3a-413e-8d31-7a9813481a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20f3c082-cf98-4430-8a91-79b85c99f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0b2f01eb-6d3a-413e-8d31-7a9813481a2d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20f3c082-cf98-4430-8a91-79b85c99f6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20f3c082-cf98-4430-8a91-79b85c99f6a1" xlink:to="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf612860-35dd-47ab-a93d-a07a25b1d6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:to="loc_us-gaap_CommonStockMember_cf612860-35dd-47ab-a93d-a07a25b1d6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2d3e2945-13aa-453b-a858-858736817a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2d3e2945-13aa-453b-a858-858736817a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_066af1b0-356b-45c5-9b98-c8eb1ecb7993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_066af1b0-356b-45c5-9b98-c8eb1ecb7993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9110608e-b6be-4c0a-ad13-e2d1fc5d4829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f238ce91-dbf7-46cf-b15b-10c8a441ce8b" xlink:to="loc_us-gaap_RetainedEarningsMember_9110608e-b6be-4c0a-ad13-e2d1fc5d4829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d963c9b3-79a9-490b-9ec2-dbb1bbb44c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0b2f01eb-6d3a-413e-8d31-7a9813481a2d" xlink:to="loc_us-gaap_StatementLineItems_d963c9b3-79a9-490b-9ec2-dbb1bbb44c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d963c9b3-79a9-490b-9ec2-dbb1bbb44c8b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5373fc83-74ae-4ef6-8ded-7b96caae6996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5373fc83-74ae-4ef6-8ded-7b96caae6996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e86fe1fc-2169-4abb-b923-330289d041b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockholdersEquity_e86fe1fc-2169-4abb-b923-330289d041b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c501ebfe-a616-4f3c-8005-849368f11a22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c501ebfe-a616-4f3c-8005-849368f11a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4cc2b5ae-4515-4154-8eea-9a9575f6614e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4cc2b5ae-4515-4154-8eea-9a9575f6614e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2a6d136f-bb47-4fcb-b90a-d362d40d33f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2a6d136f-bb47-4fcb-b90a-d362d40d33f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b55b2044-b58d-42d0-816a-d72a84debe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b55b2044-b58d-42d0-816a-d72a84debe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_882498eb-771c-4e4b-bf31-2043f6134124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_882498eb-771c-4e4b-bf31-2043f6134124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_85ad20f2-b385-49b9-ba8a-81699e1fd3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_85ad20f2-b385-49b9-ba8a-81699e1fd3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ce92afd9-6f97-4cb4-b13f-2edbfdea2c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ce92afd9-6f97-4cb4-b13f-2edbfdea2c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_65b4acc4-a382-4515-9124-5d9ddeb2091c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_65b4acc4-a382-4515-9124-5d9ddeb2091c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84d6bcb0-b7c3-4f19-99f7-754c9ff0c183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84d6bcb0-b7c3-4f19-99f7-754c9ff0c183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_550f42ee-b7c1-43f2-906a-ffac82869e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_NetIncomeLoss_550f42ee-b7c1-43f2-906a-ffac82869e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_59375902-82ef-4475-a7ae-c84d263fc245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_59375902-82ef-4475-a7ae-c84d263fc245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9a140b77-a9f4-4709-a698-8252ca2d26bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_08aa500c-a6b8-4c49-be79-fbeba7d59b62" xlink:to="loc_us-gaap_StockholdersEquity_9a140b77-a9f4-4709-a698-8252ca2d26bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lyel-20230630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e7bdb963-4ba6-410d-8aec-fc9aa0b6dfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33374a73-526c-4498-9fb7-f89d45254a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7bdb963-4ba6-410d-8aec-fc9aa0b6dfd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33374a73-526c-4498-9fb7-f89d45254a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ea5bfdc1-9bcf-4d35-81a7-1abb04da9903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33374a73-526c-4498-9fb7-f89d45254a4b" xlink:to="loc_us-gaap_NetIncomeLoss_ea5bfdc1-9bcf-4d35-81a7-1abb04da9903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33374a73-526c-4498-9fb7-f89d45254a4b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3507acfc-8c5c-420f-b1db-bc36b0f5284d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:to="loc_us-gaap_ShareBasedCompensation_3507acfc-8c5c-420f-b1db-bc36b0f5284d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_19399eb0-ed08-4ff1-94f1-f4e9a4bc7cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_19399eb0-ed08-4ff1-94f1-f4e9a4bc7cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d47a3dea-e5bf-4c34-b57f-82ba349418de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d47a3dea-e5bf-4c34-b57f-82ba349418de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d0e59d26-9710-405a-89d6-0305c8dd349e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d0e59d26-9710-405a-89d6-0305c8dd349e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_NonCashLeaseIncomeExpense_8bc35411-df44-40ba-9d6c-2ff65d46de85" xlink:href="lyel-20230630.xsd#lyel_NonCashLeaseIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:to="loc_lyel_NonCashLeaseIncomeExpense_8bc35411-df44-40ba-9d6c-2ff65d46de85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_86bc16c6-7c8c-44eb-88b1-720b6cc58718" xlink:href="lyel-20230630.xsd#lyel_FairValueAdjustmentOfSuccessPaymentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:to="loc_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities_86bc16c6-7c8c-44eb-88b1-720b6cc58718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_97c9bbf8-a5ef-4138-b52b-44a19300aa19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_97c9bbf8-a5ef-4138-b52b-44a19300aa19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a1e2985b-63ce-4a87-8f1b-66a9a347b61f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a1e2985b-63ce-4a87-8f1b-66a9a347b61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_347ee5ca-67bb-40e6-b107-cecc29391082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd4e36b3-3ddc-4282-b00c-7bd208add645" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_347ee5ca-67bb-40e6-b107-cecc29391082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7fb23940-fbb3-4c43-95ae-785477bd431c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_347ee5ca-67bb-40e6-b107-cecc29391082" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7fb23940-fbb3-4c43-95ae-785477bd431c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7813a498-5133-44a3-8390-1c7f24fea065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_347ee5ca-67bb-40e6-b107-cecc29391082" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7813a498-5133-44a3-8390-1c7f24fea065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d66c6da5-523a-4d34-8483-58ee94d3ab2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_347ee5ca-67bb-40e6-b107-cecc29391082" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d66c6da5-523a-4d34-8483-58ee94d3ab2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9c3dcabc-5280-4584-952d-5ecc32db599d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_347ee5ca-67bb-40e6-b107-cecc29391082" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9c3dcabc-5280-4584-952d-5ecc32db599d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a85742c1-39e4-465b-82d1-cb53f456b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_347ee5ca-67bb-40e6-b107-cecc29391082" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a85742c1-39e4-465b-82d1-cb53f456b39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_94f26472-0f82-4942-8c80-a3ba2d6572e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_347ee5ca-67bb-40e6-b107-cecc29391082" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_94f26472-0f82-4942-8c80-a3ba2d6572e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_76f3cc5b-239e-4f6c-ba53-d659a64e55d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33374a73-526c-4498-9fb7-f89d45254a4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_76f3cc5b-239e-4f6c-ba53-d659a64e55d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_beed3e8c-ecf4-4438-b569-09c0864fb2af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7bdb963-4ba6-410d-8aec-fc9aa0b6dfd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_beed3e8c-ecf4-4438-b569-09c0864fb2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_412e56ab-1764-460c-8b8f-e1d20a6493fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_beed3e8c-ecf4-4438-b569-09c0864fb2af" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_412e56ab-1764-460c-8b8f-e1d20a6493fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f726bd9e-0071-4abc-b448-e9ab49d7f382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_beed3e8c-ecf4-4438-b569-09c0864fb2af" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f726bd9e-0071-4abc-b448-e9ab49d7f382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8579c96b-a7b4-46e8-af82-a3ed64b2bc85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_beed3e8c-ecf4-4438-b569-09c0864fb2af" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8579c96b-a7b4-46e8-af82-a3ed64b2bc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36d94f7b-5111-4f91-9f60-9ce8d263200c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_beed3e8c-ecf4-4438-b569-09c0864fb2af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36d94f7b-5111-4f91-9f60-9ce8d263200c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bb18a1e-3b98-40a7-8dc3-393de270de33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7bdb963-4ba6-410d-8aec-fc9aa0b6dfd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bb18a1e-3b98-40a7-8dc3-393de270de33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_aeb3ca4e-ebfd-41de-99d9-016c24eff95f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bb18a1e-3b98-40a7-8dc3-393de270de33" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_aeb3ca4e-ebfd-41de-99d9-016c24eff95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_4cbf9329-6d58-4e86-8c22-b683ecff7ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bb18a1e-3b98-40a7-8dc3-393de270de33" xlink:to="loc_us-gaap_ProceedsFromStockPlans_4cbf9329-6d58-4e86-8c22-b683ecff7ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f5257293-4cc7-47be-8918-5dbaaf36abfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bb18a1e-3b98-40a7-8dc3-393de270de33" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f5257293-4cc7-47be-8918-5dbaaf36abfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a4517fe-4c33-4edf-b5c7-cbc73bbee3be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bb18a1e-3b98-40a7-8dc3-393de270de33" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a4517fe-4c33-4edf-b5c7-cbc73bbee3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25b26d9b-f84b-4335-a362-351d67b8b7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7bdb963-4ba6-410d-8aec-fc9aa0b6dfd0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25b26d9b-f84b-4335-a362-351d67b8b7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_996ba518-1eb1-4d19-8726-e7a621a019b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7bdb963-4ba6-410d-8aec-fc9aa0b6dfd0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_996ba518-1eb1-4d19-8726-e7a621a019b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a01c808-e4c1-44d9-826a-c37c2abcc750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7bdb963-4ba6-410d-8aec-fc9aa0b6dfd0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a01c808-e4c1-44d9-826a-c37c2abcc750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_11744811-d1db-4c35-82af-b94ec8d2936f" xlink:href="lyel-20230630.xsd#lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7bdb963-4ba6-410d-8aec-fc9aa0b6dfd0" xlink:to="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_11744811-d1db-4c35-82af-b94ec8d2936f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c5fdfc7-a693-44f2-974d-19f887b69ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_11744811-d1db-4c35-82af-b94ec8d2936f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c5fdfc7-a693-44f2-974d-19f887b69ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_1ad04b33-69ff-4674-8c0d-600e4c74729d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_11744811-d1db-4c35-82af-b94ec8d2936f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_1ad04b33-69ff-4674-8c0d-600e4c74729d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cb8f4e80-db4a-4428-b45d-1983fe032b49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract_11744811-d1db-4c35-82af-b94ec8d2936f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cb8f4e80-db4a-4428-b45d-1983fe032b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c73c1c16-894e-40ca-a406-18e712b91342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7bdb963-4ba6-410d-8aec-fc9aa0b6dfd0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c73c1c16-894e-40ca-a406-18e712b91342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_bec4c285-2fdd-4e22-a9e8-13ec200aa80e" xlink:href="lyel-20230630.xsd#lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c73c1c16-894e-40ca-a406-18e712b91342" xlink:to="loc_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_bec4c285-2fdd-4e22-a9e8-13ec200aa80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_659c4506-4ad8-4cdb-93d9-1d1a46f8d314" xlink:href="lyel-20230630.xsd#lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c73c1c16-894e-40ca-a406-18e712b91342" xlink:to="loc_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances_659c4506-4ad8-4cdb-93d9-1d1a46f8d314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3f0f95b5-b71a-4380-8ddb-c7b7b2fe8cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c73c1c16-894e-40ca-a406-18e712b91342" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3f0f95b5-b71a-4380-8ddb-c7b7b2fe8cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6b203ab8-5e4e-432f-a125-e28a0f1d3cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3f0f95b5-b71a-4380-8ddb-c7b7b2fe8cf4" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6b203ab8-5e4e-432f-a125-e28a0f1d3cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/Organization" xlink:type="simple" xlink:href="lyel-20230630.xsd#Organization"/>
  <link:presentationLink xlink:role="http://lyell.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_400fc8f5-0b46-42ca-9b77-500f8b1ca9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17da6648-7d58-4187-acc9-f11dc8561aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_400fc8f5-0b46-42ca-9b77-500f8b1ca9b8" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17da6648-7d58-4187-acc9-f11dc8561aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lyel-20230630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_69ee0a93-8cff-4951-9612-c6b0ed3fca90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c569c760-3ee8-46a1-bd26-322a58a0246f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69ee0a93-8cff-4951-9612-c6b0ed3fca90" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c569c760-3ee8-46a1-bd26-322a58a0246f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements" xlink:type="simple" xlink:href="lyel-20230630.xsd#LicenseCollaborationandSuccessPaymentAgreements"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_767367df-2fff-471e-9888-ccaa4cb2963f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_787180c2-ba37-448b-9c2b-874a03add478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_767367df-2fff-471e-9888-ccaa4cb2963f" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_787180c2-ba37-448b-9c2b-874a03add478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="lyel-20230630.xsd#CashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_3caecd6b-821b-4642-ad77-f61696899bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_14e9a5b6-c91c-4070-84a3-5dfb43bf1ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_3caecd6b-821b-4642-ad77-f61696899bd1" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_14e9a5b6-c91c-4070-84a3-5dfb43bf1ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/OtherInvestments" xlink:type="simple" xlink:href="lyel-20230630.xsd#OtherInvestments"/>
  <link:presentationLink xlink:role="http://lyell.com/role/OtherInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_122cfebe-d7f5-4f0a-b58b-fc77e7826043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentsTextBlock_b1c643d8-c9d0-415f-8d04-0555d29472b9" xlink:href="lyel-20230630.xsd#lyel_OtherInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_122cfebe-d7f5-4f0a-b58b-fc77e7826043" xlink:to="loc_lyel_OtherInvestmentsTextBlock_b1c643d8-c9d0-415f-8d04-0555d29472b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7f002d35-66ab-4cad-b926-e8ef907b0766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d1411309-ba2a-4d7d-b569-e09798943920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7f002d35-66ab-4cad-b926-e8ef907b0766" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d1411309-ba2a-4d7d-b569-e09798943920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/Leases" xlink:type="simple" xlink:href="lyel-20230630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://lyell.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d3d5088f-0e57-4ad8-87ce-514de85880de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_905f7b8f-480c-4968-9a23-3ca3d914e753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3d5088f-0e57-4ad8-87ce-514de85880de" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_905f7b8f-480c-4968-9a23-3ca3d914e753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_df6c4297-4271-4d07-b8a1-28742aa40c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3d5088f-0e57-4ad8-87ce-514de85880de" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_df6c4297-4271-4d07-b8a1-28742aa40c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_671e2490-99f1-40e2-ba93-9549b5c20c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0ec7afb8-bff9-4c0e-a1a7-453ffc7e9f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_671e2490-99f1-40e2-ba93-9549b5c20c56" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0ec7afb8-bff9-4c0e-a1a7-453ffc7e9f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a259c3fa-0a70-432d-9f32-4580485c47a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d76dca74-833a-43f6-ad6e-85faa5e9444b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a259c3fa-0a70-432d-9f32-4580485c47a4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d76dca74-833a-43f6-ad6e-85faa5e9444b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/NetLossPerShare" xlink:type="simple" xlink:href="lyel-20230630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://lyell.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_66ae9bc8-feeb-4ad1-a136-bcfcc8264a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1398727a-5261-4c86-bc7b-dfb2bab3a885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_66ae9bc8-feeb-4ad1-a136-bcfcc8264a7e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1398727a-5261-4c86-bc7b-dfb2bab3a885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lyel-20230630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54e49ac2-2c57-49ff-b584-d485d87e000b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3f36ac99-2821-4170-8fb5-80b7481d6dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54e49ac2-2c57-49ff-b584-d485d87e000b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3f36ac99-2821-4170-8fb5-80b7481d6dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactions" xlink:type="simple" xlink:href="lyel-20230630.xsd#RelatedpartyTransactions"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f52c64ef-5ec0-476d-b8f6-df180ade0850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_18266ee6-858d-4dd6-8116-933bb56926b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f52c64ef-5ec0-476d-b8f6-df180ade0850" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_18266ee6-858d-4dd6-8116-933bb56926b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SubsequentEvents" xlink:type="simple" xlink:href="lyel-20230630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_842a8cf7-5c24-4859-bf1f-33f133f16e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_a1133eb5-45b5-4ea7-ae64-ef5cb27fbf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_842a8cf7-5c24-4859-bf1f-33f133f16e44" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_a1133eb5-45b5-4ea7-ae64-ef5cb27fbf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lyel-20230630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a1e085e0-3c23-4b71-a232-f462195bd738" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6c624470-7d92-4fc4-9e3d-35abdb70389f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e085e0-3c23-4b71-a232-f462195bd738" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6c624470-7d92-4fc4-9e3d-35abdb70389f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ac90e1d0-b481-4b56-a9fa-6b21661b1220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e085e0-3c23-4b71-a232-f462195bd738" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ac90e1d0-b481-4b56-a9fa-6b21661b1220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7220a3b4-6cda-4761-b3d8-02b9606e0304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e085e0-3c23-4b71-a232-f462195bd738" xlink:to="loc_us-gaap_UseOfEstimates_7220a3b4-6cda-4761-b3d8-02b9606e0304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_37cffa53-fd65-4c2b-a63b-d7636eb5e249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e085e0-3c23-4b71-a232-f462195bd738" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_37cffa53-fd65-4c2b-a63b-d7636eb5e249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_520ad17d-47bd-45c1-a298-fddcb07fd795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e085e0-3c23-4b71-a232-f462195bd738" xlink:to="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_520ad17d-47bd-45c1-a298-fddcb07fd795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock_5999ae1f-d6e4-4996-8f95-4982e221f0b0" xlink:href="lyel-20230630.xsd#lyel_SignificantAccountingPoliciesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e085e0-3c23-4b71-a232-f462195bd738" xlink:to="loc_lyel_SignificantAccountingPoliciesPolicyTextBlock_5999ae1f-d6e4-4996-8f95-4982e221f0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e4ff173c-f9b1-4e9a-97bd-d2850bfccd45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1e085e0-3c23-4b71-a232-f462195bd738" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e4ff173c-f9b1-4e9a-97bd-d2850bfccd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables" xlink:type="simple" xlink:href="lyel-20230630.xsd#LicenseCollaborationandSuccessPaymentAgreementsTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d669cc09-85cd-4e11-ba07-8d58c9e31939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_420cfaa1-2c3f-4e07-a781-13ab7bcea196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d669cc09-85cd-4e11-ba07-8d58c9e31939" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_420cfaa1-2c3f-4e07-a781-13ab7bcea196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="lyel-20230630.xsd#CashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_1ae7ec43-4355-4d59-8a4c-bcaca790024b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_cc9bc036-0af0-49ee-a11c-05c04dc3fcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1ae7ec43-4355-4d59-8a4c-bcaca790024b" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_cc9bc036-0af0-49ee-a11c-05c04dc3fcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6d3ea1f0-4d97-49ac-ab3b-d858b8901036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1ae7ec43-4355-4d59-8a4c-bcaca790024b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6d3ea1f0-4d97-49ac-ab3b-d858b8901036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_deca31ba-b696-4c46-b7ba-a5527c486a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_25d03cfb-c8a3-41de-8e1b-87cf1fd553f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_deca31ba-b696-4c46-b7ba-a5527c486a9a" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_25d03cfb-c8a3-41de-8e1b-87cf1fd553f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bddbcea2-cad9-4ec2-ab9c-dd58e34cc512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_deca31ba-b696-4c46-b7ba-a5527c486a9a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bddbcea2-cad9-4ec2-ab9c-dd58e34cc512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_91bc8fa9-14c0-4f97-81c6-a36ce9a98517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_deca31ba-b696-4c46-b7ba-a5527c486a9a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_91bc8fa9-14c0-4f97-81c6-a36ce9a98517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7af6b70f-02b7-488d-9de9-c74399cfb53e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_deca31ba-b696-4c46-b7ba-a5527c486a9a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7af6b70f-02b7-488d-9de9-c74399cfb53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesTables" xlink:type="simple" xlink:href="lyel-20230630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b615b5ea-edd7-48e5-8695-f7f0a3197b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5701950a-e4f1-432b-bb67-b2c484ccfe58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b615b5ea-edd7-48e5-8695-f7f0a3197b9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5701950a-e4f1-432b-bb67-b2c484ccfe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_c8808d41-1958-4624-8501-071fa4259e30" xlink:href="lyel-20230630.xsd#lyel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b615b5ea-edd7-48e5-8695-f7f0a3197b9e" xlink:to="loc_lyel_AssetsAndLiabilitiesLesseeTableTextBlock_c8808d41-1958-4624-8501-071fa4259e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d282eab4-ef16-4a14-8568-c83a45267557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f100e2ac-9c9a-476f-8c00-9fbb9488c68d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d282eab4-ef16-4a14-8568-c83a45267557" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f100e2ac-9c9a-476f-8c00-9fbb9488c68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_2f36117e-8f2b-4a8a-a65c-54ef1d80aed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d282eab4-ef16-4a14-8568-c83a45267557" xlink:to="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_2f36117e-8f2b-4a8a-a65c-54ef1d80aed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_359cf01a-0e51-42ff-bc97-d55608f14912" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d282eab4-ef16-4a14-8568-c83a45267557" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_359cf01a-0e51-42ff-bc97-d55608f14912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a672acf4-7159-4a90-a442-b789ba4b11b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d282eab4-ef16-4a14-8568-c83a45267557" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a672acf4-7159-4a90-a442-b789ba4b11b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsTables" xlink:type="simple" xlink:href="lyel-20230630.xsd#RelatedpartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_846cc626-0542-4204-bf56-9903b51a7dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_97b33d57-546f-4e60-a96b-8d763e58a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_846cc626-0542-4204-bf56-9903b51a7dc0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_97b33d57-546f-4e60-a96b-8d763e58a0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2a6aa2bd-6816-483c-b733-a242ec968556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a6aa2bd-6816-483c-b733-a242ec968556" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_86ff08c4-c4d8-4e41-9c65-fa5f278c0db1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:to="loc_srt_CounterpartyNameAxis_86ff08c4-c4d8-4e41-9c65-fa5f278c0db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e6e57ce-bc82-499c-a348-0a3e9d1d305f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_86ff08c4-c4d8-4e41-9c65-fa5f278c0db1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e6e57ce-bc82-499c-a348-0a3e9d1d305f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_6513d9d2-643d-47b2-9110-c6630a39de8b" xlink:href="lyel-20230630.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e6e57ce-bc82-499c-a348-0a3e9d1d305f" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_6513d9d2-643d-47b2-9110-c6630a39de8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ff2fc83b-93b2-4fe9-8e8a-6e2b9395a0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ff2fc83b-93b2-4fe9-8e8a-6e2b9395a0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f69ee9c-02fb-4d69-877c-a6f250790edb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ff2fc83b-93b2-4fe9-8e8a-6e2b9395a0ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f69ee9c-02fb-4d69-877c-a6f250790edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_98cfebb1-ae66-4a1c-93d9-527945a9f8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f69ee9c-02fb-4d69-877c-a6f250790edb" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_98cfebb1-ae66-4a1c-93d9-527945a9f8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_960bbb31-b196-42b1-886f-e7c6cc833595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_960bbb31-b196-42b1-886f-e7c6cc833595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_24850a3d-3d21-45cb-8543-27c32f8255bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_960bbb31-b196-42b1-886f-e7c6cc833595" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_24850a3d-3d21-45cb-8543-27c32f8255bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_ded7e761-4f69-4862-959b-9468de44dc92" xlink:href="lyel-20230630.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_24850a3d-3d21-45cb-8543-27c32f8255bc" xlink:to="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_ded7e761-4f69-4862-959b-9468de44dc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ca58a6e-9ebe-4add-b575-d7135ebc6c93" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a121fc4a-7695-466c-9408-51227a92573e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:to="loc_us-gaap_Revenues_a121fc4a-7695-466c-9408-51227a92573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_533e8423-b315-443e-b72e-f8db0874f840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:to="loc_us-gaap_NetIncomeLoss_533e8423-b315-443e-b72e-f8db0874f840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cf4c935c-1441-4b16-8d5d-570741572388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:to="loc_us-gaap_EarningsPerShareBasic_cf4c935c-1441-4b16-8d5d-570741572388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ea376b84-3a11-4598-ac45-811f62db4186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a17a6f30-8b2d-46a1-adb9-912fabb9a6b2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ea376b84-3a11-4598-ac45-811f62db4186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4ad19f6-8109-4347-8430-32357ee72ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4ad19f6-8109-4347-8430-32357ee72ad3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c93a8f7-7837-4adf-97f3-3e970e4cb8ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_srt_CounterpartyNameAxis_5c93a8f7-7837-4adf-97f3-3e970e4cb8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5c93a8f7-7837-4adf-97f3-3e970e4cb8ba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_81bfce72-593c-476d-9e8e-ac420ebc3763" xlink:href="lyel-20230630.xsd#lyel_FredHutchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:to="loc_lyel_FredHutchMember_81bfce72-593c-476d-9e8e-ac420ebc3763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_f90fbaeb-6f40-4c49-ad51-f0a330c73fbf" xlink:href="lyel-20230630.xsd#lyel_StanfordMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:to="loc_lyel_StanfordMember_f90fbaeb-6f40-4c49-ad51-f0a330c73fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_f950d15a-b5d4-42ed-bcc7-460f97d15d0a" xlink:href="lyel-20230630.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_f950d15a-b5d4-42ed-bcc7-460f97d15d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_e3cf0bde-0114-4d6a-8628-5ab5dc543a63" xlink:href="lyel-20230630.xsd#lyel_PACTPharmaIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95f42dea-1fec-49c6-8fe9-ddef703cc5af" xlink:to="loc_lyel_PACTPharmaIncMember_e3cf0bde-0114-4d6a-8628-5ab5dc543a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0bfbd065-8fe5-4a45-827e-b1e59a94f60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0bfbd065-8fe5-4a45-827e-b1e59a94f60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b21add1-bec4-4ee5-83ff-9aa3e011afd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0bfbd065-8fe5-4a45-827e-b1e59a94f60c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b21add1-bec4-4ee5-83ff-9aa3e011afd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_2b734981-1472-439d-9644-dd53e208368b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b21add1-bec4-4ee5-83ff-9aa3e011afd8" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_2b734981-1472-439d-9644-dd53e208368b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6afaefa8-60bb-4063-8a96-6188e83c1284" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_srt_RangeAxis_6afaefa8-60bb-4063-8a96-6188e83c1284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e99be475-322f-498b-a19d-e43c3c46cac9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6afaefa8-60bb-4063-8a96-6188e83c1284" xlink:to="loc_srt_RangeMember_e99be475-322f-498b-a19d-e43c3c46cac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cfba40d8-f364-4dbc-ab81-b6b42cf8ab80" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e99be475-322f-498b-a19d-e43c3c46cac9" xlink:to="loc_srt_MinimumMember_cfba40d8-f364-4dbc-ab81-b6b42cf8ab80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2030319c-10f3-4f52-9252-9aa689a5ea6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e99be475-322f-498b-a19d-e43c3c46cac9" xlink:to="loc_srt_MaximumMember_2030319c-10f3-4f52-9252-9aa689a5ea6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3e504c02-2dff-41eb-b2e2-5a0dab269a3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_srt_ProductOrServiceAxis_3e504c02-2dff-41eb-b2e2-5a0dab269a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bcedb060-b24b-42d0-bbff-e1276dc59a7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3e504c02-2dff-41eb-b2e2-5a0dab269a3b" xlink:to="loc_srt_ProductsAndServicesDomain_bcedb060-b24b-42d0-bbff-e1276dc59a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_2e76759d-b2d7-490a-b17b-17b791856e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bcedb060-b24b-42d0-bbff-e1276dc59a7f" xlink:to="loc_us-gaap_LicenseMember_2e76759d-b2d7-490a-b17b-17b791856e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_07ad10b0-d422-42a4-b65d-f55fc4f8b24f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_StatementClassOfStockAxis_07ad10b0-d422-42a4-b65d-f55fc4f8b24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ff340f5f-5076-48f0-ba58-3155ceefb5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07ad10b0-d422-42a4-b65d-f55fc4f8b24f" xlink:to="loc_us-gaap_ClassOfStockDomain_ff340f5f-5076-48f0-ba58-3155ceefb5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAConvertiblePreferredStockMember_0b26f348-e95a-484e-aeef-efbe4ea55298" xlink:href="lyel-20230630.xsd#lyel_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ff340f5f-5076-48f0-ba58-3155ceefb5a3" xlink:to="loc_lyel_SeriesAConvertiblePreferredStockMember_0b26f348-e95a-484e-aeef-efbe4ea55298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SeriesAAConvertiblePreferredStockMember_72c9bed7-f7ae-4cf6-b80e-0d23e684de28" xlink:href="lyel-20230630.xsd#lyel_SeriesAAConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ff340f5f-5076-48f0-ba58-3155ceefb5a3" xlink:to="loc_lyel_SeriesAAConvertiblePreferredStockMember_72c9bed7-f7ae-4cf6-b80e-0d23e684de28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_24e7a2cf-c3f7-45b8-a892-338feb7aacb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_InvestmentTypeAxis_24e7a2cf-c3f7-45b8-a892-338feb7aacb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d08200ce-b106-45ff-9a6b-cf4245e82d47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_24e7a2cf-c3f7-45b8-a892-338feb7aacb7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d08200ce-b106-45ff-9a6b-cf4245e82d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_c60b4f36-18b9-4842-8fa4-8e6913e7559c" xlink:href="lyel-20230630.xsd#lyel_OtherInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d08200ce-b106-45ff-9a6b-cf4245e82d47" xlink:to="loc_lyel_OtherInvestmentMember_c60b4f36-18b9-4842-8fa4-8e6913e7559c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ad9d8848-c041-43b7-96e4-2436111073f4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ad9d8848-c041-43b7-96e4-2436111073f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_67b0428f-1ee0-4b1c-85a2-dcddd7b9edd7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ad9d8848-c041-43b7-96e4-2436111073f4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_67b0428f-1ee0-4b1c-85a2-dcddd7b9edd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_84ad7fd8-b124-401b-909f-da729745e4db" xlink:href="lyel-20230630.xsd#lyel_PACTPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_67b0428f-1ee0-4b1c-85a2-dcddd7b9edd7" xlink:to="loc_lyel_PACTPharmaIncMember_84ad7fd8-b124-401b-909f-da729745e4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_0a4a57b1-b73f-4701-865c-562e614c4a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_LitigationStatusAxis_0a4a57b1-b73f-4701-865c-562e614c4a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_25b574eb-eca5-4d4d-8a88-04fb03415d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_0a4a57b1-b73f-4701-865c-562e614c4a45" xlink:to="loc_us-gaap_LitigationStatusDomain_25b574eb-eca5-4d4d-8a88-04fb03415d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_1dbbd2a9-5322-4992-9d56-5457f641bfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_25b574eb-eca5-4d4d-8a88-04fb03415d85" xlink:to="loc_us-gaap_SettledLitigationMember_1dbbd2a9-5322-4992-9d56-5457f641bfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ef94902f-806c-4405-9cd6-76d65682e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ef94902f-806c-4405-9cd6-76d65682e5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9bb9632a-e217-40a1-a92d-e0c95fe5aa50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ef94902f-806c-4405-9cd6-76d65682e5c7" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9bb9632a-e217-40a1-a92d-e0c95fe5aa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_25de5753-ae5b-4609-9599-879a3b102518" xlink:href="lyel-20230630.xsd#lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9bb9632a-e217-40a1-a92d-e0c95fe5aa50" xlink:to="loc_lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember_25de5753-ae5b-4609-9599-879a3b102518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f3eabbc-6a6f-44df-9403-93339aa6f661" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_a3bb5dcb-1893-4314-994b-d8ad8000aa1f" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments_a3bb5dcb-1893-4314-994b-d8ad8000aa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_0e7052a4-d299-422f-90b4-ac8e0cc187cc" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments_0e7052a4-d299-422f-90b4-ac8e0cc187cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_d9630763-b1a1-4ca4-800f-0f9e993e2d42" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsResearchTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm_d9630763-b1a1-4ca4-800f-0f9e993e2d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_64891a1a-d4b6-49a2-a1d6-e07d7e533af8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_64891a1a-d4b6-49a2-a1d6-e07d7e533af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_b39cd44c-7f60-429c-9103-e8395f965063" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_b39cd44c-7f60-429c-9103-e8395f965063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_994dc1d6-a491-47ce-aad1-9c248aa05bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_994dc1d6-a491-47ce-aad1-9c248aa05bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_01063908-71e4-440b-b722-96f1b5b60a60" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_01063908-71e4-440b-b722-96f1b5b60a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_936b6835-9630-4431-ae70-67431b0665c2" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_936b6835-9630-4431-ae70-67431b0665c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_3ac2d7a6-c61b-4529-a636-993192c425f5" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm_3ac2d7a6-c61b-4529-a636-993192c425f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_6ec19227-05a3-4258-a6f2-e612d5347587" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate_6ec19227-05a3-4258-a6f2-e612d5347587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_52dde57b-f088-4d3b-a4d5-273fea7d270c" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering_52dde57b-f088-4d3b-a4d5-273fea7d270c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_34fca0c1-e48a-441c-ac73-70165720e81b" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability_34fca0c1-e48a-441c-ac73-70165720e81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_6a756238-c2db-4e68-9c22-e69dedd23894" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_6a756238-c2db-4e68-9c22-e69dedd23894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_db92a7e7-4adc-4e1c-8956-d63cfbeeab84" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments_db92a7e7-4adc-4e1c-8956-d63cfbeeab84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_0e750385-6226-464d-9b10-25b0a304b71d" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments_0e750385-6226-464d-9b10-25b0a304b71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_020ad9e3-6a5c-4554-aed9-e76bff81c09e" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability_020ad9e3-6a5c-4554-aed9-e76bff81c09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2b059a84-e0a0-4a38-bc70-a97fe12170dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2b059a84-e0a0-4a38-bc70-a97fe12170dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSold_6d8970fb-98bf-4c66-9f5b-d8cc1960ce02" xlink:href="lyel-20230630.xsd#lyel_StockPurchaseAgreementSharesSold"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_StockPurchaseAgreementSharesSold_6d8970fb-98bf-4c66-9f5b-d8cc1960ce02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare_9e54add0-d2cd-4b13-a4ff-01634174a8bc" xlink:href="lyel-20230630.xsd#lyel_StockPurchaseAgreementSharesSoldPricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_StockPurchaseAgreementSharesSoldPricePerShare_9e54add0-d2cd-4b13-a4ff-01634174a8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare_93445b84-8758-4d3c-ae07-259e6cf4b828" xlink:href="lyel-20230630.xsd#lyel_StockPurchaseAgreementFairValueOfStockPerShare"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_StockPurchaseAgreementFairValueOfStockPerShare_93445b84-8758-4d3c-ae07-259e6cf4b828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_526d7166-909c-41e6-b880-187c8eb29c5e" xlink:href="lyel-20230630.xsd#lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram_526d7166-909c-41e6-b880-187c8eb29c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c998ee61-2f60-4f57-b1e8-f2b82fbf06d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c998ee61-2f60-4f57-b1e8-f2b82fbf06d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68fffa51-df91-4c6a-9dd0-ea4a866d3594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68fffa51-df91-4c6a-9dd0-ea4a866d3594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_da9b7c00-f7a6-4fa9-924a-ba5dc00bc8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_da9b7c00-f7a6-4fa9-924a-ba5dc00bc8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement_ece24c9c-3b50-4e15-8256-18579929810e" xlink:href="lyel-20230630.xsd#lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement_ece24c9c-3b50-4e15-8256-18579929810e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased_39b9f7d2-c03f-4261-90e4-a6e463044dde" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased_39b9f7d2-c03f-4261-90e4-a6e463044dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare_1e0fd328-0a18-4987-88d9-1402b54bda4d" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare_1e0fd328-0a18-4987-88d9-1402b54bda4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare_1c780593-72bf-4ac4-8380-bbf9da5b254f" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare_1c780593-72bf-4ac4-8380-bbf9da5b254f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice_769acc6e-4214-4d44-95ff-8cf39b5e5c17" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice_769acc6e-4214-4d44-95ff-8cf39b5e5c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_f4b4efc6-1d77-42a4-8e3f-b8acbb565b8b" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_f4b4efc6-1d77-42a4-8e3f-b8acbb565b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f66b75e-bff7-44d8-909d-8043fb486277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f66b75e-bff7-44d8-909d-8043fb486277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_3793b501-9df8-49c9-8ca5-62c75e667038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_3793b501-9df8-49c9-8ca5-62c75e667038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LitigationSettlementPercentOfTotalEquityValue_b213349c-9efe-4692-9081-516f8e590725" xlink:href="lyel-20230630.xsd#lyel_LitigationSettlementPercentOfTotalEquityValue"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_lyel_LitigationSettlementPercentOfTotalEquityValue_b213349c-9efe-4692-9081-516f8e590725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3cc0c86e-0725-4e3d-a5d9-eaae254f2e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09e9eb75-7f91-4682-b0e1-651b7ae81896" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3cc0c86e-0725-4e3d-a5d9-eaae254f2e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ebde9a51-4f13-4194-8d93-741b88962835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ebde9a51-4f13-4194-8d93-741b88962835" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_246888f4-b416-4e3f-9664-7bd60a7e939b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_246888f4-b416-4e3f-9664-7bd60a7e939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1dcf131b-8690-4638-8a46-4c9f523df323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_246888f4-b416-4e3f-9664-7bd60a7e939b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1dcf131b-8690-4638-8a46-4c9f523df323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_53c5b61a-bbd5-419e-85be-d7a430f5fd19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1dcf131b-8690-4638-8a46-4c9f523df323" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_53c5b61a-bbd5-419e-85be-d7a430f5fd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleAxis_8130a01e-3644-4de0-a0ca-638bf18cc8f1" xlink:href="lyel-20230630.xsd#lyel_EquityMultipleAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:to="loc_lyel_EquityMultipleAxis_8130a01e-3644-4de0-a0ca-638bf18cc8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:href="lyel-20230630.xsd#lyel_EquityMultipleDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleAxis_8130a01e-3644-4de0-a0ca-638bf18cc8f1" xlink:to="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TenTimesMember_fba506fc-4167-45d5-87bc-99cb541dd936" xlink:href="lyel-20230630.xsd#lyel_TenTimesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_TenTimesMember_fba506fc-4167-45d5-87bc-99cb541dd936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwentyTimesMember_91bb329f-a727-4ce1-ab30-d46e8ea44013" xlink:href="lyel-20230630.xsd#lyel_TwentyTimesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_TwentyTimesMember_91bb329f-a727-4ce1-ab30-d46e8ea44013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ThirtyTimesMember_6f95166e-716a-419a-9741-d1778d0aec81" xlink:href="lyel-20230630.xsd#lyel_ThirtyTimesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_ThirtyTimesMember_6f95166e-716a-419a-9741-d1778d0aec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FortyTimesMember_eae0ef18-82e9-4691-a7a8-230d1575a588" xlink:href="lyel-20230630.xsd#lyel_FortyTimesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_FortyTimesMember_eae0ef18-82e9-4691-a7a8-230d1575a588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FiftyTimesMember_b24f6be2-0a73-414e-b583-59388959c60b" xlink:href="lyel-20230630.xsd#lyel_FiftyTimesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_EquityMultipleDomain_a7a5a6c1-c112-4789-8088-02330c021d92" xlink:to="loc_lyel_FiftyTimesMember_b24f6be2-0a73-414e-b583-59388959c60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fd999fd7-8a71-4118-a26a-4449527ba824" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:to="loc_srt_CounterpartyNameAxis_fd999fd7-8a71-4118-a26a-4449527ba824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87634e91-7ea0-4dab-a5b0-36f2d9360682" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fd999fd7-8a71-4118-a26a-4449527ba824" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87634e91-7ea0-4dab-a5b0-36f2d9360682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_e795e6fa-8bb1-4438-9391-0dd9a2a9f5fe" xlink:href="lyel-20230630.xsd#lyel_FredHutchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87634e91-7ea0-4dab-a5b0-36f2d9360682" xlink:to="loc_lyel_FredHutchMember_e795e6fa-8bb1-4438-9391-0dd9a2a9f5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_ac6f14a7-909c-4c5f-9ed0-b2c3fc2c9245" xlink:href="lyel-20230630.xsd#lyel_StanfordMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87634e91-7ea0-4dab-a5b0-36f2d9360682" xlink:to="loc_lyel_StanfordMember_ac6f14a7-909c-4c5f-9ed0-b2c3fc2c9245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bb3e77fe-91fc-44c0-8d55-6d9208710f9c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_55df5d57-ccd5-4d66-8516-f90edae7971e" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier_55df5d57-ccd5-4d66-8516-f90edae7971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_ddf3eb49-5bda-414e-a341-7d1f446b5bc1" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice_ddf3eb49-5bda-414e-a341-7d1f446b5bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_850c2ddc-9253-4b25-ab72-864bb1c0c5d1" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e74d264-f4c0-4d36-98bd-852312615f27" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments_850c2ddc-9253-4b25-ab72-864bb1c0c5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_1472fdc0-5f3d-45e5-9c52-faba1af0a589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_45478bb1-6034-4b9a-8e2e-f5cf007559eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1472fdc0-5f3d-45e5-9c52-faba1af0a589" xlink:to="loc_us-gaap_MarketableSecuritiesTable_45478bb1-6034-4b9a-8e2e-f5cf007559eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5d266f78-1ef3-424f-afc3-a8354e028c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_45478bb1-6034-4b9a-8e2e-f5cf007559eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5d266f78-1ef3-424f-afc3-a8354e028c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_262ee032-91cf-4b74-8494-8fea5b745025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5d266f78-1ef3-424f-afc3-a8354e028c2d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_262ee032-91cf-4b74-8494-8fea5b745025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_234c8848-d5c6-41d9-84b2-ed5fb000bd25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_262ee032-91cf-4b74-8494-8fea5b745025" xlink:to="loc_us-gaap_MoneyMarketFundsMember_234c8848-d5c6-41d9-84b2-ed5fb000bd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6049c959-bf4d-4cbc-85f4-ec0c088d4035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_45478bb1-6034-4b9a-8e2e-f5cf007559eb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6049c959-bf4d-4cbc-85f4-ec0c088d4035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6049c959-bf4d-4cbc-85f4-ec0c088d4035" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6acccf42-806c-464d-a2e4-fe14f8b5c0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6acccf42-806c-464d-a2e4-fe14f8b5c0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e8b1b24b-3d49-49b8-b917-70ee5da683a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e8b1b24b-3d49-49b8-b917-70ee5da683a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_38a8a73d-ef22-4a00-8fab-5f31ca62fac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac24ac34-a7bf-4405-abf1-0a98f912bc38" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_38a8a73d-ef22-4a00-8fab-5f31ca62fac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_45478bb1-6034-4b9a-8e2e-f5cf007559eb" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da118e7b-0cb1-451c-8c7b-03d6421bce13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da118e7b-0cb1-451c-8c7b-03d6421bce13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1d3e04d-41dd-48d2-b564-ba75f87b8308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1d3e04d-41dd-48d2-b564-ba75f87b8308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_898939ea-5530-4a79-8c22-ee7828ac8cc2" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost_898939ea-5530-4a79-8c22-ee7828ac8cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_33c32797-29cd-4ea8-97a2-bf85847dc32b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_33c32797-29cd-4ea8-97a2-bf85847dc32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1076bca0-2566-4c3c-8af2-b34895eb2155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1076bca0-2566-4c3c-8af2-b34895eb2155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c754fea-09a6-496b-ad69-c781d07d7184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c754fea-09a6-496b-ad69-c781d07d7184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4a77f21-7740-4692-8bf9-551de2fdfc40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4a77f21-7740-4692-8bf9-551de2fdfc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_170514b4-e3b9-40fa-bd03-db5ee4b6c350" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_170514b4-e3b9-40fa-bd03-db5ee4b6c350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_791193c8-db24-4384-806d-45c989d99171" xlink:to="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosure_44d5c963-67c0-4418-beaf-13521c7d0e2c" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosure_44d5c963-67c0-4418-beaf-13521c7d0e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_02ab1770-3765-47e1-9fee-65a6b83ea7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_02ab1770-3765-47e1-9fee-65a6b83ea7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_887611e3-ad3b-44c2-b047-1d89a4aa6c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_887611e3-ad3b-44c2-b047-1d89a4aa6c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_969cb944-7d18-4f71-bb22-c34a97d93108" xlink:href="lyel-20230630.xsd#lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract_0a4e3bd2-86cb-4ab5-a8ce-82db04c786c9" xlink:to="loc_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale_969cb944-7d18-4f71-bb22-c34a97d93108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" xlink:type="simple" xlink:href="lyel-20230630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#CashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_a6023238-baaf-4414-9382-b410f831f5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_caf1e2b5-6258-4b73-912d-2ac85843fadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_a6023238-baaf-4414-9382-b410f831f5ad" xlink:to="loc_us-gaap_MarketableSecuritiesTable_caf1e2b5-6258-4b73-912d-2ac85843fadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d28371fe-dc1f-46be-9c42-55951338ad6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_caf1e2b5-6258-4b73-912d-2ac85843fadd" xlink:to="loc_srt_RangeAxis_d28371fe-dc1f-46be-9c42-55951338ad6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c752f2f-a43e-425c-a294-d55e62bb5cbe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d28371fe-dc1f-46be-9c42-55951338ad6c" xlink:to="loc_srt_RangeMember_0c752f2f-a43e-425c-a294-d55e62bb5cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cb76a96e-3fd9-40de-86c9-b44606df7c89" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c752f2f-a43e-425c-a294-d55e62bb5cbe" xlink:to="loc_srt_MaximumMember_cb76a96e-3fd9-40de-86c9-b44606df7c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_caf1e2b5-6258-4b73-912d-2ac85843fadd" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e470f54d-d7ac-4c51-b7f1-5f0702e06797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e470f54d-d7ac-4c51-b7f1-5f0702e06797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d387edb6-851a-430b-a659-e40f5cd7e1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d387edb6-851a-430b-a659-e40f5cd7e1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_3cd50f06-9ef9-4504-bf98-5cc6681f270e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5425b833-4cbe-4e75-9494-b03636c64689" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_3cd50f06-9ef9-4504-bf98-5cc6681f270e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#OtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/OtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_fda2b36f-91ba-4b0d-aef2-6d83674ef32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_536c9113-3929-494b-9756-4fb700c3b49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_fda2b36f-91ba-4b0d-aef2-6d83674ef32f" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_536c9113-3929-494b-9756-4fb700c3b49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_086424d7-3495-4c8a-8259-7278201cc1c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_536c9113-3929-494b-9756-4fb700c3b49e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_086424d7-3495-4c8a-8259-7278201cc1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a1fc622a-24d6-42eb-99c4-941a10cc452e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_086424d7-3495-4c8a-8259-7278201cc1c7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a1fc622a-24d6-42eb-99c4-941a10cc452e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_fdfeaf4f-05fb-49a8-9e58-7c161738753b" xlink:href="lyel-20230630.xsd#lyel_OtherInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a1fc622a-24d6-42eb-99c4-941a10cc452e" xlink:to="loc_lyel_OtherInvestmentMember_fdfeaf4f-05fb-49a8-9e58-7c161738753b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_063fac03-d8d8-48cc-bfc6-87ceb9a50224" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_536c9113-3929-494b-9756-4fb700c3b49e" xlink:to="loc_srt_CounterpartyNameAxis_063fac03-d8d8-48cc-bfc6-87ceb9a50224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe84c1f6-40c0-4062-9df5-cc314022eba2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_063fac03-d8d8-48cc-bfc6-87ceb9a50224" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe84c1f6-40c0-4062-9df5-cc314022eba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_e474d28a-a71d-4a3a-ab6e-ed55f3200ee8" xlink:href="lyel-20230630.xsd#lyel_PACTPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe84c1f6-40c0-4062-9df5-cc314022eba2" xlink:to="loc_lyel_PACTPharmaIncMember_e474d28a-a71d-4a3a-ab6e-ed55f3200ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_536c9113-3929-494b-9756-4fb700c3b49e" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_0d95faae-4a66-47a0-ac61-7b3eb1d0abb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:to="loc_us-gaap_OtherInvestments_0d95faae-4a66-47a0-ac61-7b3eb1d0abb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_a92ea7bb-8807-4fb6-bb18-e30818ec2d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_a92ea7bb-8807-4fb6-bb18-e30818ec2d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6de63da1-66b8-420d-92c7-134f4d7dc672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6de63da1-66b8-420d-92c7-134f4d7dc672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_39ea1815-2d0c-4749-a6cf-fb5d54db3b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_a0d07e78-6d82-453e-b130-82eb3a18cb59" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_39ea1815-2d0c-4749-a6cf-fb5d54db3b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0efb6580-40e1-4ded-8d41-85628d98f129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0efb6580-40e1-4ded-8d41-85628d98f129" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a2e3581-fb04-435f-b81d-de52324291a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a2e3581-fb04-435f-b81d-de52324291a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a2e3581-fb04-435f-b81d-de52324291a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ef994f5d-64b3-4394-b050-fc5447e41e73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ef994f5d-64b3-4394-b050-fc5447e41e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_763ce1bb-1b99-4ca3-9f74-e6edb4a6d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_763ce1bb-1b99-4ca3-9f74-e6edb4a6d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2fcd046-7596-4529-a1f8-02d896e37808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6c19eed-335c-40c7-9cb8-69f5e74a1d1e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2fcd046-7596-4529-a1f8-02d896e37808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_0d18a99b-2b2b-4ee7-9aa7-e885cb6e94d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_0d18a99b-2b2b-4ee7-9aa7-e885cb6e94d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ec4962-58fe-4132-b042-118215ef1897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_0d18a99b-2b2b-4ee7-9aa7-e885cb6e94d7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ec4962-58fe-4132-b042-118215ef1897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b0f2c6f0-a032-4782-8455-adb985546713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_39ec4962-58fe-4132-b042-118215ef1897" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b0f2c6f0-a032-4782-8455-adb985546713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ca4d2716-090f-42ba-b5ac-4cd6af6975f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ca4d2716-090f-42ba-b5ac-4cd6af6975f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca4d2716-090f-42ba-b5ac-4cd6af6975f4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7f0c82b6-a6d0-499a-bd1b-c1cc03ed3644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7f0c82b6-a6d0-499a-bd1b-c1cc03ed3644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2be3d8ae-59b6-4c3c-97b3-ac81c7e9e8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2be3d8ae-59b6-4c3c-97b3-ac81c7e9e8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1d961405-9429-47dd-818d-78f9e5641bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f2e634a-8bd5-444d-afcd-88667bc5f60d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1d961405-9429-47dd-818d-78f9e5641bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7caa9e70-1ffe-47d3-93c2-d1e813ca671c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_480fea05-fe81-4e0c-84a3-df5238e3162a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7caa9e70-1ffe-47d3-93c2-d1e813ca671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7caa9e70-1ffe-47d3-93c2-d1e813ca671c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f26d49d9-7bb2-4e02-a5e8-6f3cef107bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f26d49d9-7bb2-4e02-a5e8-6f3cef107bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dc34ac7-7018-402b-b434-24a0f575a737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dc34ac7-7018-402b-b434-24a0f575a737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3a1b6cc3-ad9a-412c-92ac-e12283d6ab1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_22861751-e105-4f0a-80dd-e52a2b2fa5c8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3a1b6cc3-ad9a-412c-92ac-e12283d6ab1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_67731ec3-090e-4577-903c-d89734026890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7caa9e70-1ffe-47d3-93c2-d1e813ca671c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_67731ec3-090e-4577-903c-d89734026890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_0dc98e28-479b-4b59-bcac-f8bec4ddd85b" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_67731ec3-090e-4577-903c-d89734026890" xlink:to="loc_lyel_SuccessPaymentLiabilitiesFairValueDisclosure_0dc98e28-479b-4b59-bcac-f8bec4ddd85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_36e60c49-6ad5-4664-bfb3-b62e32cb3668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_67731ec3-090e-4577-903c-d89734026890" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_36e60c49-6ad5-4664-bfb3-b62e32cb3668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2a4627c1-7aaf-4f13-a071-210000d4c6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2a4627c1-7aaf-4f13-a071-210000d4c6a0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_41cc3396-c5d2-48a1-9c9e-ab07ef2e106f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_41cc3396-c5d2-48a1-9c9e-ab07ef2e106f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_97a1b331-0276-4724-ab80-1bb3d364d11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_41cc3396-c5d2-48a1-9c9e-ab07ef2e106f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_97a1b331-0276-4724-ab80-1bb3d364d11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchSuccessPaymentLiabilityMember_57db08c8-0cfb-4346-93b0-050b60e1a049" xlink:href="lyel-20230630.xsd#lyel_FredHutchSuccessPaymentLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_97a1b331-0276-4724-ab80-1bb3d364d11f" xlink:to="loc_lyel_FredHutchSuccessPaymentLiabilityMember_57db08c8-0cfb-4346-93b0-050b60e1a049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordSuccessPaymentLiabilityMember_a3471994-91f9-48a1-b281-835b8a6bfa87" xlink:href="lyel-20230630.xsd#lyel_StanfordSuccessPaymentLiabilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_97a1b331-0276-4724-ab80-1bb3d364d11f" xlink:to="loc_lyel_StanfordSuccessPaymentLiabilityMember_a3471994-91f9-48a1-b281-835b8a6bfa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f86cf14c-8480-4ab2-88c6-f196ad827d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f86cf14c-8480-4ab2-88c6-f196ad827d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f86cf14c-8480-4ab2-88c6-f196ad827d85" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6c01be57-2c01-43d6-a5ea-94763fb2c092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6c01be57-2c01-43d6-a5ea-94763fb2c092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2df41f32-7a8c-421f-a7ee-b2f42a9031d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2df41f32-7a8c-421f-a7ee-b2f42a9031d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_56e1eca0-2a9c-41dc-b3bb-442c43a1f7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c150b152-4daa-4539-a8d5-f95287f9319a" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_56e1eca0-2a9c-41dc-b3bb-442c43a1f7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81c9e33b-303d-4b98-aa67-842553ea91fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:to="loc_srt_RangeAxis_81c9e33b-303d-4b98-aa67-842553ea91fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_66440270-66ba-4e93-8590-17fca6c03801" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_81c9e33b-303d-4b98-aa67-842553ea91fa" xlink:to="loc_srt_RangeMember_66440270-66ba-4e93-8590-17fca6c03801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_39ca7f89-df87-47b2-ad8b-9b08f7697210" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_66440270-66ba-4e93-8590-17fca6c03801" xlink:to="loc_srt_MinimumMember_39ca7f89-df87-47b2-ad8b-9b08f7697210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b71eee4-c586-4a50-ae9a-496cdb3cac82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_66440270-66ba-4e93-8590-17fca6c03801" xlink:to="loc_srt_MaximumMember_2b71eee4-c586-4a50-ae9a-496cdb3cac82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df305579-ef3d-4c34-8e40-31aead82fada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bdb3af27-74ac-4aca-bbe1-dcdea69b1ba9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df305579-ef3d-4c34-8e40-31aead82fada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock_b9447ce7-0914-41ad-869b-42c4a0e053a5" xlink:href="lyel-20230630.xsd#lyel_FairValueOfSeriesAConvertiblePreferredStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df305579-ef3d-4c34-8e40-31aead82fada" xlink:to="loc_lyel_FairValueOfSeriesAConvertiblePreferredStock_b9447ce7-0914-41ad-869b-42c4a0e053a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMeasurementInput_390a13f1-35bf-4519-9674-68b074e58caf" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df305579-ef3d-4c34-8e40-31aead82fada" xlink:to="loc_lyel_SuccessPaymentLiabilityMeasurementInput_390a13f1-35bf-4519-9674-68b074e58caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f76b1782-770a-4ade-b654-5f11e4abc1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f76b1782-770a-4ade-b654-5f11e4abc1ed" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4b99aa77-9c34-4f5d-a436-b4bf0018f009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:to="loc_us-gaap_InvestmentTypeAxis_4b99aa77-9c34-4f5d-a436-b4bf0018f009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_62f506b7-1b0f-4e6f-94cd-be5a9a10e56d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4b99aa77-9c34-4f5d-a436-b4bf0018f009" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_62f506b7-1b0f-4e6f-94cd-be5a9a10e56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SuccessPaymentLiabilityMember_c17a4156-7f46-4013-9e4e-32d4e7017fe6" xlink:href="lyel-20230630.xsd#lyel_SuccessPaymentLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62f506b7-1b0f-4e6f-94cd-be5a9a10e56d" xlink:to="loc_lyel_SuccessPaymentLiabilityMember_c17a4156-7f46-4013-9e4e-32d4e7017fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7f49eccc-e9ad-4c97-b848-3b9a36b8dbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7f49eccc-e9ad-4c97-b848-3b9a36b8dbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d3ceb0f-6641-4639-8512-06782d5b6f01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7f49eccc-e9ad-4c97-b848-3b9a36b8dbfb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d3ceb0f-6641-4639-8512-06782d5b6f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1bb6cc65-79d8-4e0b-9d32-ff44969d00b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d3ceb0f-6641-4639-8512-06782d5b6f01" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1bb6cc65-79d8-4e0b-9d32-ff44969d00b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5ce7cf84-1e6c-41f2-9ed8-ffb9586b8ce5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:to="loc_srt_CounterpartyNameAxis_5ce7cf84-1e6c-41f2-9ed8-ffb9586b8ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43e6dcfe-0e98-48d5-bdc1-bdf2a784ddc0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5ce7cf84-1e6c-41f2-9ed8-ffb9586b8ce5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43e6dcfe-0e98-48d5-bdc1-bdf2a784ddc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_FredHutchMember_48c75bd1-d81e-4acc-bce2-ea348bf41a37" xlink:href="lyel-20230630.xsd#lyel_FredHutchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43e6dcfe-0e98-48d5-bdc1-bdf2a784ddc0" xlink:to="loc_lyel_FredHutchMember_48c75bd1-d81e-4acc-bce2-ea348bf41a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_StanfordMember_41a7517c-e549-4316-816c-bd5a97a6e491" xlink:href="lyel-20230630.xsd#lyel_StanfordMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43e6dcfe-0e98-48d5-bdc1-bdf2a784ddc0" xlink:to="loc_lyel_StanfordMember_41a7517c-e549-4316-816c-bd5a97a6e491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e60e90ff-d76d-42d5-baba-befd319d25e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e60e90ff-d76d-42d5-baba-befd319d25e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6867f0c1-fae9-428b-a6fa-95fc791f708e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e60e90ff-d76d-42d5-baba-befd319d25e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6867f0c1-fae9-428b-a6fa-95fc791f708e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_53de2841-58c4-49f3-a629-58655767fcca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6867f0c1-fae9-428b-a6fa-95fc791f708e" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_53de2841-58c4-49f3-a629-58655767fcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb36d070-eeb5-46ec-abfc-dc3dc4ed01c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6a49fd8d-1a30-4e64-a8c7-5f06005c3718" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb36d070-eeb5-46ec-abfc-dc3dc4ed01c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73164575-5dc0-4cd5-aff4-3b24d85d8aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb36d070-eeb5-46ec-abfc-dc3dc4ed01c4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73164575-5dc0-4cd5-aff4-3b24d85d8aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_54ecce91-40e7-45c9-8b93-74e9d1363065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73164575-5dc0-4cd5-aff4-3b24d85d8aee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_54ecce91-40e7-45c9-8b93-74e9d1363065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_269e6b45-616e-48f5-9386-0229da99f752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73164575-5dc0-4cd5-aff4-3b24d85d8aee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_269e6b45-616e-48f5-9386-0229da99f752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0009faf9-e442-41f5-9dfb-56c8962fa409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73164575-5dc0-4cd5-aff4-3b24d85d8aee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0009faf9-e442-41f5-9dfb-56c8962fa409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_b84b39af-c128-401d-9b69-935a0e459235" xlink:href="lyel-20230630.xsd#lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb36d070-eeb5-46ec-abfc-dc3dc4ed01c4" xlink:to="loc_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain_b84b39af-c128-401d-9b69-935a0e459235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7a413c61-5780-4999-ad5f-7ed0171ff64b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe95b602-eea7-420b-be7b-26bd3e5cdbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7a413c61-5780-4999-ad5f-7ed0171ff64b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe95b602-eea7-420b-be7b-26bd3e5cdbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_56beb382-4a8f-427b-8c2a-65f391face83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe95b602-eea7-420b-be7b-26bd3e5cdbc6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_56beb382-4a8f-427b-8c2a-65f391face83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e31237c2-36bc-439e-ad2b-2ae13227e041" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_56beb382-4a8f-427b-8c2a-65f391face83" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e31237c2-36bc-439e-ad2b-2ae13227e041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_OtherInvestmentMember_ed97a9a8-a127-4bd1-9c24-1a688b1dbdde" xlink:href="lyel-20230630.xsd#lyel_OtherInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e31237c2-36bc-439e-ad2b-2ae13227e041" xlink:to="loc_lyel_OtherInvestmentMember_ed97a9a8-a127-4bd1-9c24-1a688b1dbdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_db973d10-2335-4dfe-9921-a048e63f02cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe95b602-eea7-420b-be7b-26bd3e5cdbc6" xlink:to="loc_srt_CounterpartyNameAxis_db973d10-2335-4dfe-9921-a048e63f02cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_df41698f-fed2-4f43-9ee3-28d298ef1168" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_db973d10-2335-4dfe-9921-a048e63f02cf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_df41698f-fed2-4f43-9ee3-28d298ef1168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PACTPharmaIncMember_1b1088b7-d2d2-4a9c-9256-f4a6cc3a0afa" xlink:href="lyel-20230630.xsd#lyel_PACTPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_df41698f-fed2-4f43-9ee3-28d298ef1168" xlink:to="loc_lyel_PACTPharmaIncMember_1b1088b7-d2d2-4a9c-9256-f4a6cc3a0afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_809735b5-cbd0-4b9e-901b-813562a512b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe95b602-eea7-420b-be7b-26bd3e5cdbc6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_809735b5-cbd0-4b9e-901b-813562a512b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_0a469ff3-0edb-4ca1-9d4a-afad15776976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_809735b5-cbd0-4b9e-901b-813562a512b9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_0a469ff3-0edb-4ca1-9d4a-afad15776976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_4ade328b-5d63-454d-bd97-e845a05fb164" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_809735b5-cbd0-4b9e-901b-813562a512b9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_4ade328b-5d63-454d-bd97-e845a05fb164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4401efb6-de5c-4842-b907-5c854e7fec33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4401efb6-de5c-4842-b907-5c854e7fec33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_58a50f2e-9e5d-4c9f-9bdf-536bf64cd70c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_58a50f2e-9e5d-4c9f-9bdf-536bf64cd70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fd3ce004-bb68-4aa2-aa75-3520f178b289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fd3ce004-bb68-4aa2-aa75-3520f178b289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8ee66405-470a-4b3e-8125-12c67ffd7f81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8ee66405-470a-4b3e-8125-12c67ffd7f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_844567f5-b135-45f4-973d-75add6bcc4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_844567f5-b135-45f4-973d-75add6bcc4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_977a6959-8b76-4fde-aad4-8cd5e5626de3" xlink:href="lyel-20230630.xsd#lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_977a6959-8b76-4fde-aad4-8cd5e5626de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b326d456-9979-4f53-89b5-b6b68c51c3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b326d456-9979-4f53-89b5-b6b68c51c3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_95810f2f-95e1-4098-b698-ed2a3ebea5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_95810f2f-95e1-4098-b698-ed2a3ebea5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f9bcce58-2e23-4ab0-b46a-2ee354fe34c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_us-gaap_OperatingLeaseLiability_f9bcce58-2e23-4ab0-b46a-2ee354fe34c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_a2cbf725-aac4-4309-a286-8fcdb98bad8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_218a584e-455f-4d1b-a1a3-d907884b5186" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_a2cbf725-aac4-4309-a286-8fcdb98bad8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_726034d9-ab37-4d8f-9319-4385440216bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_a2cbf725-aac4-4309-a286-8fcdb98bad8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_726034d9-ab37-4d8f-9319-4385440216bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ce7c08f6-fabb-4ae6-8f41-a393d2e182a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_a2cbf725-aac4-4309-a286-8fcdb98bad8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ce7c08f6-fabb-4ae6-8f41-a393d2e182a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8995326c-ec6f-4136-8c89-b73a6d977f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_a2cbf725-aac4-4309-a286-8fcdb98bad8b" xlink:to="loc_us-gaap_OperatingLeaseLiability_8995326c-ec6f-4136-8c89-b73a6d977f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="simple" xlink:href="lyel-20230630.xsd#LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cd141ab2-38ef-4980-824a-5ca6c05fc811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd141ab2-38ef-4980-824a-5ca6c05fc811" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d9dc51-8c83-4685-adc2-eb8db1210c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d9dc51-8c83-4685-adc2-eb8db1210c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e1bf9dbf-b21e-4605-8d45-9829e82ed760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d9dc51-8c83-4685-adc2-eb8db1210c95" xlink:to="loc_us-gaap_RelatedPartyDomain_e1bf9dbf-b21e-4605-8d45-9829e82ed760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_2e437952-3336-4091-919a-282252f7d9be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e1bf9dbf-b21e-4605-8d45-9829e82ed760" xlink:to="loc_us-gaap_RelatedPartyMember_2e437952-3336-4091-919a-282252f7d9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c7602155-44e1-4ea0-8921-7c45268b6efe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:to="loc_srt_StatementGeographicalAxis_c7602155-44e1-4ea0-8921-7c45268b6efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3b2ddf4b-1958-43eb-9f92-f3fc031e8609" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c7602155-44e1-4ea0-8921-7c45268b6efe" xlink:to="loc_srt_SegmentGeographicalDomain_3b2ddf4b-1958-43eb-9f92-f3fc031e8609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SouthSanFranciscoCaliforniaMember_37de9c9f-d83c-4986-96a0-338827e1eed1" xlink:href="lyel-20230630.xsd#lyel_SouthSanFranciscoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3b2ddf4b-1958-43eb-9f92-f3fc031e8609" xlink:to="loc_lyel_SouthSanFranciscoCaliforniaMember_37de9c9f-d83c-4986-96a0-338827e1eed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c0711711-06c0-4ec1-b3e8-e0a62f5b921e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:to="loc_srt_CounterpartyNameAxis_c0711711-06c0-4ec1-b3e8-e0a62f5b921e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a6dcb43-5152-4837-8a16-bca3053cd504" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c0711711-06c0-4ec1-b3e8-e0a62f5b921e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a6dcb43-5152-4837-8a16-bca3053cd504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_3647d9eb-dd2e-4e6d-9d94-5d660f6e491b" xlink:href="lyel-20230630.xsd#lyel_SonomaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a6dcb43-5152-4837-8a16-bca3053cd504" xlink:to="loc_lyel_SonomaMember_3647d9eb-dd2e-4e6d-9d94-5d660f6e491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5e2bd4e1-878e-4cde-bf6f-12f6a711c69b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_415cb622-c251-495d-b7a3-6d838d47d8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_OperatingLeaseCost_415cb622-c251-495d-b7a3-6d838d47d8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_c1a57e5c-e2f9-4de3-8dee-9b727b889e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_VariableLeaseCost_c1a57e5c-e2f9-4de3-8dee-9b727b889e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_18c9ca52-a94c-4ced-b057-d806be52b930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_18c9ca52-a94c-4ced-b057-d806be52b930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7ed2bbf9-919b-42b5-b163-4a1cb87574aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7ed2bbf9-919b-42b5-b163-4a1cb87574aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_fb57b9ea-3659-4a32-bb41-61a3381004b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_NetRentableArea_fb57b9ea-3659-4a32-bb41-61a3381004b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_2a866ab6-7056-4946-884b-ae3d12050d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_SubleaseIncome_2a866ab6-7056-4946-884b-ae3d12050d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_73147aa0-f726-44c5-9b26-025e55784e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b9a16739-5113-4228-99c9-f5b0643b8018" xlink:to="loc_us-gaap_TenantImprovements_73147aa0-f726-44c5-9b26-025e55784e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7a47a5ec-499e-4e8f-ae98-ab2d2cb9b0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7a47a5ec-499e-4e8f-ae98-ab2d2cb9b0a1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cc11e206-12bd-4444-a03b-a38a91a4d0a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:to="loc_srt_CounterpartyNameAxis_cc11e206-12bd-4444-a03b-a38a91a4d0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e637d27-6efe-479c-9714-92f0674db011" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cc11e206-12bd-4444-a03b-a38a91a4d0a0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e637d27-6efe-479c-9714-92f0674db011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GoldmanSachsAndBofAMember_e4c0a3f0-7ca5-4ab5-b55d-55c486f7838d" xlink:href="lyel-20230630.xsd#lyel_GoldmanSachsAndBofAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e637d27-6efe-479c-9714-92f0674db011" xlink:to="loc_lyel_GoldmanSachsAndBofAMember_e4c0a3f0-7ca5-4ab5-b55d-55c486f7838d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_69766001-8ad7-459b-a1cf-3a32caf340f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_69766001-8ad7-459b-a1cf-3a32caf340f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fb5e0656-7612-4d91-aec5-435606b3e301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_69766001-8ad7-459b-a1cf-3a32caf340f5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fb5e0656-7612-4d91-aec5-435606b3e301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_AtTheMarketOfferingMember_f5e674b3-e90a-42f1-abef-c4cac27a46c5" xlink:href="lyel-20230630.xsd#lyel_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fb5e0656-7612-4d91-aec5-435606b3e301" xlink:to="loc_lyel_AtTheMarketOfferingMember_f5e674b3-e90a-42f1-abef-c4cac27a46c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_42c81a70-acf4-43e0-a50c-fad15b82e834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_42c81a70-acf4-43e0-a50c-fad15b82e834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b152a65a-1dfc-41f7-8d04-ba11634e7f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_42c81a70-acf4-43e0-a50c-fad15b82e834" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b152a65a-1dfc-41f7-8d04-ba11634e7f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_EquityDistributionAgreementMember_ac54b864-8954-499a-9569-3c6ff4f5adcc" xlink:href="lyel-20230630.xsd#lyel_EquityDistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b152a65a-1dfc-41f7-8d04-ba11634e7f97" xlink:to="loc_lyel_EquityDistributionAgreementMember_ac54b864-8954-499a-9569-3c6ff4f5adcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42c1836-3c56-4b73-8e53-0d897ac29ad7" xlink:to="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_67429e1a-54c6-4270-8e1b-73b1f2f73fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_67429e1a-54c6-4270-8e1b-73b1f2f73fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e9d329d7-96b3-448a-a9fb-dda67f7705c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e9d329d7-96b3-448a-a9fb-dda67f7705c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4228b668-e69d-4ba3-893c-3023aeb6e093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4228b668-e69d-4ba3-893c-3023aeb6e093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_62e28911-9256-47ac-8ca0-c841f7cb4af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_62e28911-9256-47ac-8ca0-c841f7cb4af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_94a49bf5-27a2-461f-9227-3a172f1a962f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_94a49bf5-27a2-461f-9227-3a172f1a962f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a3fb5b19-92ec-48a8-a10e-f9fd8a960011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a3fb5b19-92ec-48a8-a10e-f9fd8a960011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_abbdb907-ee24-4de7-ada6-b425847370c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_abbdb907-ee24-4de7-ada6-b425847370c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_PercentageOfCommissionFromEachSaleOfShares_cf9f0cc1-ab46-468a-9a28-f23d063d6463" xlink:href="lyel-20230630.xsd#lyel_PercentageOfCommissionFromEachSaleOfShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91219bc3-2bba-4209-aa3a-14e46c7bd181" xlink:to="loc_lyel_PercentageOfCommissionFromEachSaleOfShares_cf9f0cc1-ab46-468a-9a28-f23d063d6463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df0251f8-9cc3-4a48-9c7d-49e9e0274ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dceb0bf0-f335-424a-8aab-33e77d924a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df0251f8-9cc3-4a48-9c7d-49e9e0274ca1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dceb0bf0-f335-424a-8aab-33e77d924a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f1ea1e82-a53c-4cc3-93e0-534bfad23527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dceb0bf0-f335-424a-8aab-33e77d924a59" xlink:to="loc_us-gaap_PlanNameAxis_f1ea1e82-a53c-4cc3-93e0-534bfad23527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f1ea1e82-a53c-4cc3-93e0-534bfad23527" xlink:to="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_e78c7889-1a6f-463f-b001-47be3b7ce161" xlink:href="lyel-20230630.xsd#lyel_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:to="loc_lyel_TwoThousandTwentyOneEquityIncentivePlanMember_e78c7889-1a6f-463f-b001-47be3b7ce161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_8f13cde9-85e8-4318-8066-32012081ad80" xlink:href="lyel-20230630.xsd#lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:to="loc_lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_8f13cde9-85e8-4318-8066-32012081ad80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_c2e3da95-1c3b-4d64-a41f-f394b34d266e" xlink:href="lyel-20230630.xsd#lyel_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_80dd4ff9-b809-45ea-af6b-3239ffb811c2" xlink:to="loc_lyel_TwoThousandEighteenEquityIncentivePlanMember_c2e3da95-1c3b-4d64-a41f-f394b34d266e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0811df76-dbc9-444c-9c16-c775746786bf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dceb0bf0-f335-424a-8aab-33e77d924a59" xlink:to="loc_srt_RangeAxis_0811df76-dbc9-444c-9c16-c775746786bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3be84ecc-69d6-426b-81fb-233ab40604a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0811df76-dbc9-444c-9c16-c775746786bf" xlink:to="loc_srt_RangeMember_3be84ecc-69d6-426b-81fb-233ab40604a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8e669895-4a6b-4135-bb30-59014f73b170" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3be84ecc-69d6-426b-81fb-233ab40604a8" xlink:to="loc_srt_MaximumMember_8e669895-4a6b-4135-bb30-59014f73b170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dceb0bf0-f335-424a-8aab-33e77d924a59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7f8ddf17-9dbe-4c59-bce3-13b232c9577a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7f8ddf17-9dbe-4c59-bce3-13b232c9577a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a49d3f0b-e79a-498e-9843-ff7810285b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a49d3f0b-e79a-498e-9843-ff7810285b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_66fd6e17-4493-4c7f-bf9e-886855ea12d7" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_66fd6e17-4493-4c7f-bf9e-886855ea12d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e1ad16ea-79d5-40cc-b349-9c3da9edcbef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e1ad16ea-79d5-40cc-b349-9c3da9edcbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_4ed99291-69a3-4993-b4c9-2275dabddb4d" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding_4ed99291-69a3-4993-b4c9-2275dabddb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f78b6928-b34c-4f38-877d-cf9cdf456453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f78b6928-b34c-4f38-877d-cf9cdf456453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5c2ea814-5a7a-4ebf-8ade-4c37a88b15a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5c2ea814-5a7a-4ebf-8ade-4c37a88b15a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1b3483f3-bd66-41a9-8df5-74f926c2166a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1b3483f3-bd66-41a9-8df5-74f926c2166a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d94f2997-4e6a-4ed3-876c-9086daca9ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d94f2997-4e6a-4ed3-876c-9086daca9ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_daebaff9-90e2-4cde-adaa-f6337f302355" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_daebaff9-90e2-4cde-adaa-f6337f302355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_4359d020-dbb5-406f-ad45-3cc6635d8273" xlink:href="lyel-20230630.xsd#lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_4359d020-dbb5-406f-ad45-3cc6635d8273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b90d9aed-6932-4601-b815-ff72a2fc6dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b90d9aed-6932-4601-b815-ff72a2fc6dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_838cedcf-a8a2-47c8-a073-63d12b3da750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_838cedcf-a8a2-47c8-a073-63d12b3da750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f48f7835-288c-42ea-9ae3-fbb8d0877178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f48f7835-288c-42ea-9ae3-fbb8d0877178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70be2b0f-1240-4e37-81c5-8782e40ebcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_519d45c5-b171-49a2-a3b1-ca6c4867c41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70be2b0f-1240-4e37-81c5-8782e40ebcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ee330fc-afc3-45ac-be81-0f0f489568ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2245e922-f259-4629-86ec-bbe0227b72df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ee330fc-afc3-45ac-be81-0f0f489568ad" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2245e922-f259-4629-86ec-bbe0227b72df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2b04756-66b3-49b1-b470-57f54c83d708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2245e922-f259-4629-86ec-bbe0227b72df" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2b04756-66b3-49b1-b470-57f54c83d708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_29971a0b-6ff8-4520-92fd-4b56f2ff01d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2b04756-66b3-49b1-b470-57f54c83d708" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_29971a0b-6ff8-4520-92fd-4b56f2ff01d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e031a51-8ca5-4573-8ba2-f51fc5c7b2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29971a0b-6ff8-4520-92fd-4b56f2ff01d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e031a51-8ca5-4573-8ba2-f51fc5c7b2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d531a23d-7310-42ee-b880-fafdffbb631d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29971a0b-6ff8-4520-92fd-4b56f2ff01d7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d531a23d-7310-42ee-b880-fafdffbb631d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d44cf635-a169-4ce5-bf1d-2fddade981cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2245e922-f259-4629-86ec-bbe0227b72df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d44cf635-a169-4ce5-bf1d-2fddade981cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a1e018b6-500f-448c-a4d6-3aba2f1aa9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d44cf635-a169-4ce5-bf1d-2fddade981cd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a1e018b6-500f-448c-a4d6-3aba2f1aa9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensationRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98b66d0a-f9c9-4c52-a2bd-0b15eaf80bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391c709a-e53f-4662-81b8-c3132cf21bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98b66d0a-f9c9-4c52-a2bd-0b15eaf80bbd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391c709a-e53f-4662-81b8-c3132cf21bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_176cba02-0bdb-463b-bbed-56e506e6bc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391c709a-e53f-4662-81b8-c3132cf21bba" xlink:to="loc_us-gaap_AwardTypeAxis_176cba02-0bdb-463b-bbed-56e506e6bc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31d2f3ae-df16-43d7-91b9-f869a7dbd2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_176cba02-0bdb-463b-bbed-56e506e6bc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31d2f3ae-df16-43d7-91b9-f869a7dbd2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0156b4cf-79d5-463f-861f-de069a9da4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31d2f3ae-df16-43d7-91b9-f869a7dbd2e3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0156b4cf-79d5-463f-861f-de069a9da4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f3678db-5146-4ea7-b271-c1ac632fb857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391c709a-e53f-4662-81b8-c3132cf21bba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f3678db-5146-4ea7-b271-c1ac632fb857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f3678db-5146-4ea7-b271-c1ac632fb857" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90a31d3c-78de-4cfd-a773-6266e93450bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90a31d3c-78de-4cfd-a773-6266e93450bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfcccaef-87e0-4574-9135-3d8d701d96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfcccaef-87e0-4574-9135-3d8d701d96cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_365181dc-fbe5-4886-a829-2872b55a931b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_365181dc-fbe5-4886-a829-2872b55a931b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0203ff0b-298e-457a-945c-8ed9ca0a05a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0203ff0b-298e-457a-945c-8ed9ca0a05a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_31964821-99d7-44cf-b27b-52c0874b2715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a9412ae8-f2f2-48e4-bf1e-dcd3b0b64a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_31964821-99d7-44cf-b27b-52c0874b2715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f3678db-5146-4ea7-b271-c1ac632fb857" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5c325cf-e508-45e7-a86b-5b960d5cc9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5c325cf-e508-45e7-a86b-5b960d5cc9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a85d4636-eb40-44cc-8922-6e36ec928dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a85d4636-eb40-44cc-8922-6e36ec928dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b4e96ed-be3f-42c5-9c38-6382bc235c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b4e96ed-be3f-42c5-9c38-6382bc235c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0a6b3118-53d4-4df3-a309-a0093530b569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0a6b3118-53d4-4df3-a309-a0093530b569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_46aca48b-f310-484e-972b-c75bc24a816c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1778d7e6-7655-410d-b64c-84601b15c108" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_46aca48b-f310-484e-972b-c75bc24a816c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0472812c-c672-4a3e-ab89-66f147f12409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d5ebc96d-04a7-4073-abd6-1c9b5803d767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0472812c-c672-4a3e-ab89-66f147f12409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d5ebc96d-04a7-4073-abd6-1c9b5803d767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f2cf3d83-ec02-4b7f-bf52-8df140a60286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d5ebc96d-04a7-4073-abd6-1c9b5803d767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f2cf3d83-ec02-4b7f-bf52-8df140a60286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0f1c0001-8e22-4225-b84d-32fac051a411" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d5ebc96d-04a7-4073-abd6-1c9b5803d767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0f1c0001-8e22-4225-b84d-32fac051a411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a661d724-1758-43f2-beeb-0a02d6ca40cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d5ebc96d-04a7-4073-abd6-1c9b5803d767" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a661d724-1758-43f2-beeb-0a02d6ca40cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b3c2ca9c-54e5-426e-8a39-59c8c6ca7a38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d5ebc96d-04a7-4073-abd6-1c9b5803d767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b3c2ca9c-54e5-426e-8a39-59c8c6ca7a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_602cbede-47d9-4c0f-bf54-f563dff182dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d5ebc96d-04a7-4073-abd6-1c9b5803d767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_602cbede-47d9-4c0f-bf54-f563dff182dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ada0c449-f302-4605-bd6d-812b46346c94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0472812c-c672-4a3e-ab89-66f147f12409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ada0c449-f302-4605-bd6d-812b46346c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6d964fb1-d4bb-434e-a788-0b0e160d6db6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0472812c-c672-4a3e-ab89-66f147f12409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6d964fb1-d4bb-434e-a788-0b0e160d6db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fbbadf08-1d3b-4c77-9947-22b87e8ae7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6d964fb1-d4bb-434e-a788-0b0e160d6db6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fbbadf08-1d3b-4c77-9947-22b87e8ae7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6c3139b3-8faf-4ed0-8806-716510f9f76e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6d964fb1-d4bb-434e-a788-0b0e160d6db6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6c3139b3-8faf-4ed0-8806-716510f9f76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3d51f9ce-0d49-4ac1-96ca-81be4dc0d86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6d964fb1-d4bb-434e-a788-0b0e160d6db6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3d51f9ce-0d49-4ac1-96ca-81be4dc0d86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a24039de-f9db-48e1-9574-a9dd90d72d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6d964fb1-d4bb-434e-a788-0b0e160d6db6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a24039de-f9db-48e1-9574-a9dd90d72d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9aae3db0-575d-428c-9764-35f811aefcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6d964fb1-d4bb-434e-a788-0b0e160d6db6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9aae3db0-575d-428c-9764-35f811aefcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4396e58e-35b2-4591-9b17-01e605760fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0472812c-c672-4a3e-ab89-66f147f12409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4396e58e-35b2-4591-9b17-01e605760fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e66e6004-efd0-4d0c-ac17-19afc47e881e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0472812c-c672-4a3e-ab89-66f147f12409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e66e6004-efd0-4d0c-ac17-19afc47e881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c99d7d66-0757-4944-80d3-2acad1487341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e66e6004-efd0-4d0c-ac17-19afc47e881e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c99d7d66-0757-4944-80d3-2acad1487341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f432b29b-95ca-4536-9d75-be78baf1691f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e66e6004-efd0-4d0c-ac17-19afc47e881e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f432b29b-95ca-4536-9d75-be78baf1691f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_b4bac02a-6364-42d8-a4b2-de092754fefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0472812c-c672-4a3e-ab89-66f147f12409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_b4bac02a-6364-42d8-a4b2-de092754fefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_438f5eb6-fdc1-46fd-873b-fd4c5f6da69b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_b4bac02a-6364-42d8-a4b2-de092754fefd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_438f5eb6-fdc1-46fd-873b-fd4c5f6da69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ef96b122-25ad-4e18-95f7-2335ed86f02c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_b4bac02a-6364-42d8-a4b2-de092754fefd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ef96b122-25ad-4e18-95f7-2335ed86f02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8f71352b-0ccd-4958-94d3-519e20350ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3b237591-49d6-4b48-b083-2a5a8bc70a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8f71352b-0ccd-4958-94d3-519e20350ef0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3b237591-49d6-4b48-b083-2a5a8bc70a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b502874e-b3d3-425f-82f7-6d852c01ca64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8f71352b-0ccd-4958-94d3-519e20350ef0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b502874e-b3d3-425f-82f7-6d852c01ca64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd66b771-c684-4dd4-8f95-3a67a27de17e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8f71352b-0ccd-4958-94d3-519e20350ef0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd66b771-c684-4dd4-8f95-3a67a27de17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0a46a4be-ae3a-4305-a741-f741faea3324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8f71352b-0ccd-4958-94d3-519e20350ef0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0a46a4be-ae3a-4305-a741-f741faea3324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#RelatedpartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4929945b-ec14-47c3-a9a9-32c15a247189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4929945b-ec14-47c3-a9a9-32c15a247189" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2be2a44b-064e-4d8e-b1c7-a61406365f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2be2a44b-064e-4d8e-b1c7-a61406365f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2829fb17-5e6a-45c6-99a9-c22cba7fe502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2be2a44b-064e-4d8e-b1c7-a61406365f6c" xlink:to="loc_us-gaap_RelatedPartyDomain_2829fb17-5e6a-45c6-99a9-c22cba7fe502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_738b8d52-4a43-4201-96b4-05b78c72e6df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2829fb17-5e6a-45c6-99a9-c22cba7fe502" xlink:to="loc_us-gaap_RelatedPartyMember_738b8d52-4a43-4201-96b4-05b78c72e6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e8291762-d51c-4234-8ad3-27ed5810d03e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_srt_RangeAxis_e8291762-d51c-4234-8ad3-27ed5810d03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3019e31e-c8d9-49d3-8836-ab48f1e2fd00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e8291762-d51c-4234-8ad3-27ed5810d03e" xlink:to="loc_srt_RangeMember_3019e31e-c8d9-49d3-8836-ab48f1e2fd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f809761d-7156-44f4-8149-64bde0645a96" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3019e31e-c8d9-49d3-8836-ab48f1e2fd00" xlink:to="loc_srt_MinimumMember_f809761d-7156-44f4-8149-64bde0645a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a30a5b14-842c-420a-a826-53c113f072e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_srt_OwnershipAxis_a30a5b14-842c-420a-a826-53c113f072e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_513e19f1-56c2-4daf-a959-79e1d49b5e2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_a30a5b14-842c-420a-a826-53c113f072e9" xlink:to="loc_srt_OwnershipDomain_513e19f1-56c2-4daf-a959-79e1d49b5e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_LyellImmunopharmaMember_3650dd5c-9f29-4c39-a26c-36261c5edfbc" xlink:href="lyel-20230630.xsd#lyel_LyellImmunopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_513e19f1-56c2-4daf-a959-79e1d49b5e2c" xlink:to="loc_lyel_LyellImmunopharmaMember_3650dd5c-9f29-4c39-a26c-36261c5edfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_532d0117-97da-4e92-951b-aa45efecc306" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_dei_LegalEntityAxis_532d0117-97da-4e92-951b-aa45efecc306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_188490ba-3e5c-4584-bfb7-a921685dc9cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_532d0117-97da-4e92-951b-aa45efecc306" xlink:to="loc_dei_EntityDomain_188490ba-3e5c-4584-bfb7-a921685dc9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_62a28a41-8235-4561-a800-0c00ea49474f" xlink:href="lyel-20230630.xsd#lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_188490ba-3e5c-4584-bfb7-a921685dc9cd" xlink:to="loc_lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember_62a28a41-8235-4561-a800-0c00ea49474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fa28cb58-02d7-47f3-86fd-c07981fb3423" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_srt_CounterpartyNameAxis_fa28cb58-02d7-47f3-86fd-c07981fb3423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29cbd25b-0e5b-46a9-b070-bf394a621208" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fa28cb58-02d7-47f3-86fd-c07981fb3423" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29cbd25b-0e5b-46a9-b070-bf394a621208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_8bb54dbd-22fc-4d64-b03c-cc898d79703a" xlink:href="lyel-20230630.xsd#lyel_SonomaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29cbd25b-0e5b-46a9-b070-bf394a621208" xlink:to="loc_lyel_SonomaMember_8bb54dbd-22fc-4d64-b03c-cc898d79703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_GSKMember_ba231c91-cc68-4d91-bc3c-7de186759ae1" xlink:href="lyel-20230630.xsd#lyel_GSKMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29cbd25b-0e5b-46a9-b070-bf394a621208" xlink:to="loc_lyel_GSKMember_ba231c91-cc68-4d91-bc3c-7de186759ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b37f2e94-9bae-4714-9b6d-515dae1ad545" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_8777c4e4-5070-4604-aacd-073bac23d9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_NetRentableArea_8777c4e4-5070-4604-aacd-073bac23d9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_e8ac743e-94bb-4d86-9d71-1d8a7619bd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_TenantImprovements_e8ac743e-94bb-4d86-9d71-1d8a7619bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_aa18a0f3-9f17-4aba-be92-a9fe1f69fec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_aa18a0f3-9f17-4aba-be92-a9fe1f69fec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f47a3c3b-09ac-481a-80e3-e1de5d9d3a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f47a3c3b-09ac-481a-80e3-e1de5d9d3a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_86a8a7f3-b01b-4d2d-8fed-d04e1517be35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_86a8a7f3-b01b-4d2d-8fed-d04e1517be35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eff13771-243f-4431-af5b-b29ada23de4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eff13771-243f-4431-af5b-b29ada23de4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa313399-79de-4d1b-9ca5-7273e76e213d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_66a8f818-e1c2-442f-965f-e5fdd1180ae8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa313399-79de-4d1b-9ca5-7273e76e213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="simple" xlink:href="lyel-20230630.xsd#RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"/>
  <link:presentationLink xlink:role="http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_97b5d476-521f-4eeb-bc51-0f8330390991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad942493-6fc2-42a6-974d-da97775f8159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_97b5d476-521f-4eeb-bc51-0f8330390991" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad942493-6fc2-42a6-974d-da97775f8159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca1d38e-5721-4b51-99f6-c37d2f43dfef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad942493-6fc2-42a6-974d-da97775f8159" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca1d38e-5721-4b51-99f6-c37d2f43dfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_aa94cfba-ece9-40a7-b20b-f5ac896fbdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca1d38e-5721-4b51-99f6-c37d2f43dfef" xlink:to="loc_us-gaap_RelatedPartyDomain_aa94cfba-ece9-40a7-b20b-f5ac896fbdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_411ab773-b73d-4a83-aa50-aa56300824bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_aa94cfba-ece9-40a7-b20b-f5ac896fbdd8" xlink:to="loc_us-gaap_RelatedPartyMember_411ab773-b73d-4a83-aa50-aa56300824bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d62ec459-1ae3-4f8d-aea4-d3d54f0ad4b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad942493-6fc2-42a6-974d-da97775f8159" xlink:to="loc_srt_CounterpartyNameAxis_d62ec459-1ae3-4f8d-aea4-d3d54f0ad4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be56be7e-2429-4c0d-9d14-09899bc5b2a9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d62ec459-1ae3-4f8d-aea4-d3d54f0ad4b8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be56be7e-2429-4c0d-9d14-09899bc5b2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lyel_SonomaMember_7e0e8572-c4a4-4664-bed1-6e674e48457a" xlink:href="lyel-20230630.xsd#lyel_SonomaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be56be7e-2429-4c0d-9d14-09899bc5b2a9" xlink:to="loc_lyel_SonomaMember_7e0e8572-c4a4-4664-bed1-6e674e48457a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d2d13593-7491-4441-8d41-08351e3f18ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ad942493-6fc2-42a6-974d-da97775f8159" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d2d13593-7491-4441-8d41-08351e3f18ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_ebe5f9a4-88de-4d43-b4aa-21b8f5031baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d2d13593-7491-4441-8d41-08351e3f18ab" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_ebe5f9a4-88de-4d43-b4aa-21b8f5031baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_7eeb082a-3115-4bce-a69c-01e068d13352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d2d13593-7491-4441-8d41-08351e3f18ab" xlink:to="loc_us-gaap_SubleaseIncome_7eeb082a-3115-4bce-a69c-01e068d13352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_0b.jpg
<TEXT>
begin 644 image_0b.jpg
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MB%2$ 2P1$1$1$1$1$1&1BC" )2(B(B(B(B(B(E(1!K!$1$1$1$1$1$1$*L(
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M+%F_!"7+R1?@TM'50?,VS>%SST?=0R0B-8E_$X_K]Z]CQ*01,+.0MR"PL+!
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M?]@O23UF+YQ"T>)%%:IEW4:XX7GP<S7M??J%AX9C[+"QR&>93V$?>O?KG13
M$%'6%>@7B-$#1\/,Q"S%<%,_CSX:-&N W=MVXUW0.ZEB]M,"6!'1$5BQ9@6L
M\UG+ U@+&XP8, *^US,6P'XB7B<J)@K>9[S1NW]OY+/*EW;P^O\/;0-M5&M<
M#5N\MF3&H2(B(B(B(J+OA %L-A ;&XM)DR:E/JU55'UIY(25HQ4NWKR(R,A(
M=.[46>KWFE3]JJ6)ZL[5L==[K\)K1$5&P7V@.\R,Y?T(\^3)@YFS9B;UE?TO
M>_[\.6I4KX%<N>2+XXC*8!&$!+X(5/<0B2@#Q )[KP->8]'L1; L;PE=?=UD
MPU=#?4/\U/ GK-J^"OY1_GB;\!9?W6M"Q(L(>$SU@+7%5P&LJ( =F_$*6-EX
M/WR0%@8+"P_#\;/'T?>7OBAH73#-:EA# T.T:MP*WE[>:;\($1$1$1$1_6<P
M@,T&1  [?OSXM*NG<FNC0XL.N'/[#O8?WX^JM:HJ5+\V;]T<]Q_?5WB-X.!@
MV)>PAT:NSX&M"'QK5ZF-?3OVJ6&OE??LV3,X.CHJ'!<1(KN[NTNM'(@H:Q&_
MMV(1K.%_#(>9J1ER:N64INK+?L^U<Z! F0*8,&8"[EZ^B^BX:+S[^"<YHI^V
MQTH/6%LG$\".'P'?Q]\>P'XB@M@W"6\0$A*"&[=N8-K,:2A1I$2*-],L3"TP
MH.L W#A_(]/&0$1$1$1$1*K' #:+>_?N'2[?O(P.W3JD&<#JZ^ICXI")\+OC
MAQ&_CT!>J[Q)_TT$J_9V]E@P8X$4"'PI/C8>Z_Y:)UW\?QU<SI@^ U$146K:
M^_03+13.7SF/TF5**U:5&1IBU*A1ZAXB$2DI)B8&NW?N1CWG>C"S-$OVO"<J
M67_I]0L.'SR,ER]>(O%-ZC=:1 L"CW\\8&TC#V!MB]AB]H+94B]L51!!<G!(
M,(X>/XI> WM)"X-]O2\BF+6UM46_H?UP_OIYE8R#B(B(B(B(,A\#V"Q.!(LG
M+IY TW9-TPY@#?0Q==94:<IKPP8-9556HOJU5>M6N';]FL)KA 2'H$+I"M*B
M-9^>GTLS%XHY%L/F/9O5L-?*2WB;(.UWJ=*E9,=$[(>M@RWFK)BC[B$2D1*B
MHJ*P8^L.U*Y16UI([^OSG:Z.+JI7J8[Y"^;C[NV[THVD]$@I@"U2M @6+%F
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M[?-7S[-L&/4R]B46K%L ^Y+VT-+42MKO(G9%,&7&% 0\#5#W$']((OP,>!:
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MI_.%"!S'C1TG5;!_+^*[ZL&C!Q@S<8S4GSJU<T9AN\*8/&TR'CU)7__7@*
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M@1C[V]@,A:_B8L;4V!3=NG?#;3_55->)*?L/?1YB\H3)J%&W!HS,%-L-I"N
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M:-^M/4Y=^!S BO8#+T->8N0?(^6_4UI:4M_9KQ>TLK.UD\+YJ%<IW^1*>)N
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M >?:SECVUS+T^[4?K M9R_Z["&1+5"J!16L6)55X?B(6D=JT>1-L"]O*?J9
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M>\'OB1_.GSN/QC\U1FXM^<P)8V-C]!O0#WX/_62O%186)OTNYL\O[YE<P*8
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M?-XE!=A/?W]"Z(-0YIC.^SG56JI8OGZY*%I"&IF9F3AV^!B:-A8^[P<,&H"
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MP/X#1?M.QW) OP&X<?,&&P#-"\5,W+YZ&SVZ]"CP7:&MHXV%#@O9=/["*(H
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M'934A"(T%;_L8MD%/I=\2G(Z"R3@7@ &]1^$BA6%@J^BLB(F64]B[N5L:+9
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MH*6N)3A75(AMTL1)>/)$>+_0NB=.F"@U&[D@ ?9EW$ML6+D!=76$,38=NG?
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MJ?,0^SR6?8[6Z7/=!ZTL6HF.D[*J,K;LVX+D-+'X1B+IQ5,7T;5-UYSK3M=
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M#;1ITT:P#<6:BK";;X?X1.E9H1X>'J)C)WJN5:N*:3.G(?:5=,<E/?L=UCA
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MH9V7R/!(+%VT%(8&AFQ03=JSBJZ3X4.&X_&CQ[A]ZS83?ZO(Y(KY5>6J8M"
M0?"]Z5O@/N>(KVU:"5RVY$ >.7 D?*_Z%BIZ?OCK XZY'4.=VN)*]S5KUH2-
MC0W"P@N/DJ#WYU&/HVAJG/M<I/TGT>S W@/,A5XH68]M&MRPZ"1T0%)A0BH
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M'9,G3$:SYLV@K:[-(C^DM8.F\5:6JPP=/1VT,6F#\6/'X^+I@N,O_A=X$/@
MEOTMV:"%Y/&JK5<;>[?O945QOC?DW#QXXB Z]>H$F:K""!-R\%&AMP4."Q#[
M(99EO18$/0/N/[Z/N0YS8=3"B&4N2Q8ES+M0_JR6FA9Z].R!'?MW"+*/"VKO
MKOV[T*)Y"S;84%1QB9Z[5'2,Q-?[C^[CKP_?_UA_$[(>0Q&!$9AM/9M%VD@^
MLZ@8U*+YBQ =EUM Z?3ITS T-!0='RIL9FUKS2):O@<4$^%VW W&)N+( &GB
M*V5\;]FX!:]>YE^DC#+C+WE?0J=VG8HE/)(8JJFAB9&31N)6P)<7PZ/GY6FO
MTS U,66%. L47Y]^N?@J"0W:^EWWP[S9\UBA3OTZ^BS?5C!#*/LW7>G2D)61
MA8:J!AHU:<0&8MQ<W9 6E\9FKW X' Z'P^%P?AZX /L30PY8FAZHKZ<O<$>T
M,&J!JZ<+SE3]%E 5^I2X%.S=L!<:.AHBX56_GCZZ6G;%WB-[D9B2^-W;EQ?J
M[$;&1+(B69TZ=<I9.G?NC-X]>V/5LE7%6A_M?WI".JY[7,?<&7-A:&0(&049
M80[K'Z6AI*K$"NBL=UE?XNFU&6\SL./(#A;M4%"GE5R\5-'9[X%?H4XRZI"F
MI:?!_82[R!U'YT]52Q7FYN98L7 %GCUY5N"ZO@4DA <\#L#8"6.A4"-7Q" !
MJDK5*FC8I"'^M/H3)]U.?O>VY24N)HX5UJ*.LT#,*E\>38V;PFFC$R+B(K[9
M]BF&P^N<%ZND/FG,)":82U[CM%A86F#XA.%8OWD];E^^C9?)+[]9>WXFHL*C
M8&=M!_FJ0H<>B=GKEZY'<NR/<5+2.3UVYAA&31PE.(_=NG;#LGG+\/+9RR)/
MQZ9\6,KP/'WE-.R7V[,8$1)B)9]5]"ZI5JT:*]2V9.$2^/OY"_(\"R,Z(AJK
M'5:C<;W&;%IZH0);A3)L<&[Y\N4(?A',9E7\2E!AI8O7+J+_P/ZB0DS-39NS
M0E^9F9G,"7O,XQCJ-Q"[3BD>A(KGO4K)7^#\V@0]"<*$T1-0359Z'C 3SBN6
M12.C1MB\<3.2$@LOEO;NW3NX;'2!3AT=ENU:F NT3-DR;+;*S&DS\23@2:'K
M+RIT3ZU9LP8Z&CJ"02JZ7@WT#9A ^BSHV[[KJ.C6UAU;86-MP^[#O,_I[I;=
M,?;/L5CEL J>ISP1\S+FF[:'P^%P.!P.A_/MX +L3PQ--5VX=B%J:.5FI)&S
MDD2R%R]>_) VT=2^F(08.&YVA*Z>+BL>H:.N@_;MV\/ME)O4S,!?#>9$S'R+
M*_Y7T&="'Y2K4 Z5*U>&AK8&6K9NB?G+Y^/9W:Q.W1>:?]-2T^"TRHFY="K+
M"COTY)J1KR;/7&M4\;XH+M[LMM,Y(C&@8<.&D)65A;*J,JM0O<)E!2+C([^L
MT5\([<>CH$>8:CT5ZFKJD%>0AX&! 4;\.:+ "(,?06!@(%JT;(%RY<NA;*6R
M+(^V8\>..'CD('.6<?Z;D,-SX:J%J%Y#F#>LJ:V)U>M7_W)"=?9T;%L'6U2O
M69T-VI#0U[114XP?-Q['O8[C57+)!#\28=>M6L>**RG55,I7B*4"3%1HR7F?
M\R_]CJ B5,<.'4.WSMV@K*2,RA4J,_>QF:D9/-T\\>[M.Z2^3L66G5N@5UOO
M/R' 9F9DXN;9FQ@Y:"14E%5$YY!R6XU:&6'KH:TLR[8HL.*520G8?FP[.O3K
M &4U938X)4V()5<T9:;.7C@;3T*^GOB:34A@"&9.F@D55166;TOGA09(79Q<
M$!/!Q4X.A\/A<#@<SM>#"[ _,>0BF3M[KB!+C::PF9N:X\6M'R/ $B3BD5/J
M_*7S&-Y_.$[L/(&___JUW$Q%)2(B@CG(!O0=@ /'#[ B35^-?[(ZQPF9.'?R
M'/J/[ \]/3VVZ.OKH[%A8\R8/ -__57R*;P1X1$8.7PDG+8X(3DH&?@/S09.
M24G!SAT[,7/V3%P\=Q'XBH?U:T%9NV=]SJ)MY[8P[6F*S1LV(SXROO O<GXH
MZ6_2L6WW-B@I*XG$K]GS9N-YV/,?W<1OPL-G#S%FYAAT[MD9CLZ."+P9B/<9
M7U[<AZ)R AX&8/6RU>C0ID/.<TKR>671P0)']QW%7^__0P^9;P0]%_P?^L/)
MR0E]NO5!]T[=<>+PB9QG-<4W;-RV$;KZNO\) 9:@B)VGP4^QP6D#.K?O+#A_
MEATM6?NIP%9)>!;Q#"N=5J*3>2<8U#4071]M3=MB_;+UB XI>0&LPKCSZ [&
MSAB+'MUZP'&%(QX^?B@U*YW#X7 X' Z'P_D2N #[$T-NFN'#APNGZI$#MI,Y
M7D3]. &6P^%P?E98O,?>'5!2$0JP2@I*F#E^)BN Q^%\*\*CPS%_R7RH::B)
M!%@5%14L6;8$22G_P1$G#H?#X7 X' Z'4R!<@/U)H:KU@9<"T:UM-R[ <C@<
MSE?$Q\>'%7O[K53NE.BJ"E4Q9-R0KU( B,/)C_"@<,R;.@]J-<4"K*:J)K8O
MWX[BU&SD<#@<#H?#X7 X_PVX /N30I6L-Q_8C-J-:W,!EL/A<+XB3Q\^Q;#>
MPR G(Y<KP%:IBB&]A^#652[ <KX=#X(>8,34$9"O*2\68#4UL=UU.U"T6FL<
M#H?#X7 X' [G/P078']2J%B'K8TM%*HK< &6P^%POB+1\=&8OW0^:JK4%!2*
M,FMMAC,G_UO%WCB_%@_\'V#$H!&0KYJ/ +M]^X]N(H?#X7 X' Z'PRD!7(#]
M27G]^C4&#1R$/TK_P058#H?#^8JDO4Z#ZUY7:&IKYCQ;J4)[W3IUL7_?_A_=
M/,XOS-5+5]'9K#,J5:C$!5@.A\/A<#@<#N<7@@NP/RDDP/;ITT?402OS1QF8
MMS;'"S\NP'(X'$Y)^.>??W#MVC6T,6V#\N7*YSQ?-;0TX+C.$:FO4W]T$SF_
M*"=/G$2#>@WP^^^_"][M9<N4A5$C([@?=O_13>1P.!P.A\/A<#@E@ NP/RE_
M?_@;QT\>1[,6S<0.6$MSO$CA BR'P^&4E/"H<,R:.PM**DHYSU>J3+]L]3(D
MIB;^Z.9Q?E&.'S\.?7U]T>"J4G4ES!@] \\#GO_H)G(X' Z'P^%P.)P2P 78
MGY1___T7*>DI..A^$"U,6Z!TZ=*HKU<?\V?.A\\U'[S.^H?#X7 X)2/S?2;.
MGC^+=FW:Y;A@N0#+^9:\R7P#UUVNT-;1%L</Z&ABE<LJ)+U)^M'-Y' X' Z'
MP^%P."6 "[ _,4R$34N!]WEOK%BU GMW[T5L6.R/;A:'P^'\$B0E)F'_[OWH
MU;T7C%H88?R8\;CJ<Q69?V7^Z*9Q?D%H4'7]IO70U-(4";"U]&MAZ_ZMR 2_
M]C@<#H?#X7 XG)\1+L#^ I 0^S;S+3+>9OSHIG X',XO15IJ&JY?NPY/+T\\
MO/\0[]+>_>@F<7Y18J-BL7C!8J@HJPBCA<J70=,V37'<Z_B/;B*'P^%P.!P.
MA\,I(5R Y7 X' Z'P_G!A#P/@8VU#105%04"K(R<#+KW[8[+UR__Z"9R.!P.
MA\/A<#B<$L(%6 Z'P^%P.)P?S).@)Y@P:0*J*U07"+#5JE7#T*%#<>?.G1_=
M1 Z'P^%P.!P.AU-"N #+X7 X' Z'\X.Y>>,FNG?O#AD9&8$ 6T.Y!L9,'X,'
M00]^=!,Y' Z'P^%P.!Q.">$"+(?#X7 X',X/QONJ-UIV;HGRE<L+!%A5-578
MSK/%B[ 7/[J)' Z'P^%P.!P.IX1P 9;#X7 X' [G!W/ZY&DT;=049<N6%0BP
MZDKJF#]U/L*?A/_H)G(X' Z'P^%P.)P2P@58#H?#X7 XG!_,P8,'H:ZN+A!?
M:='5U,4&APU(B4[YT4WD<#@<#H?#X7 X)80+L!P.A\/A<#@_D'\__8O]^_9#
M34U-+,#JZ^+_VKM_ERC@,([C$08F7#_.M.L?J"5S#:$@(?\ 780@L* ?7(,M
MS6TA!$%+]!=$*"TM!<D-0IX01 5Q8-"D0UT11]*2/$6#$&Y=3]^Z7B]X[\_\
M&;[?VW=NQX=/!E@  /A7&6 !  IJOVW'W+6YJ!VH&6 ! * '&6 !  IJ?VS'
MW,VYJ-4,L   T(L,L   !:V^6HW9\[,QN&]PVP [<F0D[M^Y'YN?-DN?"0
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M^>+E6&PL1F>C4_HL  "@2P98 ("_1.=S)];?K<?&EXW2IP   +^) 18
M((D!%@     @B0$6     "") 18     ((D!%@     @B0$6     "") 18
M    ((D!%@     @B0$6     "") 18     ((D!%@     @B0$6     "")
M 18     ((D!%@     @B0$6     "") 18     ((D!%@     @B0$6
M "") 18     ((D!%@     @B0$6     "") 18     (,F.[T*2)$F2)$F2
M]/LRP$J2)$F2)$E24@9829(D29(D24K* "M)DB1)DB1)26T-L'_FJ5D
M@/^/ 18     ((D!%@     @B0$6     "") 18     ((D!%@     @B0$6
M     "") 18     ((D!%@     @B0$6     "") 18     ((D!%@     @
MB0$6     "") 18     ((D!%@     @B0$6     "") 18     ((D!%@
M   @B0$6     "") 18     ((D!%@     @B0$6     "#)-UG*C;3V8[.-
,     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>lseelysignaturea.jpg
<TEXT>
begin 644 lseelysignaturea.jpg
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M[.=AB.VD7RP6&XW=><KC]_3A;O$:[AM"[@44H]%X,.@/OD+*GH"G'O>$ \B
M+GE]7N[YFX6<BE D](S>H+\:B 3:R=QH4P99,(QW/"<G)QD8%:BG,@=Q45C4
M7F&>, E7_"B54T@DDCT5Y16##.-P.G9BG#=(N3W1+A;+Q(?@79)5554/<1W2
M13 8U,&O7L N2U IA=5F[<P5Y/:2<K@@? ]VZ@7X[B^<=N=C<J7\>?QMQZ)D
M>3R>C0Z[8Q,^;(W#[=A]\>+%E&'0GH/V(QZOYR52-C"&;HSY1$%AP2Y<:+?0
M;C<-WI7K\_LV:77:)$YV*IN$F[&HU*H34H5TK[/0R9WFZU'KU&\CP)]KJ&MP
M4RD%-F@/OOEGM,JAUJM[X/J>)>5@?G !QKP"U_RYS^=+[UT'\<.,+.4KW)Y7
M4HDC/Y8_"C'C;UG96<1E::UVZZ]*2TO?A $/QZ*QQ;CD==JLMM^M7KVZ%!?3
M/[?\J"7&L,QBG(0SQ-CT-<3PCRGDBJMXUZ9H870\GOD@$HB$0P6A#KBWMVBW
MC'AY7!R-1)^-CHY.I=)W0HQC,5DZL="?8:%*B;9PX4(5-L][-J=MD-%)8E)2
M7+(. ?Y+E4;U)I4YX.*$[H![,=[S#XO9\DLJ9U175T_6:74#,,R3I;%2,^+:
M@0F5$[KQ_I/18+2&=DL/&$2!HWH@,CJ2.MKXX$RXN,WPN?_2,_I^N+3?P""O
MX.(U&;Z[K[Z^_GZDKD_A2!]BS$R/R6CZ/7D.65T4@?D2DHGY".PZB4BR"'TN
M*)7*RQZWIX]EV;>1,+Q,^L(=3H(^0'SVA)()6IO+MAD[]J\U=36%I/U&-#8V
M*I#V<K?\=6O6,=@,'V5E9;5QC0";(('DX@OR2P&2%#%BXTQ<!]YW^IS;L,&6
M2>72 4_$TXB%EXXK'E?ELKGV(H-[S>EV;H#ACI&YUTRL*< SQ^$)/L')_@"Q
M:0=C8#;ZH_XF?%,?[CH1.EQZP" :G(@/QQ:/_0F5,B*1R 23V=0_.CQZCD:G
MZ<($M\^?/Y^)%<7N@X^^4E94YBJO*A^'&',5AOW*[K;?2Q_-0%!=A9-PW.ZT
M[S(QIO.XJ<^/U\?G0B.)P0 ,4DGZ)68G!$@Z.K&HQU@3^UOLS#/A4'@>]Y(;
M4#R^F,D/YN]HGM7\ *FW+&Q!;%:=AV%:N0Z@HJ+"@93Z'6R0SQ4RQ7OXEH\1
M4WZ,IA%+FI>(C%KCK^$AOM89=']"W#P;" 76(?[(IDZ=:H!K/(IY'45F=P)N
MJPN9:B5<]ALXD>O11XR^RS1:S<FN=5W*_XR6)BHK*U4NM^LC3(;[X8XD YC<
M3NR>#J[#=6!AEV.ASXMT(BTY51;&TN9RN>:0,NW"8759RQ!\&\>,&5-"ZOU[
M^P5(();#J"D#$BX?O2R"JYN,8L/W.2D8)X?$/;U6OQ]EP?3ITQF91$;JG\)-
M#KJ#3:N9YD(2L%8D$'46CRLNIS)';6VM&DG*$H% T(F8>#^5.<K+RZN$0F$G
MUN/1KJYO+CZ,N0UKL(]6TP>70K+L!ACC,,IV&.1)K]?;2]P%[9)"+I6_@!V^
M?^[<N1(JW5%@C&R<S@1BP07,XT4D&X>U&NUIN*P9:!MTD4P'9 RE7+D?Z_4B
ME=(+COE8A5+Q"7;"61CFK2E3ICAI4XJU*]:JB%MPNIP;,<';^L^IFX&<:,20
M51*Y9#=.Q"-P,2QM2CL+FA9XX!Y/(Z,D;C']D/Q>(!+,A%]>B\SK6R].N*>$
MX<LO:0W:F50::M)_^_X?7';75)S2B^%P^#O=[IVD0"@2GD%V5D7K=R-QW&'.
M()LTT?JP("J2BDYI+7>U8:8C0SL-%SKH-\4A!5E6@4@BZE<SZD&9U=T$4O(9
MN!Z0#';X_/L=:;$=&="!:#@ZATIW'5B#4JU*>Z1F4@WW*\.PH?Z^^J*6AI9O
M_,9TMT#2Y=KJVO*5BU<:J,3#P\/#P\/#P\/#\T/)R/@W0!"IQ#_G-9,
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>lyel-20230630_g1.jpg
<TEXT>
begin 644 lyel-20230630_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +G!>@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU5&2:?575/\ D'W'^X:LK]T4 +1110 44C,%&6( ]32+(K_=8-]#F@!U%%%
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M;(S^)KS']G3P7<>(KWX5^)-*\0^"="UMM3VZC=OXCG;6-5$DA$D$UNV068<
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M1_ASH'@6\L/A;J*ZCX8BU*?YHKI[F**8A2\<;L3E1\O0D<GFO5:R/"OA'1/
M^BPZ1X>TFST72X22EI8PK%&I/4[5'4^M7[[4+73+=KB\N8;2!< RSN$49X')
MXJ1EBBD5@ZAE(92,@CH:6@ HHHH **** "BBB@ HHHH **89D5L%U!],T^@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHJEJ6M:?HL:R:A?6UBC'"M<S+&"?;)H NU\1? #]F&\;]IOXQ:_\
M$#P':WF@ZA?2SZ1=:M;Q3QN6N&;=&#G&5([5]LP7$5U"LL,B31,,J\;!E(]0
M14E,#Y]_;4^&>J^-OV8]=\*^#-$^V7S26OV;3;)5C&U)T9@HX   )Q6!XZ_9
M[U[XG?L-Z+\.S&--\4VNC6)2WN& "W,"H3$Q&0,[2N>V:^H:*+@?FMXBT?\
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M% !1110 4444 %%%% !1110!5U3_ )!]Q_N&K*_=%5M4_P"0?<?[AJROW10
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MIZ1I'A#Q]XH\#:+;?#+Q1?I:6S65T[7]LCL5223)VD'!/09QVKUOX0_LN?\
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M;S6IO(T^,W32><^X+C*RG'+#KCK7T7\)?C1XQL]!U6]^.FF:!\,Y([A8]/\
M,U*-4N4VDN<F1NAQW[UX'_P4:_Y*Q\"_^PNO_H^*MK]KW7/ 6L_'KPSX8E^&
M-W\5_B&=/VVVEOJ!M;."%F9@S=BW#'G@#O5"/KO1/'GAOQ+HDNL:3K^FZEI,
M()DOK6[22% !D[G!P,#UJI8_%#P=JFI:=I]EXIT>[OM1C,UG;P7T3R7"#JR
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M#%4@"%1EG8,!@D<5Y)^WE?:E=?M<^"+;24UB2^L]%:2%O!AW:NC%I"20/X0
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M4: ;?EJ6W%06]<<TZL+_ (0^U_Y_-2_\#Y?_ (JC_A#[7_G\U+_P/E_^*HT
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M  3IO?&&B_M!>-O#WBW7M1OY+708[F:"]NI)%CD9H7R0Q.& D()^M>L^)O\
M@H]I$&LZ['X0^'OB+QKH&AN4U#7;%=MO& 2"P^4_+P<%BN0,]*+ ?8851P%
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M%%% %75/^0?<?[AJROW15;5/^0?<?[AJROW10 M%%,DE2&-Y)'6.- 69F.
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M% !1110 4444 %%%% !1110!5U3_ )!]Q_N&K*_=%5M4_P"0?<?[AJROW10
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M%12[JRM][!Z8YQUK],+ZRAU*QN+2X7?;W$;12+G&58$$?D:YKX<?"[PW\)]
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M[+5RJ>I?<@_Z[+5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'B#_ )^]/_[\/_\ %4 ;5%8OD>(/^?O3_P#OP_\ \51Y'B#_ )^]/_[\/_\
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M@#:HK%\CQ!_S]Z?_ -^'_P#BJ/(\0?\ /WI__?A__BJ -JBL7R/$'_/WI_\
MWX?_ .*H\CQ!_P _>G_]^'_^*H VJ*Q?(\0?\_>G_P#?A_\ XJCR/$'_ #]Z
M?_WX?_XJ@#:HK%\CQ!_S]Z?_ -^'_P#BJ/(\0?\ /WI__?A__BJ -JBL7R/$
M'_/WI_\ WX?_ .*H\CQ!_P _>G_]^'_^*H VJ*Q?(\0?\_>G_P#?A_\ XJCR
M/$'_ #]Z?_WX?_XJ@#:HK%\CQ!_S]Z?_ -^'_P#BJ/(\0?\ /WI__?A__BJ
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M /BJ/(\0?\_>G_\ ?A__ (J@#:HK%\CQ!_S]Z?\ ]^'_ /BJ/(\0?\_>G_\
M?A__ (J@#:HK%\CQ!_S]Z?\ ]^'_ /BJ/(\0?\_>G_\ ?A__ (J@#:HK%\CQ
M!_S]Z?\ ]^'_ /BJ/(\0?\_>G_\ ?A__ (J@#:HK%\CQ!_S]Z?\ ]^'_ /BJ
M/(\0?\_>G_\ ?A__ (J@#:HK%\CQ!_S]Z?\ ]^'_ /BJ/(\0?\_>G_\ ?A__
M (J@#:HK%\CQ!_S]Z?\ ]^'_ /BJ/(\0?\_>G_\ ?A__ (J@#:HK%\CQ!_S]
MZ?\ ]^'_ /BJ/(\0?\_>G_\ ?A__ (J@#:HK%\CQ!_S]Z?\ ]^'_ /BJ/(\0
M?\_>G_\ ?A__ (J@#:J*Z_X]I?\ </\ *LKR/$'_ #]Z?_WX?_XJH[B'7_L\
MN;NP(VG/[A_3_>H U[+_ (\X?]P?RJ>L"UAU_P"RQ;;NP VC&8'_ /BJE\CQ
M!_S]Z?\ ]^'_ /BJ -JBL7R/$'_/WI__ 'X?_P"*H\CQ!_S]Z?\ ]^'_ /BJ
M -JBL7R/$'_/WI__ 'X?_P"*H\CQ!_S]Z?\ ]^'_ /BJ -JBL7R/$'_/WI__
M 'X?_P"*H\CQ!_S]Z?\ ]^'_ /BJ -JBL7R/$'_/WI__ 'X?_P"*H\CQ!_S]
MZ?\ ]^'_ /BJ -JBL7R/$'_/WI__ 'X?_P"*H\CQ!_S]Z?\ ]^'_ /BJ -JB
ML7R/$'_/WI__ 'X?_P"*H\CQ!_S]Z?\ ]^'_ /BJ -JBL7R/$'_/WI__ 'X?
M_P"*H\CQ!_S]Z?\ ]^'_ /BJ -JBL7R/$'_/WI__ 'X?_P"*H\CQ!_S]Z?\
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MR/$'_/WI_P#WX?\ ^*H\CQ!_S]Z?_P!^'_\ BJ -JBL7R/$'_/WI_P#WX?\
M^*H\CQ!_S]Z?_P!^'_\ BJ -JBL7R/$'_/WI_P#WX?\ ^*H\CQ!_S]Z?_P!^
M'_\ BJ -JBL7R/$'_/WI_P#WX?\ ^*H\CQ!_S]Z?_P!^'_\ BJ -JBL7R/$'
M_/WI_P#WX?\ ^*H\CQ!_S]Z?_P!^'_\ BJ -JBL7R/$'_/WI_P#WX?\ ^*H\
MCQ!_S]Z?_P!^'_\ BJ -JBL7R/$'_/WI_P#WX?\ ^*H\CQ!_S]Z?_P!^'_\
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M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ I&^Z:6D;[IH K:7_P >,7X_S-6JJZ7_ ,>,7X_S-6J
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M4;O*VD_N]N1GZ^U>_-\!OC+X+^*_Q"\3> O%'A6TT_Q;>I>/%JUG-++#M3:
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MB4W_ ,52_P#"X/'7_0Y:]_X,IO\ XJN0HHY(]@Y8]CK_ /A<'CK_ *'+7O\
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M]7^+7BO2;/1M?U&TTBRTN\,7E2H=P>5_O.@RH"9  !]:^E5^">HC]J@_%/\
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M@'C--T.>5J+YOP#V7,[4G?\  ^B;Z^M],LI[N[FCMK6!&EEFE8*J*!DL2>@
MKEHOC!X(G\)3>*(_%6DOX=AE\B34UND,"R9 V%LXSR./<5Y-IO[1'AO]H3X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMX;_ ,2ZE-"LR6ZS2+'!;@,"-[%MQ[X'UK["T>Y>\TFQN)3F26!'8@=RH)H
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M;Q3X>NU:3P?X?T^67PR[*<10WLZRO"#TPC1.H'8'WKZJI-HW9QSZT +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C*'4JP#*1@@
MC@TM% 'RG\'?A3K'P]_:CUK0W5CX'TNRN=9\/DH=L+WDJB>$-Z*0V!V#5]64
MFT;LXYZ9I:8!1112 **** "BBB@ HHHH **** "BBB@ HHHH *J7'_']:?\
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M(JDD#$CMCJ>E<O#^Q3\&;?Q8/$*>";47@G^U"W,TIM1+G._R-WEY_P" XIW
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M4@\%0>M=!;P):V\<,2[8XU"*OH , 47 DHHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&^Z:6D;[IH
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MJEJ*Z_X]I?\ </\ *@!ME_QYP_[@_E4]067_ !YP_P"X/Y5/0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %2PZW'_79JMU4L.MQ_UV:K= !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4]2^Y!_UV6KE4]2^Y!_UV
M6KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %(WW32TC?=- %;2_^/&+\?YFK55=+_P"/&+\?YFK5 !1110 4444
M%%%% !1110 4444 %%%% !1110!5U3_D'W'^X:LK]T56U3_D'W'^X:LK]T4
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M_P"ATO\ _P  T_\ BJ+0[A[Q[?\ \-?_  @_Z'6S_P"_4O\ \11_PU_\(/\
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ME_\ B*\0_P"':&A?]#I?_P#@&G_Q5'_#M#0O^ATO_P#P#3_XJBT.X>\>W_\
M#7_P@_Z'6S_[]2__ !%'_#7_ ,(/^AUL_P#OU+_\17B'_#M#0O\ H=+_ /\
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M^&O_ (0?]#K9_P#?J7_XBO$/^':&A?\ 0Z7_ /X!I_\ %4?\.T-"_P"ATO\
M_P  T_\ BJ+0[A[Q[?\ \-?_  @_Z'6S_P"_4O\ \11_PU_\(/\ H=;/_OU+
M_P#$5XA_P[0T+_H=+_\ \ T_^*H_X=H:%_T.E_\ ^ :?_%46AW#WCV__ (:_
M^$'_ $.MG_WZE_\ B*/^&O\ X0?]#K9_]^I?_B*\0_X=H:%_T.E__P" :?\
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M7_XBC_AK_P"$'_0ZV?\ WZE_^(KQ#_AVAH7_ $.E_P#^ :?_ !5'_#M#0O\
MH=+_ /\  -/_ (JBT.X>\>W_ /#7_P (/^AUL_\ OU+_ /$4?\-?_"#_ *'6
MS_[]2_\ Q%>(?\.T-"_Z'2__ / -/_BJ/^':&A?]#I?_ /@&G_Q5%H=P]X]O
M_P"&O_A!_P!#K9_]^I?_ (BC_AK_ .$'_0ZV?_?J7_XBO$/^':&A?]#I?_\
M@&G_ ,51_P .T-"_Z'2__P# -/\ XJBT.X>\>W_\-?\ P@_Z'6S_ ._4O_Q%
M'_#7_P (/^AUL_\ OU+_ /$5XA_P[0T+_H=+_P#\ T_^*H_X=H:%_P!#I?\
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M*HM#N'O'M_\ PU_\(/\ H=;/_OU+_P#$4?\ #7_P@_Z'6S_[]2__ !%>(?\
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MU+_\11_PU_\ "#_H=;/_ +]2_P#Q%>(?\.T-"_Z'2_\ _ -/_BJ/^':&A?\
M0Z7_ /X!I_\ %46AW#WCV_\ X:_^$'_0ZV?_ 'ZE_P#B*KS?M=_"%KRV8>-;
M/"[L_NI>X_W*\8_X=H:%_P!#I?\ _@&G_P 544G_  35T)+B&/\ X32_^?=_
MRYIV'^]1:'</>/=/^&O_ (0?]#K9_P#?J7_XBC_AK_X0?]#K9_\ ?J7_ .(K
MQ#_AVAH7_0Z7_P#X!I_\51_P[0T+_H=+_P#\ T_^*HM#N'O'M_\ PU_\(/\
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M.E__ . :?_%4?\.T-"_Z'2__ / -/_BJ+0[A[Q[?_P -?_"#_H=;/_OU+_\
M$4?\-?\ P@_Z'6S_ ._4O_Q%>(?\.T-"_P"ATO\ _P  T_\ BJ/^':&A?]#I
M?_\ @&G_ ,51:'</>/;_ /AK_P"$'_0ZV?\ WZE_^(H_X:_^$'_0ZV?_ 'ZE
M_P#B*\0_X=H:%_T.E_\ ^ :?_%4?\.T-"_Z'2_\ _ -/_BJ+0[A[Q[?_ ,-?
M_"#_ *'6S_[]2_\ Q%5[_P#:Z^$4UI(B^-;/)Q_RRE]1_L5XQ_P[0T+_ *'2
M_P#_  #3_P"*J*Z_X)JZ%;V[R?\ ":7_ !C_ )=$]?\ >HM#N'O'NG_#7WP@
M_P"AUL_^_4O_ ,11_P -?_"#_H=;/_OU+_\ $5XA_P .T-"_Z'2__P# -/\
MXJC_ (=H:%_T.E__ . :?_%46AW%[Q[?_P -?_"#_H=;/_OU+_\ $4?\-?\
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M+_\ \ T_^*H_X=H:%_T.E_\ ^ :?_%46AW#WCV__ (:_^$'_ $.MG_WZE_\
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M /AK_P"$'_0ZV?\ WZE_^(H_X:_^$'_0ZV?_ 'ZE_P#B*\0_X=H:%_T.E_\
M^ :?_%4?\.T-"_Z'2_\ _ -/_BJ+0[A[Q[?_ ,-?_"#_ *'6S_[]2_\ Q%'_
M  U_\(/^AUL_^_4O_P 17B'_  [0T+_H=+__ , T_P#BJ/\ AVAH7_0Z7_\
MX!I_\51:'</>/;_^&O\ X0?]#K9_]^I?_B*/^&O_ (0?]#K9_P#?J7_XBO$/
M^':&A?\ 0Z7_ /X!I_\ %4?\.T-"_P"ATO\ _P  T_\ BJ+0[A[Q[?\ \-?_
M  @_Z'6S_P"_4O\ \11_PU_\(/\ H=;/_OU+_P#$5XA_P[0T+_H=+_\ \ T_
M^*H_X=H:%_T.E_\ ^ :?_%46AW#WCV__ (:_^$'_ $.MG_WZE_\ B*/^&O\
MX0?]#K9_]^I?_B*\0_X=H:%_T.E__P" :?\ Q5'_  [0T+_H=+__ , T_P#B
MJ+0[A[Q[?_PU_P#"#_H=;/\ []2__$4?\-?_  @_Z'6S_P"_4O\ \17B'_#M
M#0O^ATO_ /P#3_XJC_AVAH7_ $.E_P#^ :?_ !5%H=P]X]O_ .&O_A!_T.MG
M_P!^I?\ XBC_ (:_^$'_ $.MG_WZE_\ B*\0_P"':&A?]#I?_P#@&G_Q5'_#
MM#0O^ATO_P#P#3_XJBT.X>\>SV?[77PAC\[/C6S^:1B/W4O_ ,15C_AK_P"$
M'_0ZV?\ WZE_^(KPNW_X)JZ%-YG_ !6E_P#*Y7_CT3M_P*I?^':&A?\ 0Z7_
M /X!I_\ %46AW#WCV_\ X:_^$'_0ZV?_ 'ZE_P#B*/\ AK_X0?\ 0ZV?_?J7
M_P"(KQ#_ (=H:%_T.E__ . :?_%4?\.T-"_Z'2__ / -/_BJ+0[A[Q[?_P -
M?_"#_H=;/_OU+_\ $4?\-?\ P@_Z'6S_ ._4O_Q%>(?\.T-"_P"ATO\ _P
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MT.E__P" :?\ Q5'_  [0T+_H=+__ , T_P#BJ+0[A[Q[?_PU_P#"#_H=;/\
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M_H=+_P#\ T_^*H_X=H:%_P!#I?\ _@&G_P 51:'</>/;_P#AK_X0?]#K9_\
M?J7_ .(H_P"&O_A!_P!#K9_]^I?_ (BO$/\ AVAH7_0Z7_\ X!I_\51_P[0T
M+_H=+_\ \ T_^*HM#N'O'M__  U_\(/^AUL_^_4O_P 11_PU_P#"#_H=;/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** *>I?<@_Z[+5RJ>I?<@_Z[+5R@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJI<?\?UI_P #_E5NJEQ_Q_6G_ _Y4 6Z*** "BBB@ KC?C-_R2+QI_V!KO\
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M44 %%%% !1110 5D>+O$UKX-\+ZKKMZ&:TTZVDN9%3&Y@JDX&>YZ?C57QO\
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M1XO_ .13UK_KRF_] -:]9'B__D4]:_Z\IO\ T TUN-;GX-ZE_P A"Z_ZZO\
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MBBB@ HHHH **** "BBB@"KJG_(/N/]PU97[HJMJG_(/N/]PU97[HH 6BBB@
MHHHH \^^+_P5\._%SPGKNFZAIUJ-2U"Q-K%JGDK]H@(.Z-E?&1M?#=>U>&_
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M\FSM\_\ 7)?\*/[)LO\ GSM_^_2_X5]!_:W]S\?^ >U_:/\ =_'_ (!^!_\
M9]U_S[R_]\&C^S[K_GWE_P"^#7[X?V39?\^=O_WZ7_"C^R;+_GSM_P#OTO\
MA3_M;^Y^/_ #^T?[OX_\ _ _^S[K_GWE_P"^#1_9]U_S[R_]\&OWP_LFR_Y\
M[?\ []+_ (4?V39?\^=O_P!^E_PH_M;^Y^/_   _M'^[^/\ P#\#_P"S[K_G
MWE_[X-']GW7_ #[R_P#?!K]\/[)LO^?.W_[]+_A1_9-E_P ^=O\ ]^E_PH_M
M;^Y^/_ #^T?[OX_\ _ _^S[K_GWE_P"^#1_9]U_S[R_]\&OWP_LFR_Y\[?\
M[]+_ (4?V39?\^=O_P!^E_PH_M;^Y^/_   _M'^[^/\ P#\#_P"S[K_GWE_[
MX-']GW7_ #[R_P#?!K]\/[)LO^?.W_[]+_A1_9-E_P ^=O\ ]^E_PH_M;^Y^
M/_ #^T?[OX_\ ^.O^"7L,D/PI\5B2-X\ZP,;E(S^Y2OM"HX;>*V4K#$D2YSA
M% 'Z5)7BUJGMJCJ6M<\JK4]I-SMN%%%%8&04444 %177_'M+_N'^52U%=?\
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M*MU4U3_CQE_#^8H M4M)2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH *J7'_']:?\#_E5NJMQ_P ?UI_P/^5 %JBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "JFJ?\ 'C+^'\Q5NJNJ?\>,
MOX?S% %FEI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKK
M_CVE_P!P_P JEJ*Z_P"/:7_</\J &V7_ !YP_P"X/Y5/4-G_ ,>D/^X/Y5-0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %2PZW'_79JMU4L/\
MEX_Z[-5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *>I?<@_Z
M[+5RJFH_=@_Z[+5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_/\ ^,^N_M%V_P 5/$\?AI/%)T%;Z067
MV2U9HO*S\NT[>17Z 4549<HFKGYE_P#"1_M3_P#//QE_X!M_\31_PD?[4_\
MSS\9?^ ;?_$U^FE%7[3R%R^9^9?_  D?[4__ #S\9?\ @&W_ ,31_P )'^U/
M_P \_&7_ (!M_P#$U^FE%'M/(.7S/S+_ .$C_:G_ .>?C+_P#;_XFC_A(_VI
M_P#GGXR_\ V_^)K]-**/:>0<OF?F7_PD?[4__//QE_X!M_\ $T?\)'^U/_SS
M\9?^ ;?_ !-?II11[3R#E\S\R_\ A(_VI_\ GGXR_P# -O\ XFC_ (2/]J?_
M )Y^,O\ P#;_ .)K]-**/:>0<OF?F7_PD?[4_P#SS\9?^ ;?_$T?\)'^U/\
M\\_&7_@&W_Q-?II11[3R#E\S\R_^$C_:G_YY^,O_  #;_P")H_X2/]J?_GGX
MR_\  -O_ (FOTTHH]IY!R^9^9?\ PD?[4_\ SS\9?^ ;?_$T?\)'^U/_ ,\_
M&7_@&W_Q-?II11[3R#E\S\R_^$C_ &I_^>?C+_P#;_XFC_A(_P!J?_GGXR_\
M V_^)K]-**/:>0<OF?F7_P )'^U/_P \_&7_ (!M_P#$T?\ "1_M3_\ //QE
M_P" ;?\ Q-?II2'H:/:>0<OF?F1#XC_:E\I=B>,2O;%FW_Q-2?\ "1_M3_\
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MW_Q-'_"1_M3_ ///QE_X!M_\37Z:44>T\@Y?,_,O_A(_VI_^>?C+_P  V_\
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M V_^)H_X2/\ :G_YY^,O_ -O_B:_32BCVGD'+YGYE_\ "1_M3_\ //QE_P"
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MCRGC'=SM_P!#;\?X:_3>JMQ_Q_6G_ _Y4>T\@Y?,_-7_ (2/]J?_ )Y^,O\
MP#;_ .)H_P"$C_:G_P">?C+_ , V_P#B:_32BCVGD'+YGYE_\)'^U/\ \\_&
M7_@&W_Q-'_"1_M3_ ///QE_X!M_\37Z:44>T\@Y?,_,O_A(_VI_^>?C+_P
MV_\ B:/^$C_:G_YY^,O_  #;_P")K]-**/:>0<OF?F7_ ,)'^U/_ ,\_&7_@
M&W_Q-'_"1_M3_P#//QE_X!M_\37Z:44>T\@Y?,_,O_A(_P!J?_GGXR_\ V_^
M)H_X2/\ :G_YY^,O_ -O_B:_32BCVGD'+YGYE_\ "1_M3_\ //QE_P" ;?\
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M,O\ P#;_ .)H_P"$C_:G_P">?C+_ , V_P#B:_32BCVGD'+YGYE_\)'^U/\
M\\_&7_@&W_Q-'_"1_M3_ ///QE_X!M_\37Z:44>T\@Y?,_,O_A(_VI_^>?C+
M_P  V_\ B:/^$C_:G_YY^,O_  #;_P")K]-**/:>0<OF?F7_ ,)'^U/_ ,\_
M&7_@&W_Q-'_"1_M3_P#//QE_X!M_\37Z:44>T\@Y?,_,O_A(_P!J?_GGXR_\
M V_^)H_X2/\ :G_YY^,O_ -O_B:_32BCVGD'+YGYE_\ "1_M3_\ //QE_P"
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MO_A(_P!J?_GGXR_\ V_^)H_X2/\ :G_YY^,O_ -O_B:_32BCVGD'+YGYE_\
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M@X_>K5NCVGD'+YGYE_\ "1_M3_\ //QE_P" ;?\ Q-'_  D?[4__ #S\9?\
M@&W_ ,37Z:44>T\@Y?,_,O\ X2/]J?\ YY^,O_ -O_B:/^$C_:G_ .>?C+_P
M#;_XFOTTHH]IY!R^9^9?_"1_M3_\\_&7_@&W_P 31_PD?[4__//QE_X!M_\
M$U^FE%'M/(.7S/S+_P"$C_:G_P">?C+_ , V_P#B:/\ A(_VI_\ GGXR_P#
M-O\ XFOTTHH]IY!R^9^9?_"1_M3_ ///QE_X!M_\31_PD?[4_P#SS\9?^ ;?
M_$U^FE%'M/(.7S/S+_X2/]J?_GGXR_\  -O_ (FC_A(_VI_^>?C+_P  V_\
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M5FW=W&%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH **** *EAUN/^NS5;JI8=;C_ *[-5N@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *>I?<@_P"NRU<JGJ7W(/\ KLM7* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HKF_$WQ(\*^"]2T[3]>\1:;H]]J+;+.WO;I(GN&R
M!A QR>2!QZU'XB^*'A#PCKUAHFM^)M+TG5[_ &_9;&\NTBEFRVT;5)R<GCZT
M =116'XN\<>'_ &D_P!I^)=:L="T[>(OM6H3K#&6.<+EB.>#Q[5F:A\7O!&E
M#1#>>+-'M1KBJ^F>=>QK]L4XP8LGY@<CIZT =?117FNL?M*?"OP_KCZ/J/Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV!QN[XKZ>HHI#"JFJ?\ 'C+^'\Q5NJFJ?\>,OX?S% %JEI*6@ HHHH ****
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M3??M3_%".\G1?%=P%5R !##Z_P"Y4'_#57Q2_P"ALN/^_,/_ ,17EVH_\?\
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M $-EQ_WYA_\ B*/^&JOBE_T-EQ_WYA_^(KR:BCZM0_Y]K[D']KYC_P!!,_\
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M1110 4444 %%%% !6_\ #_\ Y'OPY_V$;?\ ]&K6!6_\/_\ D>_#G_81M_\
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M=3+'O;^Z,D9/M5V@#PN;]B'X+7&H7]U)X)MW%[O,EL;F;[.C/]YDBW[4;W4
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MJ?6OGW]D'_DDOQ-_ZY'_ -$R5]*?#O2;S3_@WH.G75M)!?Q:-'#);N,.KB(
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M3>+>:G?QVJVT.44JB1QJ3@ $\]Z.@'K]%%%2,JZI_P @^X_W#5E?NBJVJ?\
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MC9%TO2;MK9'N&C.)W*\L5' 7I6%%\=/&O@_]BC58(=<U"\URT\62>$[?6/\
M6W@MA+C<I[R;054^X]*^O?A#\&)/A=XP^)&MOJBZ@OBW6!JB0K"4-L NW83D
M[OKQ7 :;^QKI\OP9\6> -:UV6Y76==GUVVU&SB\J2RF=]\94%CDJ?IG)Z47
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M O\ S/R5\E_[IH\E_P"Z:_6K_A ?#/\ T+VE_P#@''_\31_P@/AG_H7M+_\
M ./_ .)H_MR'_/M_>+_B'E?_ *"5_P" O_,_)7R7_NFCR7_NFOUJ_P"$!\,_
M]"]I?_@''_\ $T?\(#X9_P"A>TO_ , X_P#XFC^W(?\ /M_>'_$/*_\ T$K_
M ,!?^9^2ODO_ '31Y+_W37ZU?\(#X9_Z%[2__ ./_P")H_X0'PS_ -"]I?\
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M_;D/^?;^\/\ B'E?_H)7_@+_ ,S\E?)?^Z:/)?\ NFOUJ_X0'PS_ -"]I?\
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M0!;HHHH **** "N+^-&BWOB+X2^,-+TVW:ZO[S2[B""!,9D=HR HSZFNTHH
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M@ HHHH **** "BBB@ HHHH *BNO^/:7_ '#_ "J6HKK_ (]I?]P_RH ;9?\
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M *!^H_\ @<]'N![QB?\ #QCX9_\ 0/U[_P !HO\ XY1_P\8^&?\ T#]>_P#
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M8G_#QCX9_P#0/U[_ ,!HO_CE'_#QCX9_] _7O_ :+_XY6W_PP+\)/^@?J/\
MX'/1_P ,"_"3_H'ZC_X'/1[@>\8G_#QCX9_] _7O_ :+_P".4?\ #QCX9_\
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M_P" T7_QRM6^_8*^$L-I+(-/U'*KD?Z<]3#]@7X2?] _4?\ P.>CW ]XQ/\
MAXQ\,_\ H'Z]_P" T7_QRC_AXQ\,_P#H'Z]_X#1?_'*V_P#A@7X2?] _4?\
MP.>C_A@7X2?] _4?_ YZ/<#WC$_X>,?#/_H'Z]_X#1?_ !RC_AXQ\,_^@?KW
M_@-%_P#'*V_^&!?A)_T#]1_\#GH_X8%^$G_0/U'_ ,#GH]P/>,3_ (>,?#/_
M *!^O?\ @-%_\<H_X>,?#/\ Z!^O?^ T7_QRMO\ X8%^$G_0/U'_ ,#GH_X8
M%^$G_0/U'_P.>CW ]XQ/^'C'PS_Z!^O?^ T7_P <H_X>,?#/_H'Z]_X#1?\
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M ,#GH]P/>,3_ (>,?#/_ *!^O?\ @-%_\<H_X>,?#/\ Z!^O?^ T7_QRMO\
MX8%^$G_0/U'_ ,#GH_X8%^$G_0/U'_P.>CW ]XQ/^'C'PS_Z!^O?^ T7_P <
MH_X>,?#/_H'Z]_X#1?\ QRMO_A@7X2?] _4?_ YZ/^&!?A)_T#]1_P# YZ/<
M#WC$_P"'C'PS_P"@?KW_ (#1?_'*/^'C'PS_ .@?KW_@-%_\<K;_ .&!?A)_
MT#]1_P# YZ/^&!?A)_T#]1_\#GH]P/>,3_AXQ\,_^@?KW_@-%_\ '*/^'C'P
MS_Z!^O?^ T7_ ,<K;_X8%^$G_0/U'_P.>C_A@7X2?] _4?\ P.>CW ]XQ/\
MAXQ\,_\ H'Z]_P" T7_QRC_AXQ\,_P#H'Z]_X#1?_'*V_P#A@7X2?] _4?\
MP.>C_A@7X2?] _4?_ YZ/<#WC$_X>,?#/_H'Z]_X#1?_ !RC_AXQ\,_^@?KW
M_@-%_P#'*V_^&!?A)_T#]1_\#GH_X8%^$G_0/U'_ ,#GH]P/>,3_ (>,?#/_
M *!^O?\ @-%_\<H_X>,?#/\ Z!^O?^ T7_QRMO\ X8%^$G_0/U'_ ,#GH_X8
M%^$G_0/U'_P.>CW ]XQ/^'C'PS_Z!^O?^ T7_P <H_X>,?#/_H'Z]_X#1?\
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M\,"_"3_H'ZC_ .!ST?\ # OPD_Z!^H_^!ST>X'O&)_P\8^&?_0/U[_P&B_\
MCE0WG_!1+X:3VKQC3]>R<8_T:/U'_32NA_X8%^$G_0/U'_P.>H+[]@OX2PVK
MN-/U'(Q_R_/ZBCW ]XRQ_P %&/AI_P! _7O_  &B_P#CE'_#QCX9_P#0/U[_
M ,!HO_CE;?\ PP+\)/\ H'ZC_P"!ST?\,"_"3_H'ZC_X'/1[@>\8G_#QCX9_
M] _7O_ :+_XY1_P\8^&?_0/U[_P&B_\ CE;?_# OPD_Z!^H_^!ST?\,"_"3_
M *!^H_\ @<]'N![QB?\ #QCX9_\ 0/U[_P !HO\ XY1_P\8^&?\ T#]>_P#
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M+_XY1_P\8^&?_0/U[_P&B_\ CE;?_# OPD_Z!^H_^!ST?\,"_"3_ *!^H_\
M@<]'N![QB?\ #QCX9_\ 0/U[_P !HO\ XY1_P\8^&?\ T#]>_P# :+_XY6W_
M ,,"_"3_ *!^H_\ @<]'_# OPD_Z!^H_^!ST>X'O&)_P\8^&?_0/U[_P&B_^
M.4R;_@HK\-)(9%&GZ]EE(_X]H_3_ *Z5O?\ # OPD_Z!^H_^!STR;]@?X2I#
M(PT_4<A2?^/Y_2CW ]XP[?\ X**?#2.WC0Z?KV54 _Z-'_\ '*D_X>,?#/\
MZ!^O?^ T7_QRM>W_ &"?A+);QL=/U'+*#_Q_/4G_  P+\)/^@?J/_@<]'N![
MQB?\/&/AG_T#]>_\!HO_ (Y1_P /&/AG_P! _7O_  &B_P#CE;?_  P+\)/^
M@?J/_@<]'_# OPD_Z!^H_P#@<]'N![QB?\/&/AG_ - _7O\ P&B_^.4?\/&/
MAG_T#]>_\!HO_CE;?_# OPD_Z!^H_P#@<]'_  P+\)/^@?J/_@<]'N![QB?\
M/&/AG_T#]>_\!HO_ (Y1_P /&/AG_P! _7O_  &B_P#CE;?_  P+\)/^@?J/
M_@<]'_# OPD_Z!^H_P#@<]'N![QB?\/&/AG_ - _7O\ P&B_^.4?\/&/AG_T
M#]>_\!HO_CE;?_# OPD_Z!^H_P#@<]'_  P+\)/^@?J/_@<]'N![QB?\/&/A
MG_T#]>_\!HO_ (Y1_P /&/AG_P! _7O_  &B_P#CE;?_  P+\)/^@?J/_@<]
M'_# OPD_Z!^H_P#@<]'N![QB?\/&/AG_ - _7O\ P&B_^.4?\/&/AG_T#]>_
M\!HO_CE;?_# OPD_Z!^H_P#@<]'_  P+\)/^@?J/_@<]'N![QB?\/&/AG_T#
M]>_\!HO_ (Y1_P /&/AG_P! _7O_  &B_P#CE;?_  P+\)/^@?J/_@<]'_#
MOPD_Z!^H_P#@<]'N![QB?\/&/AG_ - _7O\ P&B_^.4?\/&/AG_T#]>_\!HO
M_CE;?_# OPD_Z!^H_P#@<]'_  P+\)/^@?J/_@<]'N![QSUK_P %$OAK#YV=
M/U_YI"P_T:/O_P!M*F_X>,?#/_H'Z]_X#1?_ !RM2U_8+^$LGFYT_4?ED*_\
M?SU/_P ,"_"3_H'ZC_X'/1[@>\8G_#QCX9_] _7O_ :+_P".4?\ #QCX9_\
M0/U[_P !HO\ XY6W_P ,"_"3_H'ZC_X'/1_PP+\)/^@?J/\ X'/1[@>\8G_#
MQCX9_P#0/U[_ ,!HO_CE'_#QCX9_] _7O_ :+_XY6W_PP+\)/^@?J/\ X'/1
M_P ,"_"3_H'ZC_X'/1[@>\8G_#QCX9_] _7O_ :+_P".4?\ #QCX9_\ 0/U[
M_P !HO\ XY6W_P ,"_"3_H'ZC_X'/1_PP+\)/^@?J/\ X'/1[@>\8G_#QCX9
M_P#0/U[_ ,!HO_CE'_#QCX9_] _7O_ :+_XY6W_PP+\)/^@?J/\ X'/1_P ,
M"_"3_H'ZC_X'/1[@>\8G_#QCX9_] _7O_ :+_P".4?\ #QCX9_\ 0/U[_P !
MHO\ XY6W_P ,"_"3_H'ZC_X'/1_PP+\)/^@?J/\ X'/1[@>\8G_#QCX9_P#0
M/U[_ ,!HO_CE'_#QCX9_] _7O_ :+_XY6W_PP+\)/^@?J/\ X'/1_P ,"_"3
M_H'ZC_X'/1[@>\8G_#QCX9_] _7O_ :+_P".4?\ #QCX9_\ 0/U[_P !HO\
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M\,_^@?KW_@-%_P#'*/\ AXQ\,_\ H'Z]_P" T7_QRMO_ (8%^$G_ $#]1_\
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M/P7L$%C.()!>QJC%BN[C:QXQ15SX2_!7PQ\$]+OK#PQ!/!;WDPGE$\QD)8#
MP3TXHJ':^@SO****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I&^Z:6D;[IH K:7_QXQ?C_ #-6JJZ7_P >,7X_S-6J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"KJG_(/N/]PU97[HJMJG_(/N/]PU97[HH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI
M<?\ ']:?\#_E5NJEQ_Q_6G_ _P"5 %NBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JFJ?\>,OX?S%6ZJ:I_P >,OX?S% %JEI*6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "HKK_CVE_W#_*I:BNO^/:7_
M '#_ "H ;9?\></^X/Y5/4%E_P ></\ N#^53T %%%% !1110 4444 %%%%
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M44 %%%% !1110 4444 %%%% !1110!5U(;K"<?[)H-\BG!'(XZC_ !IVH?\
M'E-_NUCS?ZU_]XT :W]H1^GZC_&C^T(_3]1_C6-10!L_VA'Z?J/\:/[0C]/U
M'^-8U% &S_:$?I^H_P :/[0C]/U'^-8U% &S_:$?I^H_QH_M"/T_4?XUC44
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M=CX GE;]H[]J13*Y5-/L]JECA?\ 0VZ>E,#ZQ;4;2-H5:ZA5IO\ 5@R %_\
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M<_\ @#+_ /$U^<-%']C8;N_O7^0?Z_9K_)#[G_\ )'Z/?\-D?"[_ *#-S_X
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MOVN/@K:^![^T\1:AH,UQ?ZIJ&ERK-%;6A4?(\BDCD]L]Z\^T%@?V:_VM,?\
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M^P?#]Y-8W@-N/.\R.0(VU=W(RPQS7B/P/^+7A'X,_%[]H2Q\::Y:^';M]?\
M[3AAOG\MKB Q\-$#_K#TX7)YKROPQJ4.K_\ !._XQW]L6\BZUV^GCWJ5;:UQ
M&PR.QP>E.P'TC;_M]?"M]:LK>YEUC3=%OMPM/$E]ISQ:;.RKED24]2.G3&:W
M_AO^U_X'^)GCR#PG:6VMZ1J-Y"UQILNLZ<UK#J42]7@9C\PQR,@9KR3]K+2+
M!?V;?@] +.W%NFM:&BQ",; K*-PQC&".OK74?M*6T-O^TI^SB\421LNKW42E
M5 PGD?='M[4: =O\2OVM/!_P[\83^%8=.U_Q=XAM8A->6'AG3FO'M$/(,I!
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M&$6,:=<6R/ %7A0$(P .WI5/0?AAX0\+G3SH_AC2-,;3PZV;6EE'&8 _W]A
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M_$=IH-G!K;Z*LC7RI^\+/!AFSZG)_.O(/V0?^22_$[_KD?\ T3)7T5\+U8?
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MHH IZE]R#_KLM7*IZE]R#_KLM7* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M9-#'<)LEC61/[KJ"*?10 BJ%4*  H&  .*9#;Q6ZD11)&"<D(H&:DHH$5_[/
MM?\ GVA_[]BIU4(H50%4< #H*6B@$DM@HHHH&%%%% !1110 4C?=-+2-]TT
M5M+_ ./&+\?YFK55=+_X\8OQ_F:M4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %75/^0?<?[AJROW15;5/^0?<?[AJROW10 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !52X_X_K3_ ('_ "JW52X_
MX_K3_@?\J +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M5-4_X\9?P_F*MU4U3_CQE_#^8H M4M)2T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5%=?\>TO^X?Y5+45U_Q[2_[A_E0 VR_X\X?]P?RJ>H+
M+_CSA_W!_*IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J6'6
MX_Z[-5NJEAUN/^NS5;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"GJ7W(/^NRU<JGJ7W(/^NRU<H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBO@[XQ?MT>/O /Q/\2>'=
M.TO1I;'3;U[>%YK>1G*J>"2' S^%5&+EL)NQ]XT5^;O_  \7^)?_ $!]!_\
M :7_ ..4?\/%_B7_ - ?0?\ P&E_^.5?LY"YD?I%17YN_P##Q?XE_P#0'T'_
M ,!I?_CE'_#Q?XE_] ?0?_ :7_XY1[.0<R/TBHK\W?\ AXO\2_\ H#Z#_P"
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M?_ :7_XY1_P\7^)?_0'T'_P&E_\ CE'LY!S(_2*BOS=_X>+_ !+_ .@/H/\
MX#2__'*/^'B_Q+_Z ^@_^ TO_P <H]G(.9'Z145^;O\ P\7^)?\ T!]!_P#
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M\/%_B7_T!]!_\!I?_CE'_#Q?XE_] ?0?_ :7_P".4>SD',C](J*_-W_AXO\
M$O\ Z ^@_P#@-+_\<H_X>+_$O_H#Z#_X#2__ !RCV<@YD?I%17YN_P##Q?XE
M_P#0'T'_ ,!I?_CE'_#Q?XE_] ?0?_ :7_XY1[.0<R/TBHK\W?\ AXO\2_\
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M?_ :7_XY1_P\7^)?_0'T'_P&E_\ CE'LY!S(_2*BOS=_X>+_ !+_ .@/H/\
MX#2__'*/^'B_Q+_Z ^@_^ TO_P <H]G(.9'Z145^;O\ P\7^)?\ T!]!_P#
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MB7_T!]!_\!I?_CE'_#Q?XE_] ?0?_ :7_P".4>SD',C](J*_-W_AXO\ $O\
MZ ^@_P#@-+_\<H_X>+_$O_H#Z#_X#2__ !RCV<@YD?I%17YN_P##Q?XE_P#0
M'T'_ ,!I?_CE'_#Q?XE_] ?0?_ :7_XY1[.0<R/TBHK\W?\ AXO\2_\ H#Z#
M_P" TO\ \<H_X>+_ !+_ .@/H/\ X#2__'*/9R#F1^D5%?F[_P /%_B7_P!
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M:7_</\J_.+_AXO\ $O\ Z ^@_P#@-+_\<ILG_!13XE2(RG1]"PPQ_P >TO\
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MI?\ XY1_P\7^)?\ T!]!_P# :7_XY3]G(.9'Z145^;O_  \7^)?_ $!]!_\
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MPH_X171?^@18_P#@,G^%:E% &7_PBNB_] BQ_P# 9/\ "C_A%=%_Z!%C_P"
MR?X5J44 9?\ PBNB_P#0(L?_  &3_"C_ (171?\ H$6/_@,G^%:E% &7_P (
MKHO_ $"+'_P&3_"C_A%=%_Z!%C_X#)_A6I10!E_\(KHO_0(L?_ 9/\*/^$5T
M7_H$6/\ X#)_A6I10!E_\(KHO_0(L?\ P&3_  H_X171?^@18_\ @,G^%:E%
M &7_ ,(KHO\ T"+'_P !D_PH_P"$5T7_ *!%C_X#)_A6I10!E_\ "*Z+_P!
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M"+'_ ,!D_P */^$5T7_H$6/_ (#)_A6I10!E_P#"*Z+_ - BQ_\  9/\*/\
MA%=%_P"@18_^ R?X5J44 9?_  BNB_\ 0(L?_ 9/\*/^$5T7_H$6/_@,G^%:
ME% &7_PBNB_] BQ_\!D_PH_X171?^@18_P#@,G^%:E% &7_PBNB_] BQ_P#
M9/\ "C_A%=%_Z!%C_P" R?X5J44 9?\ PBNB_P#0(L?_  &3_"C_ (171?\
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MPH_X171?^@18_P#@,G^%:E% &7_PBNB_] BQ_P# 9/\ "C_A%=%_Z!%C_P"
MR?X5J44 9?\ PBNB_P#0(L?_  &3_"C_ (171?\ H$6/_@,G^%:E% &7_P (
MKHO_ $"+'_P&3_"C_A%=%_Z!%C_X#)_A6I10!E_\(KHO_0(L?_ 9/\*/^$5T
M7_H$6/\ X#)_A6I10!E_\(KHO_0(L?\ P&3_  H_X171?^@18_\ @,G^%:E%
M &7_ ,(KHO\ T"+'_P !D_PH_P"$5T7_ *!%C_X#)_A6I10!E_\ "*Z+_P!
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M"+'_ ,!D_P */^$5T7_H$6/_ (#)_A6I10!E_P#"*Z+_ - BQ_\  9/\*/\
MA%=%_P"@18_^ R?X5J44 9?_  BNB_\ 0(L?_ 9/\*/^$5T7_H$6/_@,G^%:
ME% &7_PBNB_] BQ_\!D_PH_X171?^@18_P#@,G^%:E% &7_PBNB_] BQ_P#
M9/\ "C_A%=%_Z!%C_P" R?X5J44 9?\ PBNB_P#0(L?_  &3_"C_ (171?\
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MPH_X171?^@18_P#@,G^%:E% &7_PBNB_] BQ_P# 9/\ "C_A%=%_Z!%C_P"
MR?X5J44 9?\ PBNB_P#0(L?_  &3_"C_ (171?\ H$6/_@,G^%:E% &7_P (
MKHO_ $"+'_P&3_"C_A%=%_Z!%C_X#)_A6I10!E_\(KHO_0(L?_ 9/\*/^$5T
M7_H$6/\ X#)_A6I10!E_\(KHO_0(L?\ P&3_  H_X171?^@18_\ @,G^%:E%
M &7_ ,(KHO\ T"+'_P !D_PH_P"$5T7_ *!%C_X#)_A6I10!E_\ "*Z+_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<^OJ*^7_  '_ ,)?X/O+O6]5O=6LO!;>'[BYU">^UV/4YVE50RW%N!G:<9X
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MY[P#9G3_  EI]N=?D\3E%(_M61U9I_F/.5XXZ?A70U PHHHH **** "BBB@
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MA[X?73='LHM,@@AT7G3 B_\ 'FVPH&3T(!-='13NP/F?0?V4-3L;K0[6ZOM
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M:WZ**0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279782528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lyell Immunopharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1300510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Line</a></td>
<td class="text">201 Haskins Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">695-0677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LYEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,026,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001806952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279835312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 224,372<span></span>
</td>
<td class="nump">$ 123,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">371,376<span></span>
</td>
<td class="nump">516,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,662<span></span>
</td>
<td class="nump">11,143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">606,410<span></span>
</td>
<td class="nump">651,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">36,952<span></span>
</td>
<td class="nump">70,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">32,001<span></span>
</td>
<td class="nump">44,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">113,677<span></span>
</td>
<td class="nump">123,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">41,512<span></span>
</td>
<td class="nump">43,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">4,520<span></span>
</td>
<td class="nump">4,680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">835,354<span></span>
</td>
<td class="nump">937,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,805<span></span>
</td>
<td class="nump">3,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">24,832<span></span>
</td>
<td class="nump">28,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesCurrent', window );">Success payment liabilities</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">34,390<span></span>
</td>
<td class="nump">37,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">60,221<span></span>
</td>
<td class="nump">63,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,888<span></span>
</td>
<td class="nump">4,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">98,499<span></span>
</td>
<td class="nump">104,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized at June&#160;30, 2023 and December&#160;31, 2022; no shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000 shares authorized at June&#160;30, 2023 and December&#160;31, 2022; 251,027 and 249,567 shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,637,538<span></span>
</td>
<td class="nump">1,608,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,379)<span></span>
</td>
<td class="num">(7,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(898,329)<span></span>
</td>
<td class="num">(767,480)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">736,855<span></span>
</td>
<td class="nump">833,252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 835,354<span></span>
</td>
<td class="nump">$ 937,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279967136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">251,027,000<span></span>
</td>
<td class="nump">249,567,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">251,026,997<span></span>
</td>
<td class="nump">249,567,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820278503472">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 35,741<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 36,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,471<span></span>
</td>
<td class="nump">43,719<span></span>
</td>
<td class="nump">92,101<span></span>
</td>
<td class="nump">79,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,030<span></span>
</td>
<td class="nump">30,454<span></span>
</td>
<td class="nump">38,309<span></span>
</td>
<td class="nump">64,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(569)<span></span>
</td>
<td class="num">(1,171)<span></span>
</td>
<td class="num">(1,857)<span></span>
</td>
<td class="num">(2,293)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65,932<span></span>
</td>
<td class="nump">73,002<span></span>
</td>
<td class="nump">128,553<span></span>
</td>
<td class="nump">142,131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(65,905)<span></span>
</td>
<td class="num">(37,261)<span></span>
</td>
<td class="num">(128,461)<span></span>
</td>
<td class="num">(105,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,264<span></span>
</td>
<td class="nump">952<span></span>
</td>
<td class="nump">9,761<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(326)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,923)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,923)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,015<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="num">(2,388)<span></span>
</td>
<td class="nump">1,370<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63,890)<span></span>
</td>
<td class="num">(36,323)<span></span>
</td>
<td class="num">(130,849)<span></span>
</td>
<td class="num">(104,467)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,500<span></span>
</td>
<td class="num">(1,751)<span></span>
</td>
<td class="nump">5,220<span></span>
</td>
<td class="num">(6,728)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (62,390)<span></span>
</td>
<td class="num">$ (38,074)<span></span>
</td>
<td class="num">$ (125,629)<span></span>
</td>
<td class="num">$ (111,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute net loss per common share, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">250,204<span></span>
</td>
<td class="nump">246,312<span></span>
</td>
<td class="nump">249,899<span></span>
</td>
<td class="nump">245,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute net loss per common share, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">250,204<span></span>
</td>
<td class="nump">246,312<span></span>
</td>
<td class="nump">249,899<span></span>
</td>
<td class="nump">245,251<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)&#160;&#160;&#160;&#160;None of the revenue for the three and six months ended June&#160;30, 2023 was from a related-party. Substantially all of the revenue for the three and six months ended June&#160;30, 2022 was from a related-party.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279947008">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)&#160;&#160;&#160;&#160;None of the revenue for the three and six months ended June&#160;30, 2023 was from a related-party. Substantially all of the revenue for the three and six months ended June&#160;30, 2022 was from a related-party.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820278354352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 929,787<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 1,515,748<span></span>
</td>
<td class="num">$ (1,623)<span></span>
</td>
<td class="num">$ (584,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">4,125<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">44,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(6,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(104,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,467)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">868,042<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,565,197<span></span>
</td>
<td class="num">(8,351)<span></span>
</td>
<td class="num">(688,829)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">881,249<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,540,330<span></span>
</td>
<td class="num">(6,600)<span></span>
</td>
<td class="num">(652,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,323)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,323)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 868,042<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,565,197<span></span>
</td>
<td class="num">(8,351)<span></span>
</td>
<td class="num">(688,829)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">249,567,343<span></span>
</td>
<td class="nump">249,567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 833,252<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,608,306<span></span>
</td>
<td class="num">(7,599)<span></span>
</td>
<td class="num">(767,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">832,840<span></span>
</td>
<td class="nump">833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax</a></td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">28,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">5,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (130,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,849)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">251,026,997<span></span>
</td>
<td class="nump">251,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 736,855<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,637,538<span></span>
</td>
<td class="num">(2,379)<span></span>
</td>
<td class="num">(898,329)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">783,826<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">1,622,119<span></span>
</td>
<td class="num">(3,879)<span></span>
</td>
<td class="num">(834,439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted stock units, net of tax</a></td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (63,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,890)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">251,026,997<span></span>
</td>
<td class="nump">251,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 736,855<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 1,637,538<span></span>
</td>
<td class="num">$ (2,379)<span></span>
</td>
<td class="num">$ (898,329)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279012560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (130,849)<span></span>
</td>
<td class="num">$ (104,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">28,105<span></span>
</td>
<td class="nump">44,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">12,923<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">10,089<span></span>
</td>
<td class="nump">8,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization and accretion on marketable securities</a></td>
<td class="num">(3,925)<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_NonCashLeaseIncomeExpense', window );">Non-cash lease income</a></td>
<td class="num">(816)<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities', window );">Change in fair value of success payment liabilities</a></td>
<td class="num">(603)<span></span>
</td>
<td class="num">(264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on property and equipment disposals</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of equity warrant</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and other assets</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="num">(3,592)<span></span>
</td>
<td class="num">(7,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(225)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(85,373)<span></span>
</td>
<td class="num">(92,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,466)<span></span>
</td>
<td class="num">(16,903)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(141,815)<span></span>
</td>
<td class="num">(185,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">329,347<span></span>
</td>
<td class="nump">201,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">185,066<span></span>
</td>
<td class="num">(1,103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(119)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">5,012<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">100,820<span></span>
</td>
<td class="num">(88,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">123,834<span></span>
</td>
<td class="nump">294,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">224,654<span></span>
</td>
<td class="nump">206,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Represented by:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">224,372<span></span>
</td>
<td class="nump">205,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">224,654<span></span>
</td>
<td class="nump">206,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">5,215<span></span>
</td>
<td class="nump">5,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances', window );">Cash received for amounts related to tenant improvement allowances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 3,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for amounts related to tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_FairValueAdjustmentOfSuccessPaymentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of success payment liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_FairValueAdjustmentOfSuccessPaymentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_NonCashLeaseIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_NonCashLeaseIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represented by Cash and Cash Equivalents and Restricted Cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820284773344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lyell Immunopharma, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware in June 2018. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ex&#160;vivo</span> genetic and epigenetic T&#8209;cell reprogramming technologies. The Company&#8217;s primary activities since incorporation have been to develop T&#8209;cell therapies, perform research and development, acquire technology, enter into strategic collaboration and license arrangements, enable and execute manufacturing activities in support of its product candidate development efforts, organize and staff the Company, conduct business planning, establish its intellectual property portfolio, submit regulatory submissions and other preparations to initiate and execute clinical trials, raise capital and provide general and administrative support for these activities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820280985520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures typically included in the Company&#8217;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the periods presented, but are not necessarily indicative of results to be expected for any future annual or interim period. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company&#8217;s audited financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discovers and develops product candidates that involve experimental technologies. The product candidates may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources or from the issuance of equity or debt securities. The Company believes that its available cash, cash equivalents and marketable securities as of June&#160;30, 2023 will be adequate to fund its operations at least through the next 12&#160;months from the date these unaudited Condensed Consolidated Financial Statements are issued. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#8220;GSK&#160;Agreement&#8221;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#8220;GSK&#8221;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment increased revenue by $35.3&#160;million, decreased net loss by $35.3&#160;million and resulted in a $0.14 reduction in the Company&#8217;s basic and diluted net loss per common share for the three and six months ended June&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in bank accounts and is used as collateral associated with the Company&#8217;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#8209;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820274085664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration, and Success Payment Agreements</a></td>
<td class="text">icense, Collaboration and Success Payment Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fred Hutch</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a license agreement with Fred Hutchinson Cancer Center (&#8220;Fred Hutch&#8221;) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that grants the Company a worldwide, sublicensable license under certain patent rights (exclusive) and certain technology (non-exclusive) to research, develop and commercialize products and processes for all fields of use utilizing chimeric antigen receptors (&#8220;CARs&#8221;) and/or T-cell receptors (&#8220;TCRs&#8221;), subject to certain exceptions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay Fred Hutch annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company entered into a research and collaboration agreement with Fred Hutch (&#8220;Fred Hutch Collaboration Agreement&#8221;) focused on research and development of cancer immunotherapy products. The Company funded aggregate research performed by Fred Hutch of $12.0&#160;million under the Fred Hutch Collaboration Agreement, with the research conducted in accordance with a research plan and budget approved by the parties. The Fred Hutch Collaboration Agreement has a six-year term. The Company incurred $0.1&#160;million and $0.5&#160;million in expense in connection with the Fred Hutch Collaboration Agreement for the three months ended June&#160;30, 2023 and 2022, respectively, and $0.4&#160;million and $1.0&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, the Company granted Fred Hutch rights to certain success payments, pursuant to the terms of the Fred Hutch Collaboration Agreement. The potential payments for the Fred Hutch success payments are based on multiples of increased value ranging from 10x to 50x based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $1.83 per share issuance price of the Company&#8217;s Series A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The aggregate success payments to Fred Hutch are not to exceed $200.0&#160;million, which would only occur upon a 50x increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, such that Fred Hutch does not receive multiple success payments in connection with the same threshold. The term of the success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#8217;s IPO and each two-year anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of June&#160;30, 2023, no success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payment liability was estimated at fair value at inception and at each subsequent reporting period and the associated expense was accreted over the service period of the success payment obligations as research and development expense through 2022. As of December&#160;31, 2022, the Company&#8217;s associated success payment liability was fully accreted to fair value as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. For the three and six months ended June&#160;30, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other (expense) income, net, as the requisite service obligation had been met. The success payment liability was $1.9&#160;million and $2.5&#160;million as of June&#160;30, 2023 and December&#160;31, 2022, respectively. With respect to the Fred Hutch Collaboration Agreement success payment obligations, the Company recognized expense of $0.5&#160;million and $2.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and gains of $0.6&#160;million for both the six months ended June&#160;30, 2023 and 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stanford</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In 2019, the Company entered into a license agreement with The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;) to license specified patent rights. The Company is required to pay Stanford annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the date of the first commercial sale of a licensed product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments to Stanford of up to a maximum of $3.7&#160;million per target are payable upon achievement of certain specified clinical and regulatory milestones. The Company is also obligated to pay Stanford $2.5&#160;million collectively for all licensed products upon the achievement of a certain commercial milestone. Additionally, low single&#8209;digit tiered royalties based on annual net sales of the licensed products are payable to Stanford.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company entered into a research and collaboration agreement with Stanford (&#8220;Stanford Collaboration Agreement&#8221;), focused on research and development of cellular immunotherapy products. The Stanford Collaboration Agreement has a four-year term. The Company is committed to fund aggregate research performed by Stanford of $12.0&#160;million under the Stanford Collaboration Agreement, and the research will be conducted in accordance with a research plan and budget approved by the parties. The Company incurred $0.7&#160;million and $0.8&#160;million in expense in connection with the Stanford Collaboration Agreement for the three months ended June&#160;30, 2023 and 2022, respectively, and $1.5&#160;million for both the six months ended June&#160;30, 2023 and 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Success Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2020, the Company granted Stanford rights to certain success payments, pursuant to the terms of the Stanford Collaboration Agreement. The potential payments for the Stanford Collaboration Agreement success payments are based on multiples of increased value ranging from 10x to 50x based on a comparison of the per share fair market value of the Company&#8217;s common stock relative to the original $1.83 issuance price of the Company&#8217;s Series A convertible preferred stock, which converted into an equal number of shares of the Company&#8217;s common stock in connection with the Company&#8217;s IPO. The aggregate success payments to Stanford are not to exceed $200.0&#160;million, which would only occur upon a 50x increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, so that Stanford does not receive multiple success payments in connection with the same threshold. The term of each success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success payments will be owed if the per share fair value of the Company&#8217;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary of the Company&#8217;s IPO and each two-year anniversary of the Company&#8217;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of June&#160;30, 2023, no success payments have been incurred as the per share fair value of the Company&#8217;s common stock was below the price required for payment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of the success payments to Stanford as of June&#160;30, 2023 and December&#160;31, 2022 were $2.7&#160;million and $3.3&#160;million, respectively. The success payment liability is estimated at the fair value at inception and at each subsequent reporting period and the expense is accreted over the service period of the Stanford Collaboration Agreement as research and development expense. The success payment liability was $1.9&#160;million as of both June&#160;30, 2023 and December&#160;31, 2022. With respect to the Stanford Collaboration Agreement success payment obligations, the Company recognized expense of $0.6&#160;million and $1.4&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and expense of approximately zero and $0.4&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into the GSK Agreement with GSK for potential T&#8209;cell therapies that apply the Company&#8217;s platform technologies and cell therapy innovations with TCRs or CARs under distinct collaboration programs. The GSK Agreement defined two initial collaboration targets, LYL331 and LYL132, and allowed GSK to nominate seven additional targets through July 2024, though no additional targets were nominated over the life of the GSK Agreement. The Company was expected to perform research and development services for each selected target up until a defined point (the &#8220;GSK Option Point&#8221;), at which time GSK would decide whether or not to exercise an option to obtain a license from the Company (&#8220;License Option&#8221;) and take over the future development and commercialization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, GSK exercised the License Option on LYL331 (NY-ESO-1 TCR with c-Jun) and assumed sole responsibility for future development and commercialization of the program at its own cost and expense. The investigational new drug (&#8220;IND&#8221;) application for LYL132 was cleared in January 2022, though no patients were treated, and the IND for LYL331 was not submitted to the U.S. Food and Drug Administration. GSK terminated the GSK Agreement effective December&#160;24, 2022, and Lyell has also discontinued any further work on these programs. There are no future performance obligations associated with the GSK Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a non-refundable upfront payment of $45.0&#160;million under the GSK Agreement. In connection with the GSK Agreement, in May 2019, the Company also entered into a stock purchase agreement with GSK, pursuant to which the Company agreed to sell 30,253,189 shares of Series&#160;AA convertible preferred stock at a price of $6.78 per share, which was above the issuance date estimated fair value of $4.84 per share. The difference between the per share values resulted in $58.6&#160;million additional deemed consideration, bringing the total upfront consideration of the GSK Agreement to $103.6&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GSK Agreement was deemed to be within the scope of Accounting Standards Codification (&#8220;ASC&#8221;)&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, because GSK engaged the Company to initially provide research and development services, which were outputs of its ongoing activities, in exchange for consideration. In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the GSK Agreement due to GSK and the Company mutually agreeing to conclude research activities on an undisclosed target for hematological cancers. The change in estimate decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $35.3&#160;million, decreased net loss by $35.3&#160;million and resulted in a $0.14 reduction in the Company&#8217;s basic and diluted net loss per common share for the three and six months ended June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue related to the research and development services related to the two initial targets of zero and $35.7&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and zero and $36.3&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The Company had no deferred revenue related to the GSK Agreement as of both June&#160;30, 2023 and December&#160;31, 2022. As of June&#160;30, 2023 and December&#160;31, 2022, there were no contract assets or contract liabilities related to the license contract.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PACT</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a commitment agreement (&#8220;PACT Commitment Agreement&#8221;) with PACT Pharma, Inc. (&#8220;PACT&#8221;) to jointly develop and test a next generation personalized anti-cancer T-cell therapy against solid tumors. The Company paid PACT an upfront non-refundable payment of $50.0&#160;million upon execution of the PACT Commitment Agreement. In November 2020, the parties agreed to suspend research and development activity under the PACT Commitment Agreement, and neither party would be required to conduct any further work under the development plan (including manufacturing development) nor incur any financial obligations (including milestone payments) that might otherwise arise, for as long as the parties continued to negotiate in good faith to resolve the issues that had arisen between them relating to the PACT Commitment Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 in connection with the entry into the PACT Commitment Agreement, the Company also entered into a stock purchase agreement with PACT (&#8220;PACT SPA&#8221;), pursuant to which the Company purchased 17,806,901 shares of PACT Series&#160;C-1 convertible preferred stock at a purchase price of $2.81 per share. As of the purchase date, the estimated fair value of the Series&#160;C-1 convertible preferred stock was $2.05 per share, and the difference between the estimated fair value of the preferred stock as of the purchase date and the purchase price of $13.6&#160;million was deemed to be additional consideration for the PACT Commitment Agreement and recognized as research and development expense. As a result, the total upfront consideration paid in connection with the PACT Commitment Agreement was $63.6&#160;million and was included in research and development expenses. The remaining $36.4&#160;million associated with the PACT Series&#160;C-1 convertible preferred stock was recorded in other investments. In the fourth quarter of 2021, the Company fully impaired the remaining balance of $36.4&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company filed a demand for arbitration seeking, among other things, rescission of the PACT Commitment Agreement and the PACT SPA and recovery of the consideration paid thereunder. Arbitration hearings occurred in March and April 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;1, 2022, the Company entered into a settlement agreement with PACT, pursuant to which the parties agreed to resolve their outstanding legal dispute. In connection with the settlement agreement, the parties also entered into a stock purchase agreement, pursuant to which PACT issued shares of PACT&#8217;s Series&#160;D convertible preferred stock to the Company in exchange for the Company&#8217;s tender of its PACT Series&#160;C-1 convertible preferred stock and resolution of the arbitration. The issuance of PACT&#8217;s Series&#160;D convertible preferred stock, which are non-voting, have limited conversion rights and carry no right to appoint directors, resulted in the Company&#8217;s ownership increasing to approximately 80% of PACT&#8217;s fully diluted shares outstanding. The settlement agreement also included the termination of the PACT Commitment Agreement. The Company recorded a gain of $2.9&#160;million in October 2022 for the estimated fair value of the PACT Series&#160;D convertible preferred stock received as part of the settlement agreement. The PACT Series&#160;D convertible preferred stock was recorded at its estimated fair value as of the settlement date and was included in other investments in the Company&#8217;s Condensed Consolidated Balance Sheets. In connection with the preparation of the financial statements for the three and six months ended June 30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment, resulting in the impairment of the $2.9&#160;million PACT Series D convertible preferred stock investment. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details regarding the PACT investment impairment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279668864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text">Cash Equivalents and Marketable Securities<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">292,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">291,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">95,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">94,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">611,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,410)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">609,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200,910&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">371,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">609,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">277,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">135,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">221,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">702,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">107,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">516,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">70,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of securities held by the Company in an unrealized loss position for less than 12&#160;months were $261.7&#160;million and $287.8&#160;million as of June&#160;30, 2023 and December&#160;31, 2022, respectively. The fair values of securities held by the Company in an unrealized loss position for greater than 12&#160;months were $101.2&#160;million and $278.7&#160;million as of June&#160;30, 2023 and December&#160;31, 2022, respectively. As of June&#160;30, 2023 and December&#160;31, 2022, all of the Company&#8217;s marketable securities had a maturity date of two years or less, were available for use and were classified as available&#8209;for&#8209;sale. The Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before recovery of their amortized cost basis. The Company determined that there was no material change in the credit risk of the above investments as of both June&#160;30, 2023 and December&#160;31, 2022. As such, an allowance for credit losses has not been recognized. Gross realized gains and losses were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three and six months ended June&#160;30, 2023 and 2022 and as a result, amounts reclassified out of accumulated other comprehensive loss for the three and six months ended June&#160;30, 2023 and 2022 were also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note&#160;6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding cash equivalents and marketable securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820284903008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_OtherInvestmentsTextBlock', window );">Other Investments</a></td>
<td class="text">Other Investments<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company makes minority ownership strategic investments. As of June&#160;30, 2023 and December&#160;31, 2022, the aggregate carrying amounts of the Company&#8217;s strategic investments in non-publicly traded companies were $32.0&#160;million and $44.9&#160;million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of June&#160;30, 2023 and December&#160;31, 2022 were $17.9&#160;million and $5.0&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company received non-voting preferred stock pursuant to the settlement agreement with PACT (See Note 3, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company determined that PACT is a variable interest entity as PACT does not have sufficient equity at risk. The Company evaluated whether it was the primary beneficiary of PACT, including the Company&#8217;s ongoing rights and responsibilities, to assess whether the Company has the power to direct the activities of PACT. The Company&#8217;s only involvement in PACT is its PACT Series D convertible preferred stock investment, which are non-voting, have limited conversion rights and carry no right to appoint directors. Based on the above noted factors, the Company determined that it is not the primary beneficiary and does not consolidate PACT since it does not have the power to direct the activities that most significantly impact PACT&#8217;s economic performance. The Company does not </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have the ability to exercise significant influence over PACT and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounts for its investment in PACT preferred stock under the measurement alternative. The Company recognized its investment in PACT preferred stock at its estimated fair value of $2.9&#160;million on October&#160;1, 2022, which was included in the Company&#8217;s Consolidated Balance Sheets within other investments. The Company&#8217;s maximum exposure to loss from PACT is limited to the carrying value of its investment in PACT preferred stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of the financial statements for the three months ended June 30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for the Company&#8217;s PACT Series D convertible preferred stock investment. While there was no single event or factor, the Company considered PACT&#8217;s operating cash flow requirements over the next year, liquid asset balances to fund </span></div>those requirements and PACT&#8217;s inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of the investment and determined the fair value to be negligible and the impairment to be other&#8209;than&#8209;temporary in nature. As a result, the Company recorded a $2.9&#160;million impairment expense for the investment for the three and six months ended June&#160;30, 2023, which was recorded within impairment of other investments on the Condensed Consolidated Statement of Operations and Comprehensive Loss and as a reduction to the investment balance within other investments on the Condensed Consolidated Balance Sheet. In connection with the preparation of the financial statements for the three months ended March 31, 2023, the Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for one of the Company&#8217;s other investments with a carrying amount of $10.0&#160;million. While there was no single event or factor, the Company considered the underlying company&#8217;s operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying company&#8217;s inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of the investment and determined the fair value to be negligible and the impairment to be other-than-temporary in nature. As a result, the Company recorded a $10.0&#160;million impairment expense for the investment for the six months ended June&#160;30, 2023, which was recorded within impairment of other investments on the Condensed Consolidated Statement of Operations and Comprehensive Loss and as a reduction to the investment balance within other investments on the Condensed Consolidated Balance Sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_OtherInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_OtherInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820284706864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">291,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">291,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">94,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">94,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">492,268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">609,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">626,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Level&#160;2 marketable securities include U.S. Treasury securities, U.S. government agency securities and corporate debt securities. The Company&#8217;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services applied industry standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Level&#160;3 financial instruments fair values are estimated using valuation models, including Monte Carlo simulations for the Company&#8217;s success payment liabilities. Monte Carlo simulations model the future movement of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock prices based on several key variables combined with empirical knowledge of the process governing the behavior of the stock price. The following variables were incorporated in the estimated fair value of the success payment liabilities: fair value of the Company&#8217;s common stock, expected volatility, the risk-free interest rate and the estimated number and timing of valuation measurement dates on the basis of which payments may be triggered. The computation of expected volatility was estimated based on available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.36% - 5.26%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.58% - 4.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.96 - 4.47</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 4.97</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.36% - 5.26%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.58% - 4.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.96 - 6.25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 6.75</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes estimates and assumptions in determining the estimated success payment liabilities and associated changes in fair value. A small change in the valuation of the Company&#8217;s common stock may have a relatively large change in the estimated fair value of the success payment liability and associated changes in fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at June&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The changes in the fair value associated with the Fred Hutch success payment liabilities of approximately $(0.6) million are recorded in other&#160;(expense) income, net (See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). The changes in the fair value of approximately zero associated with the Stanford success payment liabilities are recorded as research and development expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company received non-voting Series D convertible preferred stock pursuant to the settlement agreement with PACT (See Note 3, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company determined the fair value of PACT was a fraction of the aggregate liquidation preference of the Company&#8217;s PACT Series D convertible preferred stock. The Company determined that the fair value of its investment in PACT preferred stock is approximated by the fair value of the PACT business since the Company is the only party invested in PACT Series D convertible preferred stock, the most senior class of stock issued by PACT, as of October 1, 2022. The fair value of PACT was estimated at $2.9&#160;million as of October 1, 2022 using the cost approach. Under this approach, the fair value of an asset is measured by the cost to reconstruct or replace such asset with another one of like utility. The fair value of PACT was estimated by using significant unobservable inputs, including an estimate of insignificant fair value associated with PACT intangible assets. Accordingly, the Company classified the fair value measurement of PACT Series D convertible preferred stock on October 1, 2022 as Level 3 under the fair value hierarchy. In connection with the preparation of the financial statements for the three and six months ended June 30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment, resulting in the impairment of the $2.9&#160;million PACT Series D convertible preferred stock investment. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details regarding the PACT investment impairment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820283849072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of June&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining six months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(23,065)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">66,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of June&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">60,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">66,074&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all operating leases were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $2.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $4.4&#160;million and $4.7&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June&#160;30, 2023 and 2022. Variable lease costs for operating leases were $1.4&#160;million and $1.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $2.8&#160;million and $2.5&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were 7.3&#160;and 7.8&#160;years as of June&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted-average discount rates for operating leases were 8.5% as of both June&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million for both the three months ended June&#160;30, 2023 and 2022, and $0.4&#160;million for both the six months ended June&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#8220;Sonoma&#8221;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended June&#160;30, 2023 and 2022 and $0.9&#160;million for both the six months ended June&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of June&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining six months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(23,065)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">66,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of June&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">60,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">66,074&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for all operating leases were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $2.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $4.4&#160;million and $4.7&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;minimis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June&#160;30, 2023 and 2022. Variable lease costs for operating leases were $1.4&#160;million and $1.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $2.8&#160;million and $2.5&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were 7.3&#160;and 7.8&#160;years as of June&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted-average discount rates for operating leases were 8.5% as of both June&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million for both the three months ended June&#160;30, 2023 and 2022, and $0.4&#160;million for both the six months ended June&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#8220;Sonoma&#8221;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended June&#160;30, 2023 and 2022 and $0.9&#160;million for both the six months ended June&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820283097072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 10.0&#160;million shares of preferred stock with a par value of $0.0001 per share. As of June&#160;30, 2023 and December&#160;31, 2022, no shares of preferred stock were outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 500.0&#160;million shares of common stock with a par value of $0.0001 per share. As of June&#160;30, 2023 and December&#160;31, 2022, there were 251,026,997 shares and 249,567,343 shares of the Company&#8217;s common stock outstanding, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;4, 2022, the Company entered into an Equity Distribution Agreement with Goldman Sachs &amp; Co. LLC (&#8220;Goldman Sachs&#8221;) and BofA Securities, Inc. (&#8220;BofA&#8221;, and together with Goldman Sachs, the &#8220;Agents&#8221;) with respect to an at-the-market offering program (the &#8220;Equity Distribution Agreement&#8221;). In accordance with the terms of the Equity Distribution Agreement, the Company may offer and sell from time to time through the Agents shares of the Company&#8217;s common stock having an aggregate offering amount of up to $200.0&#160;million (the &#8220;Placement Shares&#8221;). Sales of the Placement Shares, if any, will be made at prevailing market prices on Nasdaq at the time of sale, or as otherwise agreed with the Agents, by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule&#160;415 of the Securities Act of 1933, as amended. The Company will pay commissions to the Agents of up to 3.0% of the gross proceeds of the sale of the Placement Shares sold under the Equity Distribution Agreement and reimburse the Agents for certain expenses. Neither the Company nor the Agents are obligated to sell any shares and, to date, the Company has not made any sales under the Equity Distribution Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820278279632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;), which on the date of the underwriting agreement related to the Company&#8217;s IPO became effective with an initial reserve of 26,662,087 shares, plus any shares subject to outstanding awards granted under the 2018 Equity Incentive Plan (&#8220;2018 Plan&#8221;) that, on or after the effectiveness of the 2021 Plan, terminate or expire before exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved for issuance under the 2021 Plan automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1)&#160;5% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by the Company&#8217;s board of directors no later than December&#160;31 of the immediately preceding year. On January&#160;1, 2023, the Company reserved an additional 12,478,367 shares of common stock for issuance under the 2021 Plan representing 5% of the total common shares outstanding as of December&#160;31, 2022. Under the 2021 Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), stock appreciation rights, performance awards and other stock-based awards. Terms of stock awards, including vesting requirements, are determined by the Company&#8217;s board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2021 Plan. The term of any stock option granted under the 2021 Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years but may be granted with different vesting terms. In conjunction with adopting the 2021 Plan, the Company discontinued the 2018 Plan with respect to new equity awards.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, 25,280,983 shares were available for future issuance pursuant to the 2021 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company adopted the 2021 Employee Stock Purchase Plan (&#8220;2021 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#8217;s IPO with an initial reserve of 2,470,000 shares. The 2021 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their earnings, subject to plan limitations. Unless otherwise determined by the Company&#8217;s board of directors, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering or on the purchase date. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2021 ESPP automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (1)&#160;1% of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31 of the immediately preceding year, and (2)&#160;4,940,000 shares; provided, however, that the Company&#8217;s board of directors may act to provide a </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lesser increase in number of shares. The Company&#8217;s board of directors elected to reserve no additional shares under the 2021 ESPP for the year beginning January&#160;1, 2023. The Company may specify offerings with durations not more than 27&#160;months and may specify shorter purchase periods within each offering. Under the 2021 ESPP, 542,921 shares were issued for the three and six months ended June&#160;30, 2023 and 283,574&#160;shares were issued for the three and six months ended June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, 3,905,099 shares were available for future issuance pursuant to the 2021 ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company established the 2018&#160;Plan that provided for the grant of incentive stock options, non&#8209;statutory stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. Terms of stock awards, including vesting requirements, were determined by the board of directors or by a committee authorized by the Company&#8217;s board of directors, subject to provisions of the 2018&#160;Plan. The term of any stock option granted under the 2018&#160;Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years, but could have been granted with different vesting terms. Pursuant to the terms of the 2021&#160;Plan, any shares subject to outstanding options originally granted under the 2018&#160;Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof become available for issuance pursuant to awards granted under the 2021&#160;Plan. While no shares are available for future issuance under the 2018&#160;Plan, it continues to govern outstanding equity awards granted thereunder.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">14,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">28,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">44,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023, total stock-based compensation cost related to unvested awards not yet recognized was $81.6&#160;million, which is expected to be recognized over a remaining weighted-average period of 2.86 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">872,077&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,997,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(127,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(117,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of June&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,623,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">53,849,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.09&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">24,887&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,586,063</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(832,840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,959,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">58,642,597</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">26,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options exercisable as of June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">30,365,614</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">92.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">85.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr></table></div>The weighted-average grant date fair value of options granted for the six months ended June&#160;30, 2023 and 2022 were $1.72 per share and $4.27 per share, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820283110320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#8217;s potentially dilutive shares, which include unvested RSAs, unvested RSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Shares subject to options to purchase common stock, unvested RSAs and unvested RSUs were all excluded from consideration in the calculation of diluted net loss per share in all periods presented due to their anti-dilutive effects.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820285042240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into certain license and collaboration agreements, including those identified in Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial milestones. The Company&#8217;s </span></div>obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs, including termination of such agreements. Due to the nature of these agreements, the future potential payments are inherently uncertain, and accordingly no amounts had been recorded for the potential future achievement of these targets as of both June&#160;30, 2023 and December&#160;31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820284903008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-party Transactions</a></td>
<td class="text">Related-party Transactions<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a sublease with Sonoma (&#8220;Sonoma Sublease&#8221;), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr.&#160;Klausner, the Chair of the Company&#8217;s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $4.6&#160;million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both June&#160;30, 2023 and December&#160;31, 2022, there were accrued liabilities and other current liabilities of $0.5&#160;million, and as of June&#160;30, 2023 and December&#160;31, 2022, there were other non-current liabilities of $3.3&#160;million and $3.5&#160;million, respectively, in connection with the Sonoma Sublease. Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#8220;other operating income, net&#8221; such as common area maintenance charges. See Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more detail on the Sonoma Sublease.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma other operating income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma sublease income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was party to the GSK Agreement with GSK, which is a holder of more than 10% of the Company&#8217;s outstanding common stock. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span>. GSK terminated the GSK Agreement effective December&#160;24, 2022. The Company had no current or non-current deferred revenue in connection with the GSK Agreement as of both June&#160;30, 2023 and December&#160;31, 2022. Revenue recognized in connection with the GSK agreement was zero and $35.7&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and zero and $36.3&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820283825456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (63,890)<span></span>
</td>
<td class="num">$ (36,323)<span></span>
</td>
<td class="num">$ (130,849)<span></span>
</td>
<td class="num">$ (104,467)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820274025792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820280043696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidations</a></td>
<td class="text">All significant intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#8220;GSK&#160;Agreement&#8221;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#8220;GSK&#8221;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">Concentrations of Credit Risk and Off-balance Sheet RiskThe Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in bank accounts and is used as collateral associated with the Company&#8217;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#8209;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Off-balance Sheet Risk</a></td>
<td class="text">The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SignificantAccountingPoliciesPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SignificantAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SignificantAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820283943184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Aggregate Potential Success Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#8217;s discretion, publicly-tradeable shares of the Company&#8217;s common stock:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Multiple of initial equity value at issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">20x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">30x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">40x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">50x</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Per share common stock price required for payment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36.58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">54.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">73.15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">91.44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Aggregate success payment(s) (in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279810128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Fair Value and Amortized Cost of Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">292,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">291,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">95,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">94,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">611,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,410)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">609,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200,910&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">371,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">609,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">277,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">135,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">221,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">702,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">107,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">516,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">70,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Fair Value and Amortized Cost of Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">292,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">291,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">95,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">94,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">611,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,410)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">609,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">200,910&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">371,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">609,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">277,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(5,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">135,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">221,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">702,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(7,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Classified as:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">107,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">516,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">70,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820283574288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">291,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">291,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">94,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">94,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">106,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">116,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">492,268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">609,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">271,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">134,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">220,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">67,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">626,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">694,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Success payment liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Estimated Fair Value of Success Payment Liability Assumptions</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.36% - 5.26%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.58% - 4.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.96 - 4.47</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 4.97</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value of common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.36% - 5.26%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.58% - 4.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.96 - 6.25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.46 - 6.75</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Estimated Fair Value of Level 3 Financial Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at June&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The changes in the fair value associated with the Fred Hutch success payment liabilities of approximately $(0.6) million are recorded in other&#160;(expense) income, net (See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). The changes in the fair value of approximately zero associated with the Stanford success payment liabilities are recorded as research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Estimated Fair Value of Level 3 Financial Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3&#160;liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Success Payment<br/>Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,356&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Change in fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Balance at June&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The changes in the fair value associated with the Fred Hutch success payment liabilities of approximately $(0.6) million are recorded in other&#160;(expense) income, net (See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Success Payment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). The changes in the fair value of approximately zero associated with the Stanford success payment liabilities are recorded as research and development expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820281056320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Commitments, Including Expected Lease Incentives to be Received</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of June&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining six months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(23,065)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">66,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of June&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">60,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">66,074&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Lease Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s future minimum operating lease commitments, including expected lease incentives to be received, as of June&#160;30, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Year Ending December&#160;31:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2023 (remaining six months)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">11,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">12,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">35,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">89,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(23,065)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">66,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Reported as of June&#160;30, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">60,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">66,074&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820276846240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense by Classification</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">9,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">36,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">14,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">22,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">28,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">44,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Value at Grant<br/>Date Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">872,077&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,997,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(127,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">RSUs forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(117,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unvested RSUs as of June&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2,623,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">53,849,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.09&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">24,887&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">8,586,063</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(832,840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(2,959,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options outstanding as of June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">58,642,597</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">7.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">26,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Options exercisable as of June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">30,365,614</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">6.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">18,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">92.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">85.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820280038192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Total Income Attributable to Sonoma Sublease</a></td>
<td class="text">Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#8220;other operating income, net&#8221; such as common area maintenance charges. See Note&#160;7, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more detail on the Sonoma Sublease.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma other operating income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sonoma sublease income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820278271904">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 35,741<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 36,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (63,890)<span></span>
</td>
<td class="num">$ (36,323)<span></span>
</td>
<td class="num">$ (130,849)<span></span>
</td>
<td class="num">$ (104,467)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Adjustment To Revenue Related To Change In Estimate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)&#160;&#160;&#160;&#160;None of the revenue for the three and six months ended June&#160;30, 2023 was from a related-party. Substantially all of the revenue for the three and six months ended June&#160;30, 2022 was from a related-party.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820269551632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,471,000<span></span>
</td>
<td class="nump">$ 43,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,101,000<span></span>
</td>
<td class="nump">$ 79,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,923,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,923,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_LitigationSettlementPercentOfTotalEquityValue', window );">Ownership of fully diluted shares (as a percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_PACTPharmaIncMember', window );">PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyel_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Convertible preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments', window );">Annual license maintenance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments', window );">Aggregate research payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm', window );">Term of collaborative arrangement for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm', window );">Term of success payment agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate', window );">Trigger period from IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering', window );">Trigger period thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability', window );">Fair value of potential success payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (gain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600,000)<span></span>
</td>
<td class="num">(600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments', window );">Annual license maintenance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments', window );">Aggregate research payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm', window );">Term of collaborative arrangement for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm', window );">Term of success payment agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate', window );">Trigger period from IPO date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering', window );">Trigger period thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability', window );">Fair value of potential success payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (gain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability', window );">Success payment liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments', window );">Potential milestone payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments', window );">Potential milestone payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Adjustment To Revenue Related To Change In Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram', window );">Stock purchase agreement portion of transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember', window );">GSK | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | License | Series AA Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_StockPurchaseAgreementSharesSold', window );">Stock sold under stock purchase program (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,253,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_StockPurchaseAgreementSharesSoldPricePerShare', window );">Price per share of stock sold under stock purchase program (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_StockPurchaseAgreementFairValueOfStockPerShare', window );">Fair value per share of stock sold under stock purchase program (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Gain on other investments</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased', window );">Stock purchase agreement, stock purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,806,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare', window );">Stock purchase agreement, purchase price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare', window );">Stock purchase agreement, fair value per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice', window );">Additional purchase price consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Total upfront payment paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Other Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Strategic equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsResearchPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Research Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsResearchPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Research Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Additional Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Fair Value Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Stock Purchase Agreement, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_LitigationSettlementPercentOfTotalEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Percent Of Total Equity Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_LitigationSettlementPercentOfTotalEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Upfront Payments For Research And Development Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_StockPurchaseAgreementFairValueOfStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Fair Value Of Stock Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_StockPurchaseAgreementFairValueOfStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_StockPurchaseAgreementSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Shares Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_StockPurchaseAgreementSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_StockPurchaseAgreementSharesSoldPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Shares Sold, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_StockPurchaseAgreementSharesSoldPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_PACTPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_PACTPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyel_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyel_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_FredHutchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_FredHutchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_StanfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_StanfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyel_SeriesAAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyel_SeriesAAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=lyel_OtherInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=lyel_OtherInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820274191504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details) - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Ten Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Ten Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Twenty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Twenty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Thirty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Thirty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Forty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Forty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Fifty Times | Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Fifty Times | Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier', window );">Multiple of initial equity value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice', window );">Per share common stock price required for payment (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments', window );">Aggregate success payment(s) (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_FredHutchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_FredHutchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_StanfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_StanfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_TenTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_TenTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_TwentyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_TwentyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_ThirtyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_ThirtyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_FortyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_FortyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_EquityMultipleAxis=lyel_FiftyTimesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_EquityMultipleAxis=lyel_FiftyTimesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820269483488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">$ 224,372<span></span>
</td>
<td class="nump">$ 123,554<span></span>
</td>
<td class="nump">$ 205,739<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">611,617<span></span>
</td>
<td class="nump">702,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,410)<span></span>
</td>
<td class="num">(7,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale', window );">Fair Value</a></td>
<td class="nump">609,238<span></span>
</td>
<td class="nump">694,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">200,910<span></span>
</td>
<td class="nump">107,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">371,376<span></span>
</td>
<td class="nump">516,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">36,952<span></span>
</td>
<td class="nump">70,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">609,238<span></span>
</td>
<td class="nump">694,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">292,610<span></span>
</td>
<td class="nump">277,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,352)<span></span>
</td>
<td class="num">(5,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">291,289<span></span>
</td>
<td class="nump">271,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">95,331<span></span>
</td>
<td class="nump">135,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(820)<span></span>
</td>
<td class="num">(1,416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">94,511<span></span>
</td>
<td class="nump">134,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">106,706<span></span>
</td>
<td class="nump">221,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">106,468<span></span>
</td>
<td class="nump">220,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">116,970<span></span>
</td>
<td class="nump">67,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 116,970<span></span>
</td>
<td class="nump">$ 67,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Debt Securities, Available-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820278942032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value of securities held in a continuous unrealized loss position for less than twelve months</a></td>
<td class="nump">$ 261.7<span></span>
</td>
<td class="nump">$ 287.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value of securities held in a continuous unrealized loss position for greater than twelve months</a></td>
<td class="nump">$ 101.2<span></span>
</td>
<td class="nump">$ 278.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Maturity of marketable securities</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279939552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">$ 32,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">2,923<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">12,923<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount', window );">Cumulative impairments of strategic investments</a></td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment | PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820277877296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 609,238<span></span>
</td>
<td class="nump">$ 694,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">291,289<span></span>
</td>
<td class="nump">271,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">94,511<span></span>
</td>
<td class="nump">134,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">106,468<span></span>
</td>
<td class="nump">220,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">116,970<span></span>
</td>
<td class="nump">67,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">116,970<span></span>
</td>
<td class="nump">67,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">116,970<span></span>
</td>
<td class="nump">67,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">492,268<span></span>
</td>
<td class="nump">626,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">291,289<span></span>
</td>
<td class="nump">271,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">94,511<span></span>
</td>
<td class="nump">134,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">106,468<span></span>
</td>
<td class="nump">220,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure', window );">Success payment liabilities</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820274069424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liability Assumptions (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_FairValueOfSeriesAConvertiblePreferredStock', window );">Fair value of common stock Series A convertible preferred stock</a></td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">3.36<span></span>
</td>
<td class="nump">3.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">5.26<span></span>
</td>
<td class="nump">4.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.800<span></span>
</td>
<td class="nump">0.800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Expected term (in years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.96<span></span>
</td>
<td class="nump">0.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember', window );">Fred Hutch | Expected term (in years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">4.47<span></span>
</td>
<td class="nump">4.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_FairValueOfSeriesAConvertiblePreferredStock', window );">Fair value of common stock Series A convertible preferred stock</a></td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">3.36<span></span>
</td>
<td class="nump">3.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">5.26<span></span>
</td>
<td class="nump">4.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.800<span></span>
</td>
<td class="nump">0.800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Expected term (in years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">0.96<span></span>
</td>
<td class="nump">0.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember', window );">Stanford | Expected term (in years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_SuccessPaymentLiabilityMeasurementInput', window );">Success payment liability, measurement input (as a percent)</a></td>
<td class="nump">6.25<span></span>
</td>
<td class="nump">6.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_FairValueOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the Series A convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_FairValueOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_SuccessPaymentLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_SuccessPaymentLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lyel_FredHutchSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lyel_StanfordSuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279019056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_FredHutchMember', window );">Fred Hutch | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Success Payment Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (gain)</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="num">$ (600)<span></span>
</td>
<td class="num">$ (600)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_StanfordMember', window );">Stanford | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Success Payment Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain', window );">Success payment expense (gain)</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=lyel_SuccessPaymentLiabilityMember', window );">Success Payment Liabilities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Success Payment Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 3,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_FredHutchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_FredHutchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_StanfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_StanfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=lyel_SuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=lyel_SuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279018864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">$ 2,923<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,923<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember', window );">PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember', window );">Other Investment | PACT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Impairment of other investments</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_PACTPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lyel_OtherInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279987328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (remaining six months)</a></td>
<td class="nump">$ 5,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">11,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">11,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">12,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">12,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">35,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">89,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(23,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">66,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)</a></td>
<td class="nump">5,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">60,221<span></span>
</td>
<td class="nump">$ 63,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 66,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279896336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term of operating leases</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lyel_SouthSanFranciscoCaliforniaMember', window );">South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Sonoma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">$ 930<span></span>
</td>
<td class="nump">$ 931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lyel_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lyel_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_SonomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_SonomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820278139040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,026,997<span></span>
</td>
<td class="nump">249,567,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyel_GoldmanSachsAndBofAMember', window );">Goldman Sachs and BofA | At The Market Offering | Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering amount</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_PercentageOfCommissionFromEachSaleOfShares', window );">Percentage of commission from each sale of shares</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_PercentageOfCommissionFromEachSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Commission From Each Sale Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_PercentageOfCommissionFromEachSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_GoldmanSachsAndBofAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_GoldmanSachsAndBofAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lyel_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lyel_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyel_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyel_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820278173888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total stock-based compensation cost related to unvested awards not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period compensation cost to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="nump">$ 4.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,662,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Proportion of stock outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="nump">12,478,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding', window );">Increase in proportion of common shares reserved for future issuance (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,280,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,280,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,921<span></span>
</td>
<td class="nump">283,574<span></span>
</td>
<td class="nump">542,921<span></span>
</td>
<td class="nump">283,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Proportion of stock outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,905,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,905,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Purchase of common stock at discount (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employee purchase of shares, proportion of fair value (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable', window );">Maximum number of shares to be purchased under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod', window );">Maximum offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyel_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyel_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyel_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820283474848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 14,223<span></span>
</td>
<td class="nump">$ 22,410<span></span>
</td>
<td class="nump">$ 28,105<span></span>
</td>
<td class="nump">$ 44,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,279<span></span>
</td>
<td class="nump">4,195<span></span>
</td>
<td class="nump">9,891<span></span>
</td>
<td class="nump">7,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,944<span></span>
</td>
<td class="nump">$ 18,215<span></span>
</td>
<td class="nump">$ 18,214<span></span>
</td>
<td class="nump">$ 36,479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820274209088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Units (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at beginning of period (in shares) | shares</a></td>
<td class="nump">872,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares) | shares</a></td>
<td class="nump">1,997,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (in shares) | shares</a></td>
<td class="num">(127,886)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited or canceled (in shares) | shares</a></td>
<td class="num">(117,669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at end of period (in shares) | shares</a></td>
<td class="nump">2,623,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Value at Grant Date Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs vested (in dollars per share) | $ / shares</a></td>
<td class="nump">5.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs forfeited or canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">4.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820278506880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">53,849,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">8,586,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(832,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled or forfeited (in shares) | shares</a></td>
<td class="num">(2,959,671)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">58,642,597<span></span>
</td>
<td class="nump">53,849,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">30,365,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">5.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">4.74<span></span>
</td>
<td class="nump">$ 5.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding</a></td>
<td class="text">7 years 8 months 23 days<span></span>
</td>
<td class="text">7 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable</a></td>
<td class="text">6 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding | $</a></td>
<td class="nump">$ 26,401<span></span>
</td>
<td class="nump">$ 24,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercisable | $</a></td>
<td class="nump">$ 18,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820283966704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.09%<span></span>
</td>
<td class="nump">2.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.40%<span></span>
</td>
<td class="nump">85.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820279952448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">$ 24,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Sonoma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Minimum | Lyell Immunopharma | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_SonomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_SonomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lyel_LyellImmunopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lyel_LyellImmunopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139820277883856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income, net</a></td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 1,171<span></span>
</td>
<td class="nump">$ 1,857<span></span>
</td>
<td class="nump">$ 2,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Sonoma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income, net</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">$ 930<span></span>
</td>
<td class="nump">$ 931<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyel_SonomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyel_SonomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>lyel-20230630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lyel="http://lyell.com/20230630"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lyel-20230630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">lyel:AdjustmentToRevenueRelatedToChangeInEstimateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">lyel:AdjustmentToRevenueRelatedToChangeInEstimateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:FredHutchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TenTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:TwentyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:ThirtyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FortyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lyel:EquityMultipleAxis">lyel:FiftyTimesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyel:SeriesAAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:FredHutchSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lyel:StanfordSuccessPaymentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">lyel:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:PACTPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lyel:OtherInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lyel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GoldmanSachsAndBofAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyel:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyel:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-04</startDate>
            <endDate>2022-08-04</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyel:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:SonomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lyel:LyellImmunopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lyel:GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyel:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001806952</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40502</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Lyell Immunopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">83-1300510</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">201 Haskins Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">695-0677</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">LYEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">251026997</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">224372000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">123554000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">371376000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">516598000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">10662000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">11143000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">606410000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">651295000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">282000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">280000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">36952000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">70117000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherInvestments contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">32001000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">44924000</us-gaap:OtherInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">113677000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">123023000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">41512000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">43242000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">4520000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">4680000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">835354000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">937561000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">5805000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">3917000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">24832000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">28755000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <lyel:SuccessPaymentLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">3753000</lyel:SuccessPaymentLiabilitiesCurrent>
    <lyel:SuccessPaymentLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">4356000</lyel:SuccessPaymentLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">34390000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">37028000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">60221000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">63168000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">3888000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">4113000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">98499000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">104309000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-66" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-68"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-69"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-70" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-71" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="-3" id="f-72" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="-3" id="f-73" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-74" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-75" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-80" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-81" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-82" unitRef="shares">251027000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-83" unitRef="shares">251027000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-84" unitRef="shares">249567000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-85" unitRef="shares">249567000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-86" unitRef="usd">25000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">25000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-88" unitRef="usd">1637538000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">1608306000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">-2379000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">-7599000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">-898329000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">-767480000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">736855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">833252000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">835354000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">937561000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">27000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">35741000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">92000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-3" id="f-101" unitRef="usd">36294000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">47471000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-103" unitRef="usd">43719000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">92101000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-105" unitRef="usd">79549000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">19030000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-107" unitRef="usd">30454000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">38309000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-109" unitRef="usd">64875000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">569000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-6" decimals="-3" id="f-111" unitRef="usd">1171000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">1857000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-7" decimals="-3" id="f-113" unitRef="usd">2293000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">65932000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">73002000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">128553000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-117" unitRef="usd">142131000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">-65905000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">-37261000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-128461000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-121" unitRef="usd">-105837000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">5264000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">952000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">9761000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-7" decimals="-3" id="f-125" unitRef="usd">1349000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-126" unitRef="usd">-326000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">-14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">774000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-129" unitRef="usd">21000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-5" decimals="-3" id="f-130" unitRef="usd">2923000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">12923000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-7" decimals="-3" id="f-133" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-134" unitRef="usd">2015000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">938000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-2388000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-137" unitRef="usd">1370000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-138" unitRef="usd">-63890000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">-36323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-130849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-141" unitRef="usd">-104467000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-142" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">-1751000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">5220000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-7" decimals="-3" id="f-145" unitRef="usd">-6728000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-146" unitRef="usd">-62390000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">-38074000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">-125629000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-149" unitRef="usd">-111195000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-154"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-155"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-156"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-157"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-158" unitRef="shares">250204000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-159" unitRef="shares">250204000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-160" unitRef="shares">246312000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-161" unitRef="shares">246312000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-162" unitRef="shares">249899000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-163" unitRef="shares">249899000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-164" unitRef="shares">245251000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-165" unitRef="shares">245251000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:Revenues contextRef="c-8" decimals="-3" id="f-166" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-3" id="f-167" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-10" decimals="-3" id="f-168" unitRef="shares">249609000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-169" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-170" unitRef="usd">1622119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-171" unitRef="usd">-3879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-172" unitRef="usd">-834439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-173" unitRef="usd">783826000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-15" decimals="-3" id="f-174" unitRef="shares">833000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-175" unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-176" unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-15" decimals="-3" id="f-177" unitRef="shares">543000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-16" decimals="-3" id="f-178" unitRef="usd">1163000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-5" decimals="-3" id="f-179" unitRef="usd">1163000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-15" decimals="-3" id="f-180" unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-16" decimals="-3" id="f-181" unitRef="usd">-50000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-5" decimals="-3" id="f-182" unitRef="usd">-50000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-183" unitRef="usd">14223000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-184" unitRef="usd">14223000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-17" decimals="-3" id="f-185" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-186" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-187" unitRef="usd">-63890000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-188" unitRef="usd">-63890000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-19" decimals="-3" id="f-189" unitRef="shares">251027000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-190" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-191" unitRef="usd">1637538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-192" unitRef="usd">-2379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-193" unitRef="usd">-898329000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-194" unitRef="usd">736855000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-23" decimals="-3" id="f-195" unitRef="shares">249567000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-196" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-197" unitRef="usd">1608306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-198" unitRef="usd">-7599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-199" unitRef="usd">-767480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-200" unitRef="usd">833252000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-27" decimals="-3" id="f-201" unitRef="shares">833000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-28" decimals="-3" id="f-202" unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-27" decimals="-3" id="f-204" unitRef="shares">543000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-28" decimals="-3" id="f-205" unitRef="usd">1163000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">1163000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-27" decimals="-3" id="f-207" unitRef="shares">84000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-28" decimals="-3" id="f-208" unitRef="usd">-119000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">-119000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-28" decimals="-3" id="f-210" unitRef="usd">28105000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">28105000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-29" decimals="-3" id="f-212" unitRef="usd">5220000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">5220000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-30" decimals="-3" id="f-214" unitRef="usd">-130849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-130849000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-19" decimals="-3" id="f-216" unitRef="shares">251027000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-217" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-218" unitRef="usd">1637538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-219" unitRef="usd">-2379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-220" unitRef="usd">-898329000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-221" unitRef="usd">736855000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-3" id="f-222" unitRef="shares">245423000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-223" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-224" unitRef="usd">1540330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-225" unitRef="usd">-6600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-226" unitRef="usd">-652506000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-227" unitRef="usd">881249000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-36" decimals="-3" id="f-228" unitRef="shares">428000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-37" decimals="-3" id="f-229" unitRef="usd">1570000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-230" unitRef="usd">1570000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-36" decimals="-3" id="f-231" unitRef="shares">284000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-37" decimals="-3" id="f-232" unitRef="usd">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-6" decimals="-3" id="f-233" unitRef="usd">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-36" decimals="-3" id="f-234" unitRef="shares">975000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-3" id="f-235" unitRef="usd">22410000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-236" unitRef="usd">22410000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-3" id="f-237" unitRef="usd">-1751000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-238" unitRef="usd">-1751000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-39" decimals="-3" id="f-239" unitRef="usd">-36323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-240" unitRef="usd">-36323000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-40" decimals="-3" id="f-241" unitRef="shares">247110000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-242" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-243" unitRef="usd">1565197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-244" unitRef="usd">-8351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-245" unitRef="usd">-688829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-246" unitRef="usd">868042000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-45" decimals="-3" id="f-247" unitRef="shares">242738000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-248" unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-249" unitRef="usd">1515748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-250" unitRef="usd">-1623000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-251" unitRef="usd">-584362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-252" unitRef="usd">929787000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-50" decimals="-3" id="f-253" unitRef="shares">2138000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-50" decimals="-3" id="f-254" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-51" decimals="-3" id="f-255" unitRef="usd">4124000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-7" decimals="-3" id="f-256" unitRef="usd">4125000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-50" decimals="-3" id="f-257" unitRef="shares">284000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-51" decimals="-3" id="f-258" unitRef="usd">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-7" decimals="-3" id="f-259" unitRef="usd">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-50" decimals="-3" id="f-260" unitRef="shares">1950000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-51" decimals="-3" id="f-261" unitRef="usd">44438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">44438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-52" decimals="-3" id="f-263" unitRef="usd">-6728000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-264" unitRef="usd">-6728000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-53" decimals="-3" id="f-265" unitRef="usd">-104467000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">-104467000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-40" decimals="-3" id="f-267" unitRef="shares">247110000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-268" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-269" unitRef="usd">1565197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-270" unitRef="usd">-8351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-271" unitRef="usd">-688829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-272" unitRef="usd">868042000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">-130849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-274" unitRef="usd">-104467000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">28105000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-276" unitRef="usd">44438000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">12923000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-7" decimals="-3" id="f-278" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">10089000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-280" unitRef="usd">8358000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">3925000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-7" decimals="-3" id="f-282" unitRef="usd">-706000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <lyel:NonCashLeaseIncomeExpense contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">816000</lyel:NonCashLeaseIncomeExpense>
    <lyel:NonCashLeaseIncomeExpense contextRef="c-7" decimals="-3" id="f-284" unitRef="usd">655000</lyel:NonCashLeaseIncomeExpense>
    <lyel:FairValueAdjustmentOfSuccessPaymentLiabilities contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">-603000</lyel:FairValueAdjustmentOfSuccessPaymentLiabilities>
    <lyel:FairValueAdjustmentOfSuccessPaymentLiabilities contextRef="c-7" decimals="-3" id="f-286" unitRef="usd">-264000</lyel:FairValueAdjustmentOfSuccessPaymentLiabilities>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">-430000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-7" decimals="-3" id="f-288" unitRef="usd">-84000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-7" decimals="-3" id="f-290" unitRef="usd">-14000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">-641000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">-9000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">2449000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-294" unitRef="usd">1170000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">-3592000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-7" decimals="-3" id="f-296" unitRef="usd">-7159000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-298" unitRef="usd">-36300000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-300" unitRef="usd">2135000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">-225000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-7" decimals="-3" id="f-302" unitRef="usd">-226000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">-85373000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-304" unitRef="usd">-92185000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">2466000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-306" unitRef="usd">16903000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">141815000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-7" decimals="-3" id="f-308" unitRef="usd">185855000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">329347000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-7" decimals="-3" id="f-310" unitRef="usd">201655000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">185066000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-312" unitRef="usd">-1103000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">83000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-314" unitRef="usd">4125000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">1163000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-7" decimals="-3" id="f-316" unitRef="usd">887000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">119000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-7" decimals="-3" id="f-318" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">1127000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-320" unitRef="usd">5012000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">100820000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-322" unitRef="usd">-88276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-323" unitRef="usd">123834000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-49" decimals="-3" id="f-324" unitRef="usd">294294000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-325" unitRef="usd">224654000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-3" id="f-326" unitRef="usd">206018000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-327" unitRef="usd">224372000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-44" decimals="-3" id="f-328" unitRef="usd">205739000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-329" unitRef="usd">282000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-44" decimals="-3" id="f-330" unitRef="usd">279000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-331" unitRef="usd">224654000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-3" id="f-332" unitRef="usd">206018000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">5215000</lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-7" decimals="-3" id="f-334" unitRef="usd">5399000</lyel:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">0</lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances>
    <lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances contextRef="c-7" decimals="-3" id="f-336" unitRef="usd">2042000</lyel:CashReceivedForAmountsRelatedToTenantImprovementAllowances>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">33000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-338" unitRef="usd">3553000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-339">Organization&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lyell Immunopharma, Inc. (the &#x201c;Company&#x201d;) was incorporated in Delaware in June 2018. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a clinical-stage cell therapy company advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ex&#160;vivo&lt;/span&gt; genetic and epigenetic T&#x2011;cell reprogramming technologies. The Company&#x2019;s primary activities since incorporation have been to develop T&#x2011;cell therapies, perform research and development, acquire technology, enter into strategic collaboration and license arrangements, enable and execute manufacturing activities in support of its product candidate development efforts, organize and staff the Company, conduct business planning, establish its intellectual property portfolio, submit regulatory submissions and other preparations to initiate and execute clinical trials, raise capital and provide general and administrative support for these activities.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-340">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures typically included in the Company&#x2019;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#x2019;s financial position, results of operations and cash flows for the periods presented, but are not necessarily indicative of results to be expected for any future annual or interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Management&#x2019;s Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company discovers and develops product candidates that involve experimental technologies. The product candidates may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources or from the issuance of equity or debt securities. The Company believes that its available cash, cash equivalents and marketable securities as of June&#160;30, 2023 will be adequate to fund its operations at least through the next 12&#160;months from the date these unaudited Condensed Consolidated Financial Statements are issued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#x201c;GSK&#160;Agreement&#x201d;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#x201c;GSK&#x201d;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This adjustment increased revenue by $35.3&#160;million, decreased net loss by $35.3&#160;million and resulted in a $0.14 reduction in the Company&#x2019;s basic and diluted net loss per common share for the three and six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in bank accounts and is used as collateral associated with the Company&#x2019;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#x2011;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-341">Basis of PresentationThe accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-342">All significant intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-343">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect reported amounts and related disclosures. Specific accounts that require management estimates include, but are not limited to, stock-based compensation, valuation of success payments, valuation of other investments, revenue recognition and accrued expenses. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (&#x201c;GSK&#160;Agreement&#x201d;) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,&#160;&#x201c;GSK&#x201d;). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:Revenues contextRef="c-54" decimals="-5" id="f-344" unitRef="usd">35300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-55" decimals="-5" id="f-345" unitRef="usd">35300000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss contextRef="c-54" decimals="-5" id="f-346" unitRef="usd">35300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-55" decimals="-5" id="f-347" unitRef="usd">35300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-54"
      decimals="2"
      id="f-348"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-55"
      decimals="2"
      id="f-349"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-55"
      decimals="2"
      id="f-350"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-54"
      decimals="2"
      id="f-351"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-352">Concentrations of Credit Risk and Off-balance Sheet RiskThe Company maintains its cash, cash equivalents and restricted cash with high quality, accredited financial institutions. Restricted cash is cash held in bank accounts and is used as collateral associated with the Company&#x2019;s corporate credit card program. Cash, cash equivalents and restricted cash amounts, at times, may exceed federally insured limits. The Company also makes short-term investments in money market funds, U.S. Treasury securities, U.S. government agency securities and corporate debt securities, which can be subject to certain credit risk. However, the Company mitigates the risks by investing in high&#x2011;grade instruments, limiting exposure to any one issuer or type of investment and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock contextRef="c-1" id="f-353">The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <lyel:SignificantAccountingPoliciesPolicyTextBlock contextRef="c-1" id="f-354">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the significant accounting policies from the Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</lyel:SignificantAccountingPoliciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-355">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-356">icense, Collaboration and Success Payment Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fred Hutch&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In 2018, the Company entered into a license agreement with Fred Hutchinson Cancer Center (&#x201c;Fred Hutch&#x201d;) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that grants the Company a worldwide, sublicensable license under certain patent rights (exclusive) and certain technology (non-exclusive) to research, develop and commercialize products and processes for all fields of use utilizing chimeric antigen receptors (&#x201c;CARs&#x201d;) and/or T-cell receptors (&#x201c;TCRs&#x201d;), subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay Fred Hutch annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the first commercial sale of a licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In 2018, the Company entered into a research and collaboration agreement with Fred Hutch (&#x201c;Fred Hutch Collaboration Agreement&#x201d;) focused on research and development of cancer immunotherapy products. The Company funded aggregate research performed by Fred Hutch of $12.0&#160;million under the Fred Hutch Collaboration Agreement, with the research conducted in accordance with a research plan and budget approved by the parties. The Fred Hutch Collaboration Agreement has a six-year term. The Company incurred $0.1&#160;million and $0.5&#160;million in expense in connection with the Fred Hutch Collaboration Agreement for the three months ended June&#160;30, 2023 and 2022, respectively, and $0.4&#160;million and $1.0&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Success Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In 2018, the Company granted Fred Hutch rights to certain success payments, pursuant to the terms of the Fred Hutch Collaboration Agreement. The potential payments for the Fred Hutch success payments are based on multiples of increased value ranging from 10x to 50x based on a comparison of the per share fair market value of the Company&#x2019;s common stock relative to the original $1.83 per share issuance price of the Company&#x2019;s Series A convertible preferred stock, which converted into an equal number of shares of the Company&#x2019;s common stock in connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;). The aggregate success payments to Fred Hutch are not to exceed $200.0&#160;million, which would only occur upon a 50x increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, such that Fred Hutch does not receive multiple success payments in connection with the same threshold. The term of the success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success payments will be owed if the per share fair value of the Company&#x2019;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year anniversary of the Company&#x2019;s IPO and each two-year anniversary of the Company&#x2019;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of June&#160;30, 2023, no success payments have been incurred as the per share fair value of the Company&#x2019;s common stock was below the price required for payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success payment liability was estimated at fair value at inception and at each subsequent reporting period and the associated expense was accreted over the service period of the success payment obligations as research and development expense through 2022. As of December&#160;31, 2022, the Company&#x2019;s associated success payment liability was fully accreted to fair value as Fred Hutch had provided the requisite service obligation to earn the potential success payment consideration under the continued collaboration. For the three and six months ended June&#160;30, 2023 and future periods, the change in the Fred Hutch success payment liability fair value is recognized in other (expense) income, net, as the requisite service obligation had been met. The success payment liability was $1.9&#160;million and $2.5&#160;million as of June&#160;30, 2023 and December&#160;31, 2022, respectively. With respect to the Fred Hutch Collaboration Agreement success payment obligations, the Company recognized expense of $0.5&#160;million and $2.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and gains of $0.6&#160;million for both the six months ended June&#160;30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stanford&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In 2019, the Company entered into a license agreement with The Board of Trustees of the Leland Stanford Junior University (&#x201c;Stanford&#x201d;) to license specified patent rights. The Company is required to pay Stanford annual license maintenance payments of $50,000 on the second anniversary of the effective date, and each anniversary of the effective date thereafter until the date of the first commercial sale of a licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone payments to Stanford of up to a maximum of $3.7&#160;million per target are payable upon achievement of certain specified clinical and regulatory milestones. The Company is also obligated to pay Stanford $2.5&#160;million collectively for all licensed products upon the achievement of a certain commercial milestone. Additionally, low single&#x2011;digit tiered royalties based on annual net sales of the licensed products are payable to Stanford.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In October 2020, the Company entered into a research and collaboration agreement with Stanford (&#x201c;Stanford Collaboration Agreement&#x201d;), focused on research and development of cellular immunotherapy products. The Stanford Collaboration Agreement has a four-year term. The Company is committed to fund aggregate research performed by Stanford of $12.0&#160;million under the Stanford Collaboration Agreement, and the research will be conducted in accordance with a research plan and budget approved by the parties. The Company incurred $0.7&#160;million and $0.8&#160;million in expense in connection with the Stanford Collaboration Agreement for the three months ended June&#160;30, 2023 and 2022, respectively, and $1.5&#160;million for both the six months ended June&#160;30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Success Payments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In October 2020, the Company granted Stanford rights to certain success payments, pursuant to the terms of the Stanford Collaboration Agreement. The potential payments for the Stanford Collaboration Agreement success payments are based on multiples of increased value ranging from 10x to 50x based on a comparison of the per share fair market value of the Company&#x2019;s common stock relative to the original $1.83 issuance price of the Company&#x2019;s Series A convertible preferred stock, which converted into an equal number of shares of the Company&#x2019;s common stock in connection with the Company&#x2019;s IPO. The aggregate success payments to Stanford are not to exceed $200.0&#160;million, which would only occur upon a 50x increase in value. Each threshold is associated with a success payment, ascending from $10.0&#160;million at $18.29 per share to $200.0&#160;million at $91.44 per share, payable if such threshold is reached during the measurement period. Any previous success payments made are credited against the success payment owed as of any valuation date, so that Stanford does not receive multiple success payments in connection with the same threshold. The term of each success payment agreement ends on the earlier to occur of (i)&#160;the nine-year anniversary of the date of the agreement and (ii)&#160;a change in control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success payments will be owed if the per share fair value of the Company&#x2019;s common stock on the contractually specified valuation measurement dates during the term of the success payment agreement equals or exceeds the above outlined multiples. The valuation measurement dates are triggered by the following events: the one-year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;anniversary of the Company&#x2019;s IPO and each two-year anniversary of the Company&#x2019;s IPO thereafter, the closing of a change in control transaction and the last day of the term of the success payment agreement, unless the term has ended due to the closing of a change of control transaction. As of June&#160;30, 2023, no success payments have been incurred as the per share fair value of the Company&#x2019;s common stock was below the price required for payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of the success payments to Stanford as of June&#160;30, 2023 and December&#160;31, 2022 were $2.7&#160;million and $3.3&#160;million, respectively. The success payment liability is estimated at the fair value at inception and at each subsequent reporting period and the expense is accreted over the service period of the Stanford Collaboration Agreement as research and development expense. The success payment liability was $1.9&#160;million as of both June&#160;30, 2023 and December&#160;31, 2022. With respect to the Stanford Collaboration Agreement success payment obligations, the Company recognized expense of $0.6&#160;million and $1.4&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and expense of approximately zero and $0.4&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into the GSK Agreement with GSK for potential T&#x2011;cell therapies that apply the Company&#x2019;s platform technologies and cell therapy innovations with TCRs or CARs under distinct collaboration programs. The GSK Agreement defined two initial collaboration targets, LYL331 and LYL132, and allowed GSK to nominate seven additional targets through July 2024, though no additional targets were nominated over the life of the GSK Agreement. The Company was expected to perform research and development services for each selected target up until a defined point (the &#x201c;GSK Option Point&#x201d;), at which time GSK would decide whether or not to exercise an option to obtain a license from the Company (&#x201c;License Option&#x201d;) and take over the future development and commercialization. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, GSK exercised the License Option on LYL331 (NY-ESO-1 TCR with c-Jun) and assumed sole responsibility for future development and commercialization of the program at its own cost and expense. The investigational new drug (&#x201c;IND&#x201d;) application for LYL132 was cleared in January 2022, though no patients were treated, and the IND for LYL331 was not submitted to the U.S. Food and Drug Administration. GSK terminated the GSK Agreement effective December&#160;24, 2022, and Lyell has also discontinued any further work on these programs. There are no future performance obligations associated with the GSK Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a non-refundable upfront payment of $45.0&#160;million under the GSK Agreement. In connection with the GSK Agreement, in May 2019, the Company also entered into a stock purchase agreement with GSK, pursuant to which the Company agreed to sell 30,253,189 shares of Series&#160;AA convertible preferred stock at a price of $6.78 per share, which was above the issuance date estimated fair value of $4.84 per share. The difference between the per share values resulted in $58.6&#160;million additional deemed consideration, bringing the total upfront consideration of the GSK Agreement to $103.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The GSK Agreement was deemed to be within the scope of Accounting Standards Codification (&#x201c;ASC&#x201d;)&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, because GSK engaged the Company to initially provide research and development services, which were outputs of its ongoing activities, in exchange for consideration. In June 2022, the Company recorded an adjustment to revenue related to a change in estimate in connection with the GSK Agreement due to GSK and the Company mutually agreeing to conclude research activities on an undisclosed target for hematological cancers. The change in estimate decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $35.3&#160;million, decreased net loss by $35.3&#160;million and resulted in a $0.14 reduction in the Company&#x2019;s basic and diluted net loss per common share for the three and six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue related to the research and development services related to the two initial targets of zero and $35.7&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and zero and $36.3&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The Company had no deferred revenue related to the GSK Agreement as of both June&#160;30, 2023 and December&#160;31, 2022. As of June&#160;30, 2023 and December&#160;31, 2022, there were no contract assets or contract liabilities related to the license contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PACT&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into a commitment agreement (&#x201c;PACT Commitment Agreement&#x201d;) with PACT Pharma, Inc. (&#x201c;PACT&#x201d;) to jointly develop and test a next generation personalized anti-cancer T-cell therapy against solid tumors. The Company paid PACT an upfront non-refundable payment of $50.0&#160;million upon execution of the PACT Commitment Agreement. In November 2020, the parties agreed to suspend research and development activity under the PACT Commitment Agreement, and neither party would be required to conduct any further work under the development plan (including manufacturing development) nor incur any financial obligations (including milestone payments) that might otherwise arise, for as long as the parties continued to negotiate in good faith to resolve the issues that had arisen between them relating to the PACT Commitment Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 in connection with the entry into the PACT Commitment Agreement, the Company also entered into a stock purchase agreement with PACT (&#x201c;PACT SPA&#x201d;), pursuant to which the Company purchased 17,806,901 shares of PACT Series&#160;C-1 convertible preferred stock at a purchase price of $2.81 per share. As of the purchase date, the estimated fair value of the Series&#160;C-1 convertible preferred stock was $2.05 per share, and the difference between the estimated fair value of the preferred stock as of the purchase date and the purchase price of $13.6&#160;million was deemed to be additional consideration for the PACT Commitment Agreement and recognized as research and development expense. As a result, the total upfront consideration paid in connection with the PACT Commitment Agreement was $63.6&#160;million and was included in research and development expenses. The remaining $36.4&#160;million associated with the PACT Series&#160;C-1 convertible preferred stock was recorded in other investments. In the fourth quarter of 2021, the Company fully impaired the remaining balance of $36.4&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company filed a demand for arbitration seeking, among other things, rescission of the PACT Commitment Agreement and the PACT SPA and recovery of the consideration paid thereunder. Arbitration hearings occurred in March and April 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;1, 2022, the Company entered into a settlement agreement with PACT, pursuant to which the parties agreed to resolve their outstanding legal dispute. In connection with the settlement agreement, the parties also entered into a stock purchase agreement, pursuant to which PACT issued shares of PACT&#x2019;s Series&#160;D convertible preferred stock to the Company in exchange for the Company&#x2019;s tender of its PACT Series&#160;C-1 convertible preferred stock and resolution of the arbitration. The issuance of PACT&#x2019;s Series&#160;D convertible preferred stock, which are non-voting, have limited conversion rights and carry no right to appoint directors, resulted in the Company&#x2019;s ownership increasing to approximately 80% of PACT&#x2019;s fully diluted shares outstanding. The settlement agreement also included the termination of the PACT Commitment Agreement. The Company recorded a gain of $2.9&#160;million in October 2022 for the estimated fair value of the PACT Series&#160;D convertible preferred stock received as part of the settlement agreement. The PACT Series&#160;D convertible preferred stock was recorded at its estimated fair value as of the settlement date and was included in other investments in the Company&#x2019;s Condensed Consolidated Balance Sheets. In connection with the preparation of the financial statements for the three and six months ended June 30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment, resulting in the impairment of the $2.9&#160;million PACT Series D convertible preferred stock investment. See Note&#160;5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional details regarding the PACT investment impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments contextRef="c-56" decimals="-3" id="f-357" unitRef="usd">50000</lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchPayments contextRef="c-56" decimals="-5" id="f-358" unitRef="usd">12000000</lyel:CollaborativeArrangementRightsAndObligationsResearchPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchTerm contextRef="c-56" id="f-359">P6Y</lyel:CollaborativeArrangementRightsAndObligationsResearchTerm>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-57" decimals="-5" id="f-360" unitRef="usd">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-58" decimals="-5" id="f-361" unitRef="usd">500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-59" decimals="-5" id="f-362" unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-60" decimals="-5" id="f-363" unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-61" decimals="0" id="f-364" unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-62" decimals="0" id="f-365" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-63"
      decimals="2"
      id="f-366"
      unitRef="usdPerShare">1.83</us-gaap:SharesIssuedPricePerShare>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-62" decimals="-5" id="f-367" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-62" decimals="0" id="f-368" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-61" decimals="-5" id="f-369" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-61"
      decimals="2"
      id="f-370"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-62" decimals="-5" id="f-371" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-62"
      decimals="2"
      id="f-372"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm contextRef="c-56" id="f-373">P9Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="c-1" id="f-374">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Fred Hutch in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate potential success payments, which are payable to Stanford in cash or cash equivalents, or at the Company&#x2019;s discretion, publicly-tradeable shares of the Company&#x2019;s common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Multiple of initial equity value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;10x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;20x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;30x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;40x&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;50x&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Per share common stock price required for payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;54.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;91.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Aggregate success payment(s) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-64"
      decimals="INF"
      id="f-375"
      unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-65"
      decimals="INF"
      id="f-376"
      unitRef="number">20</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-66"
      decimals="INF"
      id="f-377"
      unitRef="number">30</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-67"
      decimals="INF"
      id="f-378"
      unitRef="number">40</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-68"
      decimals="INF"
      id="f-379"
      unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-64"
      decimals="2"
      id="f-380"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-65"
      decimals="2"
      id="f-381"
      unitRef="usdPerShare">36.58</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-66"
      decimals="2"
      id="f-382"
      unitRef="usdPerShare">54.86</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-67"
      decimals="2"
      id="f-383"
      unitRef="usdPerShare">73.15</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-68"
      decimals="2"
      id="f-384"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-64" decimals="-6" id="f-385" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-65" decimals="-6" id="f-386" unitRef="usd">40000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-66" decimals="-6" id="f-387" unitRef="usd">90000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-67" decimals="-6" id="f-388" unitRef="usd">140000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-68" decimals="-6" id="f-389" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate contextRef="c-56" id="f-390">P1Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering contextRef="c-56" id="f-391">P2Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-69" decimals="INF" id="f-392" unitRef="usd">0</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-69" decimals="-5" id="f-393" unitRef="usd">1900000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-70" decimals="-5" id="f-394" unitRef="usd">2500000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-57" decimals="-5" id="f-395" unitRef="usd">500000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-58" decimals="-5" id="f-396" unitRef="usd">2200000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-60" decimals="-5" id="f-397" unitRef="usd">-600000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-59" decimals="-5" id="f-398" unitRef="usd">-600000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments contextRef="c-71" decimals="-3" id="f-399" unitRef="usd">50000</lyel:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsMilestonePayments contextRef="c-72" decimals="-5" id="f-400" unitRef="usd">3700000</lyel:CollaborativeArrangementRightsAndObligationsMilestonePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments contextRef="c-73" decimals="-5" id="f-401" unitRef="usd">2500000</lyel:CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchTerm contextRef="c-74" id="f-402">P4Y</lyel:CollaborativeArrangementRightsAndObligationsResearchTerm>
    <lyel:CollaborativeArrangementRightsAndObligationsResearchPayments contextRef="c-74" decimals="-5" id="f-403" unitRef="usd">12000000</lyel:CollaborativeArrangementRightsAndObligationsResearchPayments>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-75" decimals="-5" id="f-404" unitRef="usd">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-76" decimals="-5" id="f-405" unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-77" decimals="-5" id="f-406" unitRef="usd">1500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-78" decimals="-5" id="f-407" unitRef="usd">1500000</us-gaap:ResearchAndDevelopmentExpense>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-79" decimals="0" id="f-408" unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-80" decimals="0" id="f-409" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-81"
      decimals="2"
      id="f-410"
      unitRef="usdPerShare">1.83</us-gaap:SharesIssuedPricePerShare>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-80" decimals="-5" id="f-411" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier contextRef="c-80" decimals="0" id="f-412" unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-79" decimals="-5" id="f-413" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-79"
      decimals="2"
      id="f-414"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-80" decimals="-5" id="f-415" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-80"
      decimals="2"
      id="f-416"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm contextRef="c-74" id="f-417">P9Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-82"
      decimals="INF"
      id="f-418"
      unitRef="number">10</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-83"
      decimals="INF"
      id="f-419"
      unitRef="number">20</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-84"
      decimals="INF"
      id="f-420"
      unitRef="number">30</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-85"
      decimals="INF"
      id="f-421"
      unitRef="number">40</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier
      contextRef="c-86"
      decimals="INF"
      id="f-422"
      unitRef="number">50</lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-82"
      decimals="2"
      id="f-423"
      unitRef="usdPerShare">18.29</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-83"
      decimals="2"
      id="f-424"
      unitRef="usdPerShare">36.58</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-84"
      decimals="2"
      id="f-425"
      unitRef="usdPerShare">54.86</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-85"
      decimals="2"
      id="f-426"
      unitRef="usdPerShare">73.15</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice
      contextRef="c-86"
      decimals="2"
      id="f-427"
      unitRef="usdPerShare">91.44</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-82" decimals="-6" id="f-428" unitRef="usd">10000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-83" decimals="-6" id="f-429" unitRef="usd">40000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-84" decimals="-6" id="f-430" unitRef="usd">90000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-85" decimals="-6" id="f-431" unitRef="usd">140000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-86" decimals="-6" id="f-432" unitRef="usd">200000000</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate contextRef="c-74" id="f-433">P1Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering contextRef="c-74" id="f-434">P2Y</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering>
    <lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments contextRef="c-87" decimals="INF" id="f-435" unitRef="usd">0</lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-87" decimals="-5" id="f-436" unitRef="usd">2700000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability contextRef="c-88" decimals="-5" id="f-437" unitRef="usd">3300000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability contextRef="c-87" decimals="-5" id="f-438" unitRef="usd">1900000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability contextRef="c-88" decimals="-5" id="f-439" unitRef="usd">1900000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-75" decimals="-5" id="f-440" unitRef="usd">600000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-76" decimals="-5" id="f-441" unitRef="usd">1400000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-77" decimals="-5" id="f-442" unitRef="usd">0</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-78" decimals="-5" id="f-443" unitRef="usd">400000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <us-gaap:ContractWithCustomerLiability contextRef="c-89" decimals="-5" id="f-444" unitRef="usd">45000000</us-gaap:ContractWithCustomerLiability>
    <lyel:StockPurchaseAgreementSharesSold
      contextRef="c-90"
      decimals="INF"
      id="f-445"
      unitRef="shares">30253189</lyel:StockPurchaseAgreementSharesSold>
    <lyel:StockPurchaseAgreementSharesSoldPricePerShare
      contextRef="c-90"
      decimals="2"
      id="f-446"
      unitRef="usdPerShare">6.78</lyel:StockPurchaseAgreementSharesSoldPricePerShare>
    <lyel:StockPurchaseAgreementFairValueOfStockPerShare
      contextRef="c-91"
      decimals="2"
      id="f-447"
      unitRef="usdPerShare">4.84</lyel:StockPurchaseAgreementFairValueOfStockPerShare>
    <lyel:RevenueRemainingPerformanceObligationAmountStockPurchaseProgram contextRef="c-89" decimals="-5" id="f-448" unitRef="usd">58600000</lyel:RevenueRemainingPerformanceObligationAmountStockPurchaseProgram>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-89" decimals="-5" id="f-449" unitRef="usd">103600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-55" decimals="-5" id="f-450" unitRef="usd">35300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-54" decimals="-5" id="f-451" unitRef="usd">35300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetIncomeLoss contextRef="c-54" decimals="-5" id="f-452" unitRef="usd">35300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-55" decimals="-5" id="f-453" unitRef="usd">35300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-55"
      decimals="2"
      id="f-454"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-54"
      decimals="2"
      id="f-455"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-55"
      decimals="2"
      id="f-456"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-54"
      decimals="2"
      id="f-457"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="-5" id="f-458" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-5" id="f-459" unitRef="usd">35700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-5" id="f-460" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-5" id="f-461" unitRef="usd">36300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-96" decimals="-5" id="f-462" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-97" decimals="-5" id="f-463" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-98" decimals="-5" id="f-464" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-99" decimals="-5" id="f-465" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-98" decimals="-5" id="f-466" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-99" decimals="-5" id="f-467" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <lyel:PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement contextRef="c-100" decimals="-5" id="f-468" unitRef="usd">50000000</lyel:PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement>
    <lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased
      contextRef="c-100"
      decimals="INF"
      id="f-469"
      unitRef="shares">17806901</lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased>
    <lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare
      contextRef="c-101"
      decimals="2"
      id="f-470"
      unitRef="usdPerShare">2.81</lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare>
    <lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare
      contextRef="c-101"
      decimals="2"
      id="f-471"
      unitRef="usdPerShare">2.05</lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare>
    <lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice contextRef="c-101" decimals="-5" id="f-472" unitRef="usd">13600000</lyel:CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice>
    <lyel:CollaborativeArrangementRightsAndObligationsUpfrontPayment contextRef="c-101" decimals="-5" id="f-473" unitRef="usd">63600000</lyel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-102" decimals="-5" id="f-474" unitRef="usd">36400000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-103" decimals="-5" id="f-475" unitRef="usd">36400000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <lyel:LitigationSettlementPercentOfTotalEquityValue contextRef="c-104" decimals="2" id="f-476" unitRef="number">0.80</lyel:LitigationSettlementPercentOfTotalEquityValue>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-105" decimals="-5" id="f-477" unitRef="usd">2900000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-106" decimals="-5" id="f-478" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-107" decimals="-5" id="f-479" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-480">Cash Equivalents and Marketable Securities&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;292,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;291,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;95,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;94,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;611,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(2,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;609,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;371,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;609,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;277,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(5,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;135,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;221,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;702,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(7,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;107,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;516,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;70,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of securities held by the Company in an unrealized loss position for less than 12&#160;months were $261.7&#160;million and $287.8&#160;million as of June&#160;30, 2023 and December&#160;31, 2022, respectively. The fair values of securities held by the Company in an unrealized loss position for greater than 12&#160;months were $101.2&#160;million and $278.7&#160;million as of June&#160;30, 2023 and December&#160;31, 2022, respectively. As of June&#160;30, 2023 and December&#160;31, 2022, all of the Company&#x2019;s marketable securities had a maturity date of two years or less, were available for use and were classified as available&#x2011;for&#x2011;sale. The Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before recovery of their amortized cost basis. The Company determined that there was no material change in the credit risk of the above investments as of both June&#160;30, 2023 and December&#160;31, 2022. As such, an allowance for credit losses has not been recognized. Gross realized gains and losses were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the three and six months ended June&#160;30, 2023 and 2022 and as a result, amounts reclassified out of accumulated other comprehensive loss for the three and six months ended June&#160;30, 2023 and 2022 were also &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de&#160;minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See Note&#160;6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information regarding cash equivalents and marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-481">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;292,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;291,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;95,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;94,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;611,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(2,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;609,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;371,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;609,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;277,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(5,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;135,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;221,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;702,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(7,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;107,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;516,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;70,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-482">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and marketable securities by major security type are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;292,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;291,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;95,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;94,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;611,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(2,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;609,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;200,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;371,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;609,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;277,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(5,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;135,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(1,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;221,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;702,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(7,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;107,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;516,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;70,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-108" decimals="-3" id="f-483" unitRef="usd">116970000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-484" unitRef="usd">116970000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-109" decimals="-3" id="f-485" unitRef="usd">292610000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-109" decimals="-3" id="f-486" unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-109" decimals="-3" id="f-487" unitRef="usd">1352000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="-3" id="f-488" unitRef="usd">291289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-110" decimals="-3" id="f-489" unitRef="usd">95331000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-110" decimals="-3" id="f-490" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-110" decimals="-3" id="f-491" unitRef="usd">820000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="-3" id="f-492" unitRef="usd">94511000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-111" decimals="-3" id="f-493" unitRef="usd">106706000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-111" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-111" decimals="-3" id="f-495" unitRef="usd">238000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-111" decimals="-3" id="f-496" unitRef="usd">106468000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost contextRef="c-3" decimals="-3" id="f-497" unitRef="usd">611617000</lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-498" unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-499" unitRef="usd">2410000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale contextRef="c-3" decimals="-3" id="f-500" unitRef="usd">609238000</lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale>
    <lyel:CashEquivalentsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-501" unitRef="usd">200910000</lyel:CashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-502" unitRef="usd">371376000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-3" decimals="-3" id="f-503" unitRef="usd">36952000</us-gaap:MarketableSecuritiesNoncurrent>
    <lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale contextRef="c-3" decimals="-3" id="f-504" unitRef="usd">609238000</lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-112" decimals="-3" id="f-505" unitRef="usd">67970000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-506" unitRef="usd">67970000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-113" decimals="-3" id="f-507" unitRef="usd">277056000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-113" decimals="-3" id="f-508" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-113" decimals="-3" id="f-509" unitRef="usd">5257000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="-3" id="f-510" unitRef="usd">271799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-114" decimals="-3" id="f-511" unitRef="usd">135460000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-114" decimals="-3" id="f-512" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-114" decimals="-3" id="f-513" unitRef="usd">1416000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-114" decimals="-3" id="f-514" unitRef="usd">134045000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-115" decimals="-3" id="f-515" unitRef="usd">221608000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-115" decimals="-3" id="f-516" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-115" decimals="-3" id="f-517" unitRef="usd">930000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-115" decimals="-3" id="f-518" unitRef="usd">220681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost contextRef="c-4" decimals="-3" id="f-519" unitRef="usd">702094000</lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-520" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-521" unitRef="usd">7603000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale contextRef="c-4" decimals="-3" id="f-522" unitRef="usd">694495000</lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale>
    <lyel:CashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-523" unitRef="usd">107780000</lyel:CashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-524" unitRef="usd">516598000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-4" decimals="-3" id="f-525" unitRef="usd">70117000</us-gaap:MarketableSecuritiesNoncurrent>
    <lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale contextRef="c-4" decimals="-3" id="f-526" unitRef="usd">694495000</lyel:CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-3" decimals="-5" id="f-527" unitRef="usd">261700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-5" id="f-528" unitRef="usd">287800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-3" decimals="-5" id="f-529" unitRef="usd">101200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-5" id="f-530" unitRef="usd">278700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-116" id="f-531">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-117" id="f-532">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <lyel:OtherInvestmentsTextBlock contextRef="c-1" id="f-533">Other Investments&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company makes minority ownership strategic investments. As of June&#160;30, 2023 and December&#160;31, 2022, the aggregate carrying amounts of the Company&#x2019;s strategic investments in non-publicly traded companies were $32.0&#160;million and $44.9&#160;million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of June&#160;30, 2023 and December&#160;31, 2022 were $17.9&#160;million and $5.0&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the Company received non-voting preferred stock pursuant to the settlement agreement with PACT (See Note 3, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The Company determined that PACT is a variable interest entity as PACT does not have sufficient equity at risk. The Company evaluated whether it was the primary beneficiary of PACT, including the Company&#x2019;s ongoing rights and responsibilities, to assess whether the Company has the power to direct the activities of PACT. The Company&#x2019;s only involvement in PACT is its PACT Series D convertible preferred stock investment, which are non-voting, have limited conversion rights and carry no right to appoint directors. Based on the above noted factors, the Company determined that it is not the primary beneficiary and does not consolidate PACT since it does not have the power to direct the activities that most significantly impact PACT&#x2019;s economic performance. The Company does not &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have the ability to exercise significant influence over PACT and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accounts for its investment in PACT preferred stock under the measurement alternative. The Company recognized its investment in PACT preferred stock at its estimated fair value of $2.9&#160;million on October&#160;1, 2022, which was included in the Company&#x2019;s Consolidated Balance Sheets within other investments. The Company&#x2019;s maximum exposure to loss from PACT is limited to the carrying value of its investment in PACT preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the preparation of the financial statements for the three months ended June 30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for the Company&#x2019;s PACT Series D convertible preferred stock investment. While there was no single event or factor, the Company considered PACT&#x2019;s operating cash flow requirements over the next year, liquid asset balances to fund &lt;/span&gt;&lt;/div&gt;those requirements and PACT&#x2019;s inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of the investment and determined the fair value to be negligible and the impairment to be other&#x2011;than&#x2011;temporary in nature. As a result, the Company recorded a $2.9&#160;million impairment expense for the investment for the three and six months ended June&#160;30, 2023, which was recorded within impairment of other investments on the Condensed Consolidated Statement of Operations and Comprehensive Loss and as a reduction to the investment balance within other investments on the Condensed Consolidated Balance Sheet. In connection with the preparation of the financial statements for the three months ended March 31, 2023, the Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for one of the Company&#x2019;s other investments with a carrying amount of $10.0&#160;million. While there was no single event or factor, the Company considered the underlying company&#x2019;s operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying company&#x2019;s inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of the investment and determined the fair value to be negligible and the impairment to be other-than-temporary in nature. As a result, the Company recorded a $10.0&#160;million impairment expense for the investment for the six months ended June&#160;30, 2023, which was recorded within impairment of other investments on the Condensed Consolidated Statement of Operations and Comprehensive Loss and as a reduction to the investment balance within other investments on the Condensed Consolidated Balance Sheet.</lyel:OtherInvestmentsTextBlock>
    <us-gaap:OtherInvestments contextRef="c-3" decimals="-5" id="f-534" unitRef="usd">32000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-4" decimals="-5" id="f-535" unitRef="usd">44900000</us-gaap:OtherInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount contextRef="c-118" decimals="-5" id="f-536" unitRef="usd">17900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount contextRef="c-119" decimals="-5" id="f-537" unitRef="usd">5000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-120" decimals="-5" id="f-538" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-107" decimals="-5" id="f-539" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-106" decimals="-5" id="f-540" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:OtherInvestments contextRef="c-121" decimals="-5" id="f-541" unitRef="usd">10000000</us-gaap:OtherInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-122" decimals="-5" id="f-542" unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-543">Fair Value Measurements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;291,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;291,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;94,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;94,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;492,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;609,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;626,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical assets or liabilities. The Level&#160;2 marketable securities include U.S. Treasury securities, U.S. government agency securities and corporate debt securities. The Company&#x2019;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services applied industry standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Level&#160;3 financial instruments fair values are estimated using valuation models, including Monte Carlo simulations for the Company&#x2019;s success payment liabilities. Monte Carlo simulations model the future movement of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock prices based on several key variables combined with empirical knowledge of the process governing the behavior of the stock price. The following variables were incorporated in the estimated fair value of the success payment liabilities: fair value of the Company&#x2019;s common stock, expected volatility, the risk-free interest rate and the estimated number and timing of valuation measurement dates on the basis of which payments may be triggered. The computation of expected volatility was estimated based on available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.36% - 5.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.58% - 4.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.96 - 4.47&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 4.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.36% - 5.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.58% - 4.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.96 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 6.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes estimates and assumptions in determining the estimated success payment liabilities and associated changes in fair value. A small change in the valuation of the Company&#x2019;s common stock may have a relatively large change in the estimated fair value of the success payment liability and associated changes in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3&#160;liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Success Payment&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Change in fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The changes in the fair value associated with the Fred Hutch success payment liabilities of approximately $(0.6) million are recorded in other&#160;(expense) income, net (See Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). The changes in the fair value of approximately zero associated with the Stanford success payment liabilities are recorded as research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the Company received non-voting Series D convertible preferred stock pursuant to the settlement agreement with PACT (See Note 3, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The Company determined the fair value of PACT was a fraction of the aggregate liquidation preference of the Company&#x2019;s PACT Series D convertible preferred stock. The Company determined that the fair value of its investment in PACT preferred stock is approximated by the fair value of the PACT business since the Company is the only party invested in PACT Series D convertible preferred stock, the most senior class of stock issued by PACT, as of October 1, 2022. The fair value of PACT was estimated at $2.9&#160;million as of October 1, 2022 using the cost approach. Under this approach, the fair value of an asset is measured by the cost to reconstruct or replace such asset with another one of like utility. The fair value of PACT was estimated by using significant unobservable inputs, including an estimate of insignificant fair value associated with PACT intangible assets. Accordingly, the Company classified the fair value measurement of PACT Series D convertible preferred stock on October 1, 2022 as Level 3 under the fair value hierarchy. In connection with the preparation of the financial statements for the three and six months ended June 30, 2023, the&#160;Company performed a qualitative assessment of potential indicators of impairment, resulting in the impairment of the $2.9&#160;million PACT Series D convertible preferred stock investment. See Note&#160;5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional details regarding the PACT investment impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-544">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;291,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;291,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;94,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;94,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;106,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;116,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;492,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;609,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;271,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;134,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;220,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;67,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;626,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;694,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Success payment liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-123" decimals="-3" id="f-545" unitRef="usd">116970000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-124" decimals="-3" id="f-546" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-125" decimals="-3" id="f-547" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-548" unitRef="usd">116970000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-126" decimals="-3" id="f-549" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-127" decimals="-3" id="f-550" unitRef="usd">291289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-128" decimals="-3" id="f-551" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="-3" id="f-552" unitRef="usd">291289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-129" decimals="-3" id="f-553" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-130" decimals="-3" id="f-554" unitRef="usd">94511000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-131" decimals="-3" id="f-555" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="-3" id="f-556" unitRef="usd">94511000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-132" decimals="-3" id="f-557" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-133" decimals="-3" id="f-558" unitRef="usd">106468000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-134" decimals="-3" id="f-559" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-111" decimals="-3" id="f-560" unitRef="usd">106468000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-135" decimals="-3" id="f-561" unitRef="usd">116970000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-136" decimals="-3" id="f-562" unitRef="usd">492268000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-137" decimals="-3" id="f-563" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-564" unitRef="usd">609238000</us-gaap:AssetsFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-135" decimals="-3" id="f-565" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-136" decimals="-3" id="f-566" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-137" decimals="-3" id="f-567" unitRef="usd">3753000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-568" unitRef="usd">3753000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-135" decimals="-3" id="f-569" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-136" decimals="-3" id="f-570" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-137" decimals="-3" id="f-571" unitRef="usd">3753000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-572" unitRef="usd">3753000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-138" decimals="-3" id="f-573" unitRef="usd">67970000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-139" decimals="-3" id="f-574" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-140" decimals="-3" id="f-575" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-576" unitRef="usd">67970000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-141" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-142" decimals="-3" id="f-578" unitRef="usd">271799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-143" decimals="-3" id="f-579" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="-3" id="f-580" unitRef="usd">271799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-144" decimals="-3" id="f-581" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-145" decimals="-3" id="f-582" unitRef="usd">134045000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-146" decimals="-3" id="f-583" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-114" decimals="-3" id="f-584" unitRef="usd">134045000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-147" decimals="-3" id="f-585" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-148" decimals="-3" id="f-586" unitRef="usd">220681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-149" decimals="-3" id="f-587" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-115" decimals="-3" id="f-588" unitRef="usd">220681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-150" decimals="-3" id="f-589" unitRef="usd">67970000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-151" decimals="-3" id="f-590" unitRef="usd">626525000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-152" decimals="-3" id="f-591" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-592" unitRef="usd">694495000</us-gaap:AssetsFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-150" decimals="-3" id="f-593" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-151" decimals="-3" id="f-594" unitRef="usd">0</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-152" decimals="-3" id="f-595" unitRef="usd">4356000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <lyel:SuccessPaymentLiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-596" unitRef="usd">4356000</lyel:SuccessPaymentLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-150" decimals="-3" id="f-597" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-151" decimals="-3" id="f-598" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-152" decimals="-3" id="f-599" unitRef="usd">4356000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-600" unitRef="usd">4356000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-601">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.36% - 5.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.58% - 4.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.96 - 4.47&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 4.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.36% - 5.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.58% - 4.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.96 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.46 - 6.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <lyel:FairValueOfSeriesAConvertiblePreferredStock
      contextRef="c-153"
      decimals="2"
      id="f-602"
      unitRef="usdPerShare">3.18</lyel:FairValueOfSeriesAConvertiblePreferredStock>
    <lyel:FairValueOfSeriesAConvertiblePreferredStock
      contextRef="c-154"
      decimals="2"
      id="f-603"
      unitRef="usdPerShare">3.47</lyel:FairValueOfSeriesAConvertiblePreferredStock>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-155" decimals="4" id="f-604" unitRef="number">3.36</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-156" decimals="4" id="f-605" unitRef="number">5.26</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-157" decimals="4" id="f-606" unitRef="number">3.58</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-158" decimals="4" id="f-607" unitRef="number">4.65</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-159" decimals="3" id="f-608" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-160" decimals="3" id="f-609" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-161" decimals="2" id="f-610" unitRef="number">0.96</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-162" decimals="2" id="f-611" unitRef="number">4.47</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-163" decimals="2" id="f-612" unitRef="number">0.46</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-164" decimals="2" id="f-613" unitRef="number">4.97</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:FairValueOfSeriesAConvertiblePreferredStock
      contextRef="c-165"
      decimals="2"
      id="f-614"
      unitRef="usdPerShare">3.18</lyel:FairValueOfSeriesAConvertiblePreferredStock>
    <lyel:FairValueOfSeriesAConvertiblePreferredStock
      contextRef="c-166"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">3.47</lyel:FairValueOfSeriesAConvertiblePreferredStock>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-167" decimals="4" id="f-616" unitRef="number">3.36</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-168" decimals="4" id="f-617" unitRef="number">5.26</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-169" decimals="4" id="f-618" unitRef="number">3.58</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-170" decimals="4" id="f-619" unitRef="number">4.65</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-171" decimals="3" id="f-620" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-172" decimals="3" id="f-621" unitRef="number">0.800</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-173" decimals="2" id="f-622" unitRef="number">0.96</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-174" decimals="2" id="f-623" unitRef="number">6.25</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-175" decimals="2" id="f-624" unitRef="number">0.46</lyel:SuccessPaymentLiabilityMeasurementInput>
    <lyel:SuccessPaymentLiabilityMeasurementInput contextRef="c-176" decimals="2" id="f-625" unitRef="number">6.75</lyel:SuccessPaymentLiabilityMeasurementInput>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-626">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3&#160;liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Success Payment&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Change in fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The changes in the fair value associated with the Fred Hutch success payment liabilities of approximately $(0.6) million are recorded in other&#160;(expense) income, net (See Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). The changes in the fair value of approximately zero associated with the Stanford success payment liabilities are recorded as research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-627">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3&#160;liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Success Payment&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Change in fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Balance at June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The changes in the fair value associated with the Fred Hutch success payment liabilities of approximately $(0.6) million are recorded in other&#160;(expense) income, net (See Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). The changes in the fair value of approximately zero associated with the Stanford success payment liabilities are recorded as research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-177" decimals="-3" id="f-628" unitRef="usd">4356000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-178" decimals="-3" id="f-629" unitRef="usd">-603000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-179" decimals="-3" id="f-630" unitRef="usd">3753000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-59" decimals="-5" id="f-631" unitRef="usd">-600000</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain contextRef="c-77" decimals="-5" id="f-632" unitRef="usd">0</lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-180" decimals="-5" id="f-633" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-106" decimals="-5" id="f-634" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-107" decimals="-5" id="f-635" unitRef="usd">2900000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="c-1" id="f-636">Leases&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of June&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2023 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;35,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(23,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;66,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of June&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;60,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;66,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for all operating leases were &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $2.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $4.4&#160;million and $4.7&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de&#160;minimis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and six months ended June&#160;30, 2023 and 2022. Variable lease costs for operating leases were $1.4&#160;million and $1.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $2.8&#160;million and $2.5&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were 7.3&#160;and 7.8&#160;years as of June&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted-average discount rates for operating leases were 8.5% as of both June&#160;30, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million for both the three months ended June&#160;30, 2023 and 2022, and $0.4&#160;million for both the six months ended June&#160;30, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#x201c;Sonoma&#x201d;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended June&#160;30, 2023 and 2022 and $0.9&#160;million for both the six months ended June&#160;30, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-637">Leases&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of June&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2023 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;35,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(23,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;66,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of June&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;60,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;66,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for all operating leases were &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $2.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $4.4&#160;million and $4.7&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The operating lease costs and total commitments for short-term leases were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de&#160;minimis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and six months ended June&#160;30, 2023 and 2022. Variable lease costs for operating leases were $1.4&#160;million and $1.2&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and $2.8&#160;million and $2.5&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively. The weighted-average remaining lease terms for operating leases were 7.3&#160;and 7.8&#160;years as of June&#160;30, 2023 and December&#160;31, 2022, respectively. The weighted-average discount rates for operating leases were 8.5% as of both June&#160;30, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2&#160;million for both the three months ended June&#160;30, 2023 and 2022, and $0.4&#160;million for both the six months ended June&#160;30, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (&#x201c;Sonoma&#x201d;), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As a part of the sublease, in September 2021, the Company received a $4.6&#160;million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5&#160;million for both the three months ended June&#160;30, 2023 and 2022 and $0.9&#160;million for both the six months ended June&#160;30, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-638">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of June&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2023 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;35,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(23,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;66,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of June&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;60,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;66,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <lyel:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-639">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s future minimum operating lease commitments, including expected lease incentives to be received, as of June&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2023 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;11,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;12,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;35,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;89,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(23,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;66,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Reported as of June&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;60,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;66,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lyel:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-640" unitRef="usd">5630000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-641" unitRef="usd">11347000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-642" unitRef="usd">11859000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-643" unitRef="usd">12209000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-644" unitRef="usd">12569000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <lyel:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-3" decimals="-3" id="f-645" unitRef="usd">35525000</lyel:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-646" unitRef="usd">89139000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-647" unitRef="usd">23065000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-648" unitRef="usd">66074000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-649" unitRef="usd">5853000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-650" unitRef="usd">60221000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-651" unitRef="usd">66074000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-5" id="f-652" unitRef="usd">2300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-5" id="f-653" unitRef="usd">2200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-654" unitRef="usd">4400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-5" id="f-655" unitRef="usd">4700000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-5" decimals="-5" id="f-656" unitRef="usd">1400000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-6" decimals="-5" id="f-657" unitRef="usd">1200000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-5" id="f-658" unitRef="usd">2800000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-7" decimals="-5" id="f-659" unitRef="usd">2500000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-660">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-661">P7Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-662" unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-663" unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:NetRentableArea contextRef="c-181" decimals="-3" id="f-664" unitRef="sqft">11000</us-gaap:NetRentableArea>
    <us-gaap:SubleaseIncome contextRef="c-182" decimals="-5" id="f-665" unitRef="usd">200000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-183" decimals="-5" id="f-666" unitRef="usd">200000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-184" decimals="-5" id="f-667" unitRef="usd">400000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-185" decimals="-5" id="f-668" unitRef="usd">400000</us-gaap:SubleaseIncome>
    <us-gaap:NetRentableArea contextRef="c-186" decimals="-3" id="f-669" unitRef="sqft">18000</us-gaap:NetRentableArea>
    <us-gaap:TenantImprovements contextRef="c-187" decimals="-5" id="f-670" unitRef="usd">4600000</us-gaap:TenantImprovements>
    <us-gaap:SubleaseIncome contextRef="c-188" decimals="-5" id="f-671" unitRef="usd">500000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-189" decimals="-5" id="f-672" unitRef="usd">500000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-190" decimals="-5" id="f-673" unitRef="usd">900000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-191" decimals="-5" id="f-674" unitRef="usd">900000</us-gaap:SubleaseIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-675">Stockholders&#x2019; Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 10.0&#160;million shares of preferred stock with a par value of $0.0001 per share. As of June&#160;30, 2023 and December&#160;31, 2022, no shares of preferred stock were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 500.0&#160;million shares of common stock with a par value of $0.0001 per share. As of June&#160;30, 2023 and December&#160;31, 2022, there were 251,026,997 shares and 249,567,343 shares of the Company&#x2019;s common stock outstanding, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;4, 2022, the Company entered into an Equity Distribution Agreement with Goldman Sachs &amp;amp; Co. LLC (&#x201c;Goldman Sachs&#x201d;) and BofA Securities, Inc. (&#x201c;BofA&#x201d;, and together with Goldman Sachs, the &#x201c;Agents&#x201d;) with respect to an at-the-market offering program (the &#x201c;Equity Distribution Agreement&#x201d;). In accordance with the terms of the Equity Distribution Agreement, the Company may offer and sell from time to time through the Agents shares of the Company&#x2019;s common stock having an aggregate offering amount of up to $200.0&#160;million (the &#x201c;Placement Shares&#x201d;). Sales of the Placement Shares, if any, will be made at prevailing market prices on Nasdaq at the time of sale, or as otherwise agreed with the Agents, by any method permitted by law deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule&#160;415 of the Securities Act of 1933, as amended. The Company will pay commissions to the Agents of up to 3.0% of the gross proceeds of the sale of the Placement Shares sold under the Equity Distribution Agreement and reimburse the Agents for certain expenses. Neither the Company nor the Agents are obligated to sell any shares and, to date, the Company has not made any sales under the Equity Distribution Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-676" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-677"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-678" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-679" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-680" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-681"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-682" unitRef="shares">251026997</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-683" unitRef="shares">249567343</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-192" decimals="INF" id="f-684" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <lyel:PercentageOfCommissionFromEachSaleOfShares
      contextRef="c-192"
      decimals="INF"
      id="f-685"
      unitRef="number">0.030</lyel:PercentageOfCommissionFromEachSaleOfShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-686">Stock-based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company adopted the 2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;), which on the date of the underwriting agreement related to the Company&#x2019;s IPO became effective with an initial reserve of 26,662,087 shares, plus any shares subject to outstanding awards granted under the 2018 Equity Incentive Plan (&#x201c;2018 Plan&#x201d;) that, on or after the effectiveness of the 2021 Plan, terminate or expire before exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved for issuance under the 2021 Plan automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1)&#160;5% of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by the Company&#x2019;s board of directors no later than December&#160;31 of the immediately preceding year. On January&#160;1, 2023, the Company reserved an additional 12,478,367 shares of common stock for issuance under the 2021 Plan representing 5% of the total common shares outstanding as of December&#160;31, 2022. Under the 2021 Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards (&#x201c;RSAs&#x201d;), restricted stock units (&#x201c;RSUs&#x201d;), stock appreciation rights, performance awards and other stock-based awards. Terms of stock awards, including vesting requirements, are determined by the Company&#x2019;s board of directors or by a committee authorized by the Company&#x2019;s board of directors, subject to provisions of the 2021 Plan. The term of any stock option granted under the 2021 Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years but may be granted with different vesting terms. In conjunction with adopting the 2021 Plan, the Company discontinued the 2018 Plan with respect to new equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, 25,280,983 shares were available for future issuance pursuant to the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company adopted the 2021 Employee Stock Purchase Plan (&#x201c;2021 ESPP&#x201d;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#x2019;s IPO with an initial reserve of 2,470,000 shares. The 2021 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their earnings, subject to plan limitations. Unless otherwise determined by the Company&#x2019;s board of directors, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first date of an offering or on the purchase date. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2021 ESPP automatically increases on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (1)&#160;1% of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31 of the immediately preceding year, and (2)&#160;4,940,000 shares; provided, however, that the Company&#x2019;s board of directors may act to provide a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lesser increase in number of shares. The Company&#x2019;s board of directors elected to reserve no additional shares under the 2021 ESPP for the year beginning January&#160;1, 2023. The Company may specify offerings with durations not more than 27&#160;months and may specify shorter purchase periods within each offering. Under the 2021 ESPP, 542,921 shares were issued for the three and six months ended June&#160;30, 2023 and 283,574&#160;shares were issued for the three and six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, 3,905,099 shares were available for future issuance pursuant to the 2021 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company established the 2018&#160;Plan that provided for the grant of incentive stock options, non&#x2011;statutory stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. Terms of stock awards, including vesting requirements, were determined by the board of directors or by a committee authorized by the Company&#x2019;s board of directors, subject to provisions of the 2018&#160;Plan. The term of any stock option granted under the 2018&#160;Plan cannot exceed ten years. Generally, awards granted by the Company vest over four years, but could have been granted with different vesting terms. Pursuant to the terms of the 2021&#160;Plan, any shares subject to outstanding options originally granted under the 2018&#160;Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof become available for issuance pursuant to awards granted under the 2021&#160;Plan. While no shares are available for future issuance under the 2018&#160;Plan, it continues to govern outstanding equity awards granted thereunder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;9,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;14,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;22,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;28,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;44,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2023, total stock-based compensation cost related to unvested awards not yet recognized was $81.6&#160;million, which is expected to be recognized over a remaining weighted-average period of 2.86 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s RSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Value at Grant&lt;br/&gt;Date Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;872,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,997,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(127,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(117,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,623,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;53,849,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;24,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,586,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(832,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(2,959,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;58,642,597&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;26,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options exercisable as of June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;30,365,614&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;85.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted-average grant date fair value of options granted for the six months ended June&#160;30, 2023 and 2022 were $1.72 per share and $4.27 per share, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-193"
      decimals="INF"
      id="f-687"
      unitRef="shares">26662087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-194" id="f-688">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="c-194"
      decimals="INF"
      id="f-689"
      unitRef="number">0.05</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-195"
      decimals="INF"
      id="f-690"
      unitRef="shares">12478367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding
      contextRef="c-195"
      decimals="INF"
      id="f-691"
      unitRef="number">0.05</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-196" id="f-692">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-194" id="f-693">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-197"
      decimals="INF"
      id="f-694"
      unitRef="shares">25280983</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-198"
      decimals="INF"
      id="f-695"
      unitRef="shares">2470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="c-198" decimals="2" id="f-696" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-199" decimals="2" id="f-697" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-199" id="f-698">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="c-199"
      decimals="INF"
      id="f-699"
      unitRef="number">0.01</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable
      contextRef="c-199"
      decimals="INF"
      id="f-700"
      unitRef="shares">4940000</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable>
    <lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod contextRef="c-199" id="f-701">P27M</lyel:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-200"
      decimals="INF"
      id="f-702"
      unitRef="shares">542921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-201"
      decimals="INF"
      id="f-703"
      unitRef="shares">542921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-202"
      decimals="INF"
      id="f-704"
      unitRef="shares">283574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-203"
      decimals="INF"
      id="f-705"
      unitRef="shares">283574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-204"
      decimals="INF"
      id="f-706"
      unitRef="shares">3905099</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-205" id="f-707">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-205" id="f-708">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-206"
      decimals="INF"
      id="f-709"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-710">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the Condensed Consolidated Statements of Operations and Comprehensive Loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;9,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;36,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;14,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;22,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;28,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;44,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-207" decimals="-3" id="f-711" unitRef="usd">5279000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-208" decimals="-3" id="f-712" unitRef="usd">4195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-209" decimals="-3" id="f-713" unitRef="usd">9891000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-210" decimals="-3" id="f-714" unitRef="usd">7959000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-211" decimals="-3" id="f-715" unitRef="usd">8944000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-212" decimals="-3" id="f-716" unitRef="usd">18215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-213" decimals="-3" id="f-717" unitRef="usd">18214000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-214" decimals="-3" id="f-718" unitRef="usd">36479000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-719" unitRef="usd">14223000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-720" unitRef="usd">22410000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-721" unitRef="usd">28105000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-722" unitRef="usd">44438000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-3" decimals="-5" id="f-723" unitRef="usd">81600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-724">P2Y10M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="c-1" id="f-725">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s RSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Value at Grant&lt;br/&gt;Date Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;872,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,997,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(127,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;RSUs forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(117,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Unvested RSUs as of June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2,623,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-215"
      decimals="INF"
      id="f-726"
      unitRef="shares">872077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-215"
      decimals="2"
      id="f-727"
      unitRef="usdPerShare">5.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-216"
      decimals="INF"
      id="f-728"
      unitRef="shares">1997177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-216"
      decimals="2"
      id="f-729"
      unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-216"
      decimals="INF"
      id="f-730"
      unitRef="shares">127886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-216"
      decimals="2"
      id="f-731"
      unitRef="usdPerShare">5.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-216"
      decimals="INF"
      id="f-732"
      unitRef="shares">117669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-216"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">4.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-217"
      decimals="INF"
      id="f-734"
      unitRef="shares">2623699</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-217"
      decimals="2"
      id="f-735"
      unitRef="usdPerShare">3.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-736">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;53,849,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;24,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;8,586,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(832,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;(2,959,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options outstanding as of June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;58,642,597&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;7.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;26,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Options exercisable as of June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;30,365,614&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;6.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;18,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-737" unitRef="shares">53849045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-738"
      unitRef="usdPerShare">5.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-218" id="f-739">P7Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-740" unitRef="usd">24887000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-741" unitRef="shares">8586063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-742"
      unitRef="usdPerShare">2.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-743" unitRef="shares">832840</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-744"
      unitRef="usdPerShare">0.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-745" unitRef="shares">2959671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-746"
      unitRef="usdPerShare">5.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-747" unitRef="shares">58642597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-748"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-749">P7Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-750" unitRef="usd">26401000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-751" unitRef="shares">30365614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-752"
      unitRef="usdPerShare">4.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-753">P6Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-3" id="f-754" unitRef="usd">18878000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-755">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to employees, directors and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;2.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;85.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-756" unitRef="number">0.0409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-7" decimals="4" id="f-757" unitRef="number">0.0228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="3" id="f-758" unitRef="number">0.924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-7" decimals="3" id="f-759" unitRef="number">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-760">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-7" id="f-761">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="2" id="f-762" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-7" decimals="2" id="f-763" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-764"
      unitRef="usdPerShare">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-7"
      decimals="2"
      id="f-765"
      unitRef="usdPerShare">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-766">Net Loss Per ShareBasic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#x2019;s potentially dilutive shares, which include unvested RSAs, unvested RSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Shares subject to options to purchase common stock, unvested RSAs and unvested RSUs were all excluded from consideration in the calculation of diluted net loss per share in all periods presented due to their anti-dilutive effects.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-767">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into certain license and collaboration agreements, including those identified in Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;above, with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial milestones. The Company&#x2019;s &lt;/span&gt;&lt;/div&gt;obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs, including termination of such agreements. Due to the nature of these agreements, the future potential payments are inherently uncertain, and accordingly no amounts had been recorded for the potential future achievement of these targets as of both June&#160;30, 2023 and December&#160;31, 2022.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-768">Related-party Transactions&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a sublease with Sonoma (&#x201c;Sonoma Sublease&#x201d;), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr.&#160;Klausner, the Chair of the Company&#x2019;s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $4.6&#160;million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both June&#160;30, 2023 and December&#160;31, 2022, there were accrued liabilities and other current liabilities of $0.5&#160;million, and as of June&#160;30, 2023 and December&#160;31, 2022, there were other non-current liabilities of $3.3&#160;million and $3.5&#160;million, respectively, in connection with the Sonoma Sublease. Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#x201c;other operating income, net&#x201d; such as common area maintenance charges. See Note&#160;7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more detail on the Sonoma Sublease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma other operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was party to the GSK Agreement with GSK, which is a holder of more than 10% of the Company&#x2019;s outstanding common stock. See Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Collaboration and Success Payment Agreements&lt;/span&gt;. GSK terminated the GSK Agreement effective December&#160;24, 2022. The Company had no current or non-current deferred revenue in connection with the GSK Agreement as of both June&#160;30, 2023 and December&#160;31, 2022. Revenue recognized in connection with the GSK agreement was zero and $35.7&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively, and zero and $36.3&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NetRentableArea contextRef="c-187" decimals="-3" id="f-769" unitRef="sqft">18000</us-gaap:NetRentableArea>
    <us-gaap:TenantImprovements contextRef="c-187" decimals="-5" id="f-770" unitRef="usd">4600000</us-gaap:TenantImprovements>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-219" decimals="-5" id="f-771" unitRef="usd">500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-220" decimals="-5" id="f-772" unitRef="usd">500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-219" decimals="-5" id="f-773" unitRef="usd">3300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-220" decimals="-5" id="f-774" unitRef="usd">3500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c-1" id="f-775">Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in &#x201c;other operating income, net&#x201d; such as common area maintenance charges. See Note&#160;7, &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more detail on the Sonoma Sublease.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma other operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sonoma sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-188" decimals="-3" id="f-776" unitRef="usd">648000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-189" decimals="-3" id="f-777" unitRef="usd">658000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-190" decimals="-3" id="f-778" unitRef="usd">1317000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-191" decimals="-3" id="f-779" unitRef="usd">1317000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:SubleaseIncome contextRef="c-188" decimals="-3" id="f-780" unitRef="usd">464000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-189" decimals="-3" id="f-781" unitRef="usd">466000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-190" decimals="-3" id="f-782" unitRef="usd">930000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-191" decimals="-3" id="f-783" unitRef="usd">931000</us-gaap:SubleaseIncome>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-221" decimals="2" id="f-784" unitRef="number">0.10</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:ContractWithCustomerLiability contextRef="c-222" decimals="-5" id="f-785" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-223" decimals="-5" id="f-786" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-224" decimals="-5" id="f-787" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-225" decimals="-5" id="f-788" unitRef="usd">35700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-226" decimals="-5" id="f-789" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-227" decimals="-5" id="f-790" unitRef="usd">36300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-791">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-792">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-793">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-794">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc xlink:href="#f-98" xlink:label="f-98" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-101"
          xlink:label="f-101"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-100"
          xlink:label="f-100"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-99" xlink:label="f-99" xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1)&#160;&#160;&#160;&#160;None of the revenue for the three and six months ended June&#160;30, 2023 was from a related-party. Substantially all of the revenue for the three and six months ended June&#160;30, 2022 was from a related-party.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-98"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-101"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-100"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-99"
          xlink:to="fn-1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=81[F",O9&[WO9Y,JSAH%L[Z%[B )&52:5BOV' .BC+M16[U.UM\7BX_.R
MGQ'80._5Z+V+T)G6J]/8O3V:7=YC$0W0?@W:OP@43@9MB$B86)ZB[9^D/1;1
MH UKVO H[41F&>S@?RCH\+R"/AG6P!_4^(.S\2^HYL'>,O9P>SF?$]D@'];D
MP_/)SROFX1Z+W_.P'^Y3MT1VA[U^>)#:PW]/0WP^]P6U7<GNT?>'PW"'OBVT
MP ^ZP0Z^NW6NVTO59Z*63&C$Z0)R<2<$$57>4\J.D7EQU,^E@8M#T4SA;D>5
M#8#G"RG-2\?>'NK;8O0'4$L#!!0    ( +N""%<]M)<[C08  #\=   8
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M=C&Z1AXKB#KR/ #?^?JJ_\$+#'];.?DO4$L#!!0    ( +N""%<TS01JIA,
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MQ,.B+!Y'P[ ],@=9)8L!XLTMXNC2SBWS7%5D@OIW)995F38)2-!'^(-DK8Q
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MX' P>&_]>@ B?']<D*7/_<(!*NA'_^Y;>/\![.]\_4[*Z;?%_B)JW"!^8:M
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M^*:H/0?4,,U$\K=U4$#@!&=CEG44LGXGCO9#SW_'K@[78ROJ(28H-%C0S-E
M?&!%O(L4X1J%&%JMI<[(#.:R2CV::H-IF!=Q.NS[EISCZ)N1<E7-^?N?J/%H
MBMI^25)X&KYBZM)^LU([W'X_%;+>G-X R=0,4T?#)V='-OKX/^IRR=^S-"WK
MNLSY5Z1/Q%\:@,]G)3;O_B "X8NW7OTO4$L#!!0    ( +N""%=LYEG]HP4
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MV:@'#OHVKOVP:N%;)Y .C9@?ENA\23L!K,\4(M)]N TVO?3YOU!+ P04
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M; =MK/NRY6^L*MS7I*FR5F7N[T*@D=,T >,S!>.K&]J@^;QX\U]02P,$%
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M.<U%1=\;4:7*ICJB&U$HR*V4B+R@N13.%4'HM78Y"C"BGX3-(=>A+C<*,E*
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M\]--?':*1^?!^.0T&(Z&.VFY+:.VIG8_U1TQ CHH;87^J"O6(?RL8%9G=(S
M:">-3B!4#EE9J4@<H3:]<BMIE\A%[<_-6680Z1AVC20_4'>59#H7">WW=Z*L
M+@DNA,^?;^ ]YQ='EWLV?FUP^9UG>*V7,YAC4AOI)-H /JDD[/SX:VL>>'.G
M,V39#H1NB+2.LXSRVT;RUJT0T# 3[@/9?Z"+YX%N.KVDEB*YJ+ET9D0)[W?
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MRL]A"^UHJO./.8W1:-B OB^U=IL7#M -YM._ 5!+ P04    " "[@@A7/*A
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MA6B\ >WGFBYB-_$'](_K] ]02P,$%     @ NX((5]U8U6O^ @  X@8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULG57+;MLP$/P50@%R<B-9=AY(
M; .VTZ(MFL)(^C@4/=#22B)"D2JYLN-^?9>4K"B%8Z"]V'SLS,Z2W-%DJ\VC
M+0"0/952V6E0(%;786B3 DINSW0%BG8R;4J.-#5Y:"L#//6@4H9Q%%V$)1<J
MF$W\VLK,)KI&*12L#+-U67*S6X#4VVDP#/8+]R(OT"V$LTG%<W@ _%JM#,W"
MCB45)2@KM&(&LFDP'UXOQB[>!WP3L+6],7.5K+5^=),/Z32(G""0D*!CX/2W
M@25(Z8A(QJ^6,^A2.F!_O&=_YVNG6M;<PE++[R+%8AI<!2R%C-<2[_7V/;3U
MG#N^1$OK?]FVB3V/ Y;4%G79@DE!*53SSY_:<^@!KJ)7 '$+B+WN)I%7><N1
MSR9&;YEQT<3F!KY4CR9Q0KE+>4!#NX)P.%OJLA1(IXR6<96RI58H5 XJ$6 G
M(5(*%Q@F+=VBH8M?H;M@=T106/96I9"^Q(<DK=,7[_4MXJ.$'VMUQD;1@,51
M/#K"-^KJ'7F^T?_4RVZ%3:2VM0'V8[ZV:.C1_#QT"DV2\>$DKI&N;<43F ;4
M*1;,!H+9Z<GP(KHY4L*X*V%\C/W?K^PHW6&QQX_IDTBH+:'=D9*OM>&^R>:Y
M 6A@7PJ@S;+B:L<*;ADM@H&4"86:)6"0'(/)'E/R@HEW3 .")+).*3_#0E.T
M2&E=9,*SL<\:@8T&>U6#OR0YZH<Z2<!:MN([1]F728$;PFP%%L0N3,HJ;M!5
MB07'-C70!%A6*R]"9YW^%#;D:Y6C&E!;JCJC%U,;%]645)9@$L&E^-VH@8R,
ME-*V^8!5I)Z*X9+1!J5 ]_A*(8%:7S4'8_2.2]R1L%VCN:Z(R8%Y4@A2X&LB
M571_;PC'UU*0(Z1]=5P.R$/S6G+49N=H0TKWK.\YI3WK7]WIR54\O+RQ[-##
M#7N^0SRY=U=+K+7"QH*ZU<[ YXUO/8<W[G_'32Z491(R@D9GE^<!,XVC-A/4
ME7>QM4;R1#\LZ",$Q@70?J;I(-N)2]!]UF9_ %!+ P04    " "[@@A7O,$Y
M_,,$  !1"P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R=5FUOVS80
M_BL'-RM:P+7EESA9DQA(TG;KN@Y!W6T?AGV@I;-%5"(UDHKC_?H]1RF*W<8!
MNB^42-X]]WZ\\XUU7WS.'.BN+(R_Z.4A5*^'0Y_F7"H_L!4;W*RL*U7 UJV'
MOG*LLLA4%L-QDLR&I=*F-S^/9S=N?F[K4&C#-XY\79;*;:^XL)N+WJAW?_!)
MK_,@!\/Y>:76O.#P>W7CL!MV*)DNV7AM#3E>7?0N1Z^OID(?"?[0O/$[_R26
M+*W](IOWV44O$86XX#0(@L+GEJ^Y* 0(:OS38O8ZD<*X^W^/_B[:#EN6RO.U
M+?[46<@O>J<]RGBEZB)\LIN?N;7G6/!26_BXTJ:AG8 XK7VP9<L,#4IMFJ^Z
M:_VPPW":'& 8MPSCJ'<C*&KY1@4U/W=V0TZH@28_T=3(#>6TD: L@L.M!E^8
M?^)"!<Y>5<J%+7UVRG@5_>7/AP'X0C5,6ZRK!FM\ &M&'ZT)N:>W)N-LGW\(
MO3KEQO?*78V?!/RE-@.:)'T:)^/)$WB3SMA)Q)L\;2S=?&,L_76Y],%A]_=C
M=C>PT\=AI6Y>^TJE?-%#87AVM]R;/W\VFB5G3R@][92>/H7^G1'ZOUCTWM""
MJ\#EDIWX>]2GD#-=V[)29DML CNX3IM@2:&&EP6C&)"M(:>%-;94].+YL]/Q
M.#EKMXN6)IZ.SE[V&^)-;LL]Z%QY2FU9HD:1[NF7W!89.]]0+ZUR&7E&ZP%_
M#AV6VSUNM78,O:!5IY.J*F?O-$J6BRV-3OM)DJ#<:^685M+H[(IBO& -=*_%
M F7H'=R1:I_:/EVK0J/A&:U0@\[!> !%\(SVY0_HC1O0AT+5WK!K?98K[43(
M#ITX871RYEN#<)EIA\YD'>Q2A8?ZDC>>X(RK2+*'\BV7;!I'#^@2;"0QO2?_
M*@*00$?3P0P-I"BD%P8VR@32)1QUR^BQ 1$PP>EE'7MEI;;Q< -M2I6Q&-U@
M2A!TFI/V:,FI71O]+WP"$!<%(TG* TI$-7&UM/ W*IN[RB9E,GK#:9-[DU$\
M'4=?(F(;652:NAJ""JV6NM!!BZ? 987F/D9[MY!TE R.[TWN1W(5S[]7>"/$
M6//JD*#)8-+Y5O!PL",9/:'B^/H4V[[D''QMVE<I)OFCWOIL@RH(KZ]309LU
M^% D2&"'\FF)151[[&TAR:Y"$T0%%*F)1Y!)RL#G=F-$E1BT2+V4!YI>Q#-;
M>V#[EP>UP*>H,UC?[A^3ZQ^R#\6,=U>^*LNT&+X'BJ+<2R?HT+:2QO5?B^^3
MX="V%8A!.CZT$%BG2*:1F..H\317;LU^@/;&])L-3"=]^E44\]0G5#F5%A[)
M."@-I<R!:.1H,WOO&RWTW?Y!3"?)GIV_%N@).^B(9M-368]E'?4GHY/NV[)W
MK:UU]Q%-9].XSK#^.$GB.H*6#XU1:K?I\VT\?EI\H$OIEDUI2^+A:*>@%36M
M5U(Z^B3D:(NCY(=#O0RMTP<DBEBTV\%W?#V!KW6*(0[&8G(JU-**"]HZ6=1I
MRM[C06[Z3:>>?^SA'.Z,.24CJ#+,2>!K$YJ)ISOMYL7+9DQZ(&^&S8_("8U7
MK^ 56)/!R7&/7#/ -9M@JS@TH5MA!(N_.69>=D* ^Y6%=>U&!'13]/P_4$L#
M!!0    ( +N""%=D]QZ1@ (  +P'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;*U5;4_;,!#^*U:&IDT:.&\-T*61:--IF\14P=@^N\FUL4CLS'9:
M^/>SG30K*%05XTMCG^]YSL_Y>A=ON;B7!8!"#U7)Y,0IE*K'&,NL@(K(,UX#
MTR<K+BJB]%:LL:P%D-R"JA+[KAOABE#F)+&U+402\T:5E,%"(-E4%1&/4RCY
M=N)XSLYP0]>%,@:<Q#59PRVHNWHA] [W+#FM@$G*&1*PFCA7WG@>&G_K\(O"
M5NZMD5&RY/S>;+[E$\<U%X(2,F48B/YL8 9E:8CT-?YTG$X?T@#WUSOV+U:[
MUK(D$F:\_$US54R<"P?EL")-J6[X]BMT>D:&+^.EM+]HV_J.1@[*&JEXU8'U
M#2K*VB]YZ/*P!_!> O@=P'\."%\ !!T@.#9"V '"8R.,.H"5CEOM-G$I422)
M!=\B8;PUFUG8[%NTSA=EIDYNE="G5.-4LB"/:"/1 H2M.98!2JG,2BX; >@4
MW=VFZ,/)1W2"*$,_"]Y(PG(98Z5C&P:<=7&F;1S_A3@!NN9,%1+-60[Y #X]
MC(\.X+'6W OW=\*G_D'"[PT[0X'["?FN'PS<9W8\W!^2\W_1YZ^._B0905\%
M@>4+7E,%0X_=TH7#=*:WC65-,I@XNGE)$!MPDO?OO,C]/)3IMR1+WY)L_D9D
M3]XD[-\D/,2>_-!#0C_ X'^M1486:2;!)CF-@HM+-\:;_<0.N 518 INWRT=
M</,"]R*\?.HW'_)SPS Z[_U:H7BO'54@UG8.2)3QAJFV)GMK/VJN;(=]9I]Z
MXYDW8$_U:&HGR3_Z=JY=$[&F3*(25CJ4>W:NNZ5H9T6[4;RVS7#)E6ZM=EGH
M\0K"..CS%>=JMS$!^H&=_ 502P,$%     @ NX((5UB-)I5$ @  B@8  !D
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M&SQPETYXHIL?,9V<O.$23$NVJ-HB=2AM0W(Z':8"?,2/TTEW(S,Y:OB#(AB
M#N>YXX_AOO7>63QG*6X'[V'^7\+%+V"0@Q:->]=-I4*#0I=JW)?:F&Z>VM'V
MXFZ>KJNZY>G6[RWZ&RJ>1JVP=3)ZB2]=GR[2TDMT%5]>+5V,KN3' CVS\K0
M\ROGXNZ%#FBO,V_^!%!+ P04    " "[@@A7A(K ;50#  "W"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6SM5DMOXS80_BL#;;'( JGUL.PX6=N
MDS;8%@UJK+?MH>B!EL82$8K4DE1L[Z_OD%34I/ :O>RM!_$]WWSS($?SO=*/
MID:T<&B$-(NHMK:]B6-3U-@P,U(M2MK9*=TP2U-=Q:;5R$HOU(@X2Y)IW# N
MH^7<KZWU<JXZ*[C$M0;3-0W3QUL4:K^(TNAYX2.O:NL6XN6\915NT/[6KC7-
MX@&EY U*PY4$C;M%M$IO;G-WWA_XG>/>O!B#LV2KU*.;_%0NHL010H&%=0B,
MNB>\0R$<$-'XW&-&@THG^'+\C'[O;2=;MLS@G1)_\-+6BV@608D[U@G[4>T_
M8&_/Q.$52AC?PKX_FT10=,:JIA<F!@V7H6>'W@__12#K!3+/.RCR+']@EBWG
M6NU!N].$Y@;>5"]-Y+AT0=E83;N<Y.SR%UZ0A_$2R"S!MDHSYZQ+8+*$35<4
M: RLV9'"8&%5:40W,G#QB6T%FG?SV!()!Q47O<+;H##[BL(I/"AI:P,_RA++
MU_(QD1\LR)XMN,W. O[<R1&,DTO(DFQ\!F\\>&3L\<9?P?M55TSR+[T?[I0T
M2O"2A1PBKZPU&O)!6% [N.>2R8(S 1M:[/WSYVIKK*:4^^N4AP*!_#0!=PUO
M3,L*7$2MTZ6?,%J^?9-.D_=GS,L'\_)SZ,L-7>NR$^BHKRJ*:$6D8:TL\?9&
MO ZZ.<7_K(;3_#_5"#M*,;7GL@+KLJ=_"/@7-&!IFPULVH&-Z=FT/9M+V->\
MJ(%I=&L>QBJXUUC"A\[2#I=0,%.#TJ''SQU_8B((TR*S7MF=:EHFCV_?S++T
MZKV!DIM"8XAYVVT%+\3Q>XI@B8%J31J-\]DIX4(U#24#7=;B\08>Z$'@;? P
ME]S;X5C8(Q"1#AT%;DQ'68.0)@=*W ,E\ %R^B;TK5$'A:^ H=5T5^DA)"AG
M+CW(SVZ![R"=C;)KZL?3T61&_20?S:;47XU'Z83ZZW24YR\"_B_'7IAW<$&N
M:[@0Y .:$61"3>Z::]>D?DB//7S;6-(MDF1;^7\DOWTD3[TG\8MBTJ"N?,ET
MGNFD#75E6!VJ\BH4HW^.AY+^P'3%I0&!.Q)-1E>3"'0HDV%B5>M+TU99*G1^
M6-.?!6IW@/9WBK*GGS@%P[_*\F]02P,$%     @ NX((5\"*4F_X P  IP\
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MH$D UZ=*V>T#;=!])(W^!E!+ P04    " "[@@A7<6^PQ \#   7!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q]56UOTS 0_BNG#"$FE29-7U:V
MME+'BP !FM8!'Q ?W.3:6#AVL2]TX]=S=M+0;5V_V#[[[KGG+O'CR=;87ZY
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M[-8O;ZUL9R]_<W-A;?&A63Q4LTM-NQM\5/< 0@<=UT4U#]4$JDE4\U%-H5J
M:B&EZ=5?Y>R&YK4,/YU4V6A2#M7L4M/7H.S6ES8:@T,U#]4$JDE4\U%-H5J
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MP-8K*EV4C\2Z2Y5*Y^7B3(J)S(HWZ.W3-%5/*\53MC:/81O_!U!+ P04
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MV@@**KXYRWC]%SPV6&\$YALN6-X$RPSRM-C^)]^;0NP$0/^) -0$H$,#<!.
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M=7[41H)V1L)4N5@;?FE\8^UFT&'0BZ*) DNL^0Q4"[W.D7E6O3N]GK>]WFB
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MUZ:V!X*MZQ>);ID0+*\_KBA9T+("R.^7C(F?!]6[2>W+:]/_ 5!+ P04
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M(:RH_(U;S'U!T*S-N31T?LS(*FCU: GIZE:N&E8MRHMMJBQ=D^5C1A\RJ%T
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MDSR[13KR7#I8X,6,T2-BV=.2EAWDALC5,H51FGGW7C!Y-Y(ZL?@HMH2AF_1
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M'I#WUY2*QY,L0+7C<O$_4$L#!!0    ( +N""%>AF!_E9@<  %(_   9
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M$.@"K9IU1&R#OE:$8TG++=*]:,F*@DI8.RG0YS+)ZU3U_?%0P5*0M!T$'3
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MS.!*2[@: /T;QN130UV:NDORXC]02P,$%     @ NX((5_\J6.6\!0  XRT
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MR._7G(N7#T6"PV*OB_\!4$L#!!0    ( +N""%?\ZPR)MP,  ",1   9
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;,U86V_;-AC]*X16#"VP1E=?E-D"
M8DOM.JQH$+?=P[ '1OIL$:%$E:3M9+]^I*2HDJP8Z:8"?;%(ZIS#[^9/HA9'
MQN]$"B#1?49SL312*8M+TQ1Q"AD6%ZR 7-W9,IYAJ:9\9XJ" TY*4D9-Q[*F
M9H9);@2+<NV:!PNVEY3D<,V1V&<9Y@\KH.RX-&SC<>&&[%*I%\Q@4> =;$!^
M*JZYFIF-2D(RR 5A.>*P71I7]F5D6YI0(CX3.(K6&&E7;AF[TY-WR=*PM$5
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M*6AD'^U(V+9/!SYZS[^4U:>0QOND_1XY1+I],O"KWXS]+#^%L[]W#N,>'OR
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M1A2&_\J(KJJLM F^@"%90$KPI6DWW2ADVP]5/TQ@ &OM&7<\P*;JC^_X$E_
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" "[@@A7SJ\;[1X$   V(   #P   'AL+W=O<FMB;V]K+GAM;,69WV_;-A"
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M2>*H\DGO<3>QS9HDVMJJS'2(XVS=Y-]2!ON$-*[LYOBBM+X?)R3L9$([\G/
M?MWKFIPK<^K-M LONHZSV*9B/FPK\NGY$B=Z-/-YF5%NLE4=EZ3>.M*Y+XA"
M7:6[HOWSR2'N,.VN_.K\KLRYP#ASYHSU\<0<71YW.))V]<#&0N1">?X3CXFQ
M]-7?1^UIYY3_,CMN[X=QR^X\/.MNU^_QUS,^UK^P#P'2AP3I0X'T<0/2QPBD
MCUN0/NY ^K@'Z8,/41I!$96CD,I13.4HJ'(453D*JQS%58X"*T>15:#(*E!D
M%2BR"A19!8JL D56@2*K0)%5H,@J4&25*+)*%%DEBJP215:)(JM$D56BR"I1
M9)4HLDH4616*K I%5H4BJT*15:'(JE!D52BR*A19U7_*^F[,\J__P+7WM-9E
M<\AGW6_.Z2=02P$"% ,4    " "[@@A7!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +N""%?<]*R&
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( +N""%>97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ NX((5S-P&[/)!0  NQX
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M965T-2YX;6Q02P$"% ,4    " "[@@A7RT) ]U0*  #]7@  &
M    @(&#(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
MNX((5]M.Y=PT"   7R0  !@              ("!#2P  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( +N""%=#:^+XK0(  ,(%   8
M          " @7<T  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " "[@@A7B"0>$>P)  !G&0  &               @(%:-P  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ NX((5S3-!&JF$P  A$L
M !D              ("!?$$  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " "[@@A7;.99_:,%  !7#P  &0              @(%950
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +N""%<]-FA5
M1 8  #H/   9              " @3-;  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ NX((5S?7Q"A."0  :AP  !D
M ("!KF$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "[
M@@A7NA[7JL0&   4(   &0              @($S:P  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +N""%?LL_#WN 0  *0+   9
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M970Q.2YX;6Q02P$"% ,4    " "[@@A79/<>D8 "  "\!P  &0
M    @('8C0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M +N""%=8C2:51 (  (H&   9              " @8^0  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ NX((5T.?9EL#"   VA0  !D
M             ("!"I,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " "[@@A7A(K ;50#  "W"   &0              @(%$FP  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +N""%? BE)O^ ,
M *</   9              " @<^>  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ NX((5V'Z(<1Y!0  P!,  !D              ("!
M_J(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "[@@A7
M<+X(R7\#  "-"@  &0              @(&NJ   >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( +N""%>NX,#U604  # -   9
M      " @62L  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ NX((5W%OL,0/ P  %P<  !D              ("!]+$  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "[@@A7$E[)L;,$  #^%0
M&0              @($ZM0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( +N""%?C1E5U9!<  +^% 0 9              " @22Z  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ NX((5T!QM#MS
M!P  DDT  !D              ("!O]$  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " "[@@A7ZU=<4_ %  #()@  &0
M@(%IV0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( +N"
M"%?[CC/IVP(  "8)   9              " @9#?  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ NX((5]YBTFSD!   ?2D  !D
M         ("!HN(  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " "[@@A7H9@?Y68'  !2/P  &0              @(&]YP  >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( +N""%<IZ;!88@4  %PH
M   9              " @5KO  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ NX((5Y0VWIL+!   <A4  !D              ("!\_0
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "[@@A7CU>_
MRQP$  #9&P  &0              @($U^0  >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( +N""%?-C+_ZV@,  # /   9
M  " @8C]  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
MNX((5_\J6.6\!0  XRT  !D              ("!F0$! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " "[@@A7^U7"B[H#  !8$   &0
M            @(&,!P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( +N""%>WW)7[KP@  /A5   9              " @7T+ 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ NX((5_SK#(FW P
M(Q$  !D              ("!8Q0! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " "[@@A7PWNYMTX#   I"P  &0              @(%1
M& $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( +N""%<-
MZNCFQ@0  &<6   9              " @=8; 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ NX((5S$)NET- P  3P@  !D
M     ("!TR ! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
M" "[@@A7._'^$7L%  "5+   &0              @($7) $ >&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( +N""%> ("/K2 ,   L-   9
M              " @<DI 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L!
M A0#%     @ NX((5W,:S@9+ P  T!0   T              ( !2"T! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "[@@A7EXJ[',     3 @  "P
M        @ &^, $ 7W)E;',O+G)E;'-02P$"% ,4    " "[@@A7SJ\;[1X$
M   V(   #P              @ &G,0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ NX((5Y(LH):X 0  YQP  !H              ( !\C4! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ NX((5XQ/ZH^Z 0
M[AP  !,              ( !XC<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     #@ .  _#P  S3D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>227</ContextCount>
  <ElementCount>267</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - License, Collaboration, and Success Payment Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Other Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/OtherInvestments</Role>
      <ShortName>Other Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Related-party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactions</Role>
      <ShortName>Related-party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lyell.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954702 - Disclosure - License, Collaboration, and Success Payment Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954703 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/CashEquivalentsandMarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954704 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954705 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954706 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/StockbasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954707 - Disclosure - Related-party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactionsTables</Role>
      <ShortName>Related-party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyell.com/role/RelatedpartyTransactions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954708 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954709 - Disclosure - License, Collaboration, and Success Payment Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954710 - Disclosure - License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails</Role>
      <ShortName>License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954711 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954712 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954713 - Disclosure - Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/OtherInvestmentsDetails</Role>
      <ShortName>Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/OtherInvestments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954714 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954715 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liability Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liability Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954716 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954717 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954718 - Disclosure - Leases - Summary of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954719 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954720 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyell.com/role/StockholdersEquity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954721 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954722 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954723 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954724 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954725 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954726 - Disclosure - Related-party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails</Role>
      <ShortName>Related-party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lyel-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954727 - Disclosure - Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails</Role>
      <ShortName>Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lyel-20230630.htm">lyel-20230630.htm</File>
    <File>lyel-20230630.xsd</File>
    <File>lyel-20230630_cal.xml</File>
    <File>lyel-20230630_def.xml</File>
    <File>lyel-20230630_lab.xml</File>
    <File>lyel-20230630_pre.xml</File>
    <File>lyel-20230630x10qxexx101.htm</File>
    <File>lyel-20230630x10qxexx311.htm</File>
    <File>lyel-20230630x10qxexx312.htm</File>
    <File>lyel-20230630x10qxexx321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lyel-20230630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="612">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lyel-20230630.htm": {
   "axisCustom": 1,
   "axisStandard": 23,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 612,
    "http://xbrl.sec.gov/dei/2023": 29,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "contextCount": 227,
   "dts": {
    "calculationLink": {
     "local": [
      "lyel-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lyel-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lyel-20230630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lyel-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lyel-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lyel-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    }
   },
   "elementCount": 515,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 5
   },
   "keyCustom": 45,
   "keyStandard": 222,
   "memberCustom": 26,
   "memberStandard": 23,
   "nsprefix": "lyel",
   "nsuri": "http://lyell.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://lyell.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - License, Collaboration, and Success Payment Agreements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements",
     "shortName": "License, Collaboration, and Success Payment Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Cash Equivalents and Marketable Securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecurities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lyel:OtherInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Other Investments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://lyell.com/role/OtherInvestments",
     "shortName": "Other Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lyel:OtherInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://lyell.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://lyell.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://lyell.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stock-based Compensation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://lyell.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://lyell.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://lyell.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Related-party Transactions",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://lyell.com/role/RelatedpartyTransactions",
     "shortName": "Related-party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "shortName": "Pay vs Performance Disclosure",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "shortName": "Insider Trading Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954702 - Disclosure - License, Collaboration, and Success Payment Agreements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables",
     "shortName": "License, Collaboration, and Success Payment Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954703 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954704 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://lyell.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954705 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://lyell.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954706 - Disclosure - Stock-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://lyell.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954707 - Disclosure - Related-party Transactions (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://lyell.com/role/RelatedpartyTransactionsTables",
     "shortName": "Related-party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954708 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-54",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954709 - Disclosure - License, Collaboration, and Success Payment Agreements - Narrative (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
     "shortName": "License, Collaboration, and Success Payment Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-104",
      "decimals": "2",
      "lang": "en-US",
      "name": "lyel:LitigationSettlementPercentOfTotalEquityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-69",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "lyel:CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954710 - Disclosure - License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
     "shortName": "License, Collaboration, and Success Payment Agreements - Schedule of Aggregate Potential Success Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-64",
      "decimals": "INF",
      "lang": "en-US",
      "name": "lyel:CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954711 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Cash Equivalents and Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lyel:CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954712 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
     "shortName": "Cash Equivalents and Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954713 - Disclosure - Other Investments (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://lyell.com/role/OtherInvestmentsDetails",
     "shortName": "Other Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-121",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954714 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-153",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lyel:FairValueOfSeriesAConvertiblePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954715 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liability Assumptions (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
     "shortName": "Fair Value Measurements - Summary of Estimated Fair Value of Success Payment Liability Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-153",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lyel:FairValueOfSeriesAConvertiblePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-57",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lyel:CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954716 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-177",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954717 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lyel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954718 - Disclosure - Leases - Summary of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails",
     "shortName": "Leases - Summary of Operating Lease Commitments Including Expected Lease Incentives to be Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lyel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954719 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://lyell.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954720 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://lyell.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-192",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954721 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954722 - Disclosure - Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails",
     "shortName": "Stock-based Compensation - Schedule of Stock-Based Compensation Expense by Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-215",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954723 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Stock-based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-215",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-4",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954724 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954725 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails",
     "shortName": "Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954726 - Disclosure - Related-party Transactions - Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
     "shortName": "Related-party Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-220",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954727 - Disclosure - Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails",
     "shortName": "Related-party Transactions - Schedule of Total Income Attributable to Sonoma Sublease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-188",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-8",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-45",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-45",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://lyell.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://lyell.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyel-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address Line"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Security12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lyell.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "localname": "Additional402vDisclosureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToCompAmt": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "localname": "AdjToCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AdjToCompAxis": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "localname": "AdjToCompAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "localname": "AdjToPeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AggtErrCompAmt": {
     "auth_ref": [
      "r693",
      "r704",
      "r714",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "AggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "auth_ref": [
      "r696",
      "r707",
      "r717",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AllAdjToCompMember": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "localname": "AllAdjToCompMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllExecutiveCategoriesMember": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "localname": "AllExecutiveCategoriesMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllIndividualsMember": {
     "auth_ref": [
      "r700",
      "r708",
      "r718",
      "r735",
      "r743",
      "r747",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "localname": "AllIndividualsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllTradingArrangementsMember": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "localname": "AllTradingArrangementsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AwardExrcPrice": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "localname": "AwardExrcPrice",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "perShareItemType"
    },
    "ecd_AwardGrantDateFairValue": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "localname": "AwardGrantDateFairValue",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AwardTmgDiscLineItems": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "localname": "AwardTmgDiscLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgMethodTextBlock": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "localname": "AwardTmgMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "localname": "AwardTmgMnpiDiscTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "localname": "AwardTmgPredtrmndFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "localname": "AwardUndrlygSecuritiesAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "localname": "ChangedPeerGroupFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CoSelectedMeasureAmt": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "localname": "CoSelectedMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_CoSelectedMeasureName": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "localname": "CoSelectedMeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "auth_ref": [
      "r693",
      "r704",
      "r714",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "localname": "ErrCompAnalysisTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompRecoveryTable": {
     "auth_ref": [
      "r690",
      "r701",
      "r711",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "localname": "ErrCompRecoveryTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ExecutiveCategoryAxis": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "localname": "ExecutiveCategoryAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ForgoneRecoveryIndName": {
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "ForgoneRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_IndividualAxis": {
     "auth_ref": [
      "r700",
      "r708",
      "r718",
      "r735",
      "r743",
      "r747",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "localname": "IndividualAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTradingArrLineItems": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "localname": "InsiderTradingArrLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "auth_ref": [
      "r689",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "localname": "InsiderTradingPoliciesProcLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "auth_ref": [
      "r689",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "auth_ref": [
      "r689",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_MeasureAxis": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "localname": "MeasureAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_MeasureName": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "MeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "localname": "MnpiDiscTimedForCompValFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonNeosMember": {
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r735",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "localname": "NonNeosMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoMember": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "localname": "NonPeoNeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "NonRule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "NonRule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_OtherPerfMeasureAmt": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "localname": "OtherPerfMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "auth_ref": [
      "r695",
      "r706",
      "r716",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "OutstandingAggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "auth_ref": [
      "r698",
      "r709",
      "r719",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "localname": "OutstandingRecoveryCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryIndName": {
     "auth_ref": [
      "r698",
      "r709",
      "r719",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "OutstandingRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "localname": "PayVsPerformanceDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "localname": "PeerGroupIssuersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "localname": "PeoActuallyPaidCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoMember": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "localname": "PeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_PeoName": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "localname": "PeoName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_PeoTotalCompAmt": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "localname": "PeoTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PvpTable": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "localname": "PvpTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PvpTableTextBlock": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "localname": "PvpTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "auth_ref": [
      "r690",
      "r701",
      "r711",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDateAxis": {
     "auth_ref": [
      "r691",
      "r702",
      "r712",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "localname": "RestatementDateAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDeterminationDate": {
     "auth_ref": [
      "r692",
      "r703",
      "r713",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "localname": "RestatementDeterminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "dateItemType"
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "auth_ref": [
      "r699",
      "r710",
      "r720",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "Rule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "Rule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "auth_ref": [
      "r694",
      "r705",
      "r715",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TabularListTableTextBlock": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "localname": "TabularListTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TotalShareholderRtnAmt": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "localname": "TotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TradingArrAxis": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "localname": "TradingArrAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TradingArrByIndTable": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "localname": "TradingArrByIndTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrAdoptionDate": {
     "auth_ref": [
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "localname": "TrdArrAdoptionDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrDuration": {
     "auth_ref": [
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "localname": "TrdArrDuration",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "durationItemType"
    },
    "ecd_TrdArrIndName": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "TrdArrIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrIndTitle": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "localname": "TrdArrIndTitle",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "sharesItemType"
    },
    "ecd_TrdArrTerminationDate": {
     "auth_ref": [
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "localname": "TrdArrTerminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "auth_ref": [
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "localname": "UndrlygSecurityMktPriceChngPct",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "pureItemType"
    },
    "lyel_AdjustmentToRevenueRelatedToChangeInEstimateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment To Revenue Related To Change In Estimate",
        "label": "Adjustment To Revenue Related To Change In Estimate [Member]",
        "terseLabel": "Adjustment To Revenue Related To Change In Estimate"
       }
      }
     },
     "localname": "AdjustmentToRevenueRelatedToChangeInEstimateMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Lease Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyel_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents And Debt Securities, Available-For-Sale",
        "label": "Cash Equivalents And Debt Securities, Available-For-Sale [Abstract]",
        "terseLabel": "Classified as:"
       }
      }
     },
     "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleAbstract",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost",
        "label": "Cash Equivalents, At Carry Value And Debt Securities, Available-For-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Fair Value Disclosure",
        "label": "Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsFairValueDisclosure",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale",
        "label": "Cash Equivalents, Fair Value Disclosure And Debt Securities, Available-For-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CashReceivedForAmountsRelatedToTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for amounts related to tenant improvement allowances.",
        "label": "Cash Received For Amounts Related To Tenant Improvement Allowances",
        "terseLabel": "Cash received for amounts related to tenant improvement allowances"
       }
      }
     },
     "localname": "CashReceivedForAmountsRelatedToTenantImprovementAllowances",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments",
        "terseLabel": "Aggregate success payment(s) (in millions)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPayments",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price",
        "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Potential Success Payments, Share Price",
        "terseLabel": "Per share common stock price required for payment (in dollars per share)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAggregatePotentialSuccessPaymentsSharePrice",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Annual License Maintenance Payments",
        "terseLabel": "Annual license maintenance payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenancePayments",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Commercial Milestone Payments",
        "terseLabel": "Potential milestone payments due"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsCommercialMilestonePayments",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Milestone Payments",
        "terseLabel": "Potential milestone payments due"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayments",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier",
        "label": "Collaborative Arrangement, Rights And Obligations, Potential Payment Multiplier",
        "terseLabel": "Multiple of initial equity value at issuance"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPotentialPaymentMultiplier",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsResearchPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Research Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Research Payments",
        "terseLabel": "Aggregate research payments due"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsResearchPayments",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Research Term",
        "label": "Collaborative Arrangement, Rights And Obligations, Research Term",
        "terseLabel": "Term of collaborative arrangement for research"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsResearchTerm",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Additional Purchase Price",
        "label": "Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Additional Purchase Price",
        "terseLabel": "Additional purchase price consideration"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementAdditionalPurchasePrice",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Fair Value Per Share",
        "label": "Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Fair Value Per Share",
        "terseLabel": "Stock purchase agreement, fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementFairValuePerShare",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Stock Purchase Agreement, Purchase Price Per Share",
        "label": "Collaborative Arrangement, Rights And Obligations, Stock Purchase Agreement, Purchase Price Per Share",
        "terseLabel": "Stock purchase agreement, purchase price per share (in dollars per share)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementPurchasePricePerShare",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Shares Purchased",
        "label": "Collaborative Arrangement, Rights and Obligations, Stock Purchase Agreement, Shares Purchased",
        "terseLabel": "Stock purchase agreement, stock purchased (in shares)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsStockPurchaseAgreementSharesPurchased",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Fair Value Of Liability",
        "terseLabel": "Fair value of potential success payments due"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementFairValueOfLiability",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Liability",
        "terseLabel": "Success payment liability"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementLiability",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Term",
        "terseLabel": "Term of success payment agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTerm",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period Thereafter",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period After Initial Public Offering",
        "terseLabel": "Trigger period thereafter"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodAfterInitialPublicOffering",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Agreement, Trigger Period From Initial Public Offering Date",
        "terseLabel": "Trigger period from IPO date"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentAgreementTriggerPeriodFromInitialPublicOfferingDate",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)",
        "label": "Collaborative Arrangement, Rights And Obligations, Success Payment Expense (Gain)",
        "terseLabel": "Success payment expense (gain)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSuccessPaymentExpenseGain",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "terseLabel": "Total upfront payment paid"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_EquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Distribution Agreement",
        "label": "Equity Distribution Agreement [Member]",
        "terseLabel": "Equity Distribution Agreement"
       }
      }
     },
     "localname": "EquityDistributionAgreementMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_EquityMultipleAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Multiple Axis.",
        "label": "Equity Multiple [Axis]",
        "terseLabel": "Equity Multiple [Axis]"
       }
      }
     },
     "localname": "EquityMultipleAxis",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lyel_EquityMultipleDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Multiple Domain.",
        "label": "Equity Multiple [Domain]",
        "terseLabel": "Equity Multiple [Domain]"
       }
      }
     },
     "localname": "EquityMultipleDomain",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_FairValueAdjustmentOfSuccessPaymentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustment of success payment liabilities",
        "label": "Fair Value Adjustment Of Success Payment Liabilities",
        "terseLabel": "Change in fair value of success payment liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfSuccessPaymentLiabilities",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_FairValueOfSeriesAConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the Series A convertible preferred stock.",
        "label": "Fair Value Of Series A Convertible Preferred Stock",
        "terseLabel": "Fair value of common stock Series A convertible preferred stock"
       }
      }
     },
     "localname": "FairValueOfSeriesAConvertiblePreferredStock",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lyel_FiftyTimesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifty Times (50x).",
        "label": "Fifty Times [Member]",
        "terseLabel": "Fifty Times"
       }
      }
     },
     "localname": "FiftyTimesMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_FortyTimesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forty Times (40x).",
        "label": "Forty Times [Member]",
        "terseLabel": "Forty Times"
       }
      }
     },
     "localname": "FortyTimesMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_FredHutchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fred Hutch",
        "label": "Fred Hutch [Member]",
        "terseLabel": "Fred Hutch"
       }
      }
     },
     "localname": "FredHutchMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_FredHutchSuccessPaymentLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fred Hutch Success Payment Liability",
        "label": "Fred Hutch Success Payment Liability [Member]",
        "terseLabel": "Fred Hutch"
       }
      }
     },
     "localname": "FredHutchSuccessPaymentLiabilityMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_GSKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK",
        "label": "GSK [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GSKMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Smith Kline Intellectual Property (No. 5) Limited And Glaxo Group Limited",
        "label": "Glaxo Smith Kline Intellectual Property (No. 5) Limited And Glaxo Group Limited [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineIntellectualPropertyNo5LimitedAndGlaxoGroupLimitedMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_GoldmanSachsAndBofAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goldman Sachs and BofA",
        "label": "Goldman Sachs and BofA [Member]",
        "terseLabel": "Goldman Sachs and BofA"
       }
      }
     },
     "localname": "GoldmanSachsAndBofAMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_LitigationSettlementPercentOfTotalEquityValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Percent Of Total Equity Value",
        "label": "Litigation Settlement, Percent Of Total Equity Value",
        "terseLabel": "Ownership of fully diluted shares (as a percent)"
       }
      }
     },
     "localname": "LitigationSettlementPercentOfTotalEquityValue",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyel_LyellImmunopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lyell Immunopharma",
        "label": "Lyell Immunopharma [Member]",
        "terseLabel": "Lyell Immunopharma"
       }
      }
     },
     "localname": "LyellImmunopharmaMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_NonCashLeaseIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Lease Income (Expense)",
        "label": "Non-Cash Lease Income (Expense)",
        "negatedTerseLabel": "Non-cash lease income"
       }
      }
     },
     "localname": "NonCashLeaseIncomeExpense",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_OtherInvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Investment.",
        "label": "Other Investment [Member]",
        "terseLabel": "Other Investment"
       }
      }
     },
     "localname": "OtherInvestmentMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_OtherInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other investments.",
        "label": "Other Investments [Text Block]",
        "terseLabel": "Other Investments"
       }
      }
     },
     "localname": "OtherInvestmentsTextBlock",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/OtherInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyel_PACTPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PACT Pharma, Inc.",
        "label": "PACT Pharma, Inc. [Member]",
        "terseLabel": "PACT"
       }
      }
     },
     "localname": "PACTPharmaIncMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Upfront Payments For Research And Development Agreement",
        "label": "Payments Of Upfront Payments For Research And Development Agreement",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "PaymentsOfUpfrontPaymentsForResearchAndDevelopmentAgreement",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_PercentageOfCommissionFromEachSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Commission From Each Sale Of Shares",
        "label": "Percentage of Commission From Each Sale Of Shares",
        "terseLabel": "Percentage of commission from each sale of shares"
       }
      }
     },
     "localname": "PercentageOfCommissionFromEachSaleOfShares",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyel_RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represented by Cash and Cash Equivalents and Restricted Cash.",
        "label": "Represented By Cash And Cash Equivalents And Restricted Cash [Abstract]",
        "terseLabel": "Represented by:"
       }
      }
     },
     "localname": "RepresentedByCashAndCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "lyel_RevenueRemainingPerformanceObligationAmountStockPurchaseProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program",
        "label": "Revenue, Remaining Performance Obligation, Amount, Stock Purchase Program",
        "terseLabel": "Stock purchase agreement portion of transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationAmountStockPurchaseProgram",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_SeriesAAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series AA Convertible Preferred Stock",
        "label": "Series A A Convertible Preferred Stock [Member]",
        "terseLabel": "Series AA Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAAConvertiblePreferredStockMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Additional Shares Authorized, Number Of Shares As Percentage Of Common Shares Outstanding",
        "terseLabel": "Increase in proportion of common shares reserved for future issuance (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedNumberOfSharesAsPercentageOfCommonSharesOutstanding",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding",
        "terseLabel": "Proportion of stock outstanding (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Offering Period",
        "terseLabel": "Maximum offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lyel_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable",
        "terseLabel": "Maximum number of shares to be purchased under ESPP (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyel_SignificantAccountingPoliciesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies",
        "label": "Significant Accounting Policies [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesPolicyTextBlock",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyel_SonomaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sonoma",
        "label": "Sonoma [Member]",
        "terseLabel": "Sonoma"
       }
      }
     },
     "localname": "SonomaMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_SouthSanFranciscoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South San Francisco, California",
        "label": "South San Francisco, California [Member]",
        "terseLabel": "South San Francisco, California"
       }
      }
     },
     "localname": "SouthSanFranciscoCaliforniaMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_StanfordMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stanford.",
        "label": "Stanford [Member]",
        "terseLabel": "Stanford"
       }
      }
     },
     "localname": "StanfordMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_StanfordSuccessPaymentLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stanford Success Payment Liability",
        "label": "Stanford Success Payment Liability [Member]",
        "terseLabel": "Stanford"
       }
      }
     },
     "localname": "StanfordSuccessPaymentLiabilityMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_StockPurchaseAgreementFairValueOfStockPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Fair Value Of Stock Per Share",
        "label": "Stock Purchase Agreement, Fair Value Of Stock Per Share",
        "terseLabel": "Fair value per share of stock sold under stock purchase program (in dollars per share)"
       }
      }
     },
     "localname": "StockPurchaseAgreementFairValueOfStockPerShare",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lyel_StockPurchaseAgreementSharesSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Shares Sold",
        "label": "Stock Purchase Agreement, Shares Sold",
        "terseLabel": "Stock sold under stock purchase program (in shares)"
       }
      }
     },
     "localname": "StockPurchaseAgreementSharesSold",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyel_StockPurchaseAgreementSharesSoldPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Shares Sold, Price Per Share",
        "label": "Stock Purchase Agreement, Shares Sold, Price Per Share",
        "terseLabel": "Price per share of stock sold under stock purchase program (in dollars per share)"
       }
      }
     },
     "localname": "StockPurchaseAgreementSharesSoldPricePerShare",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lyel_SuccessPaymentLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success Payment Liabilities, Current",
        "label": "Success Payment Liabilities, Current",
        "terseLabel": "Success payment liabilities"
       }
      }
     },
     "localname": "SuccessPaymentLiabilitiesCurrent",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_SuccessPaymentLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success Payment Liabilities, Fair Value Disclosure",
        "label": "Success Payment Liabilities, Fair Value Disclosure",
        "terseLabel": "Success payment liabilities"
       }
      }
     },
     "localname": "SuccessPaymentLiabilitiesFairValueDisclosure",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyel_SuccessPaymentLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success Payment Liability, Measurement Input",
        "label": "Success Payment Liability, Measurement Input",
        "terseLabel": "Success payment liability, measurement input (as a percent)"
       }
      }
     },
     "localname": "SuccessPaymentLiabilityMeasurementInput",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "lyel_SuccessPaymentLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success Payment Liability",
        "label": "Success Payment Liability [Member]",
        "verboseLabel": "Success Payment Liabilities"
       }
      }
     },
     "localname": "SuccessPaymentLiabilityMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_TenTimesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ten Times (10x).",
        "label": "Ten Times [Member]",
        "terseLabel": "Ten Times"
       }
      }
     },
     "localname": "TenTimesMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_ThirtyTimesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Thirty Times (30x).",
        "label": "Thirty Times [Member]",
        "terseLabel": "Thirty Times"
       }
      }
     },
     "localname": "ThirtyTimesMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_TwentyTimesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Times (20x).",
        "label": "Twenty Times [Member]",
        "terseLabel": "Twenty Times"
       }
      }
     },
     "localname": "TwentyTimesMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eighteen Equity Incentive Plan",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one employee stock purchase plan.",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 ESPP"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyel_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one equity incentive plan.",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://lyell.com/20230630",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r252",
      "r258",
      "r379",
      "r649",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/OtherInvestmentsDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails",
      "http://lyell.com/role/StockholdersEquityDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r286",
      "r413",
      "r455",
      "r493",
      "r494",
      "r557",
      "r576",
      "r581",
      "r582",
      "r613",
      "r644",
      "r645",
      "r657",
      "r661",
      "r667",
      "r674",
      "r815",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r286",
      "r413",
      "r455",
      "r493",
      "r494",
      "r557",
      "r576",
      "r581",
      "r582",
      "r613",
      "r644",
      "r645",
      "r657",
      "r661",
      "r667",
      "r674",
      "r815",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r179",
      "r415",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r646",
      "r662",
      "r673",
      "r763",
      "r811",
      "r812",
      "r816",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r179",
      "r415",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r646",
      "r662",
      "r673",
      "r763",
      "r811",
      "r812",
      "r816",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r278",
      "r286",
      "r314",
      "r315",
      "r316",
      "r389",
      "r413",
      "r455",
      "r493",
      "r494",
      "r557",
      "r576",
      "r581",
      "r582",
      "r613",
      "r644",
      "r645",
      "r657",
      "r661",
      "r667",
      "r674",
      "r677",
      "r808",
      "r815",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r278",
      "r286",
      "r314",
      "r315",
      "r316",
      "r389",
      "r413",
      "r455",
      "r493",
      "r494",
      "r557",
      "r576",
      "r581",
      "r582",
      "r613",
      "r644",
      "r645",
      "r657",
      "r661",
      "r667",
      "r674",
      "r677",
      "r808",
      "r815",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r252",
      "r258",
      "r379",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/OtherInvestmentsDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails",
      "http://lyell.com/role/StockholdersEquityDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r486",
      "r489",
      "r491",
      "r563",
      "r577",
      "r598",
      "r619",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r647",
      "r663",
      "r677",
      "r816",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r486",
      "r489",
      "r491",
      "r563",
      "r577",
      "r598",
      "r619",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r647",
      "r663",
      "r677",
      "r816",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r672"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization and accretion on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued liabilities and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r23",
      "r63",
      "r111",
      "r440",
      "r460",
      "r461"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r2",
      "r7",
      "r23",
      "r336",
      "r339",
      "r372",
      "r456",
      "r457",
      "r775",
      "r776",
      "r777",
      "r783",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r58",
      "r672",
      "r866"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r473",
      "r783",
      "r784",
      "r785",
      "r846",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r45",
      "r46",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r318",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/StockholdersEquityDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r85",
      "r106",
      "r133",
      "r167",
      "r173",
      "r177",
      "r221",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r331",
      "r333",
      "r353",
      "r436",
      "r515",
      "r672",
      "r684",
      "r813",
      "r814",
      "r852"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r102",
      "r112",
      "r133",
      "r221",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r331",
      "r333",
      "r353",
      "r672",
      "r813",
      "r814",
      "r852"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "order": 3.0,
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r185",
      "r230",
      "r435"
     ],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r186",
      "r230",
      "r428",
      "r788"
     ],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26",
      "r104",
      "r648"
     ],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "lyel_CashEquivalentsAtCarryValueAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      },
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r26",
      "r70",
      "r131"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r70"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r30",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r30",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r99",
      "r108",
      "r109",
      "r110",
      "r133",
      "r154",
      "r155",
      "r157",
      "r159",
      "r165",
      "r166",
      "r221",
      "r243",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r256",
      "r257",
      "r260",
      "r263",
      "r270",
      "r353",
      "r465",
      "r466",
      "r467",
      "r468",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r503",
      "r524",
      "r546",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r761",
      "r781",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r165",
      "r256",
      "r257",
      "r258",
      "r260",
      "r263",
      "r268",
      "r270",
      "r465",
      "r466",
      "r467",
      "r468",
      "r661",
      "r761",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r92",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration, and Success Payment Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r19",
      "r52",
      "r437",
      "r502"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r237",
      "r238",
      "r634",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Future issuance of common shares (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r783",
      "r784",
      "r846",
      "r865",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r57",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r57",
      "r503",
      "r521",
      "r867",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r57",
      "r439",
      "r672"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 500,000 shares authorized at June\u00a030, 2023 and December\u00a031, 2022; 251,027 and 249,567 shares issued and outstanding at June\u00a030, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r117",
      "r119",
      "r125",
      "r430",
      "r447"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r53",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidations"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r272",
      "r274",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r272",
      "r273",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r664",
      "r666",
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r88",
      "r232",
      "r658"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair value of securities held in a continuous unrealized loss position for greater than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r88",
      "r232",
      "r658"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair value of securities held in a continuous unrealized loss position for less than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Amortized Cost of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Maturity of marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r5",
      "r170"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r287",
      "r291",
      "r319",
      "r320",
      "r322",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r126",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r154",
      "r157",
      "r158",
      "r159",
      "r163",
      "r344",
      "r345",
      "r431",
      "r448",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r126",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r154",
      "r157",
      "r158",
      "r159",
      "r163",
      "r344",
      "r345",
      "r431",
      "r448",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r151",
      "r160",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total stock-based compensation cost related to unvested awards not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted-average period compensation cost to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r8",
      "r100",
      "r120",
      "r121",
      "r122",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r150",
      "r164",
      "r222",
      "r223",
      "r271",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r372",
      "r456",
      "r457",
      "r458",
      "r473",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r107",
      "r352",
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Preferred stock at fair value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "negatedTerseLabel": "Impairment of other investments",
        "terseLabel": "Impairment of other investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Strategic equity investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount",
        "terseLabel": "Cumulative impairments of strategic investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r0",
      "r5"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of equity warrant"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r347",
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r347",
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://lyell.com/role/FairValueMeasurementsNarrativeDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Success Payment Liability Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r10",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Estimated Fair Value of Level 3 Financial Liabilities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r253",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r348",
      "r386",
      "r387",
      "r388",
      "r659",
      "r660",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r49",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r253",
      "r279",
      "r284",
      "r348",
      "r386",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r253",
      "r279",
      "r284",
      "r348",
      "r387",
      "r659",
      "r660",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r253",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r348",
      "r388",
      "r659",
      "r660",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Success Payment Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r10",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Estimated Fair Value of Level 3 Financial Assets"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r253",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r386",
      "r387",
      "r388",
      "r659",
      "r660",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r231",
      "r233",
      "r234",
      "r254",
      "r268",
      "r341",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r446",
      "r658",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r801",
      "r802",
      "r803",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r779",
      "r806",
      "r807"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss on property and equipment disposals"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "terseLabel": "Gain on other investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66",
      "r526"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r236",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r778"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued liabilities and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r414",
      "r778"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r762",
      "r778"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r485",
      "r487",
      "r488",
      "r490",
      "r492",
      "r554",
      "r563",
      "r577",
      "r585",
      "r598",
      "r602",
      "r603",
      "r619",
      "r623",
      "r624",
      "r625",
      "r626",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r485",
      "r487",
      "r488",
      "r490",
      "r492",
      "r554",
      "r563",
      "r577",
      "r585",
      "r598",
      "r602",
      "r603",
      "r619",
      "r623",
      "r624",
      "r625",
      "r626",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Commitments, Including Expected Lease Incentives to be Received"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r850"
     ],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (remaining six months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r133",
      "r221",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r332",
      "r333",
      "r334",
      "r353",
      "r501",
      "r655",
      "r684",
      "r813",
      "r852",
      "r853"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r62",
      "r86",
      "r442",
      "r672",
      "r782",
      "r805",
      "r849"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r103",
      "r133",
      "r221",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r332",
      "r333",
      "r334",
      "r353",
      "r672",
      "r813",
      "r852",
      "r853"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r773"
     ],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r773"
     ],
     "calculation": {
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails_1": {
       "order": 3.0,
       "parentTag": "lyel_CashEquivalentsFairValueDisclosureAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofEstimatedFairValueofSuccessPaymentLiabilityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "terseLabel": "Ownership interest (as a percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r64",
      "r72",
      "r87",
      "r101",
      "r115",
      "r118",
      "r122",
      "r133",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r156",
      "r167",
      "r172",
      "r176",
      "r178",
      "r221",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r345",
      "r353",
      "r444",
      "r523",
      "r544",
      "r545",
      "r656",
      "r683",
      "r813"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Rentable area"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (loss), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.",
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "terseLabel": "Off-balance Sheet Risk"
       }
      }
     },
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r167",
      "r172",
      "r176",
      "r178",
      "r656"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r365",
      "r671"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating Lease Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/LeasesSummaryofOperatingLeaseCommitmentsIncludingExpectedLeaseIncentivestobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r369",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted average discount rate (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r368",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term of operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r73",
      "r74",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r55",
      "r83",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r8",
      "r14",
      "r116",
      "r119",
      "r124",
      "r354",
      "r355",
      "r360",
      "r429",
      "r445",
      "r775",
      "r776"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r113",
      "r114",
      "r214"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInvestments": {
     "auth_ref": [
      "r771"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments classified as other.",
        "label": "Other Investments",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "OtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other operating income, net",
        "terseLabel": "Other operating income, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r25",
      "r127",
      "r183"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r56",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r56",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r56",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r56",
      "r503",
      "r521",
      "r867",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r56",
      "r438",
      "r672"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized at June\u00a030, 2023 and December\u00a031, 2022; no shares issued and outstanding at June\u00a030, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r774"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r127",
      "r128",
      "r789"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r13"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r433",
      "r443",
      "r672"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r285",
      "r376",
      "r377",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r520",
      "r522",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyMember": {
     "auth_ref": [
      "r134",
      "r135",
      "r376",
      "r377",
      "r378",
      "r379",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r520",
      "r522",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.",
        "label": "Related Party [Member]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r527",
      "r528",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r285",
      "r376",
      "r377",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r520",
      "r522",
      "r553",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r470",
      "r471",
      "r472",
      "r529",
      "r530",
      "r531",
      "r550",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r54",
      "r327",
      "r860"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r89",
      "r772",
      "r780"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r59",
      "r80",
      "r441",
      "r459",
      "r461",
      "r469",
      "r504",
      "r672"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r100",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r150",
      "r222",
      "r223",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r335",
      "r337",
      "r338",
      "r340",
      "r343",
      "r456",
      "r458",
      "r473",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r168",
      "r169",
      "r171",
      "r174",
      "r175",
      "r179",
      "r180",
      "r182",
      "r275",
      "r276",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r123",
      "r133",
      "r168",
      "r169",
      "r171",
      "r174",
      "r175",
      "r179",
      "r180",
      "r182",
      "r221",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r353",
      "r432",
      "r813"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Aggregate offering amount"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Amortized Cost of Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Potential Success Payments"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofStockBasedCompensationExpensebyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense by Classification"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investments owned by investment company.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/OtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r50",
      "r51",
      "r527",
      "r528",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Total Income Attributable to Sonoma Sublease"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/RelatedpartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r288",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r11",
      "r12",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in Black-Scholes Option-Pricing Model for Estimating Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r78",
      "r79",
      "r80",
      "r108",
      "r109",
      "r110",
      "r165",
      "r256",
      "r257",
      "r258",
      "r260",
      "r263",
      "r268",
      "r270",
      "r465",
      "r466",
      "r467",
      "r468",
      "r661",
      "r761",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "RSUs forfeited or canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs forfeited or canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance at end of period (in dollars per share)",
        "periodStartLabel": "Balance at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Value at Grant Date Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "RSUs vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r288",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails",
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Purchase of common stock at discount (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModelforEstimatingFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Employee purchase of shares, proportion of fair value (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r99",
      "r108",
      "r109",
      "r110",
      "r133",
      "r154",
      "r155",
      "r157",
      "r159",
      "r165",
      "r166",
      "r221",
      "r243",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r256",
      "r257",
      "r260",
      "r263",
      "r270",
      "r353",
      "r465",
      "r466",
      "r467",
      "r468",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r503",
      "r524",
      "r546",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r761",
      "r781",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r8",
      "r21",
      "r100",
      "r120",
      "r121",
      "r122",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r150",
      "r164",
      "r222",
      "r223",
      "r271",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r372",
      "r456",
      "r457",
      "r458",
      "r473",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r164",
      "r415",
      "r464",
      "r484",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r525",
      "r526",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r164",
      "r415",
      "r464",
      "r484",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r525",
      "r526",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r8",
      "r56",
      "r57",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r8",
      "r56",
      "r57",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock in connection with restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r56",
      "r57",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r56",
      "r57",
      "r80",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://lyell.com/role/StockbasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r8",
      "r56",
      "r57",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r8",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock in connection with restricted stock units, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r21",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r75",
      "r505",
      "r521",
      "r547",
      "r548",
      "r672",
      "r684",
      "r782",
      "r805",
      "r849",
      "r867"
     ],
     "calculation": {
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets",
      "http://lyell.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r132",
      "r255",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r271",
      "r342",
      "r549",
      "r551",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r367",
      "r671"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsScheduleofTotalIncomeAttributabletoSonomaSubleaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r862"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails",
      "http://lyell.com/role/RelatedpartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r254",
      "r268",
      "r341",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r446",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r801",
      "r802",
      "r803",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/FairValueMeasurementsSummaryofChangesinEstimatedFairValueofFinancialLiabilitiesDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsNarrativeDetails",
      "http://lyell.com/role/LicenseCollaborationandSuccessPaymentAgreementsScheduleofAggregatePotentialSuccessPaymentsDetails",
      "http://lyell.com/role/StockholdersEquityDetails",
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r653",
      "r664",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r653",
      "r664",
      "r666",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CashEquivalentsandMarketableSecuritiesScheduleofFairValueandAmortizedCostofCashEquivalentsandMarketableSecuritiesDetails",
      "http://lyell.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r91",
      "r93",
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r366",
      "r671"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r153",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used to compute net loss per common share, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r152",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used to compute net loss per common share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lyell.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(4)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-30/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(3)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r686": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r687": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r688": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r689": {
   "Name": "Form 20-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "16",
   "Subsection": "J",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r691": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r692": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r693": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r694": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r695": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r696": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r697": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r698": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "iii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r699": {
   "Name": "Form 20-F",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r701": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r702": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r703": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r704": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r705": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r706": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r707": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r708": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r709": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Form 40-F",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r711": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r712": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r713": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r714": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r715": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r716": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r717": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r718": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r719": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Form N-CSR",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r721": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r722": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r723": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r724": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r725": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r726": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r727": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "vi",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r728": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r729": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r731": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r732": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r733": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r734": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r735": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r736": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r737": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r738": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r739": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r741": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r742": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r743": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r744": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r745": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r746": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r747": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r748": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r749": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r751": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r752": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "F",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r753": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r754": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r755": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "A",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r756": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "B",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r757": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "C",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r758": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "D",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r759": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org//320/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org//808/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001628280-23-028215-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-028215-xbrl.zip
M4$L#!!0    ( +N""%<J[>LFIA," //-%  1    ;'EE;"TR,#(S,#8S,"YH
M=&WLO6MSXTB.+OQ]?P5?S>Z>J@C*YDTWNUHGW"Y7CW>J;(_MGMEYOTRDR)3%
M*8I4\V);\^L/D"1UET5*E)2D<F.VVA*I9!)X@ 202.#+_WT?.M(K]0/;<W^I
MJ6=*3?J_W2__7[W^O[\^?I>^>F8TI&XH7?N4A-22WNQP((4#*OW=\W_:KT1Z
M<$C8]_QAO<Y^=>V-QK[],@@E3='T]*[DHG_1[C<;#4I[]7:[V:L;O;9:[YBZ
M4F]VFLV.V6J9I*W++Q?44#3+U$B]HY!FW5"(7N^HQ*SW^\VF2INJT>FILG6A
M66J_WR=*NT^)875Z/<7J69K1;^H41FCW\+&#$-X/WM$-+MY[OF/_4AN$X>CB
M_/SM[>T,OSGS_)=S35'T<]L-0N*:M);<3TUK<C>[,Z#FV8OW>@X7SO'U:C,#
M6_;\O<FHS?/X8GJK_1ZNGH'M.K9+D>CGH4_< &E*0F */DFI*UI=U2;/@UM_
MS@WSIK-!U$ZG<\ZNIK<NW3G_RGBY1X+TE=>/B61,QXR"^@LAH\G-?1+TV*W)
MA3G:6-1>342X,'<C4*8.U^:FD-[[$7'41EUIUW5U0IS 7O4:\+KJ^?_^^/YD
M#NB0U!=Y'87^6C)USN'J9)J!9VAJZR,8Q7>D/PC\<)E2\.7"RZ\;4-5GWG["
MU3%U)C_ #\Z9Z0W9B$I35]AM%PYQ7WZI4;?^^U,-Y( 2J_ME2$,BX>_J](_(
M?OVE=NVY(<AW_7D\ EJ8\:=?:B%]#\\9S\^[__$?__$EM$.'=O%)]?0A7\[C
M+[^<QT/W/&O<_6+9KU(0CAWZ2\VR@Y%#QA>NYU*8@/U^@3=2/_[3MBSJLC_A
M^ATH&=\VX^>_AX^T_TO-K -+73+$D:A]<>/"X\;7,#N?.+>N1=__0L<UR081
M[=>U1JVK (/;2K/3T+Z<SXV:XR'7D>_#$[[9@4F<?U#BW[C65]![-2E&W"\U
M0.F%!=_4AS#* ']9M\BX3MW)5)JU[E=JTF&/^I*N;C^75/5.)_,-O@DFSVG5
MNLB*HA[P +=[UOPCVK7N7W>@YA6,;K$G..1EGH1]^YU:]3YQ4/4D3^O4NNR+
MI0>>S^/%IWT*7#)IL +FJ- N B;C,"6)Z<*+$,#]2RVPAR,'!9Y]-_!QQG.(
M/GL/+!CB?'Z,^/G3AR9S"+S(9Y_8JG*1D(&]"Y(A_9XRV*:?; L_]VV !AN?
MKM1VU[=_F8?SXH^[Z5?SHX\8"]-/H-_\$,'+8%)75/A?^KOIM<DTK9E;FW44
M[_DKZ>?T(>=S[[V:#!H'9(@5?9B\6;NNZ).!DBO9WBQR[?BU@@$![D_>;$A)
M$/FTFQ"674R'2*^EGW&,U932N:/4+ :VI%3$Q&F>%,GB>/'[T]?\5#+XHA*:
M9'5=W9U*H'N?$#B3UX-5%*8U>RM3AB3T_"T)NO1[_/(K=;VA[:X:-BN<YX8X
MGY_]1GXV..#GHIHT#J\FF[R10<M.!JTX,K0X)$/61;- ,K3W38;D;>@+FF;Q
M1PL>]CYR;-,.?\26JV7#U3@FD'AU%X_4P1#  U!A_(Q>&#'1!0M^'<]>N7JW
M87%<]9MXY"_G*Q\XH<UD7N60W8[@UK;<.H)!JBJ\LNLIA'?"W]R 7PY^KC<<
M@=OLAL$\A^![<#R?0L_\63R#Y@U ?6O39H'F>W>&]DSS*\NR473 1R:V=>M>
MDY$=$J<T]-^[%[9O^IMF-(R89KH/!]3'^WPZP-%>Z:UK>D-:&E[LW<_;,R\>
M:4ALEUHWQ'=M]R4H#>$Y<QV+?+6]>U%E7M,X,!'5O?MW55D >6#6WKW0*JZ6
M/#".6[^9FZ65!RYQZR_SL%@5%8%?V(4IN]-[) >L,/J7W@$^O@-6&"_*[@P?
MV@$KC/!E]WP/I?AWVE1<H/G>G=X**OXBZ5]VS_S8BK](7I3="3^HXB^2\&5W
MJ \:GCI&DE;9'>>CA:>.P:RR^\]<A*>.P#B][$[XX<-3Q^!2V5WUPWDIA>U?
MZ65WR8_CI11'_[)[YL?W4HKC1=D]]@-[*<41GH=4Y#V]6MD]W\,Y8,?)>];+
M[B$?QP$[$K-*[RT?W0$[$N/*[CD?V $[#I>,LKO)!W3 BMJ:,\KN]![) 2N,
M_J5W@(_O@!7&B[([PX=VP HC/&<)VD6^6MFW@0^UIJG%[3H:97=ZC[&F%4G_
MTONT1U[3BN1%V5W6@ZYI11)^[R[GT5ZM(?RT'([T$:H(-(135R)F"0^PI(P3
M[F(9N,3=KFK@A[ "13!)?X3%-N[(D,:,P8)T%[\YY-U[&MKAX"]8^?$6[G,<
M:H81*$/?@U>'7WB-[S;<0:TKUV+W_^9[T2CY;@,;,Z,(JT+>]Z]\G[@O#$V+
MBZCCD)[GDQ#$?.:NF7HC?X>7B&N0>.ON+FJRUP,<\=8%982D!3C?!*$]!-3\
M.L87F2'PE?6O* C95+U'^DK=B":U3V":R3#ICRL99V]P%Y,0(B%$XKBK!+<A
MHU) ;H/\?O.I]><H- ?[=-[5=H$>+K<1+ $'WD^Y-[B-N GL<&^9<9NG(K##
M^_&%)K=168$=WLW?)K<!XU/"3J;G/.*DX\'QXP_;M8?1D%_#>E+JW(UP+FM*
MYX_@SW2 ["7AF]R&S@5L-\"6O/,-VP6@\1_JOW9($-SWV:;F#!.?X"UI<'7M
MN:_4#^V>0Q]8-Q/@[=YS>@KE '=A?"'J*Y[#1HMWG7Y$3FB/G-G'/%/W&>[=
M:PY'H:#C+E N0)<?=&_P*N-RX8Z[:/0&$@]L/QN)!<"YQIT(>W, AQV%\9N7
M41;Y@1UW$?,-%+;[0MM50-N)8'O9X5!DD=*6B)^7'@X%EBYLB9#X'N'P!'SI
M>_ZFQ*S=UHI.@6@0D>:C1( /A+-,CWGP/2LRPWO_B?JOMDGG"?T=OG&#O9X+
M*Q30W$:T2P-H ;LM8"?"^,>'W6XVEE)7E:+0(.+KI40#!UF6+>Y"Y (ZN:%S
MI%;C(LI=?N@<)\>RQ5VD6D!G&ZUSA!3+EH@V'R7UD5]0[L>F;HLP=I4C5?S@
MC-OX.,\ID85R0,2DCR^/&Q]S_(S(0C$GPL;EQ]QA$B(+A1UW86.1$'D*-HZ(
M3W.0IWARJ.,NM"W2(4\ =2(J7G8T%)@,V1:![K*CH<!<R#9WL6M1,*Y@M/*0
M9:0T"L)KA[L8N,#K'@H<9@ST;AWIY5EP9G<T8]')M*.Y*&6[[&AVN-L!$%(F
MI*P,RQ-W&S="<+(+SJ[I)\?)E^QPMW$C,'<XS!TGT;+#W:Z-P-Q!]=P1,C0[
MW&W9",P=5,\=(;6SP]V&C<#<7C&WGYA[A[L=& &C0\&HP&!]A[NM&P&CJ@7K
M"U5[8G-)X'7?>"U0OZH*=[M+I0/$!]+U<'7]_# @_I#<NN:>W04%M5@V=T$I
MSEU0%>XV3@2 MLN^*FP15!7N]@1.%1.9"7/KOM*D:=Y\-SW6!7=ZM3P8Y'*/
MX F>:$4.8##)0*7AP+.FY%W^EM(CKBDJIF1F6U,66K+OMJ9P%VN?FG>A_4)0
M#^!.<K30@_B)AJ%#K>E-^S8#9YFSF[24+=)\2"G0LDO!PJV[24'9(K&%+DP%
M:<N]+U\<;!.I2MF"K0(IQTF<4!7NXJD3TYL$@RO7PO\@LUZ) []?6%]_>"X=
M_R#^3QI^BUQKOR<^"XP*J@IW8<&4I-]LE[BF39Q;>#\_6G:)?G]Z]ED/L_$3
M-2,?3)L]G[0MDNXJM]&M#'3_S7NEOLNNO%"XEP9?:2\L(Q>X#1%MY,*UYX_0
MP:=E)3VWD1CN]'V14765N^ #O_J^4+IS&SC@7=\7R@7N@@E<Z_M"2<]ES&"K
M&F0<$95+]_H(1"W4,N'.$RU+'&%?#.'.1RTA0XI4.QIWSBLWF]5%;GUHW'FG
M)<0]*"*],-QSY[.6A2$\[$5H_+J^Q/;_1IR(_CJ>_/EG&)'XYF#\G;Y29]X7
MF-QTZXZB,&!WJ$7E6W 7_BC2E-#X=<,+P( F,) % _P& 0K @"XPD 4#W$4C
MN%P+^(O)%@H"[J(G7"X&%0<!=]$>+E>#BH. NPA369>#RJ0&Z-S%N,JZ.%0'
M$MS%X\JZ5%0'$MQ%!,NY<)0]FTFO=&SQ<*M%Z7%0Z?CBX9:(TN.@TC'&3>L"
M1WRH=)QODU[FB ^5#K5MTHL<\:'2T:[J[H$6F;VC5SK85=T]T"(Q8%0ZNE7=
M/=!",5#I<%:%]T +!4&E U@5W@,M% 25CEY5> ^T4!!4.G1U,GN@A4*BTE&L
MD]D#+102E0ZHG<P>:*&0J'1LK]I[H(7BH-*QQ6KO@1:*@TK'%ZN]!UHD#AJ5
MCC'N=P^T4#Y4.LZWWSW00OE0Z5#;?O= "^5#&:)=WVW2LQV8'&L'.W-4]YM/
MK3]'H3EXBDR3!L$#&>-3)O>79BNZ489X$Y]L*%0:RA#CV1<;,L_E!POKLAKZ
M3.=-2]&ON^/1#G["[%C?&I\&X2,8<KO.9E5Q'=LM57&=1AGB1T>#V];5D_@"
M,D=P*T-L2FBW8VJW0A?3,H3 A'8[IG8K%&YEB+254+L]^+9)_^8Y)"R72]4L
M0\1-X.%@^J%9AL@?5\M1)GMCCTB[>1]1,Z36,_7+X],URQ#8Y IFQ[9ZR@FS
M4X[;"FUVL$7SE./20IL=#&:ECKL_P8OW/=\J^R94L]3AZ&-RH5!9*'64=C<N
M[%$O5BA(6ZC,ESI(NV>T\;B^EWH'JEGJ&*W0;>7:@&J5.@(L=%NY]I]:I8XO
M<ZO;RKK]U"IU'%C H6CM4.IX[1'6HI,)UQ:J=$H=KCU!BZ><*#OA:*W090=;
M,4\X&BUTV<%05H9H^_'/YT[;(4YQ$..\Y+LMK3+$OP7_^6B:V2I#^%J 96^&
M;YN[@'*!K9XS/:L,[77G5XK"&E"WN8OO,H:$H,WP_M^H]^*3T< VB3,K<EX4
M#IZ(^\W'^AJ!Z5T3QP;#U+7)7BD/ZKFQ]1H=N79,]N"/?CBA^C"V-[M1Z%_@
MA?3'Z??I9_SU.AYR%Y3ECH>+ZZQQA'6VS5VPE&\V:=G9I!7))NZBC=RS*:O5
M6BB;N O7\<VF(SD7;6[C78_4@;>R'M# ? 9V!,0,X8;@U_'LE7D'8_;*O@V-
M3F'V/;?!H#VS8%<_X\ESO>'>#<KB^,QMT.=$^<R%T<EM<$> XF@F;H>[B(\
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MX;'XGW,N.?BO@X*_>GR6;MD)/^WRV^W=U=WU[=5W"5SC^\<?5\^L%'(.+7"
MG=!9@(BUH0@8-&O=6U#YDGJV%:\%WX['MV^3V/ETV98^12Z)+.P^^'F?#!4+
M]<$6:N"T7H:%.AFBCO<#T/'LB;#?"T% !T]S86@>=\S@+V9?LX2<7XD#*H!*
M3P-*<]KL0N!Y%?B.$/C3%GC,3%@C\#,KO=>7[D<T?DS \O9QN]"G VRX]4JE
M[UX@-$(E- +BP2B#1I@)WREG+2PO(G3$OG1$(Z..8+O9 \^!1\RI Q%#*80'
M27VDPU'V9- MW?P1V>%8+&&56,* H8TR+&%BP=J32.MJQ@7KF@0#Z9OCO0GK
MM1*BCXQO"=$_9=$W\"A9"',*/>GW-#XMK=$&J\+:0A-40A, #MJ[:0*QWW2L
M'!(EV2C4Q$;A\>>2DW$_B$M>F":=E//]:@=F%'=EPM#AE4N<<6 S VRJ@%%#
MQX=Z\)Y'&D3.8N!1:.8J:&:&$FW'?" AXD<2<3W5S;K0S<>?2T[&_16/-=HA
M.S3"U"Q\X:2?44L[7A#A2:&KGA>E-0FE1SOX*51O)50O@D 7JK>D$JPGJM?8
MJ^J='-,77"N*:WADQP?&,)W[X'LFM5#-"J5:#:6J[ZY417Y[B?=F5;V9)KBG
M&>[WSW^^>139[2>EZ#LBO;VTC/M.7X@3+\VLO+)8FRNR-F."JR8<GE(*IJ&E
M&O5*J-3CSR4GYS!L)'TC9NCY0IM60YLB6X4V+:E,MC2QJUI:QOWNSG2-?").
M7,TKSEJ=;76# :;? U8G)C%FA>ZMANY%%#1%1DM)1;@A=DU+R[BOM$]8,LKO
M(VS81%W;\V=TKM"OU="O#:%?RRNF[8-LC0K&[8-Q/^ W8-/V*9BR,TDH0J]6
M0Z\"AYL=H5=+*9YM-=&K#:%7CS^7G(R[9Z7\;]VXEC@,)31J)30J\E9HU+(*
M9BO1J$VA48\_EYR,NWD?V#U;'!&LBB)MY56DA12@%O)8!/,Z6&D:2$M"<!:%
M0%9"()&GK0\S:?EMD+*"WGDZ.VVFLHJ]!NPB.K!@/6[1@D6T8#E0YY*GAQM6
MZ_ON_OE&>KSY[>KQZ^W=;]*W^\>_PY_U[_?W?\'/3\]7SS<_;NZ>GWCI(Y:)
MX\"K@1W@23H?2.R,I4?6[%;R7.QX,)14I?Y7UAR,V&Z ?;U8$P0G:8(03,I.
MG$E7CC/S6?*23GSLA6:+UL#C0L_'%4KJ$Q.^2T:/._&%&V>#[1A-)[+FGX\-
MSY).#5[D2_T(UU7X<G(.VYLO #GMIICJ3EGJ):UK)6R<%M*7L8Q=%:W(#"43
M.XEAT8T OG.(Z[(&CS /VV5O$H0PH22!8?)EB H3?C SBSR_H<0W!^RJ15^I
MXXWP18%:03@S"7CM"%8)SQ]+0=0;VNR<.OO]Y'LRPMZ0)#F_@\WA0GN(A,*/
MCOV3.O; \RR<7A"9)A! ED@@O6'G(?@O/BG^J=?[%_:3?(VS-X:3D_*L@65"
M\2F981#X_!%BG@?PDK,\M-U7SWFETD_7>XL/TD=N_+=O!S]AQ,@UP;H!L$RR
M16*8V4.$"3:[Z\<9>PB\D$T ,!5X0PH<#. G/3KV\%>1SV#G>PX;94C&< .V
MZL0K,$0$K$C8)F-7.1:$PO+!'EX>V,"0>,JA!V/"[P&NP#A K&7W^]1G5/&]
M(6OD.0_&C\>C[R.X#RN]>.RU'!O^[(T9VSZ@9<ETSNTL4V1I[$4H8;#^P[SL
M_OB#-V6TH/XP0*P.$)]X9$53+H&%,OM3O4R_>K,=9_&[8.!%CK5TYZHO@14
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MG\")6K-HPL>^4-"P9#2P3;11"0-^WS.CQ&E%)[,'J S'.,\7WWN3B!2P<Q$
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MQ'Y:8G43I8FCW"Z1,'A8*SL#1%J<0>2DCI;#E)'<Q)&P'368[)))1K@A*I(
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MZVJ:;*@\10(%*H7N$%P27.)2PV^PY[A3\$T.%?P);/6PPB;,39I6#A'=S46
M1W!)<$EPJ;I<RG?DI)WQR E;3>;*4$W;']_1\+[_3-YS6P8MS %I-50^FB +
M= D=4!$NY=(!2_[$(55 FRL5< )[*,"I[=V TOK7(@HBN"2X)+@DN"2XQ!.7
M\CEKG8R6&JSQ4],LMTG6J77UIJRO*,V6NZ6HP!&/.,IJ\.\$(T/A"T:G6203
MN[,D-3(76[3L6B.S^":ZW$E5SDPK@/S!*F@:> S$:,GJ[MMJ!;*U'#5>1/OG
M_5"FG+*\8H'<),B9:G,:6O&U.85P"N$\>>'<HG!NSK559V>3FPU9[125X2\$
M6 APA04XE_]I+-7MW5N=0\.H==NR7L3^DI!@(<%"@A,)/EQ%8 ,K K?;<EM;
MKJ0H9%C(L)#A+<WHI6+#A4MN$];>9EM6#*T"1C2+'Y^'!![77>Z=-B3^B^W&
MS]96M;M* -']TO//NVM;L.TX#! 1YS>A8TP0H*%#1@&]2/^XM.Q@Y)#QA>TR
M#+$?72;/3HC;6"[1RB837[Y,&J9WSAH-UH<]":PG#][<:MU0SIK&=KW?/QJV
M>::W]M-M/EM?^*K.M7.F-+8;5<SUX[EJK4YYYMHV,HVZ8:MMXPZMOGSO"GN$
MJS:""BM/8+]+/^"N02#=N!:UV.Z;M+3Q-D.B=()I=_=#M;(4@XA!2CS(&NE1
M=Q&?3NET3MH9'(LX,FN]H :FE>X8/3T0RWL?9#RP6[==WJ>9G"@6/<LKV(^>
MG?C@?9)S)U*D[[-'&P06JX/%K[1OFW8H>)N58,\>J&5I-HR7TJ[0R;!N/YMG
MP]+16Y>\HRR.=*X V6J3$X-TA_'82F&,QEF-&<S0 SD-I2#:U="+W+ @V_WP
MMYYF7O57:M)AC_I);K7*0CQJ8;G5)YD]O:$I7Z'9TRW,GM;DEKYS\S#1 [-2
MN\.GL_^[10_,93EJHQP)$1(B=)(BE*6R\FXI%'%;.[4AMPRQ4@DQJXR8Y<LV
M7"IIO+=LPP9K2];<Z="JD#,A9[R\=#XYRUH,K@ Y4VO=1MN0]>9R;J"0-"%I
MY9.T7(*V5,BC</G2:MV.UI%;A;6H.4!V[>Z%UV+I4%:(!_MLNQ9UPXMZ9SFY
ME<^FG"/XDR8M5O%J_+47]UX]K0IN.:.)C2Q'N-=VO2FBPVU#KW4U6=T]PBAJ
MZ7""M!6:?$N8?=1'>1E(!O@D D05!E&6$^W[;,;=:-2ZAJSN'LD5*#LLRD21
M/\$EP:7#:^P=6C\7H[";L<+FJ=]B08D@57/A8+Z^1)/.LLF7HZ2WK#1RR';-
M2TM;F?Z0;MS:?K[!*I'"E)!V47O9' 4>JXTGT8^B#%PZE#>4IX-WH\U;!V\!
M)2'P@DN"2URJY1U<GEQ:N<.;5CZ!GD",,776#Y8U#$T;PHH=IKWM,.&_ORXV
MX,T;!FBR;*5.@Z?.NB+6)"*"%>%2D5X+;UVYFVJM:QBR(;:GRX9*H3L$EP27
MN'. N%/P&H<*_M"'A8\ *58SA7E1TZ(D6_=;+6UD0<1_!)<$EP273H=+N4[:
M-+)VP-A'S_6F7NLVY9:V;!@<I>>Z0)?0 17A4BX=D/50ZUY4@,&5"CB!+1;@
MU/9N0&G]:Q$%$5P27!)<$EP27.*)2_F<M:S-SF"-GYIFN4VR1JVK*H9L-)>3
M7[(;90)(' ,IJ\6_&XZ:G.'H- N$8NN7I#CH8O^778N#%M_:CSNQRELZ=$,J
M5I&E0YNL=&A+5M6=LZXXZ&IWV.(VHBFE:$KY<6&<+#F5FXJ2-K$HZ<XG(X5P
M"N$4PCDGG%D.9NU4M:H9ESMM-F2U4W#=*B' 0H"K*,#Y"CQFW7;>791;2JW;
MEO7&<N$BT;1=2+"0X&TE.&LLL@ )5FO=9KLMM[6.D&$APT*&BS*CC7V;T2T-
MUMYF6U:,Y>+*Y3.B6?SX/"3PN.ZT;US,YNZ7GG_>7=M4;DC\%]N-)Z:MZ@-6
M-%JFS?#8B!>8]&^;'P-(8\WZ!E0B)F:-$W<,%)-<+X3G$1^^=B4;YOKB$T<:
M$3_$Z'(XH $%E)'(LD-J2=<>ED4*XK\8_;&EH_3-=HEKVJP-('S!#B><K:56
M,B&C >\P\@)V].#"IPX)[5=ZF32(9XW.9W^58$*9_H3T8 91N/XG!V3#.J*K
M#9A3<R$D/_,OSA:ER=8LM=_O$Z7=I\2P.KV>8O4LS>@W=4H-I=W[IZ[6TA\-
M)NT!1^2%UGL^)3_KI \O>$&<-S(.:N?S\ 1LSA)]D5YKJ=+O[X<J ,581D"W
M>#X[G'+!"ECA73 GPLU<I(&/VO1/F_G3 N%"W8%B<XV*&&3@RSGIKN+]&M71
M/JSJ6-<MD"F*[V/J.-+M<!BYWFA 8%F0I5O77"_5O$Q\C8J:*B;&(!(,I&^.
M]Q;P\#XY=?@GVP7%[$4PJA5\+N,+3!:4];.?D8MFW/N4"==D,6"6 +R"0T8!
MO4C_N+3L8.20\87MLL>R'UTF8R4K2&.YHA\C57QYJAS/E%A!)EO*R9.3RV?L
MTH)9$U]KJ6<=??UEY4Q=>^VC857M3&FO_^E'PWY\S5":^YFLGFG8#=OV'^S.
M<V>=K[9Y)R_5R?)27/6-90+P9+]+/^"N02#=@&JUF"F,:0>2KLAS+WLZK%S9
M'%@Y:Y2X/;"F8#.J0MXW7T_ETI--RR,$Y3IZO/J=KZ^>_BQ]^W[_]R?IV^/]
M#^G^X>;QZOGV[C?IZOKY]F^WS[<W3UF@E*$%S"(X\L)LZW-#>YKF"9] V3DI
MD[<7S1Z?7/6&7"]_N?8*EK;K]Y%NVM)K79B;W#9VV27@+VU92$5%I>(@2=@M
MX\23L(^ @ID"/%+H23X%OINV0R4W6?CP6_S;Q"!3A)$HVY6\$<7@HOLB(7M>
M[="FP<4N1A(O5M ^S9SU/1HXPL.ZHJ82?<>_Z6F=Q-W)<%C8H"RD=FFK@?T6
M9%7AJ8>)./-4,)0V58TN!DK-ZI8Z*X6JO1V.B.WCTHN;.!ZK@&:[KS19CD^K
M]%F!FC9._WBB9N0SP^3;ZYW]N^M3>,E_4VLKP[0%AJDF=U8TN!>U92H#JPU:
M-R^L^O8[M>K_IKZW"E'MR:%WCB!U2H;N5SH"9\>.C5OB6A(9>C"Y?PMKMP@=
M/$M=^-NA^,>5:UW-$#FW%L9S+HJLM)=C9L+VK0RP-FCA?0"KG9RZ$(;P\?98
MYK0O4\>FZ3/F2O"_(?%_TB1G9K( GY:!O-LFQD+5[92VLU)SW_]J!R;0*@Q
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MVF$_\?]M.'"U3C/#@OA2\2UOK(R-\1CH!Q(V]7Q%57S55.WZ@=,+\;C+C'E
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MNFCX^<)] J[EN80$7H.Q*[(+?S%Z*"GX!<B<K%1N1JV "GW.1*0,JB( V\-
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MABZ#QLWD:PD_Y.4L1F4<AC)5H## B[*'(KWPH<B#$ (66!?XO3]&=XA!*R+
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M0O-,_)BTFAMR/)THI"?/@S\9+\RG3UN>&+R7[Z<,R;,JA5("GZ>,* ,;R!Y
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MR'IFN5/YQ6R)U S)Q>@MEVT$W$\NVZE6D].D'LI&X5;BZ:A;B&=&1T'8LC]
M=&ZYK"/]L4[E]0P6^1(%$&,FW$MJ+N+#C1"'E*.(UC[$D;6@M=.\;"7\D\SE
M^'9WFQ3.Y=JW\5#+7_ZC]&7QO"5*9<"-,0V[0%^)Q<2QR$CBA<4DMJ04)O$/
M1]+W+,%77F09E1)="/R_ HE5H%:B/[&3[L$&.'0L^)WN%*\C%S6DK1\CEYU
M;(8->&:F[I'Q9$[6\$H^9.F4&GW%3.0\-T2OB/W !$F7VV"=UFUPM UNPTCZ
M.[BK,;I-<MU)KG7MXUGS/N&=W*2=M C^SS\XC_$=-U_,7-NRCM?:5W'SGJ7)
M*B4)GK!\KQ1;^0'F##$\R_B:,MSDJL(F_[4*N4[E@1C&C-R-:E43=%%3) 2*
M:(,XJ)ZW#R'&93P,$=)W8=%U6^FP=R^$ZHRWKZ>]=Y>8R. FXYOP*<#G^XU
M=C\*L]G;4F.2W90U6Y$=N[W&1B5/-_,TR5 +<-_<7D, A/]*LT"_4#Z7UI?
M\R*+Y3QZ KU,Q)>^9N'="\\&;=AU-2GTX>[KUWI2:"V/4_6= PR5.7-PT/&
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M.\&)2[XUD+^GL0;G\NK&D!UCH['^F<?M8#1E:09*#:).F:HNVV82,+QS2QD
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M<T59PZV<M=N"%,W=9<(M!6]#<Q-1T8=7\NYM-@<]$C^5<GYB'WP\![_OBF.
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M9BCVY/_:VM7F5A/5?@;1; ;64I61U"_ ^^#&V"299*RPWN)D69P]@')P2NC
M*S;S-5M5;6VL&?A_I\[8=E3+]6W/\,Q)O27J,TNE3U&22"5HCA8??W,'SWEK
MP$ZRW(!$P(F@6/K!?(5:+032S)$TA=0&B03\[JWFU$XU>>)A #9!Y5^&/Z9-
MRC3,H'7@P!:@)/D3J]?%?9HN1K]?D@#*TF. &!8I-76!<>?C$DCA9H^A_C#V
MURH ]8P3E4;2]P:XL664PH>!.Y\_\0V"[(DEP$MF@3>3@M";KWP&6BB'5;V%
M#U=5E%4@4*;^TTA:KF)O!KJDLAI90EIE*^;=:A/6NF!Z)OXB"F%Q8A6^%/!F
MM8S>N&T@WH;#>9PQ^@E8*C:=@GK!X\KV.N+,G4C):O(O_ S6U+V/"BEHG55J
MD T#FDKLAUCU-(X6M</JO1'X 3Z3LP!\ ,MF9&=],+^P6+Y'T,7!=7Z4?,?)
M096I?<;*5.VK3$$@%D%*,\=N0_\]4>B>A5[ DE^#Q(,C6#5JV'%=PXYMP]7'
MILH<2S5\U9E8EF)IMF>;FNUXGE'7L*47$P=57KU9V3:JLN[W5]>KC=V)ZT^U
ML3=Q#,VV;=.=6IH^=6S%=335W]06>[S3I2=NCTKY*?# F6&"@/.Y.XF$=-W>
MQXR/DKLP0U72TM(,VW2IOH]Z#T3<@[C)!3TP+^W;J^S;S?<M"YW)34<$W\8H
M, VF =>BGT'U"R=<SI7!<Q]K,PW$L<JU,\7=WJT\CZ%?PIW4TCD?>P\;5PR+
M?&#<+ .Q@]B7EBZ$N/""=.:FN0VE#ND5M^IH\L5Q^@P\WFB)VY E6,MJBI=?
MR.CS$UXL\.8 4._?G!*@UJ,8^[CY^UAAQ\D'F*YPEI($^P2C%(6<3^+HR9VG
M3["P)TZOU5(T?KO>+( 5$#UA56!8KN%W$ ('R0S-2[$Z=XY.^CW:JRA^PL?^
M)%P.OK[BE2W^1NTB[*9(6M#7P+[M990$^(5W,4-3^<"*=NV_5165:/96BI^X
MDR1"F]KZDZ-C%W;SD(K8E*I3HT[I?V=QT?=[SZXG,7/_O':GL-AW[OS1?4JN
M?JKJ-E!L90+6]]ZZP^GT:%+"-2Q$J4*>WX$@L!B_!6MRSV8MTBQ&7^'_='M"
M8]#6=#L!A ;--[<V[DW3,9[ ENX0#W4[!1%HA7O^"[!'J,M0A20L5TD8"V6N
M3,IU3.YX@!Y\B.9"TPC_=QE'][&[2#)E@G_#"R=(5+2!K@^1$C[_@906J5,O
M6LU!+;JKA*M4'SPUL9?08QFT<O;DBB%D,8A&[FTG*PAP"I,YDG[-76GP$TF)
M\H>AK2U95J['Z?-"\^:*E3OK,S#;80JARRH4>E[F(8T'3(>+@8_"2'(7T0I_
M-',A<F00JL3(E'XI?5;2[?R5-7W-EY<"5[$T$2,(0 W.VM)LS1A_#2'"KA&"
MHYYQA*#UC1"^,0KKOX(]?_H>PZMYXFIS>&#7W6U']573LAUWJC!C8L#_U5S?
M'FNNX^N^A>%$-3P0;[U&-^))*K]WA]B@^^75Q1J6:5J&/[5-3S/\B>),'391
M33AKU])5G$I^_G[TQU"Z8\N4.!T97)7+>.M5M]K%\'_.,- GC^HN"F$!TAMT
M6S3E9_&?=^([]%?UY[?"W7N<06B?UKSV<KY@%LW!M@AG;1*YX!PFS$TIP0)K
M$)FA[->D9B@WDJ_)78(J^T&7]4!GM$_'^&N:KN7$[?'F.ZV?&7PUI'K'+3@5
M?4=;6 Y=1(6C7$_L)G^M4!-.&2,U!4S@41+C+EHAC8$EX+L0[H+N!D\?'#!X
M=1BXDK>*A>:D[?M2E4*@I.,1UUW_,P<3$+)8'.T,JQ%"^=<=3TYW2K"(2Y&@
MC><)4)G%#XS4YB_TE<I3UG^%_\'Y821A[H?\_.SK-4:!-VQ.YG>=EED_K>\L
M=,/TXP+X@>O_+<%WK/S Q@KFX:V6<A_(X9Q,.[U'"HH7T4KC8++BMS]%](7W
M2!<N!#9P1'SS>=8P(4-V'X+( @7!AO\_]MZTN6TD2Q?^*XB:G@GY!L3BHM6>
MJ0B5EVI/5Y7=MFLZYM,$2"1%M$& A44R^\/[V]^SY0(0H$A9E$@;-^+VN$02
MR,QS\NSG.71"5,+5?%ITGO=2741^C/11V&TRR=#4B*-@C*6$Z(-1=!*_HWFK
M\BF\<RLJ#0>7ZZETQ4OXU;[C*@G?X?N=/VU-N,%VO>P@N)YBE5A T5">N9[?
MQ#!J 4_:E/),87C)\:-0N7Y4OZ>)O'?K0P.%.NJUS0?2=_+.U.#6'/" .SC!
M';15Y1HJN_D]M,IQP8GBG9A0QHI8N"]J0)OAUH(+<'ZZDC0;7X9G)]-@U _5
MR4"-QJ.3R?EH<A%.PXN+8+QBLWU*"S#2TP5%^,'9 +<CG2N._<NND(CRYSR-
M49T'!8M5<B3%]:@= 3D4^2R]-4D#_O98Q>FM5QUHWO-:5B$AJ%S_=]-[<ZNX
M,(D1Q_A_L:(#SZWR4%#J%0$/:Q!CB6]A_?4^)C3$<!*ORQA)L+O 0^07TCI@
M(TQFZ,N -_91*2=,>8YARF;;MSFY=R?YJN0>3X+1>*@FYY>#4_!K^F FCZ;P
MM].!&H['I^$31+U;PJ-(H_PIPYT^.:?S%/@R5.#:QAI#HGYYC7.RZEO>&19I
M).H&1#H8Q(B3D][H].3A01B&O?[%P2!&=(O=Y6)/.RR.=BR.3S,$"=@,C>/[
M.ID.I:1#*7G4(QL^Q&7[%@^FXZ4.\>;.$G:QNM>X7KN!>=A[=,O^O6#M-]S\
MWG81]K?%O1Q<7*S/$E"DZ)UFK+?$5]A>DN3J=U4T %2>G_WPT]G)WH../.8\
MB.Y*?5]7ZO*AK]0Y7*G3[DIU5^I[O5*7_:^[4MMA+)]?_/#3P!\-OAK)OKMQ
MW8W;GUUO=^,&CWKC+@_IQGT/N!;B6)I*)/8HOVI:P#<F&@YJ(,+#.X8ZT<=7
MO^%.7V"]T=F>(-5U4T ZIG\ U^UNIA\@T[<5V75,OT>,T3']AL[5W4P__.&G
MR]'3 LET3-\Q_4/Z-W<S_0B9_JOGK^YL"E-+V=570A@U5F;=V312*[<+!R=J
M?'%Q>C$=3D].+@87X^ RO!B-IX&Z')Y/3_:@_QK+V[D!1PHD?_GX-]MQS"6K
M\">GYCWPN-L#RXVI/*Z8P1:VQ @;#M=#&?T6)6D6%4L-_?[N-E%9/HL6[U6&
M&=G@6OV\Q&)>+-E/8]CC-7^E"?WK E&)5J7VO[<U4KC )&Z72[U:\]MH*F^O
M7]R?ILV[+U*/&%?W/JJP@9<9* 0A0ZJ5]L,3:0]TV[FI67&[4O3A^E)T/?'Q
M'W"E7I; 4'-;F;ZLQI&FT1<5'O]+96E#(?K%Z;9=$J-'6MC9#S\EZ=U]$:9#
M):VV,H1JJC)L6,NP$;94;=7S5:K>NQG4^R"OJ=9XM[TQL#(17KD= 4[6$T 6
M\B9+YTVT>/U%6GNO\ARNL H_!5^V(<OY#S_A1ZMTN$>[Q>F.=W)W'P9B\XQ.
M>VT!5-U*HCN+"RJ W!2:K]Z_@7_?[H#.GI34EP](ZCOZ]!Z!U."O_30ZN[-K
MZ#X8C/<!XOM>03N&_7;0CLT[YF%_IF6^@_KX)J$^GA#SX&VAYA[H]-^")&"X
M3V/-(XA!F>?:$+Y*@GB91V0UO(FP&PMA)V##W )&W_F@<(PL?44R?VF2]UHE
MPI.A VSI'OQO6F*/'0*+P(T+:\-LP^HY!<XYI67F3<U932IGE=FS2LU9@3-Y
MK:A4DVPH_'V9!* /T#+'LT8WA?Y%&4LRV"TQ/A;P!PL;A\O,N-$1[,6"^_L8
M<U#%N2*$ >X:A-7^O01G%GA_"41<I-BWGGAO0.MX@_[QW]'")V3$YIW:'FKT
MB'-V#^]Z)NE-1+@"-81PLL=QFG[&\\SM+F@P@0#%B+$[5G&DIKGO+6*@,;U:
M$9BU'*#>,"'0$"2*H,/0(DL#@&7) H=/ZA7;"P61BY!HO"S*/Q.:I6"TF'YQ
M9UJQ;SH6G65GZCK(&,@+7DC-B_)E6K3OI00H&=VHA@V@5L:?C7%P,E@ />\=
M_!=/O#=,H\E;1'/!"\M5S&,&9+N,@Q-&X+ME'L)#9(SD21VGC/D6JGR216,V
MW^&MT7P11P93(5?K*(/-G[(:?CMBEL8>@I,1?D(=7RY7!3ZNF.DVU5Q\A2(J
M8GBG=(CBY#KO#3]$MX3"#[!/EPV2MV]]#V46_]?@:C->XP $83JTO_LC$ 'Y
M >,4\!!-PC=R"+_*(=A+UI,5WA<+9] ?W0&&\Q@0*<UZX1W0\R92M_LGN]=*
MZG]P0W3@3> SBH/F&/+R)MBPC!(J6"PQ-+40^"@4 8BDYRVBA<+',<A=&I:3
MPIM@* ME+%_*!5Q0XGT2S5PQ4I1S!/XH<3+5O_2%A]\OLD@50;:$J^W=1#>I
M=ZT250A:L%I$^C\_(0OU+U_0^C(EL%1SAJ.:S!(XMNM(B0R("$A6(+8"O1\4
M2AKL2I9H W*W"6V=[BMQ?H'0@_#T10IB"84DK@1'X'HS.$:X/;2C8U!S))]\
M+TZ3:Y4=QT'.S=T@#>7UG^31=!PJF:$ !=G(X0]\-,8E@J)R4GHC27I#9O^:
M/6-S>8:1MUN4R;>*)?\-$Y@QO,#]@2,>!QF<=B;X7S%(1,$^S@N*<\")XR;,
M%M"!@8\5H?A6"* 9!"2.N^CGU6^I+[, G#6M!34@65AFTERLYE9N5W=$/=$Y
M.":LH,S95XZ28!?M*8)ZPJW0NT#(3V4IH SARMS.(GAEF$4W @;-+?NX;&^R
M+-(B_1)-X$$^J04K>XM"U 9<T6@^+Y,T+Q>(&IPC4?CW\VB2I2JYB;(T07G'
M&[I.@?01(R!G*4Z/J%T,O1>B1F!0T%;I@.!*C%9F%HX Q?QR0Z3>;B+%PXW$
MR9/BAJZP#\@C!,4.%JRF$?-9H-V\X!HHB (%WIH@GD[JS4$U1PLXU KSSM,P
M8$0/5T<#&1A  PEPS4!S:@%*V#MZ>?7AF2]2(4JF45Q(!U&\G"]F*3 9K.SH
MT]M?GQ&%:P)-/^73RP_/K+SJM0<)]E>MP*DO2;Q7:&)O;#1GF4> J$URQ7Q=
MH)-"AHX7UM<*"Y,HF% 4^7&=L9-1TT_S*">ZX=,;U)4&_'.D&% [A.>SC4G+
MB/%+8-W.@7\2I4+GRB(2@H[QZ*L8X2I1#U8AQP87?83X@HT'&$ 2"?/'1]A<
M4J+%V?->PS77WI"!=-3"(UV@M881M8@E,AC#C(2"\L'BB[C+'ZME*@:PR!X0
M,@M!2D=T$H%9C 2]GH\##HS/-$8?KN'4"$JEG ,+ZIAV#4_E^59L6XM 17,P
MH+/)?_T0+U5\C$&U_MFH_W_7@]X_%]<_@'%:_-</@_[?_@^C;/_W7LC]?S<C
M_K@:0QL-3Q9?[H-(<7;67WS!(%$7G1L..DC=/5C+(T/J[I%&N>7P"YS) H^%
M)0X!*0S[@PL65=K&)6O<B$B:KS0+;I0-Z(C>0:7PZ;BJ='P=X1#C5P491BR2
ML(HM'DS^+*.L8H6CV8@WE!N&$782E;^Z)J2M>J+<X,X[6+@J0:1P@2I77]2D
M)-.A!F-N]X:&=[E@]]WHBZJ8=A>M@85]+\VN@X0],+*3BV ZU>Z8N'N^B:A0
M% ;'Y, "-9:Y&ZPAW8?1%G3D%)9XX(JFH$M3A&#_S.=HD,[S<@SJ."?5XT3"
MP+,);%1/M%&AG*-PE'Z!T1G81Q:(8@?*(507?IDU)?Z5_07^:Q "/2,B",UE
MD6.3G [2P1QKSQ.W&"A/XU)HIVV<8-":]8P5C+_0H).!7:_[?:#4K__[Z_GE
MN4_/_?#NPT T+D8JKSYHAEPA):<)X;<7)Z?\6S C5[_6\S[=5DR!)H,'+1<5
M."-IP,-4<9O;O<[KY!T#^9HV^QR7.QA<(GSGYAOEH\2P$YHMXO7AO6G9+Y K
M3#%DRY<<8Q7RK9RMKQN!@,Z#6!VD,0UNQB1:X-$0Y9#VBGN#]+P@#52 @V[(
M<([1!IQDU&L"5PX+C<2\,PBB<"3 U(J4!(=YN31%Z1&LY@% 8?,^>O28O6CV
MD=DR)O36,=O\X+>F55D%[M-40U/>JHTM0RGC.\:Z3R)"A2K'@U'O],D(0^',
MLQ=/Y_-63P=_\L-/NC"P[49J1:'S T@2#;_>8.*39Z$EL14I29J8A^<%.,4J
M;PCK=B1]()+.@7(3/:)&Z%O3A5O1M:/5KFC%,7)%I+B',K50H6P5W65T=(3<
M%2$EK()T7)TB! 2D(E>7(F""&O3?CBR[(@N8*Y\K8Y/(O,,P8"?^]H \SJTQ
M11HXZ,I6#^#'<U,\X^5+S/]T%-F=0BJH9-+W9I',1,X4E9'\6>*8"$R,8,8,
MBY'CC@H[HP(%BU0E\&/#1EA,XOS7 F0;QI^Z6[%[+\FFH'Q4% 7.K65;:ZI$
MD-T1XGJ!W^\(M2-"13A&P?4\8W6-"@4G?Y4)9^4S,99-A (C=B8@XM:&5>NL
M*A[M),VI3"M/)Q$%E[F@T#R&"K@6Y3BF8"Y/S]F0ZD]4DJ1S8MY[9RR<K3.%
M/?^Q('/HR;?16EZZX<8.,*"'NL"44TV11V]G:1POC]-;+'99M5DKK'N;-@5K
M[@@\^Q)V=J+(&X2*?8G@;A>3]>^("V\<A-T;II.S._:NM%]/L=2J;T]_LOX]
MSC#'H/?:6+<I<,( -=>?THA"E$%4"C19VL('J7+2^7E;M-)2N;"'M>0;70TL
M'C'YJ./_+CEE]GH129G(AYUHJ3/4OANHJ95T/Y[B,>GNE89RN(^<0_[TVU,6
M1U7C3&#UI+JP@YC3K;YIN,PZ7V5ZLTV& )Z$)5:8!@ _XT8E:9G'2WF<SKG1
M=,#6]UANY@)\J8$JEEF*6MO[#+YCKH[CZ+,"7;_ )G#SI8%WA#?L&=MN4=+C
M"T?=XU-5L$3##W#%&?6'X47"EZGY.%NF>'%U27Z4ZYI)O:]HCF9>P!-6N1XL
MNF:Y!^9B&@?8.LX9U#*[B6Z"N.>]+>2 Y'68HY5J[PF&!G%GBYH\S_ .'R?J
MFI.36#^1%_KK1Y]^__GE,Y]:6/,YB!A>25Q2WI._\OO'E[_B=](;6!(<D/R=
M L:S+ 7Y:^O/\-^J_*SF4>#K?4NF% 5:S0("HR=-N0XI 7KD/:U%I!T!3QI)
M*U\^.1[\_/./+U^-_N/?+D_[+Y@M<+TE')87IG.>W0I;!F:>(PV"1-F_H^&&
M-?I83Y3CD$/]&ZU^X+C@I"8S_!/ME7)767!-T82C?/+FYAF(5$Q-A5R[#\_\
M,!AZ(#S'48%]>^DD)EV'^;!Q&BXYI6::<YD7QB +I>X+"WT][.$#;WDB1::S
M<H[/!5XSYT'5\DYY0BZ""[-MP@VF$:12\FQW7&1E,J&CQSF],E>77_7ZES<?
MO"/\WQU)OI/S^XN^0>]DG>2##3ZEZ'N&Y=XR AAX\;.6-"20I/A6#U"&-RQF
M=%?'<9JB H9[6,!U+.8ZJHA5I41KD _T8/(,\@#$S=*;P\7%F*,M<W3*#IB>
M$U646 TXIHPH%A*JT#!1E#O19FSE:2V4=W2A$SLX4'UO2P^=NAPY$M-@;:@
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MG Y\FZ-JA#K,H#SI&&A[(U "]2/O>3]GJ5QC-<7HXP3!77-^(,%L,%80Y5/
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MB"SBONDZ]D#KKZ*$<%>+;6JQ3[M:[#U8R_=1B\U=YUA(0?EF*4D<8]:ZK?Z
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M R#*%^5,#/[.WM9Q;JF$WI%PM)VW;Z77X'=U:"VJO!/+RD[7A.Y)S1V$"/0
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M27F1,2HI#VVU8?]%,X'IP\$+?#%*M(0-P@]E+,+G9'"J#\!RGG<UH1,=7(Y
M*L%/@SD[)T>KWWM& I2.")QP(EQ$14W&?N5M60J->OU_U^^LB2_YJU:D363!
MLOC0\>S7WU7DPDQ%\W&9Y<I=#2H%711ETC\@:B*Z7V4.ZB9SOX_A$8E&2/H+
M>1O))(P+;_+Q[ZBWK')$I<5L@]\D=MMPZ9N*U[VQ']^45-#U!O:'-^,#VA:9
MJD*R'8:F^(=R# TR;UP/B T:K0B!CU2N%)E,4SZ!  LS4.>2]2%%Q_7RR=62
MU"D\"F\_.VY4U\:/8(<P,?6%>0$?ZY+G>M&A/))^ Z?19%*!4P;+C?(9"["U
ME713H6;-:F;K*\8XZL]4KI%R-3I9@A7S;Q$';"N.51S!VK@,E4O]@._YI=O9
MHT8>Y^44;33%-:ISI?C!MVGV639#'AF=D_R;KCJ0$NF4D,@AG0^6P%G/^VMZ
MBQ8A+1>,V @+/ M9\:W(./P1]2,$),$M6^@W:+XH=7DC'F'M_%PB3\N,1([+
M"Z($5XEG6@Y<ZSG019XH8RA:?M,5T+@%-!== <T>K.7[**!9O;-L6HN@8!]/
M78.3B7$WG:X@(7&,,H6$+=5#EXD5PVA6PZ'"5_U&>[I='KFB9@%&4!FPM-S
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M X7]Z??=TM>P)SV+)&EOKT25]E6"MS#RW7QLN!(LDBC!>,&L>I_Y-."WUUE
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ML2)R[XINTF\\<NM#E'\^-.Z4^5\@JM*<64GFA_$(,.EV!]L1S)H,@>5H:JN
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M5 D*;:Q1[3#6:F6JT ,0=<K#823U!1Z<HS.W[*SM)V"+RDBE2I,"$BI*IED
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M)C$^G;D14[Y$NO4EE/[47#4M2-^S!O>,S"6!BX:="8BT!?ZE+P:Z>4<WA3=
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M+<B10,PV[O#VTURMD(-CW'-P*6F?B 2H>N9\[34(G5EJ=A AKF,S2[@1ZAD
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M3[Y +$R]X:00$)Q(+TCC'<>^+OR)CT#^0+1ZT>-7&K''O_L9OBP$,BI23NZ
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MRX8.&[0V#I!!)]YO:C>!MV!/*AV;6JP%^B&9,5!;B\<)!$EL(=-OG]G!+]1
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M;?&Y[>\$3ZV!+B;#+;6\AY'7G5]LV39SKOXC8'7A9@&_0S,E(3:('D(@)5K
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MEXIL4421VZ] ?4')[Y???"WU<?YBV&N<%I%@H5ADZYJ;7MW$A%7 )5IVRC%
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MU]CA1XX^YX?ZR)RYTSZUC,G6FRB)<<X.TGNDN9+=%6WB.R'=C/'><[?B0F8
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M(:BOAX&V;X3,I60*:NL]VYC$"F-3#X1AYTU6,2 S@5<?@?_Y1I1[W8"%O<H
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MZW]O>[==67R%L=.R'[5*U4Y*SR,</\T/#)ZOPK5;Y 6$F U!+,OH4<!D7.V
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MQPR<F%,\LB8)Y/>;7G(5.T:1XNP?3V^B?EANPIJI%5$ B$+Q.CGVC61N*NN
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M_]OSWW[R&7.M//\5K\84O24YQ&T[C/C=MHTD%4K8%ID2-'?Q(EC,\ 9A-3!
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MA<H@3KJ[QO$!P>4RX$D;+)T%$M=R\-!-/AK01UA<=B9 NFCTAJ"HR7LCX']
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M_(O3_-P"0-*UW!M ?.04OD#=#]]T"'@%KW:!0'N4[.&%TMTM'(@>Q^Y>\Y3
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M_ZO%P_<F]!WVA[Z/S_/QROUG5BWF/_Y_4$L#!!0    ( +N""%>;%?%>8Q
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M^$F79O3H[S9P.5ZX6)Z)#2<BAQ1F>G\PA:X\OEL>XB_?J&^&/,&2CCSGF[-
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M&]ZHA\F;QBIIM_CD/*S2"*/789A_&S\+Y\-Y& UL3DQS;D$F&>M*2!&@5I[
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MI_&N',&^78A P<#M-Y8^.;#""V4% Q:YI(B12? ^9LC!L:2DE>0/=G!B?F_
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M*L S<JA*"<D)9SS:UMON-P >-R%VE_4:S>]]Y7#_M9B75GLFP DLH)35$&Q
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MW\695+BJT4XT6!6B .>2@<)];5\H;':Z\2ZY"<O3=E*::*B/;N=K<%W5H.V
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MQ08 ;UHE"=9FQO-;?>M>??E]^))>5#>GQ7O3\B\#%I3QA68>PQQ!I5IT-ZL
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M+BCO!7:<^\IF:NQ&CSUT<'"BU*0M'E@$4XH#I06KO3YJPV%MBBB%\>8-U8Y
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M5"_.2A'T:E.D4\[Z@$E;Y9+U/K(4V*#S6_:=YXO7O%MYS8TK8TQPQ7$'R),
MI40!;W2](RPY<^Y8P-91)0]AVG=M^[UVI1G/JWW\8HIAX*RU2:$"S2RK/<H4
MA) R,"MC2$)FW_RZ;P7"X=>OIGI?78OV$7 /Z44?<1S&\]?GGZ>3+\NU>8 N
M)*LD@E>Q%I1U!GPF!YUG%ZSA/F;9.N;Z+HI'IO4]Q=R#$?,BI>D%YC?#$(<C
M$BW.:,]='./=^F@0 G>!%0F^< LJQ  1O8#@"_)BZ,_4>H7K!.R1T:.],GJX
MME[%\_MDG"ZF4R+SH"@;9"T_S7Q(H!P/X!A*$D5&G7V6@;?N][@9S2/C1B.Q
M]W#U^=MP/)DN[@'F."43^^V?8YS.SH:?+WN=AT_X\]<*=S*>DSCI,9^67QDX
MDD>PQ.3(>%W[1 97R*/,3"'7O#8V:!TZO3/81T:GPRBMATNZEQ402>*_AO.S
MEQ>S^>3\9EI\'6 I7%K:/H6J9[E*<@A%1XC"AUQK?*!J;;3<"^B1L::=\.\R
M0^]_'O,%QQ?XBD2R#N>O?Z71128>OYC-D/Z;/X:_!B5(+J7WU>E'(C,QVM>:
M0598B=:@X+)U$9X=8#XR%O6MJ+O<,NVNES=(9O;SUV]^L[A9BM(6@5Z!CX%
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M4'I)E!(AA,-OK;7W7GN=LL^]Y]R_[LC\GF<^<\XQYWCG'./[WG=\(\?3QPN
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M]K8-]9J"[<T3)2GD!KM*3E5_/S5O]#3+JM&,?RA?W@1]JB6?DFA!OOY*H*#
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MGJ=+[834&$]U*8DBG+OK6@%DNZ=:%_P(DX@M;RGEGO<ZFCOW+WQ)4\M-(K9
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M2]S'-5BOQC1>B&#THON>FQ>0IVL_@)(EP>)D3EZH-P5J:0FT\3;4MY!/]E*
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M6CGHH.YG\ %='*+4IC8'.AS(N]VZ]PSFZ\DAD=2K\-'F":G!"J%M*0_^%=L
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M6Y590:=(?\6$=?3C5S8"NA+/P2"_?4P\DR./98(;)(&.:4F=VV9 PC2.Y[K
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MX7G\5!<WS'A"E*QGXK+1J3G;.<$9H- .8NJ[<+G]^& =X@X]9&,US(J]CI4
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M1<47OD7]+:P7;\N=6Q78!3V)C07N!]XN/=)YL,Q/XZ+4>:3^LMN+1/X?]+W
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M=:*>L5Y6@:UBCP#<S8QSI%<,OGZY%!@&W'G$?X.>\GBM[<)[Z0LLK+JWT):
M#Z&+&RY5=RK?06&K0=B>JV]^+<!Z[3LH<K&M&YVEXA].1K68W8>R(S37%HQ>
M%DV@W2@SVOV([X\O2\9WZ?4.U*U3N/L+G5$V7:&49Q/F7[P/!;Z1ZC&\='S]
M!_7S82V]P8':+@%&%^HPXX3)7"7R)*DBM< EPYR>^$EI"TD\?V;HPHM'QM@L
M%<+@KR*3+8)T@6L>7.O3@)G(9@O4+@[F-&R_)N0B3GX))MRT2]NSUWZ_7A85
MY*/:U:?IS4;&*Q%%?_$99/9[:+PV.2)VKRZTJ>;NFYSQ3AN?PL4:9'+<:+O>
MI_I/JTW"Z)?RMLAN=0D ,S6^?[9%E*VR>[9'#FZTLS-!>)*XMB;W] O/K0MY
M:_N]A./@(,]\RY-DVS?DVVT8YIP>6SXS"UH\X"]P%^4E4O"TZZ,W#^3:6?^5
M^WH:Q_^Y+'JL./U]!39"%$+JG\@C,0Z)WO08-:JOCB%;FA>\"W4-$.<W''M/
M:TF%XU^ *J@W%ZIJ4)^VE^5&PXOD#QGM]-X)@'F=/5E>EO[SY@]AV_JK]\\%
MBX!:X1+AJJZ/R!&Z_E7)<ND6B@_ZVLI9W(.K_+/.^?8S#%8D)\_Z_7[__KMV
M[H^\4_,_,E3N[W/^[>6RY"Q:"-F?'(FXUD<[2OK2:#QY='-<C,D@53*SO*S,
MFG9(-H##!Z4J"-H1C2#A E'E)/)6#!9Q@#C)-@EGPC__X)OK8-Q3V#W6/$Y(
M>"8,SB$^@^%(,JV=K$2^<%6KM'D=Z"A"!E'CN_6.W_ 2[YB",*T9*]>X;(\5
M!L3(\89 ]+1+Q,C=HD,)19A@S^YL4VV0C5U4MON)\U>?[EAC;U&.N[?_T-]G
MGSN=JF2:(&XLV<1^M57R:VP!G^>]^MO"C_T@&E>]?5DPUFH_6R)%RH^6E]Y\
M<2ZW _H2^WI#9I2I3?UR<-UU B10&1^F"I(V&Y=_O4J\_:;?"G9;I)+C_[#W
MWF%-;=O><! 4D1)1>HL*B@J(!41I$1$0$1$0D!H5D1(IBA0A)(A2I$5 8(M"
M1'J-2(= Z* (H2.A)DAO"5*6D/+%O>\^9^]]SKWGW.]]S_?=][S[C_4\*T_6
MG&O,.7]SS/%;<\PQ3C.4ZK:BPT/$,V('SH^(F'6=MT2:5(K6KRG%C007)SA]
MJK@AO_L\)[M28$KX]VH2=HE_DB")[!R4.M>+D'0EH_:WYHW</(*VAPX9DZ,]
MI>B=UB]P&*NM0P-SXT9!_MG-Z05B)3'%[%-%H'@"0NK8DWOAU#Q8E%AIZY*Q
M#Z5WL<Q1.Z+Q8YY"3\BWS\$;D^>'RZ7Z%TL"Y:2;F:#58PNP]2D51B#<[H,Z
MBW<?2BEE@NQ,4;.[DD;@GA3WWWWR*,I!M5U<8%3A&<]<:@*^;QS4$;A^\K_K
MO52((;G37A)V,T%?['J9(+W#GH*]-)8FC7U%@FQS$U&S7W,2&SXF?/Z9X$X8
M1?^KCZY@8_'WT=$0$:28LRJK0YZ6P!4X&\64$O*@85Z[]#-J'UOJ);J##QQ/
M:#SC)W']1X3%GQ#>U!;LA/O09K/FL1[9R\JO)65&M<ZT2)I?Y?-. =O%^]0A
M%?N5"8%)D.<KAUET"<O7G&UP_.V>>W"/KTL2;-6E)S7VA%,)0\)DS6JJXP0X
M!&=,-@A;7G_=^V#&4,) +#FN+6(5RSYE?!6H)F&B-.6I%XF <#-1,0BA(IA;
M5)/4NI08-[+O8;7UU UV=XW'2FR+?1;ML.*5I5-D<7P($R0P T27E?L1&E]7
MO_8?7CKOK>=7)'WVPJQ(O'3T>0D+7D4TWJD:'51 ;5$4<'H_-^[(^&+$P00Y
MY&C?3OYR!H-!)7Y#6<E++\W+-:P3]B*N (,3BNQP%+=7LG2#U;W*.XHKZPI7
M1D9MK$-TCDD8TP?.G^!RU[(I7YRDVI/WT>Y36QN@8551Z.?*"KL&Q+=MO5M&
MM&9T#IB679)@#X6UK;]KU$Q^5WN*7@IU81%M=N.:;J1(N[O$F%@Y2_:FJI==
M^1_=BB\7U;NQ[U I<FVMY1RH;>A>MONF7U3Q<EK_EMX=SH=ODT"5?XD0^5O?
MN*H,S$;(:Q]X<BU"42A Y1ADH,#X N0UM C21(=L> +)DW@.WXTI!/3PYW8Q
MV]&@HOSWQ5'YHT_EONYOE5I?'ZO<MD:HV4*;M;6I.VO+_5-GO[E\>'T5=\Y$
M\(;^IH&P@PAGC3OB.OTU4H)V!V<P+@"XC&U>-^/>^)*<^E/V+'?JSL#-CGMS
MD \6#<G@!C],Z'V:+(>?=V9V>6CGBX[3>9S7'48K0'42.S@%Y\P*+I;4I/?6
M)A); ZZ\=*E]+.M)6AE*U =F9$,1QF3T+D#[,G4G.B(C5JU]U$J']X1HTQ.M
MF&L]G4.3L1IY)3_8D^]3,\">:MT*V8/3YWJ/3SI;86!^ZZ+-)4TO$SX^^_M?
MO7;+K2CN M3T !0I3Y+]P@=#-?T/AB^L4V6.RL1]E(G5EY4=J,QAL -BDV07
MA%8 +V?$#52;UKT8??IX8NR3LKCB:!UG];LNGBW&'_Q]>N'Q\C<<"<*2D#5T
MI^(0?L.196(Y1<#"[_BWYRFX7_52O?^B@E]4Y-.#0S%MAT$3D7<'NZ$40T*8
M!S2$ID-9W6@8-!PL,7AZ:I7,W^X1'(Y_A<:U-8IJ_.1GT8OB9>SQ/4.2V"H9
M$^B.NQ)WPRMV*<$2\OE $>1Q-&AD!&R%)8T'CNVB8)HDM5N(UX(E$Y^[TP@E
M=GI*/P5\%593<1655M\C9R]M>8UOP[L\;D]%=K])1$U)T:P@!5:'^GXYL0FV
M->5#(V-KY(*[&+L!Q4;4WE)%"6?B<6L 8VQN_9HD_ZSBOMMW U=1HBI??ZMN
M;I9H5O_-Z0SCBZ>-<HM&+69DFZ(>H!R-@*,'J*BP.[%0L$MHI[ 6-QO/^]VO
M0@M;.0]X/EF!I7E]1.@"1B3%"*LKSK7R74NEKYTZ9VD3VDU&)M&[':#:1F!+
MD[AI"T/+X#WAKQ'MNOD/'3>R )A7OE.2)H:\(&EM.E H75)<WONE<WB$Y+.T
M_50F8-&B'LI1@#"TIPZ3KR4Z4S4))&359O'W#_/F11\W/E_[FNV\&Q09LLE)
MK%T!_+</(^2 VX7:^;-V0B$:)D*CO/U]/=>Z57+=[PAL/TDJHJIL6 (.5)^;
MJN7/U94%6[+K.'%E\1.Q%\Z)?^*OCIY)FLNP"Y9R:MF %^"E_;R<37'V_E"C
MMN_C)+WZ)142$Q2B>0Y^=GQ?"5YJWF?K<%W??H,HL]LQ WICPS<CXZJ?K-@I
ML![ZKLL$/<<ONJ"_U\/>UG+2,0AVRF2C:MD3UG_@1OO,^6X1]\'//O[/CEOP
M+#97G?%9,5/XD=$K]"R>[P2.$Q)JC%#P]-SX>!_9K=AQ\KCVRF@U]/CFDGE1
MS+3KZ#SF6G#^57<?GUR4!V'(G6$XR:J5'G2;839OEDC"\#K7\E+H(<_3K;DU
M3C<(!HWMO%._]Y&H3!PPD/'8,U'I3:)IT,/I.*=?-PW?!OUK/&AV&>ZQN42]
MG#KI=?Q3XX&G];MJ;])3&,)P#!_*R5T \%NR,N($4$8),)[J8TW7QSH_X ZL
M-2A=>^O-.5:;FTY4<938ZMK1_0^.AOYZF9P.-<EG/R9R()I708!M%5,_'JS:
MVCA.1%MUC=X$( 8?*@<0FE<DW]=\S95]IO+NQ1?)IQ;]+U_K+DZFO,K(9/M[
MVO2?\#C>.\,I"9\" [*ORMPY:;H^]0.OFP?Q1 XZ?;C6=G3K7NU[[!O<[>W#
M\^9,$+^RNQCB)!"<C3C7[_4.<J,TO$>M6BT1LMK[Z>&.(IK_I&@FI^SV1:O6
M'.0PA+W 5<L_1Q[;\_V.C,J0Z.Z#85_YK"%1#V$?4(L+$V&UZ@BK2FNY%;4&
MS<//E6*]1-LB']^E3?JLG&<PX&.:/(S/94P0+^UV-C#>E'($3YU!NY.WU9/&
MTB-$0B#?9WC@#8I=##/SQ@W7 =P9*L&,.ABBCGK\;K9JZ:L/<3P4V2R1\_C0
MB9.'[5]R?G'$*BU+US.$D)VUDL 2-6]R$BC<O/':H(0JK2,4[_SX,$[*4_=R
M<AE_99_'F=:!RIN,$[[X!FB1%#;SRX)8?&>J^R07XIA[=OIKK%!O1TN?9_=&
MT-N-C@ ,)6T"A^+&65*YK=$W7"\ U>9B:1>[G@E]L:UF^SBZ/CEGHYNX+3DK
M1WG:C 0-*,.3=0DV [(#L1LB36<L/Z_4['GX^*)J"HYRM *B-EO+/H 0GQQG
M<\%S:PHBM"AE&>[9S4(U7@4VG.5]KN+/Q6[/G!S]Z :"9'A+*0%09VKOQB0U
M,=2+#C.-:-A@2!155_7<7TX1P+F%B>1,'#M<,0\?1( ILN20I_E.DS; : [<
M;U?BH0]SU+GKP^T/([J/_+3OLT8 O+@;R=.:1D-0A9OJ<TL^P,4,:Q,>K<BP
M";\<&L>KSTB> KH]U"1E&_R\T20U%&^C1*SS=:N Y_9)%Q?O#)?O1,M&KU,[
M"TCX<,A[M[B /-\[RX.M,$Z%9</FE@A?];RE$RJHGUKH>X("6K>E"P)2L<YR
M6">_D*3!_42%KV"VBM* V-;*RR-10R$/P06(]AQDJZ8R]5Y"BC#5L947!:.(
M//JFE/ A7.UU6%^0=,+7?9_/B;9-Q[*_IEI;,_HQ)=/Q$_0[C UHJ+>F<#EU
MQ^S&)MB=GBH#''<XJG502X*=F ' WV("4:6U>11"H\5FK"_$BC*25.6LXJ.H
M^N5:*.?M.Y=YE_TWL=> Y&VY5K+B?E_/9N1.JL9@X[C0K+E<IO6XU7!&DPDQ
MNZ%9_OZ%6YPY>4P0)TO135)8M@YQ,Q)A0(X@B ,+5H%6A'S;AO?Y)Z-CM/=1
M(H"-+ ]-O9+JE'8&5V-!NZMZPBI:H),CYCQK(J&9(&.[(JHI2\4&SVSK(]0!
M:^SXN,Y$NSM/LMLWH](*)]W4DPVYU<<XGK1J+RS8SC-:S<<IG3[X/4;/IU<+
MO?3Z.K,VM"H-C&;N#U53.N'P2<Y% A1=2N "LAJE3E118%$X%?<- U>[L5%'
M_51I7HFB4VRA=EF5;\$2P!E*N1$ W?:!:T)Z%+'+:QA 1\C_LA=W2'(!?SJD
M4M<^.3#H@L89&'PPD"9-CY\!W*GW%LA2>9/)1LUC!_"]'<EK2<^.O].3Y_NZ
MYX$8"+1[%V>!__H1-DM-!1.&X("@UCWX^4#COMC0':6YOPE "MAGT]2HQGTG
MT#1IO_*M028H\1@*AQK*9?'^0IP9$W1QK( )"CS-!%&5M_%%J"KH<?52QBPM
M;XPQ@/H(I+1N1#!@3;0#K"[S(F.WA-;=:6PLI?\\C2$X&(Z?M>['4W;!&$?P
M/K0?I;)7![?35K/H^4Q0'!6\)$S#/P>TF* ]"\VP-87Y<8!=D0G:KT>3PPJB
MNLKS4!,\>)HA<N4[G-[]W7@*NZDWI;=1S#!J@I; 5AFR),[?/PCY.P+_4B@!
M/PJ)AQ )WZ%[&=VH=@#S[&^>54(U5%$MZ-Q^Y0Q0.PM"@\M,T,_%I*R8H$?(
M&R@X]"M->UN'"5(D(_?^X>'N/S8!5LWXI=CCGT7_=VMO#R04>1R$ 71_'6WL
M&%CA!S2BIVY8?[H8N:A1D_TS/$)_08<TC/7\K=V4L0+T%O7'\QE_A MV]+4R
M+YSK.!=1S?_&V"\BX$LQJ\B#]'<L2%*ANZ$D6]\\1G"--1,$<F""R$Y_6P43
MI/ 7?+(0_C]OQ![A>9 0WW>0YU(",32UW'='"EP^=S@< '&]C-N$;RRTPY;1
MGZ(B6%69/,YS&<&$I=PBEBN25<./8CE6_[4'66KOL'A/A VKLWBJR;LCLV6V
M;6.&*MR8(+ODO#GB*C@,_P'6@(V0.EI)!8?C3E05%GADQW8.)NX6.10,B[_+
M7<=>>O(,WH4K[?6&/K4[^M(+7HX@LR<0+W@+C7W[P*Q?^2(]%4Z8Q$AI*S'$
MPRG$>JRJ=9ZXQ[;@J0;'J-KX-3T61;W'!(6F\%/X*B=JY!K)PXU6W?:HNVZ9
M#TX=%Z!]G@K=H\K?4^VJV%!E%T'R=^>S)(8]@L-UBL+[3AV\S?7^B#YA=++0
MJ0+-S6I(0!3^@WM0JTU /NIK7VG.]A5&5RQ-.;JU?HP_2,.1[!/V)/1*[R8H
MX=-#WL]-E&Q<BE_,+*\?-A#!]I9VDE* ":$IWZIRBW+$?RRS<.2NC"B7US]_
M3Q;K1ZH]C/R$XD:> ))QVF0\=VLNG'=?G5MMO_I58UV!VQ)\1^<Y8T<1[!$D
MQT5KJG"C'_)M[0'JM8S,41>_9IJ\Y/+RD,]YD1D1V[1!J<PPQC%?-R@@:S5?
MD$T,@Y+ C/956CVF]+&47AQZQ7U2< FUAPERA(6.[SRA? PG25KON=N7=K/P
M>672[4,Y,CR7EZ*S,AY2&,W07:ZTF^H74[A*A8-0I=R>2IE]!F]65E4>/V;-
M=7)R'8FF0/4C;,#H,9KBS?G6^H_)U35'QH8-*#2$D<_#^3V9:D?E5:3&38XS
M076P8,8!P)$$D?3=M(@=;!H7P1GS)$5UO-E_[/*H<:20DV=#SH']O>47Y/J0
M<LA.#!AYUM:Y7.H,9=&OB?A0R3O?,4%1X6;0A=4A_R>6X[PH!]B/W-6(J[4'
M*)@0W?B\?$-0Q?;=55I45"/?5^^U=,YZ)DA ADH(8H(<P&)S=L< VT)+./)@
MGWW?^HK0V$B#?:SGP\@TI\-!($$![T[X&FR"-=.]H$((C1YE25ACN9U0C=,S
MQVNXF+LQ9K[FGZ@A[-(+%HR#"#66&=!LQ#7F"V\6\YOW4QC25LY3.W G4O2Q
M"7BGUH+M3AP7W%WBU(DOD]?#:P-YV'3J8L./IO^WO[J]^W<[Y#A!LZ7.D 8#
MO7*4T/M\>W6ZE2]WWX4;##=%ZYB+FFAI["Y<Q?EOO 0>DUSM24;1RBRKBW=.
MI0KGI]S2OAUQ=,QK6-RU,7[DU'#*4794([1$MM%(#&Z^I1L\F0PV[S]Q^F!)
M28U>#.6T!]M,^-IQ(*W>1Q56C_YRIG%\OSJ4%,7)V,\+U0[Q+>6.TA"[N$BR
M?-4B$LNU8H>G;DYZXRF$"5@([79Z\[VMS%2?3*W3-KI6!\IW(CZ#M BR$M2K
M>CACF!+"!1BEJN@ WTF$4 AXK4"(X0K7C?U&Z(_(M5*MW'7O^,.VMP%UI_4E
M!D5)J"@FJ$3V.>XQV>@99<Y. "8R>[]<1?/HBS9Y\^[!4S&@[Z^^O.%KY#P4
MP;-]//P[O Y5.IUF3SE#!K/*9%BWDMUWC!MDPH:=O^:K>$8^OJ<>5W+J]AI=
M+H4JW.).E"41&JN-PE,.]:K+^I/N'*K"4T9CKY0G),3RA^R+*ZG@.=.'NMB@
MV?*NUA+HW[[LNVT$1%&&&V$\)5&*%II*W5,UP:47)JR+B.86#M ' K$6$@/N
MD4@5A#4%'X40I#0P01:4>\%DNDF+_P*>?[Q5\<L1XI1]$,=ASX.2GH#Q;8R-
ML<U@8P+5U%>WE;'?:+&1?')W98 $?@@35QKG(RW-*=C3\PLH_DYH^NL[<ZVN
M6/W=+8G?;4_\>DXKU^HW80= KG\YJ:7UFW2T%WZ78>SO7(+RJB.HP7MY7B:-
M!:UT;Y?R?UA"8%VQDI/N;55YX]>;?UCD?^F2#N@UN#S^J&NGZZ\Q2,TL_KHW
M^E]ZWIKU0[]"'C!(>7*;.N:_N0<I_*N$_6MZ>U:/_NKV&ZCPZY</"V%JEFX-
M5;@!*N*<Y%5M.SXZ9[&W?D? G&3:@:-;24M'WX(3"QB[@;@F)NB]<F+C*_G.
M9'+<6YD=G7-!2\GB'KH:NQZ@6W!9Y("9%G04A)-V;.(KH)WM%/'.SKDCS];.
MYJ"SE; 9Y-YUI,.DYZG9<X*;-0++TC.CGG5V!RKH);B#Y+:22DQC68IP53'F
MNLCJY"O,\= W7WMK)7S!36)&2X^I1DV;27>[G,0RX[+J'1%?ALYD^F3/G!=<
MVRG  Q2"A_*:[<X! =LZO@]7F]<B\/Q 5"FO&#QSAUI@>'Y4#.9E?$O /%04
MB)A4:3%ZZD&385F,1MF^_E:U09(J9H/8&?2VJLCU[,?V!Z;:=\YJ^ \."Q@_
M@)R9Q^SVJA'>> '(/<YR_F8+>#8B):MZW4H/UUT>OY,;,G/^_KU\1F^/I-\Z
M3HT,?K(YO@^G=KAP6\'4(/9L$O?3%^T?P4+GOM?3Y&:WCE9(G=H^"$":Q\'(
M7;-$E2@IX[Q6F1X]N'(KYG!&M>:=)YA*L\GP#;__6'K^G(@['[N'H9Q70J0$
M!U:4HBR:R\K\HMZ$')MP^GI8PHN3.WS]^'<]LLHB9QKM$K6SG&Q)LWSL?"+K
MX:#"#JLT#H4ODB/]NJ.75KK6\ "<"7H&65,=8H+&<U! .)2$9>Q%=2TX,D%(
M5N>0Y9J@)**8,)V/11V 79@?/JM+O-R,4-9DIK$;,8X7=BTK^FZP_OM?K"="
MN\*_M9P):H3]X,BI P0&G?57DS%KW411GC)"K:';ZRQ*P6]WD GBZ^K"SS["
ML\PPI5^\@T.=G&!KJC F:$(,1;UA)=DXIH%GB#%!)$XZ7QEJ<Q[&.(3^HX!4
M,. =PK*ZM%G2,=BR?O:Q5=.^R'IW#Q/$XDZ]3%#XNZYE*>H2B^&SZ/YNZ*Q7
M,1.$-V&10@'4'\2T"$,UEB@I;DFR1*3P0G]X(?^NL4*A'IMH=R8H!/^#)&D7
M8.A;K+_"TOX@)$Z;(9F:BNJ:0[$L4N=?O'G_T-@2M5"</XJFS 0U@+<D[S-!
M*WUXF@[DCQ(*DO_0O^@_ME8G=41C<ICU^M^/T]&_$1*[]X\=_(>V*O"15J3&
M_SA0>G^4T3?T;_HW[8_-=?(!_STP@9<"*$\Y&7+_) @._0J"E,:-:D!;,-UE
M3+FXC4#[D#A(_U3T-X@29KV-H[\KJUR/]5:6<)BM1T:PS5S8_\D]]N?T^Q=.
M/\W4;5O:P81/=V%B0[&?+M!_C-5-2.EF P^J;>DO/=ZPC)](JA*LP<6B&IQ1
MJX6HR6Z69(E_#N#__P/X?YO^_!-,?X+I3S#]7PZFX[CQTO$&(5S9[4EK]1.+
MC'F[2?HGZM^4-M;_V1J*)8NP:E#"?]]$M2=Y0U9^1L.FT9]@^/< P[^S9C'S
M9X*("R2!@=A#P !!%K+Z"6;,:/9M_1NYL@M_L="J/S)!7*P7LA"?>&F="?+[
MN>(JUN@C_M=!VOR_K],@?T+B3_WR=_1+]C(4/OY,@2-<'>X8FX[*3>QE*7:C
M/\IEF,C@RDK5VU]..\(J=%26H;'_+[(EX$MG&D26R*:LI2$8Q/C1THR_A0-O
MZ(\:]/= ?Z[A)"=#_4?K6'7_B8K_@:CX-UIU"([;MHB#Z$Y"U'V&LPAZ]&<M
M_S>=3JE& 4<*@U5>L01@O>W3%(MQJZ'J_OR0\R?4_]50'\+BX=AG)O(7? <(
MSP71RS]&RH7P-S"P)=#V6U\,MH=2DF"T3F&6_L33]F3\W4^7?_;[GU;,GY/X
M_U,PS:-"F2 !G +U2LO\MP8BSJJFM"3HV-WGEA>+1%L_<[K(Q=!3H(X+T*%-
MK7ZE=@TK5UOW92%2>M)!41-A-Q!'MV4U3"NE6$? 1.2?\I=7&54JB=HT!)G_
M]:"PV:-?<W?^ET$3=]J:,K0V(<MB'_"/S%S_>G_]GW;6_^]>9@9_+^U4]H[1
M?VI[_5\5')+[+PFH_N&V[Z\.@+F_>@3^PQ)9OT;B_\O-/RSR#R_L(:!U^[JO
MVH1/!$Z11. _\G:0<2@@(:23[9!B9T[BX9!=-Q]UF '=VQ: XH1B! WZUO>#
MPK71]0Q>]P#>]_YWQ3>2%V_R!VF=XP2%W_+7$)P:EX(Z$3@9G0SAHD&$J?+G
MA,W>"/^;\M+[VN5<Y2_O#"2"OLY4K!?ZM(R7"3]A0#HF1+Q>V]X90XEI2;9@
MA(=VS<9_"O[VQ/WEU."3)-"FZC'1H)P['F_OQL$T?$,W%@'35)I1+X++-<=F
MH:IF:<1;TSM^7X<K3R=I!^YUX#G9Y,KF YHA[XK75_8ZIPAU+Y?:WF&,7^UU
MO?Y1N;\OZ-RD\4@15A30WG9$J $DZJ'M^I3]B==Q-:5!!D_\#[\W<#;>S9$F
M-$K3%C5FO=Q%[B-2$]DGM9/^YM'V>9R%_ZF:&L+0HV$1VO#SP/GZAZ#KOA\/
M6"A3(!M$P'/[@F^X$7BV9WS.:BOM<A*R8/?S:3-1U^";01=F1#O/-)_48(0?
M3?\90Y?''_7TL.8:VW]U-O\_V][W,OK..8*J</E$[S8K_>O]!>Y_)MW:_YOK
MKRG=1O_JE?*6^]%?_&-N*"^Y##;Z'684(*;5Y$2DIAV-8_D%BO>J48[NH M^
M2XC;#D <Z4NI7SZQ'G6DX7N3AXM5=)R2>633!'*3@VVEIP9%EFU&<]&.42(
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M/+16O(O!"[<[_*&[X-;@NJ&[@7#2BZN$HY9]QY?5 SEO/[&+H?I/I. +$9Z
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M9X)$E=V%DJT"S-M;!C?,R[VKTBE*IX+R4R^6C7%+O1W,0GX>.TB%-F*B[50
M:;*"WTJS*C+.4:@@U27IZ4JE4.$-D71W,M%2;\+_%O@T/9EE,&-VTSBIG"V&
MTLU/S9^:U5)+Z4L%&86)ZDM*EW)S3/+*8[-R!.>AQ4:A" ,J]R0J6O,L$*%5
M3:D)*7#FBTMU]@NZ7[5]_%;)!T7*\O%TL.<P1R1?WD93#24C- @A*QOQ2*W
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M@9I4A!90C74J]P0>JMA"="B+IS-*3"H:KR[)?K:6S$UYO2T/WX!Q,90!L](
M#:RZ9[:M[=!5]N\>\F]W[GOP)M(SLHM3G*4)&:>I(3$4;E)M#-E_:<>W%F\N
MG[R% 0(CX7;TX1/\A(,_Q74X?*&=&M 49(Q >)3:5T3GQT[UW.U1YE*:'I0P
M\'*I?G!(J4*\_IRTAJI%)NT2_2>$?KXOE.0U$^PU+"E'!@?>B5)P/Y'F6%(I
M=5-?VF/7Q3=^9NY<2 )>P N,3A$"4B=7A)RJHEI>PSU=MG3CW64\K-(*!2Y:
M)WR4*;HOE>S$/C?_';;A":6RUL<2*#W@)A,TFPJ[81%%DP-D<WW!D^[-8#';
M<>+(3: 0_EC!E<0[?5':, NIJ[IE(MJ);$<J#.#TJ>#)Y+*\W-'YLUONX<@.
M!\&FC($Q1<7E U"O@&#?VF2J=O/2]GZ:'97=-\Y4=1J#A6D[9XLGG*F+>/C$
M3/P\:,<%J9 :%6-Z"D,.4"1G12EC0I GN];P8-\>KZH^^_X".^L(KJ+2C'+N
MU6+[<R,/EFZ40(? 3570Q8))=' /$,3BI5:#BC-5H:8O5%NTVZ)YWMP]1?0,
M?*RTQC\-$5A3#!_G1.QG+0IDG<3F#O@-JFZUOZ-]@"-2>^Z6S5NN#^,BXJ=/
M/Y;Y9EOL5*OTR_?LX+*'-)U!G&.6+U%_L=3?T.VVS$4OM&\"!SM_Y)JQ70$5
M.W$"2SU#<G]".W4[VY(X.JL:_?JQ^J!XV>6R"4[NP&O7SG6X(&P E1S:1:"
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M4J;C*/M;4HZ6=A<<HO)E>65EC&5-/54/CWV7NZP>")+@V<.R)^SH!;6"M'L
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M$<->C2EV]I!=I-TL(./G[_M^V2*[\#,TJG84\(+)I\)>RL,K'LPP-FXA?X/
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M(\+2Q?.MI30?A[06IM QDPA114A0(83P^_"M(J$&^^$'*/0:K9Z$!257M:Y
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M48G.WX$4*^5N0 H,P8]44*K\/3$//]]*-'M"^W"KA,?GH&O':#4E>>8X5X>
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ME^VKW^Y4G&!J!H3N-#]S])_U)D)9 -M^G @@3S'NN[* 9>?^S>YT" N(76Q
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MB4BS+S8?X<_HGY[NCO/?QJ4"LX.KDKD;"Y38-G$E9;%1'BG8XN7H6K \QW]
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M:\FWU6C3 ?)B\R)H[/C+H=?]EN]/J0TMJK. SFS(X=.1:1D-'$MV6L3JDQ'
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MIWP_/2W:5GFH)NIYVCTKNU-90-N2?R_;+JO%;H5,@U^P#<\[79^YJZ[_S1C
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M=%#Y6: "7C?*,$@'K.>FA6F3)X]-U^Q_\?A(UX_7N(=L'[1Z/:'[R6,A6^N
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M%H1W#'D0(#V-DE*PDB4;-K[$)AM-3HWN>P@^/S4<<S;]?CWS9YITP.>=@*-
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M,C,'18P Q11W5'TK3+P!3L*V_J)(D;P_+,IIE67MVN?KD!!=YF#0ZUO;I2R
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MK0@.>[/**U7#_59PE26.8AN.??I?(,4S9Z=4UU.,$N]E+C].>9#F*ODB.,>
M4XA4,APM</LF=S.3V=)?KUCNAE)]#&E$^U[:KX(IJJ7YYZ9$^RC'"Z$IG]>F
M/3QWL+O#3&FZ]S'W:FKVMNB@T6R*0B-VO916!7(<L )/N!+I('_,UCM:CYL;
M995AT2Z(;IJ%;EO[8>80>\ZP\JDIVBX=M'J=U5\P:R]I=FYGC!'+Q:Y5;]-!
M3;^ZSOAGNA90DZSM$WB@Z9Y^B@[Z6QC[P<J-/J42P"N*VCCZ&C QSQ.V(S8S
M$CWWS-K+3/E243+L].T/L7+=1#O"WT-%]W7-C?4KGZU%U0OIH+\+G;<35:JR
MEQFP;PE<Z?A4+P2MX^Y]-VZZ^%LQ,9%)GO]$\ZT#+2)KR%'L;R@9_QG.$^BU
M0>QM35>]=E_67#(SWCR\Z<CD?3[YE,?)^>^OR-SKG!D_&M^\'(5ORG42K<OP
M;?Q[&%Y0E^12>CG!!HGX^U]K[KL"Z1>)FM_ZSPCXQ3XA65&M_XQ]-8Z0P0<R
MD*U5<SKH[]!PIM3USK"+8E&)\.?J#^&X),C>UWNG]+XBOZ8B -D<7ZD7^8!G
MVYPPQ#83D#%YD?.!M/=!1SR$TE,?]=4]0;U+O;3\[W6;UHQCQ)G*_0%< (\!
M*32D>';NRM!P&'5T1J9,W=%S)KRDI!+VM\WB_C\4M/^LZ[_LV)K\N;,\G8-5
M=4\/4#IB;;8%F++_6Y425.$ .9E$NU,\\EN&_$R.FY7/*_^A_KWYVSG8FU6_
M;77<!$W]^1QLX%\V.OYAAH53OY5.6?FMF,H_;')R!>'!L[M6Y9'_V\O_FEP/
M=_N['J8>B[X+_UX7>'+S^KY3P=<S09FW0.??ZK@)UL4+Z(O('CWR-"4A@L6<
MUL=04QGW,>OC^2-_.IGT$+1T\GXFG\$MALX4^8U-)FHS*I71.X8@L[\<,#/U
MP@+D2#+-H?B_3C=N>X-V<0?\7:P<ZV7J^I?WZ_L&_A?8SW^ZYOD_>FZ.P B=
MB+:?$35_%JHG"B:#)O\PK?J_QN'J)FZ@@^*%HC3#^*GZN!E-@X'<LB$WNUGA
ME-G+'@6HHZ',L.";=[Z]3RW;B1;\64\'\0@#R730!7\V.H@I]]^2Q'70CM%!
M_6"&)]#LA &^(2KB/L3OZNH&/&#X=K_[#DPB8\(QFVS]&)(8@J:N5Q'G*;,9
M$4&=H8-"(ZD&=% F-(@1)S.$[E?^3SP=Q$<'+?%D,F)Z%2S5(]91>D%O6?"_
MB8?4EXN?8P=/R6UXTZ24R$JT)[L\-&:#?\]4\WM@6J^#7H%S;IHOK%,A"#QB
MCVD33&5-_O<<4K\'Y:?.=@9VY5UI[QR PK9C=YF78 "7TK^E'/UK2-L>W'<#
MXHT1J=C?$?Y[*&M?);KWCKS!JF'^ENK? YGH5F?P]\J<U]C"SM_!5NCO87M9
MY;?):[[P&48R5@J_?JDL&JS=2@<-53* Y/Q+\.3_#)D;B/Z+UC-?^)49GL%N
M\T,-CGK][]O8]GXA8<)HV?17+94<#_\S:&54Q/W\/X;@?]U)]@=__^#O_RO^
M%OPE]5: U]] OSQ',@:'PU4\),':GQS!2X,[=%#U\\8_@1G^[X'9^V/,_S>,
MN>F?RV_);?R>5Z?4L?-O$'QYX=D:T&!&.Z/!/Q4-L?L3%"NK_[Y"_S^*XG]1
MB?K+FB+V//9O^D^5I0K<P-\,^^3ES\&I_&_GW\B?_C22 W\)$JE3L33VD^13
MYT=88[-N7X81)AG]&_T=3@9\T?ZG!DGGCR']YX?4[M^7=A&IQIB62TW'=+!B
MT. -93=@.QF[5YGWM[W\X6G];QIPH=_RA@6X]-)!^WF!%Z>O,R;6MUMSC&C9
MC>)D\C<T*OU3'(']B_/O7]ZJ_I/\9=Z+AVJB@@A=P5N]>NU"U685$[9%O,7/
M72)N9KJD??;I%4PU>RRZ_B)-+=0K]56Z966/^CW/).\:[?;=!-W[ U<<$-0C
M=4I[^^0Q)%%8:RR@ZX789;%@$'L&$^QL?$$40XI8PFX>*&,0=)<.8H?A! <P
M2[SV#)P_T@3S=7^E*6B5>\.@^4@7 [5$*H.P9^:Z#+IT8VG,LH!9K@ 3 _$#
M)9$,[",9],!)V31>6V':4R$8P)F!LWI^G?4/#/[ X \,_L#@#PS^P. /#/[
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M@@;F=2H=K-?2>'^@<]^]+['R:>TFFOU;S4&][5R_'S,^]O<VFZ\2)YT=UQ7
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MH'M0^ -TYBC*K"R3W5K>H[$SQU GX)+OYUF(HW,BV:@OKC_>0_E-OJ7[N<.
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MR%UZF3X8,:]=485B'7J+*@D9+W/UW+'EF%36RA\NW#8ULG5+YTW1L] T^N0
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MJ6G5IZ_%UEN_=?(@3Z]2I S#EO_1R8;U=?G)O;H(K!7!Y11UP3QSBG'?HH?
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M]#94PD)5C_N)1H2,VJWP1V,0AN4A#I$.!O<ZG2#!D:+A$Y"(8Z?48[LO\<(
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ML%Z#Y" XXX5UCD 6IF$J_BVD$HMPBGO\E\.>7$(##;6[??#XHRN \.X5P#F
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MOI1'E=Y"MQ:;#P8V%EMU'RQ\6)$%1H:3HR'ZUTPGVXCU$)[^E2AM_1EGJZ%
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MKV-(OC_^2\MY5ZH4'K)F"M5OB#T'337&2 B9Z(@S 5*G_1J8MY\,=)X6A\9
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M(!^^R_,DOD@#RBEW&"11FD+D800Q27P8Q:F/4^*Q*%*:I$J]S6WJ=L("O&*
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M\)Z+'A^S54-$4F+%I'C'8#IM(Y^)D&62'@8'?)/B&K*&!X 8904?:F\RZW=
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ME7AN=+%)9<!:(<%+QI>*7O/3C;/:UF=6HV?[!/G\X,C>F6=/;QDKV7X3G>I
MZCZ#<$G=87KK\$EE>?\<X92Z\!L+K]3N^ R7YR8&Z_VZ:&SQ+&=-;)9TO"XR
MV6/]6"W79UY=IQ_S(N59);,T+-) K$"N'XMM)?<@XE$ "4Y\Z$9.&' GIG[@
M:+M"GR/1W)8;J4M]DI6G@.:/CX*O&L<#8>>)SW?%FT/AVM(K-OJUSZQ76576
M>?WJ0V3\_8QP_;.'6G%%FG( ;:\X]2 TRH!&&]"H<]&L,J4\MMR,6?-XN]1\
M;L:LIYAAGVX3&)OT]3Y+GNE]P$W =] WW$C#X^C\8[825)/AY8D;<!+[W.4.
M@C2(78@"0=H8!SY,'<_SD,\#GSLZN5,5^]6BYLDRJ::=\.,3/JOBKL:@%M"T
MS),;B?L>!K8<#$;"9(CJ5'N=E- TH=BG+=W7QY%3K_&V3N8E*>MST 7"08)"
MGLB:/1PB-^!B$TD]Z 8NQSX.G(#'.IO(XUW-;7?X[G6N><7"70JPJM&-&; L
M,\R.YU('VK=.4(,.ZJ?1,$0D QU-RAVG%=ZG"X4W1G@H[<0=]"SD+[)*H,S\
MNKT;+G>]IBX[AQN9W&'A1MBE'DN@1R("49S&,/%B GT>>2$.(Y^IE0,S*=3<
M6$?*)(V3<L_!=>.ZI.'\8FK<ALGJK4;#,JT=C= 1=F6M%!!:]7Q@!/GM^W1N
M5+L8+@QK;^0TW)?>8 0G<F.:<"3U_)D,0S[HUV2JK^G\FPRCL^/G9+KML9%@
MK<=.XTN%B^NBCF9E]>Y^D^ M0@&/ NY +XD]B)@OE\W(AWX0AR%/*8L=7R\R
M3*7;N2V,-W;SZRF.A=J^W3S"EA>[+;BW#;A"9O$I@T;J]J3 0B8^/:",19TI
M=3IQ%)H.$*^CTK3>-L%6=<L+'PLFXH*5W,1)!#4E/L0.8C!B,?()3AG7R[9S
MH(_9\]#_Z?S%<1QWRT?_ ESG0ORHO0P">%T]Y$7V#_$*KL#_O5[Q__'/;NC\
MB^]< /EQUB'?[SFM,]:WOW+K7WG_ E9YUTS6W'7(A_-U55;B+_+20[?)<VBQ
M&?0Q'*@]E%,37BW@17NA9(O@=E"PPF9-#V](73LJ#O/4[J,3.W4U^8&N5F55
MU#9(6>=9N'O JS9]\N>\J1_,_L[EII"SRV=>X'O^JVBZ+JR^.8;](K8>'_-"
MMKK@B.. N$T)&HC\-(4)BT/H)*&;8#\.TT"K(LW,])L;&7>RPU;X=J<B.+%6
M T@]%/8M?XI/2_&.?UY2SXCR#?BHM=G@>B#UT[-LTOMOD+H '5:@^T![WV7O
M$L[&<?E,OX2W=H.SI-V?PVG.[M :<[&S+.9(#XZ>WQ^O#XEZMRUM-2IVO?HB
MBX9+!Q/Q@!"SZ/XIE,S*.UF-8>'[D1-%+(((<0I1B*35Y*201*DGS*>$(J1E
M-1F3;&[+^Y8AI3-7*VYMV_3E!]]JX36SBYD;3D77D;<8)-O.)6;&1]^_Q#26
MICQ0C,DUK8^*:3A?>;$8[^!MZIOUW &%B!^^/V5%<T=PM6K<"?>6H[8$#Z^+
M:"QHBA(OB1V(O-B'B 8>) $AT/4='% _B.-$*5''++29VU+Q3CIR+Y=BIYT7
M(&TT$_\P5GKGS;X:RV;?U-_"_(V\C1G7PZ1>TWJHR B!SMO\E8G78=,4,)J!
M06=RC-_:?#.BRY_#6#,Y;*:+RYD1:MPJ_@$7,C=)V=UKO<^6:]'3(O0)=V(4
MPAAC85:AB,/835W(8N:D2>H2Y"DE1SS1S]Q6/AG-LLS+9GWKPIBDO!> -1(;
M606/H:ZV/AG TO+*T4FX/2Z^ *V4YBC\! R&R/58+Y/2W@E5]PGIU.,C-_ST
M@;/UDE^G5_6!47V8U%CM*'&PCR-75FJ@,CH2P9C$(21>ZCM1Z)' U]N-'^UJ
M;H3122K=3'NRCCM&&4!8<>=J!#?;V\J1D.GO\4ZB86H#=KRC:7=')Q5^M74Y
M_89^7;L;GM<A9W(W=/E8J1:OVWMM;C/]YL,U:"+I=FVA.H&;>F6Z?7"&)_:9
MN-AV_!@%B58YN2/*CZH9M]_69(7ACBC1K_YV[)$1$2;-A<]OZV65/2WY^URF
M'UPD8>Q%GA-#5I=R2Z($8AHF,,*N[Z6IP[&CE$[G: ]SFZ[M]7(G)/C6B*FX
M(A\'<GB^&H'']N;<$C(:\1'G(C11L,,^4HV@?S$4L3 $PF#XP<$7IXLE&))[
M)S!@\,&SB:W.9<=CAP:I[\*0)P@BWZ$0^[X/"4\#E.+02]A86IMC"L!74U<C
M$> Q"+4);69) 6U@,IK*=+%Y(R*38MJAL=<Y%)5(;+I4B2=D'B"P,](FRAW>
M78&EC_EE4?SR<K5BC5FO:!H=>G=NW-3*V+\<*B_D]9 06&;R6N.ENI5T$*S3
MIM*Y.%FF*@6(S)V"G,)CE EUL,')[*@A=?K&U.!S9SJL7:V>UE7YB3_SI?];
M'1*R2%#LT8ABZ,:<0['M<&$2.*ZPLI@7L<"E@:^5.GV@K[E-^EHVX(_T%CN
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MEC4/.2388Q![,<$!<TD0^*-2#![H;&X[REYI[YZT*F6^]7%68P!3Z%GF@O'
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M\1QAYL9H4LAZPM5_Z8FK6;71R$"IL=M4\-NVL\8CKTUY)B S1(-GB3(I-9H
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MG@O>9,>_-BZVU:&P<AA\L,,W/!P> F#XL'CPS1')O62-UQN<L8]YT>S=A+U
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M]V!,L(L2E\5BTJI,UX$^YC9G.S'!1D[0"*HVAX?0')[(AC"R/)OUX5&>U H
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M2WP7.Z%6[-](.>9&KU*ZQJ7EL9$^:[+I/N+B=U[527++C?":)3Y&CI0:B4Z
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M!LZP4CNVS8E'QU:O+A_D?Q_^:YT]XZ4\)9%&5)%1T;[\Q>6*[?Z@]^3"B:+
M(9$# P]AB!('PSA.*41.B+C#2<@X7SPU#D:5(""U,]VS9-*9'?N265PSA9 7
MH*XLS[>RUIXCQ4:3YO>X H3?9ZNZEH>LD%T+J5O<^IQ137S/]Z. P]AS XA\
M[$'L)EAF*T:$(4PC![6C^F&EF*5XXC'MY)K+B'*9?>@MQC*,'>Q1GT'&HP2B
MT/,@B1"!04!=% =^1*FWJ/(*+V<VCEN9[(WAG>QCRM%0NV29#&/;AD(]1>2?
MH"?@!=C*#II'Y*39^V'_#9.EYPT@:ZP>_3FR3%RDW@!LKRO7FVAT M^</_*%
M0ST6\#B$:1R(W4U(*(PCBF#$$T*"."5Q:,\SYX]\;K:1^)8#BWXY G UHK0(
MHV5J'.>3\T?^1AXY6^S>PA]']#Y?;YPM-&?YXO2:&4=IOXGFUT5M?E^MGM:5
M+% MB5/616NO'/PX=MV4.M"+(EFX,PPA]L($TL!+ IIZ01@H75NK=SDWXNHD
M!'5"41EH]B+ UXTS4X!:C;_, FB9LGK"@EK:"["!4PIL(6V".CZ&:$FAPTF9
M2!V ??+1>%/_!/BV^OVFH-?%75FT-0:R?/4;KQYRMG4H4SP.5FEK;C32QD:*
MG2D7F(&[VR]@*SMHA%<_(%9"\_1IL6D@+=.)"H:&*Z_IHC3J2%FI@\G.EW74
M[1\V:[TW;L/R-UQD,D"JWA>]R\MJ0;&'&(D"F*# @8@E/L1^2&#B.FY 7<^/
ML%:VI5<]S(U'.@';?.8TURUX]AI#M8W'6<A8)H8-**U%]&X(%>TMQ5'-#>T@
M7K<_Z8;AJ'K[^X/C#YHH9%!_BEX8)U$<1) E3@H1#0,8.]R#/DU3'J. I$@K
M=OMU%W.;SUMK?NR$/@"CVHP^#QS+4_K5*8?9.7U<=RMU J:?U<<5'*X'8&!>
MRUCV;>SR?E2SK+^>K=;YNORZ*CA>9O_@[%->EC=YF<D=@^O])IYX**^+3_GJ
M7GH].FD0NZX+"7(Q1)RY8G5''+K,83%V@I!3K70Y9L6;&Y_T\K;);&T;/<$#
M7S:%3@3%="J"]49'L,QEW8!62Y"*_?6]^)T0&50/> 6J/_CRF8/'6GD]@C+\
M/:B1V]N-LF5B5,@4(<ER,\1;!8'4$'0J7@#7 XV6TIAJ]#1'L';P-T3.AH6;
ME-CM +N_*%CJ9:3#49T-K+;^FYQ#32ZBA4,P\^+ @]3SN P']6'L.<(6)-CQ
M<)(DH:=UQ7:DG[E1_+M^<K2L2<TU.@':,6S56-8 8I;IL@6K%G&;LJP1TZ"3
MP# .IJ[_C_0R[<7^L*JOKNQ//#XR]:)LZA>Q767]:J(]=])?7K:/M/=FEW_@
M@GVH"S!<K<JJJ&-<RFM9W^U.['"NG^HLX7_C9<79U:I)<;9P(A3Y'@EAF'@,
MHB#", Z3& 8X2!%#?N0SMNA7NS^=$W BT97F8-+,P;X"]J;BE]NO)7BNA3PC
M8>-4(Z]&@+,:S8E.X:4^L%9HKY9OSYN;O(#^<UW=A5KU"] H#WK:@UK]QM1H
M ;@ #032:+D9=H+4SR4Y\;"92CXYE=C39JN<>#!>I;><NO^1:QY]X&R]E$F,
M#TI3K[%=QWBY;K00J^UC\[,[N8'?W@YZ+&2$103Z;IA Y#H<8N)[,/(H<<1J
MY[H>T\I";%2\N>VY.^WDH4I/:/"U; CJER6FOT/Q5"ZS;#9J0GE3*4\P?\N9
M&$]YI-)=C(D?]K*'YUWV\!8>\*OX])0#ABQ]'XKKWYN-NNU5KC?@ RO9SKA=
M@(V*.Q_)MUI+._EA[ R J?7*K'#3KDI6@'VU]MCI13]/:'O8\_+A.WV0ZYX,
M^UR$C";R)$6,+*<0)7$ $Y\ZD!-&/3]( L:4UHAC'<R.Y5L902=D':NLGBWT
M((C#1&H"&MM4J(>*5L[0(=5'90T]V.!D>4.'U.EG#AU\;MSV4) "K\I-J8OW
M64F7N?3G6S"<8BQV=3 )(PQ10!'$B4LA1QYR,6%NY'*=>*ZC/6E-YZEBM4":
MK?"*RNI_N!9<;U=U'%:U#9(1L"Q/\$;&G8(V6SG-;55.0F%HUW&\GTDW$"?5
MW=\+G'YAI.&(EUWEFW=BRY"Q^KX_7\D\DMDS9]>K.V%OE)C6:84"GR1,6(+0
MI6*E1SC&$'L>@L@A$:(T\JD7+YYY07)ERU"G?YUIT9?"XNS85.S.TY37%5#P
MHTR0H6F>:8V"HO5E"UG;.PJ\W%J]]6WU5G;0"0_$WWOB&S29QJ!FRB+2ZGM:
M@V<,+*_LF5&-C-SQ4+I^7"_ES45]\"9/[PK^P$6WS_QJ1?-'+B^E/_/J.KW#
MWQ<D#6,G\2AT&$DABI$/B>MY$!$WC3V'NIY>95;-_N=F[/3$!WE]^D[["M0.
M09I[)<T!4=Q!V8/9]KZJAW!SO[$C.VB$!S]*\7^Z $(#28I"!X-[KG'@F=J)
M:?8^[?YL'#2O=FTCFQGK"G.XX/5VL[@]P0U\3*,T0-!W&8'("WT82\=)^;<X
MQ2[S].H,:O0]-ZYK"PK+K<9&!^D")[-(W*XIY=(QKCO9[;*@:;*?SM"H,9\E
MP"VSWH[4.Y?"6[D-1VF= 9@QUQSUGB=VU]&&Y+4+CWX3X]AMIY9@<^K=!D=K
MT-311N9&2GMU,QM1]3CG.&!J#&,$*\M\<A F"Y'C)[$P1!7'^YF4&$ZJNT\#
MIU\8DR6]5YJ9%]+56)B-S[RH,K+D-P)P7A2\N05;^#$*$ M<&.'(@0BE"!+&
M.?2(BSW,?>P3)?M-M^.Y\<9NB,=.J>1&%7 I8SPZ9<!3ITWSD$X&<HW1&28<
MFYA;YI^],N\=PCW1P4;VAJ,L(:R3_MT.TE-EAM_YP(51I?1=&TL?KX_=<&9Y
MC?8F3#JOK^5N/OH1[Y^Y*>3%LS#C#GOK?9:=2V>[VFNBK&_^^K^788V?\^H_
M>?6%T_Q^)2-6&J^\CWG1_JB.7%D@E]&0)Q3&'G,A"F($X\0-(0T#FJ2(8>HJ
MY;Q_&_'GME9MTOW\P;/[!_$7B,5'@N]YF]>T/G/<>!#+X.<VAUFQT7/DCGB:
MKT5SFSV[;\#V1<\AS[FM!7D!-DIW#G522_'3"KSP"FP5O6A=P&LORIZR%K;_
MDXZ1:9MB&N'?QE"9=&".6C_32J%?W>4W_#U[7'=)Y5R41)0R82DE;@)1Q%*8
M)%$$L=BBA,CG4>HZJA5<=EJ>VT+3"J=>DF47IV$>/TM[RQ3;RF7P0.2HMF<4
M3=EM;[+"* ?5Z!<_.?S Z##E_9N?S55G0+P$A]B!;DC%KI*32":V22&.X\3C
M<11')-#*J7Z\K[EYX;T[\U9Y"%;5>Q0C8%F_-U&Z&[X EU559&1=U4$%8K=\
M(Y:B 6^D,<',I^ R%]!\M*>I@YI/J7P@L/GD*S,S>!<D33S7"V11AXB)/QP*
M$R:LW"!**$O<R G(/&S;N>TN&D_B^I@)DMJ:>6VW%KSQ]! S<MT9-;A6&:Q:
M>V9V1NU;VZ\SHE^#INKEL'OH?$S3/XL5^M_$X)S<MARY$,D(E??M4?^=>'5!
MPS!-G91"1^ )$>7"@/3$'YQ1@MW4BT(W58T#ZS<\-YKO9 -2./6PKQVLAAGU
M' 0L$Z":\EK178<T'175M=/09-%<A\3O1W$=_/VYP?U?FFW$C:R]V?.5W@_/
MIL2-4N:G,ME5#!$*/9CX$88\<(G+N!-$*1H7OJ\FP-RF;C]>N]FMM1;4OK5T
MFZ_R1PQNUZ1.N#HVQEYQF-3V5S;!M[UMZN'>"@]JZ?NQ&U.%P.NA9SS(7;'[
M-PICUP/G>*"Z9COZI2)$0^LE+CYE9;4WFQ3K0QQM8&ZDU0H*I*07H)95O0;$
M<9B&2<<80I:9I0^.%?Y0 F)408?CK4Y6Q>&D8OW2#:<?UC<@/JRJK'JY9$Q\
M$V7[OT_9BKL+:42$:1S"T(DH1'XDD[P3!J,T03%U$R]T U5KXF@O<YOJC:"@
M%1%(&=4-C.-8GK8VC"!D>:KO@G.Q@Q*X'D!*RQHYB<0HT^1XJY/9*2<5ZQLM
MIQ\>64P.%[_S>I>]S1O\6<B^+N3MQ,)%?H!I1&!$ Q>B%/D0I[Z8^4&4H)3[
M,4Z4+J+5NIO;[-]*VTO)?@%6^0JV$FN6DQL&6\WJ, >A]2ON#7K]Q.=;60V6
MCU/"Q%3IN.'.IBT;IZ3XJY)Q:F^-CN\NUIQU]2^EC^FJB;'L_6CAXS1 'L;0
MX3B0%: 03,+0A5X2T\3SPRA*M2I4*O4Z-WYIA0;+K8AU;&,;U]T,1_^WVH'=
M"B.AQCK&\;5,/AVTG_:@;0*Z/RE .B9H6QTB<Z':"GU.':"M#L.!L&R-ET=$
M+G75>*_3KT]"]E75_:!VY2NY:$V6(W_/G_DR?ZH3^G6!Q0LD:"ITB -QA'V(
M7)?!F*8(\C!U!94E;A JY=4[5Y"YT5BK 'AJ--"(HSEG-(9Y:TJ,+5-9)[2,
M8^J@WOSL8^U8W:@"A"Z@I\PV)GZB(=$(=9IH:"8*?;(Y1'IA4 9P'0R+.J?]
MZ<*D#*"P$S9EHKV15=DVT?K7:=]OH#W.E^X#Y:L<M.7V4-D/0M^+$P\23_R!
M L^#F-$ >BR*<(1\3GVM??:9\LQMZ;KM^8;UU=$LE7;F(*EMP2>$WO;MX[#3
MEJ4T(X;P,U7,[$QIIJU>9@:Z5^7*##4[CEI%HYE@=&%R2+^_;'5_DR\S^M+\
MN9V<2>Q1/Z(1#)$G739\#A-$?!B(_7_DI*&3I%K%;=6ZG1M1UE)+;X$;T6JW
MH=)C246\U<C0/(J6.6\#X%;D"]"("[ZU_[=">WI(&6(WQ4XG)3$](/:Y2O/M
M<92TH;C\DO[7.BOX?@G'[7FM+/6XB'S/BYTD@MS#!**$)A!3&1G@16D:\S#F
M7JQ7YTQ3 J4)-FFYLAO1T(-8+NJY]GCH D>/M72'1(V^;, \\6E$E8-6=J!0
MW-8<GXV$SA"QZ?8^*<.-A&:?ZL8V,W%1R+:^RO6Z*BN\8H*2_]YFJ[ALDE5\
M^,X+FI5<%G3B7_+E4GR,\L4%(B3$:4I@R"B&B+H>C"-A'KLA3ESFA3%"L987
M[N0JS&U[V(D-02LXZ"0'M>@R#T13D&FBNI'C/PXU I_WD$]HOX^L);FIO=4#
MX@)T4!S[BKY=DK(J,*U,^B&_V4B^=7G)\0K\.0I-GCU QDI.GB_)R)CDNM3E
M=KG^^/PYVZW]OG C[F*./.@[D0_%RLAA[(4)C!/D4>ZSD =.9T+<:<08G^QY
MA.EP-\%*=O7XA+.BIBIA0#2>&%D=PS<BN;0"_A%UL.L$ G"?1#(]I@<3UV.0
M4A_'#J-NS'RMX&XSP$^X=Y@:<;4%WBR.EA?DMC)SWP3[^#?X^>H";$4&GX9R
M>.A'-ROC8RI,^72'T\8;*P/P*G!8_<V)3:HVK\XFLGE-2EID]>+U11#P B>!
M$X<\AH[K"<,I#E*8(#^$) @QC[CO<+W:!+8$G1O%=8=2KS+_X@JPK*R/%,&/
MN 18)EBD0LN?)K*33HVX96O(X#C.W^;I<GYM4Z/WU 52WQE8-8HC\M:VRRDQ
M_QP6BB+8QNP0U?[&+3M?Q)9-V"_RYA:7#[W AB0*9:*B (9I+&P,'&*8)*X+
MH\AW@Y"D/J:NSK)QK*.YT?Y63D"%H'J4?A1--4HV@9%E2NW!(V6T$QIR"@=#
M1':TFTF)Z)2R^T1R\OD1'M;'ZLY\D0<>M3LW66;W-6.5FR*=-WDE'LGPLBWK
MU%U!U#16'XHL0LX"%'HI3)$?R7K(+L01(C!Q4LJBT'?32.G0WJ:0<R,@>>I>
M2NEV=YU/]6%JP>O+G28Y<^N[#7[,5H!)<(I2;D6;MQ4WHU:'?YCUYC*HEAGS
M:)&N"] H6?L7]]2\ -LZN!M-]VNGB:=J;9M#]AF,M88?^0S&?"(?\S<=>STG
M=,N#,NB@;JOOZ9S7+:.WX]ANNZ\1^X=SC9OZE^556:ZEQ\(BY0X/ NK!N XT
MI1C!.$PXC'SN)*[G1V&D7G[*K&QSVRUTYQ.KM4RK+<^JZM6_;&M[/+6'6 RL
M5V(LP8?;FYMZO] \I;-),#S&"GN#MQNY2<ZE7D<P[)Q+_=*=2Y&A<ZE&1] I
M^7;CJ;'^O]VX3K3LO\'XZBWV=D9@<(TWW.5T2[L=K'96=$M=G)L?\VI[H?LI
M6_&KBC^6"U^8[CQV(AAY.(&(\ #&KN]!\3./$$20GVC=?0]W-[?EMI^#L2<O
M^"8E!K7(Q]V<QL"M>)=C#$3;*]\Y^)V1KG((%N/)*0]V]D:I*(<4/YYX<O M
M_01U[;7YB^N1NZP2FP4W\F)*D ,92<0&WX\))!X+8,#32%"(&X9^HIJ7;K_Q
MV5'&5CY0"ZB>C.X5;L-L<"X:EN=^+8^<^*[W(_FI<WQY,9-Q[IC>HQ+-O6IL
MLOQRQ]3HIY4[^HQ^_M>K59F))^\*5L=$9;R\*7)ZR?*GBK./2WROF@?V9$-S
MFY6MP#)ULG3M!)W8=<(A*;M@0KGQ;E50SQ5[&M+A26P<3<NS6A-(\$W*;RBE
MK#).HU++GFY]LA2SRHKV4\VJOS2R"!LN90(-^3_I'?>,EW*_L*E6O T4%S8#
M\UR",&32#ZU.0XLC)X1N&(<."2D+0BU? N6>Y\8ZVP+GFH79E*%V6,Q<QEV8
M8#>0WGZ>^)O/H.\Y*/(8=5S?7SSS@N1O"G9? HN'H_F*O[0!I2!=KYAN/3QE
MV-7,-"M0VKZ^%,+67%[_I2?V!=A^S6 KNL'B>+IHF2J5I]SOM(7S=.%X549/
MNP'+GB2[5U&;[$MW179_SXNF6N]E*GCY2M;JQ<N;M7B77J>I^,WJ?A$YU/&3
M((*12\2JDH0<$C],8""OCK#G4Q\K&9$3RSVW-:D5NZL2+T,Y.);26W(J.'/4
M%>Z-YCF6MGE:W]5@SZU@F]?N G0?15L*OD8 M!" !@/0@3#/[\22/\ITW\M\
M7534OYN[TV1BSTO%S% 9<UPY4YQY^K*8P7BT>XNA[D=>E+5US9KJ9POL!RC%
M@0\#)AWF$\^#<<P(]%W*&0EPZ#I4ZV)LI_FY[1HZZ4!6BZ=YY[6+G.(=UV@\
M;-]I=5!<#4.A?WUU4&-3UU6[C4][/750L5?748>?&AOGLBVE]CY_Q-EJP5S/
M2UE$(4M\#!%B(8S%3(5!*&8KIV% ':74X,>[F-NDW:T:^*T14O.^^@"0:O/W
M/'@LS^$=9"[JNJRG\1D1UW(, F,1+:\ZF#B6Y9B"KZ-8CCXY\C3Z06X4KE;;
M9'\?RBI[%)W\\B*'\_)[5BXP)A&A:2Q6YL01:S1)(?;\ "8>8VGBQCAV(JV#
M:(5.YT8"C<QBW>YEM02=V#(:MOGXI>B:U* T!(HGI8:!M6U\F\!4_X!4 R13
M9Z,J74Y[+*H!PJL349UWQ[C%"S.#EY?O9#WYHLK$=N9&# ,O"L[J).:_<>FT
MO?"P[Z0A22!/9<UWS!G$(8TA8\A)_W_NWK4Y;AQ)&_TKB-@3>[HC"A.\@!?L
M?I)MN5?OVI;"5L_$GOY0 0*@Q)U245LLJ:W]]0<@656L&PF@ (K][FQWVQ()
M9#X@$IF)O-"8YZF&(U-MSJD)I89J< 4Z=(,MX:"F7">V60UX!5^B?3A=6R,*
M2((_&K(5Y;L.I#IAX-:A'2N\^Y*/53-06PNC_@!LM:%&#*S6XFT_8%KO5?W
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M8V_"P//ZUPPR_/.J+F"P>+LC!?M[=2+Q63N[4&_4J0F$_1CJE@T@^0"OU=_
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MO)N[8#';@JPYNR_O9:V_]<W3\ZI\K8F]6BS*/Z5(J^8LS'P2,@)]3_P+Q2B
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M*%,3IC6UX+YX$B?;# B:P==O=S?@8[FL"H%:3X$Z7?CZ!:M=Y!S+U$'0+/?
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MOBO7@BRI^3UM2 7/+:V ]21UNELV%??H^(OAVH?:Y:B;F3L##5- < 4Z;,W
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M)>:-*9F<O!8GXIH_%'33Q:)8OO*F"8">1F>^-FHJWRB(.Y;P#0_=GM)_-ER
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M/"00AYQ!A'$,B6PRQ7R4^#P*">9*43V' T]MXTG:@"0.2.K4$V3WP.K?>9=
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MC><ET>=QSR5B\+IITMB2_/.V+->,?EJ+<^5[<[75C'WZU)H1%M$T1!# & 4
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MI$EQVU#IU61Z@D[=U+]#((>%O!5X'(MC;60,TO]ZN+\@_^]PQ)$3 'L8.LX
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M!=X60E2PLKHMA&["Q)2L*-G=LMA6O[QCU0SRG"09\@'.LA! $J0 DX@!"%%
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M3^IWO[NOXD___F_M3\2_9%':?_^W_P502P,$%     @ NX((5V$@X'Y-BP
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M&"[N,"09I!."@;*.6! 4)@<K'# F$+-.QEG?&+4/D#'V-;;Q4'&_J/LH%76
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MWHVVD2O@AH'&O5!D #TUPU^K,6.OEQ]P?M6@_ Z1NPT2N_/WQXT*>YR41L/
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MTI>!&:-C^U!K#P+'K4SZ!E%_H.Z_)OP_,DMG$YQ*C")9-! -#Z"T\(!&&J#
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M)D>I:/-,O"AE@@YQMT3E0 2.>_3Y]<%]*-U_4_B?.,VB2"F"%UJ""D(#!BO
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M"2P!YB+ )">-5;E(41HOP-TH.];XW(P4N/7P"V=;TT+QG$N07M2;_BJ M]J
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M=+_Y?I0U@L?3PF83>,O)L"5D/KD,7^QO%;<%Z8F!I/*,"9^#MPH9G^QQ::(
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M.36*MY5B>I).:"*231.LS?WG#+(Z"!2-H%I%PX@IW5%J,S65AVH6D78/"!W
M^@9!]'DT^S-9!^D22-^ V?RSG=\-7)8>$P="(9I^2-9 D#D=Q"+#E631I3\U
MI;N.]J>N/9 =@H<=,"LDG 9A]VDZ\O!'E[OW/C( :(B<1$:1LCJ=\I1$9!5
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M3H:+U3'M,VU1>VJ1%)'E)DX>-.L#XAU)9\?0V A63PNIKH)\*^-XTSY6:3[
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M@05K!"*>.<23SXPL)S'=[X8[Q@.5<J?#N?=7Z[XH#H"CLGRN7<&7;<'%U9Z
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MPU6B0W*)!8&*%#.R*K <T$D#B0!)S#%9&6UK/4?D?IJ!#^K52(V.6!925S'
MV)KW2AI)K\421MON14:8QY>*I4(4\,3VZ%W]#15)EUUHF@U0G3?PZX(VTK)T
M7@3C_7%/ J& <VJ;4&@79WP?16K];U@;7GVHA?UFR.#F[4G22L=S0I\%(QBS
M3; &RA^/BJ4J@/X.D< (&N.FY/XY*<4K,*4;JS_M/AMCP-#?;24)97UAY0 Z
M^&)KWD=+SG6Q?W4L1J$A>0_QFY&]F]\2=MB1RQ*<$4P#:;\1%G7<<B["?JS-
MMH[&'"1%A-P07D5(K&;.I"1C>EW(\/ EX,,[[D&.(.U-3'J4S^O=@*^C9'"E
M\PGQL6S N9'4S6FK>%;(-PN4R)Y<#\.1NF%P\KJC/,_#9KQ=,"]EW!^F]84/
M'3FF3D4)^F^+15)[(S5$R77<[T>@ZB\4J'J6BN3>,U(DL053&ZIOC[G)1>G>
M7^59\ =YDG1$N8W<#RW288<!,!6Z<P*%7-$XZ-&KB^R]5%T8"I=8"=V*!IYI
MK^'* &S6&DHRS,EG:6T9YAR3Y71,*9F"'LC^(#-P8LUG993*L68!:9B=*0 F
M@%)2 *[89O97_LWK+&]U L,V2<H29*NH3)4KY_YXEJ7:DF0CL7%=Z"-K"O]5
MM3G6B[D/A^?Y$M(TU/6%2OD&REIJ8/:H.Z+Z@P*45\7-12J5U$_N2FM_6G.O
M19TV;N,X!=7<)2F;A^PX>F+W^?!KH!8Y'A0O?<=3A>L%L<WHW<K'M? ]9PYR
MF \:\A7:D(YS7ELF03H1-[?%AC/F2!H3NK'';>:VDULA3;$4"B_"(!?II/Q3
MF9MH=Y[SPUW!,&DZ&78=*4\M 7+0H'Y ;<TJFRPJ'J[$\2CY,(U:XAC[$'QH
M:,&_"P^QF?(.OF\*N WT=EU<@$LP+?(0\B./&SX,SWG^Z"*]%D&4W\)A1A0=
M.J?HT%LZ.@&'<9^ZG4\I:SUW?)F#PW:2WT.V#AOB9?UU&MHA=O ZZX*WX^!Q
M&7C1:TT0)I[##C9KR\32QFZWEFNPXS!?P7$Z3VS[KKX2M9Q93+6M(][8L9=V
M.+E_KD*GAIE>6V634G.JF2N87(F5R3VYC@!&2=M/<(L @FZ+MQ& <SLB+RM]
MN'PP( 8WH\G*\IS,$^-2LL?=M 1A8)_FGB!L;%A-PGW."LPB4:&!A6#156;P
M<:EPV6&1CU,IT5$HCEFBFKB1-ZV.DX&8#$"U PT %?#WDES:#(KA7(,>SD3S
M4KC4D4THJTQU_*;W-'B#4XIC F;=%0^1\PWZ0K_FUW/7E,45G4H\TD=M,2@N
M#5',<E).;W 1-J-0-&]62NE;U#F<.H^[G>>4L0HW7<6--<9F(#->>2/R\#IO
M'I=Z/++JLM]RKM<BD*%;N!XG^:,9<&([RO[#:]K6*B9H#1>_.ZS%ELW3PK )
MBLM1,,T=(D1A<%B0N6E"TGA^@8GAD0V4=9T,7;M#!J^PU0Q33CPN/3"H\M!S
M$'Y%ZKB$@^<3R09%YGQ.05*DW+'(($,DY/^G>!:=;;]WG@@5'DK,\C/AOMN]
M5LY_8SPZ*WX<RU2-C%AQZ]CM-K>X+/!ZKG8"# R'8\C@55^/;X+F"6T /2F(
M9)&5$2!Z9B!C$^S+G)H7KG<XP6O7P1?E8.A65$<.X:#[+&SJ@56.Y!:),3$S
MP=MWL&D),QF*C2J;IB!8>=NFB$G'I"X"Z+F3-O;Z??KE7R99HO]\T'D&+@Q6
M]JIJ%3,U55^FG0VG(B(_=?I9J348;!;BM[ZE6#_8ITD9_>NXK@-P..9)Z'HN
M.\^WTZ::P^(U[D/'S<3W,T4X!/F,.)C+D$0UJFP9SL:E=0NSAN.[>S&2B@CC
M.7N4R["E<HWKFH0)WN; #)K\: A%5]F7BF%\@RO-X1U-L7<0[&4(NN^2V]?I
MR'CF;.S48.@8")]F<=#^T",.K<._O]#C7M#;D;V7>^&DOQOLA*_VQL'VONJ'
M^R]W#N0D_-?NBS]'N/([XHY[K>J(61>=E<C*M6O)QRE99=6,B?3(O%J?@F<3
M:;AKN_E-$3F2I; !'L$\!4^X<J+'FLB.ESE23J6F.[":U1![,V-W8-C4/$!7
MQL_+MAKVR/FGD$:CU I*HPGR@A.MW!69Z6)(/?JX6.S)/4@M-Z3ZSP>KZA"3
MFU2*O/_)?;Y-@MX)<16!Z$F3F F17<3KKS8V0ES,Q\H8*.4Z.TZNL7R]1O3-
M+"GOIBZ3W'A!A4Y@AO@LRK%+@ IUC$X@AV)IQ\J3*4=I5O@,<@2KVV<@MTM-
MI2O.'<"J#DJ45JR3Z'@+[XCSHW>F,2SU.E<6]M/R"Z-+^(NU6U.8GE^15H75
MA.PZ,I>1M"A2S#AZ9$2C;RBN:\\9?SX56 ,707&(*IB0\<EWC3YQ4/GC^<G9
M[\.A&!QB[^^3X='[X27U!!^\OQC"1VI/[J[Z,+@4[SYA^^^+X>"H(SZ='@TO
M+D=P_66'[OKGV<FGT]'@XA@N&9Z.X$=Q?#HZ@V&.+WE([ [^7<_],( ?3\79
M^?G9Q>C3Z?'H=^Q^/KC\+_'_/@TO1\=GISS (7SX=&(ZD,,-@]'H[.)T^#NU
M0#<#_G(I#C^<'1\.Q=OAN[.+H;@\?G_*G='7S//=IXL1MCBOS+<R21@31QF,
M/EW@L"=GGP6.=5H.A_.U;=>IX_O9Q_/!Z>_BW<791X$?:/TG)^+P9'#\T0Q_
M"".\=>W:X7<8$_NPP][BBDX&G[\->_?';S]^^_';P_[6*'U[WRZR=[LK$OME
MK[O?7Q':]EM/; <*-9%O22W>W7L^]OW!7\*^=X,;M6MGC^;Q1(K7\2G*U-/A
MY:7X#*)P>/:N4PD@$V@*41TIO&3 $[*RJ^]!+=RDBZ R=,CP*:4Q86(HA#@_
MT: B8:DW#&I<C'=4COO?X]Y^C&T]:-S6$VS')HX1O2M9(!*O[(CC./@VJ=YL
M)=R/D;!*^?V#'8^=/38=OEU6<(3U?(KM'__^@EO<<;U, 6R@^\=B^D)D:;#V
MIRK[>[GX^L9LA6%LN'(P17,T?<T!I^/(/SO&T5]\??'\M_443&/:6*^?87O.
M3O.<1PCGP),^-Z'87/S\TP[\?3A#N*8A5SP!#SECA)5[E_$MX2+6"FF&V+Y7
M16;G7A295?+?Z1U8\>;.M)Z#4/_7]M@[R[6OJF?XX/O.<']_E\[P(]-P[Z!R
M[B[D+),R%J-9,E]DIO\%__2/(E:BM]\1_>W^SL.^WOYW^)::%=4&2#'[[3I%
M]0$VGT9\K7-X6G G$(-7O3>75E* <C.E0-K=M1@88&<]R+TEU'V*G3^=JOVW
M<1(NX3^S?![]]O\!4$L#!!0    ( +N""%?\WS*U'P@  !PI   <    ;'EE
M;"TR,#(S,#8S,'@Q,'%X97AX,S$Q+FAT;>U::T\C.1;]OK_"2VN[04I"GD "
MC92&]$PD-O1"T$Q_6CE5KL2BJEQCNQ(ROW[.M2L02-A.BYG>;+0M-5#E:_L^
MCL^]=OEL8I/X_&PB>'C^M[._E\OL4@5Y(E++ BVX%2'+C4S'[)=0F'M6+A=2
M%RJ;:SF>6%:OUAOL%Z7OY93[=BMM+,X7XYP=^N>S0S?)V4B%\_.S4$Z9##_N
MR7K(V[7VB1B)DVJS61.\73UJG;2CQK%H'[?JQ_^N[:$KQ'T?8^>Q^+B7R+0\
M$31_I]G*[.E,AG;2J56K_]AS<N=GD4HM)M/H[/_T8ZR.Q/48@UF5=6IUC&3%
M@RWS6([3CK-OSP^U$ ]4K'3G7=7].Z66<L03&<\['X8R$88-Q(S=J(2G'TJ&
MIZ9LA):1%S3R=P$=,8E[G'G]CS%.+%.QL*=6)R-Z#Q,YDI8U:I7:<PLVTSV
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M:404_7ET&7=?Y9J)6/<B9(&EGLO'(I^YOZL^RZO$ WV%^3=02P$"% ,4
M" "[@@A7*NWK)J83 @#SS10 $0              @ $     ;'EE;"TR,#(S
M,#8S,"YH=&U02P$"% ,4    " "[@@A7FQ7Q7F,0  !RM   $0
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M,'%X97AX,S$Q+FAT;5!+ 0(4 Q0    ( +N""%=-##;]&0@  /XH   <
M          "  ?[#!0!L>65L+3(P,C,P-C,P>#$P<7AE>'@S,3(N:'1M4$L!
M A0#%     @ NX((5ZXL/2-7!0  R1P  !P              ( !4<P% &QY
M96PM,C R,S V,S!X,3!Q>&5X>#,R,2YH=&U02P4&      L "P#T @  XM$%
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
